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Abstract 
 
The pro-inflammatory cytokine tumour necrosis factor (TNF) exerts its bioactivity via 
two plasma membrane receptors, TNF receptor (TNFR)1 and TNFR2. Both receptors 
are fully activated by membrane-bound TNF, while soluble TNF (sTNF) activates only 
TNFR1 efficiently. Preliminary data from our group suggest that the membrane 
proximal extracellular region (stalk region) and/or the transmembrane region of the 
TNFR control the differential responsiveness to sTNF. The aims of this project were to 
ascertain the region determining sTNF responsiveness and to investigate the underlying 
molecular mechanism(s). 
 Fibroblasts from tnfr1
-/-
/tnfr2
-/- 
double knockout mice were stably transfected 
with chimaeras consisting of the extracellular and transmembrane domain of TNFR and 
the intracellular portion of Fas (TNFR-Fas). Using this cellular system, I could show 
that 42 amino acids within the TNFR2 stalk region control responsiveness to sTNF. 
Replacement of the stalk regions of TNFR1-Fas and TNFR2-Fas with artificial linkers 
proved that stalk region length does not determine differential responsiveness. 
Furthermore, responsiveness to sTNF was not affected when either conserved proline 
residues or O-glycosylation sites in the TNFR2 stalk region were mutated. Moreover, 
partial replacement of the TNFR2 stalk region with overlapping artificial linkers also 
left sTNF responsiveness unaltered. Therefore, the underlying molecular mechanism 
controlling responsiveness to sTNF appears to be more complex and remains to be 
elucidated.  
Importantly, the critical role of the TNFR stalk region in sTNF responsiveness 
could also be confirmed for wild type TNFR2 at the level of signalling complex 
formation. Data from chemical crosslinking and confocal microscopy studies revealed 
that the stalk region controls ligand-independent receptor pre-assembly and formation of 
larger receptor clusters.  
Taken together, data obtained in this PhD thesis indicate that the TNFR2 stalk 
region is a major determinant of differential sTNF responsiveness and ligand-
independent receptor-receptor interactions, the latter being a potential prerequisite for 
the formation of larger ligand/receptor clusters and signal initiation. 
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siRNA Small interfering RNA 
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CHAPTER 1 
General Introduction 
1 ihydgfv 
1.1 Tumour Necrosis Factor 
 
Cytokines are soluble or membrane-bound signalling molecules involved in autocrine, 
juxtacrine and paracrine cell-cell communication. They mediate their action via specific 
receptors and influence various biological processes including cell differentiation, cell 
migration and inflammation (reviewed in Foster, 2001, Ozaki and Leonard, 2002, 
Feldmann, 2008). 
A cytokine, which has been found to be involved in e.g. inflammation, immune 
responses, regulation of cell proliferation and differentiation as well as various 
autoimmune diseases, is tumour necrosis factor (TNF). TNF was first described in 1975 
as a serum-factor from lipopolysaccharide (LPS)-challenged mice, which was found to 
cause necrosis of transplantable sarcomata (Carswell et al., 1975). TNF was then cloned 
successfully and characterised biochemically in the 1980s (Pennica et al., 1985, 
Aggarwal et al., 1985). It is expressed as a 26 kDa type II transmembrane protein that 
exists as homotrimers in the plasma membrane (Tang et al., 1996). Proteolytical 
cleavage of these homotrimers from the plasma membrane by the metalloprotease TNF 
alpha converting enzyme (TACE/ADAM17; Black et al., 1997) results in a soluble 
form of TNF (sTNF). The bioactivity of membrane-bound and sTNF is exerted through 
two plasma membrane receptors, the type 1 (TNFR1; CD120a/p55/p60) and the type 2 
TNF receptor (TNFR2; CD120b/p75/p80). 
 
1.2 The TNF ligand and TNF receptor superfamilies 
 
TNF is the name giving member of a large family of ligands, the TNF ligand 
superfamily, which is complemented by a family of corresponding receptors, the TNF 
receptor (TNFR) protein superfamily (reviewed in Locksley et al., 2001, Aggarwal, 
2003). In the years following the discovery of TNF, more and more members of the 
TNF ligand superfamily, such as receptor activator of NF-κB ligand (RANKL), TNF-
related apoptosis-inducing ligand (TRAIL/APO2L) and Fas ligand (FasL), were 
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discovered. The members of this superfamily are type II transmembrane proteins and 
are characterised by a C-terminal 150 aa long “TNF homology domain” (reviewed in 
Bodmer et al., 2002). To date, the TNF ligand superfamily comprises 19 members and 
29 members have been described for the TNFR superfamily (Locksley et al., 2001, 
Aggarwal, 2003). Members of both superfamilies are schematically depicted in Figure 
1.  
While for receptor expressed in lymphoid tissue (RELT) the ligand has yet to be 
determined, for several of the ligands interaction with more than one member of the 
TNFR superfamily has been described. Lymphotoxin α (LTα), for example, has been 
found to be able to bind to TNFR1, TNFR2 (Brockhaus et al., 1990, Schall et al., 1990), 
the cellular herpes-virus entry mediator (HVEM; Mauri et al., 1998) and, in a 
heterotrimer with LTβ (LTα1β2), to the lymphotoxin β receptor (Crowe et al., 1994), 
while TNF can interact with TNFR1 and TNFR2 (Hohmann et al., 1989, Brockhaus et 
al., 1990). Furthermore, recent evidence emerged that the growth factor progranulin can 
compete with TNF and LTα in binding both, TNFR1 and TNFR2 and can inhibit TNF-
mediated signalling (Tang et al., 2011), further highlighting the complexity of TNF 
ligand superfamily signalling. 
Most of the members of the TNF ligand superfamily can exist either in their 
membrane-bound form or can be shed from the plasma membrane, resulting in their 
soluble variants (Aggarwal, 2003). For several of these ligands differences in their 
signalling potential and biological function have been described. The pro-apoptotic 
activity of FasL, for example, was found to be strongly reduced for the soluble form of 
the ligand (Suda et al., 1997, Schneider et al., 1998). In contrast to its membrane-bound 
form, soluble FasL was found to promote autoimmunity in FasL transgenic mice and 
was proposed to trigger non-apoptotic, pro-inflammatory signalling pathways (O'Reilly 
et al., 2009). Differences in receptor activation potential between the soluble and 
membrane-bound forms of several other members of the TNF ligand superfamily 
including TRAIL (Wajant et al., 2001), a proliferation-inducing ligand (APRIL; Bossen 
et al., 2008), OX40 ligand (Müller et al., 2008) and TNF-like weak inducer of apoptosis 
(TWEAK; Roos et al., 2010) have been described. Ligand trimer stabilisation and/or 
oligomerisation have been identified as important parameters for the efficient activation 
of some of the TNFR superfamily members including TNFR2 (Müller et al., 2008, 
Wyzgol et al., 2009, Rauert et al., 2010). 
 
  
3 
 
 
 
Figure 1. Schematic representation of the members of the TNF ligand and receptor 
superfamilies. 
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Shown are the members of the TNF ligand superfamily and the TNFR superfamily. The latter 
are characterised by presence of cysteine-rich domains (CRD) in the extracellular portions of 
the receptors. Some of the TNFR superfamily members contain a so-called death domain (DD) 
and are hence referred to as death receptors. Due to their pleiotropic nature some of the ligands 
can bind to more than one receptor superfamily member.  
The ligand superfamily comprises TNF, lymphotoxin alpha and beta (LTα and LTβ), Fas ligand 
(FasL), vascular endothelial cell-growth inhibitor (VEGI), TNF-related apoptosis-inducing 
ligand (TRAIL), ectodermal dysplasin (EDA), receptor activator of nuclear factor κB ligand 
(RANKL), TNF-like weak inducer of apoptosis (TWEAK), a proliferation-inducing ligand 
(APRIL), LIGHT, CD27 ligand (CD27L), CD30 ligand (CD30L), CD40 ligand (CD40L), 4-
1BB ligand (4-1BBL), OX40 ligand (OX40L), glucocorticoid-induced TNF receptor ligand 
(GITRL) and B-cell-activating factor (BAFF).  
Members of the receptor superfamily are TNFR1 and TNFR2, Fas, decoy receptors 1, 2 
and 3 (DCR1, DCR2 and DCR3), death receptors 3, 4, 5 and 6 (DR3, DR4, DR5 and DR6), 
EDA receptor (EDAR), X-linked EDAR (XEDAR), nerve growth factor receptor (NGFR), 
Osteoprotegerin (OPG), receptor of nuclear factor κB (RANK), transmembrane activator and 
cyclophilin ligand interactor (TACI), BAFF receptor (BAFFR), LTβ receptor (LTβR), FN14, 
CD27, CD30, CD40, 4-1BB, OX40, glucocorticoid-induced TNF receptor (GITR), B-cell 
maturation antigen (BCMA), herpes-virus entry mediator (HVEM), TROY and receptor 
expressed in lymphoid tissue (RELT). Data on LTα binding to TROY are conflicting (Bossen et 
al., 2006, Hashimoto et al., 2008) and for RELT the ligand is yet to be determined. 
Nerve growth factor (NGF) and beta-amyloid precursor protein (APP) are no TNF 
ligand superfamily members but act as ligands for NGFR and DR6 (Nikolaev et al., 2009), 
respectively. (Graphic was adopted from Aggarwal, 2003, and modified). 
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1.3 The type 1 and type 2 TNF receptors 
 
As mentioned above, TNF exerts its bioactivity through the two receptors TNFR1 and 
TNFR2. In contrast to TNFR1, which is ubiquitously expressed in all tissues, TNFR2 is 
strongly regulated in its expression and mainly expressed on cells of the immune 
system, neuronal tissues, cardiac myocytes, mesenchymal stem cells and endothelial 
cells (reviewed in Faustman and Davis, 2010). With Kd = 1.9 x 10
-11
 M for TNFR1 and 
Kd = 4.2 x 10
-10
 M for TNFR2, both receptors are capable of binding homotrimeric 
sTNF with high affinity at 37 °C (Grell et al., 1998b). However, sTNF was shown to 
lead to an efficient activation of only TNFR1, whereas membrane-bound TNF is 
capable of activating both TNFR1 and TNFR2 (Grell et al., 1995). The molecular basis 
of this differential responsiveness is not yet understood.  
 
TNFR1 and TNFR2 have been characterised biochemically. O-glycosylation has only 
been described for TNFR2 while N-glycosylation has been reported for both, TNFR1 
and TNFR2 (Hohmann et al., 1989), with the two asparagines N149 and N171 as 
potential sites of N-glycosylation in TNFR2 (Pennica et al., 1993). Furthermore, O-
glycosylation in the membrane proximal region of the extracellular portion of TNFR2 
has been described (Pennica et al., 1993) and TNFR2 has been found to be 
predominantly phosphorylated at serine residues (Pennica et al., 1992). To date, several 
crystal structures of the extracellular domain of TNFR1 have been published (Banner et 
al., 1993, Naismith et al., 1995, Naismith et al., 1996a, Naismith et al., 1996b) and 
recently the extracellular domain of TNFR2 was crystallised and its structure solved 
(Mukai et al., 2009, Mukai et al., 2010). Further biochemical characterisation in 
combination with molecular modelling revealed specific functions for the different 
domains of the TNFR.  
 
1.3.1 The cysteine-rich extracellular domains of TNFR1 and TNFR2 
 
The extracellular domains of members of the TNFR superfamily are relatively diverse 
in their primary structure. However, in their tertiary structure, there are cysteine-rich 
sub-domains (CRD) which adopt similar folds. Typically, the TNFR superfamily 
proteins contain one to six of these sub-domains (Naismith and Sprang, 1998) with 
TNFR1 and TNFR2 each containing four CRD (see Figure 1 and Figure 2).  
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Figure 2. Schematic representation of the human TNF receptors TNFR1 and TNFR2.  
TNFR1 (UniProtKB accession number P19438) and TNFR2 (UniProtKB accession number P20333) each consist of four cysteine-rich domains (CRD), which are 
connected to the transmembrane domains (TM; aa 212-234 of TNFR1, aa 258-287 of TNFR2) by a stalk region, and a cytoplasmic domain. The intracellular part of 
TNFR1 is 221 aa long and contains a death domain (DD, aa 356-441), whereas the intracellular part of TNFR2 is 174 aa long and contains two TNF receptor 
associated factor 2 (TRAF2) binding domains (aa 420-428 and aa 448-459 (Grech et al., 2005)). 
6
 
  
7 
 
The CRD of TNFR1 and TNFR2 have been described to be composed of different 
modules. The nomenclature of these modules is based upon aa composition and length 
(module type A, B or C) and the number of disulphide bonds occurring within the 
module (one or two; Naismith and Sprang, 1998). CRD1, CRD2 and CRD3 of TNFR1 
and CRD1 and CRD2 of TNFR2 are composed of A1 and B2 modules. A1 modules 
have the consensus sequence Cys1-X2-Gly-X-Tyr/Phe-X-X4-9-Cys2, whereas B2 
modules have the consensus sequence Cys1-X2-Cys2-X3-6-X5-Cys3-Thr-X2-5-Asn-Thr-
Val-Cys4 (X is any aa; Naismith and Sprang, 1998). CRD3 of TNFR2 consists of an A2 
and a B1 module (Naismith and Sprang, 1998, Mukai et al., 2010). The resulting 
module compositions are A1-B2-A1-B2-A2-B1-A1-B1 for TNFR2 and A1-B2-A1-B2-
A1-B2-A1-C2 for TNFR1. The C2 module is unique to TNFR1. 
A crystal structure of the extracellular domain of TNFR1 in complex with the 
homotrimeric ligand LTα has been solved (Banner et al., 1993), in which the receptors 
bind to the grooves between the individual LTα monomers of the trimer. All receptor-
LTα contacts are mediated by CRD2 and to a lesser extent by CRD3 of TNFR1 (Banner 
et al., 1993). Homology modelling data by Fu et al. (1995) suggested similar 
interactions for TNFR1 and TNFR2 with TNF. This is in agreement with recent 
crystallography data of a TNF-TNFR2 complex, which indicated interactions of TNF 
with the A1 and B2 modules of CRD2 and the A2 module of CRD3 of TNFR2 (Mukai 
et al., 2010). 
 
Furthermore, ligand-independent oligomerisation of TNFR can occur (Chan et al., 
2000, Branschädel et al., 2010). TNFR1 and TNFR2 are thought to self-associate prior 
to ligand binding via their pre-ligand binding assembly domains (PLAD). These PLAD 
are located in CRD1, which has been shown to be not directly involved in ligand 
binding (Chan et al., 2000). Fluorescence energy transfer (FRET) data suggest that upon 
ligand binding a conformational change in the pre-assembled receptor complex takes 
place, which might affect downstream signalling (Chan et al., 2001). Deletion of CRD1 
was found to abrogate TNF binding to both TNFR1 and TNFR2 (Chan et al., 2000, 
Mukai et al., 2010). Molecular modelling data suggest that in case of TNFR1 the loss in 
TNF binding may be caused by a destabilisation of the A1 module of CRD2, which 
results from the deletion of CRD1 (Branschädel et al., 2010). For receptor activation  
TNFR pre-assembly on the cell surface alone is not sufficient but presence of the ligand 
is also required for signalling initiation. However, data from arthritis and systemic lupus 
erythematosus (SLE) mouse models highlight the importance of TNFR pre-assembly 
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for receptor activation as the use of soluble PLAD proteins interfered with both TNFR1- 
and TNFR2-mediated signalling (Deng et al., 2005, Deng et al., 2010). In addition, 
microscopical and biochemical data indicate that efficient signalling requires the 
formation of large TNF/TNFR aggregates (Krippner-Heidenreich et al., 2002, 
Schneider-Brachert et al., 2004). Thus, instead of occurring as single receptor units, 
TNFR appear to exist as pre-formed complexes on the cell surface and form vast 
clusters after ligand binding. While there is a good understanding of the biological 
functions of the first three CRD of TNFR1 and TNFR2, only little is known about the 
role of CRD4.  
 
1.3.2 Transmembrane domain and stalk region 
 
The four CRD and the transmembrane domains of TNFR1 and TNFR2, respectively, 
are separated from each other by a stretch of aa residues which is here referred to as the 
stalk region (Figure 2). This stalk region consists of 15 aa residues in TNFR1, whereas 
the stalk of TNFR2 comprises 56 aa residues. Unfortunately, neither crystallographic 
data nor information on structural functions is available for the stalk regions so far. 
Additionally, the high proline content of the stalk region of TNFR2 makes it unlikely 
that it adopts a defined secondary structure.  
 However, the stalk region might play an important role in determining the half-
life of the receptor. Both TNFR can be shed from the cell surface by membrane-bound 
TACE (Reddy et al., 2000). For TNFR2 the presence of proline 211 (proline 247 in # 
P20333), which is located in the stalk region, has been reported to be a requirement for 
PMA/LPS-induced shedding of the receptor (Herman and Chernajovsky, 1998). 
Furthermore, O-glycosylation in this region as described by Pennica et al. (1993) might 
play an important role in signalling initiation. Interestingly, O-glycosylation has also 
been reported in the stalk region of another TNFR superfamily member, TRAIL 
receptor 2 (TRAILR2/DR5)(Wagner et al., 2007).  
 Interestingly, the stalk regions of other members of the TNFR superfamily are 
also relatively diverse with, for example, short stalk regions for CD40, Fas and 
TRAILR1 and long, proline-rich stalk regions for TRAILR2, NGFR and TACI (Figure 
3). 
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TNFR1: PQIENVKGTEDSGTT 
TNFR2: STSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPA 
EGSTGD 
Fas:  EEGSRSN 
DR3:  AVCGWRQ 
TRAILR1: VHKESGNGHN 
TRAILR2: VHKESGTKHSGEAPAVEETVTSSPGTPASPCS 
DCR1: PAAEETMNTSPGTPAPAAEETMNTSPGTPAPAAEETMTTSPGTPAPAAEE 
TMTTSPGTPAPAAEETMITSPGTPA 
DCR2: KNESAASSTGKTPAAEETVTTILGMLASPYH 
DR6: GTLPSFSSSTSPSPGTAIFPRPEHMETHEVPSSTYVPKGMNSTESNSSASV 
RPKVLSSIQEGTVPDNTSSARGKEDVNKTLPNLQVVNHQQGPHHRHILKLL 
PSMEATGGEKSSTPIKGPKRGHPRQNLHKHFDINEHL 
EDAR: APPNTKECVGATSGASANFPGTSGSSTLSPFQHAHKELSGQGHLATA 
NGFR: EIPGRWITRSTPPEGSDSTAPSTQEPEAPPEQDLIASTVAGVVTTVMGSSQ 
PVVTRGTTDN 
RANK: SSSLPARKPPNEPHVYLP 
LTβR: NPLEPLPPEMSGTMLM 
CD27: PTHLPYVSEMLEARTAGHMQTLADFRQLPARTLSTHWPPQRSLCSSDFIR 
CD30: DTTFEAPPLGTQPDCNPTPENGEAPASTSPTQSLLVDSQASKTLPIPTSAP 
VALSSTGK 
CD40: PQDRLR 
4-1BB: PSPADLSPGASSVTPPAPAREPGHSPQ 
OX40: DRDPPATQPQETQGPPARPITVQPTEAWPRTSQGPSTRPVEVPGGRA 
GITR:  VPGSPPAEP 
BCMA: NASVTNSVKGTNA 
TACI: CENKLRSPVNLPPELRRQRSGEVENNSDNSGRYQGLEHRGSEASPALPG 
LKLSADQV ALVYS 
BAFFR: GLLRTPRPKPAGASSPAPRTALQPQESVGAGAGEAALPLPGLL 
XEDAR: AFQLSLVEADTPTVPPQEAT 
TROY: ASKVNLVKIASTASSPRDTAL 
RELT: GDCWPGWFGPWGVPRVPCQPCSWAPLGTHGCDEWGRRARRGVEVAA 
GASSGGETRQPGNGTRAGGPEETAAQ 
 
Figure 3. Overview of TNFR superfamily member stalk regions.  
Shown are the aa sequences of the indicated TNFR superfamily member stalk regions. 
Sequences were retrieved from UniProt KB and the corresponding accession numbers are stated 
in brakets: TNFR1 (P19438), TNFR2 (P20333), Fas (P25445), DR3 (Q93038), TRAILR1 
(O00220), TRAILR2 (O14763), DCR1 (O14798), DCR2 (Q9UBN6), DR6 (O75509), EDAR 
(Q9UNE0), NGFR (P08138), RANK (Q9Y6Q6), LTβR (P36941), CD27 (P26842), CD30 
(P28908), CD40 (P25942), 4-1BB (Q07011), OX40 (P43489), GITR (Q9Y5U5), BCMA 
(Q02223), TACI (O14836), BAFFR (Q96RJ3), XEDAR (Q9HAV5), TROY (Q9NS68), RELT 
(Q969Z4). 
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The predicted transmembrane domains (TM) of TNFR1 and TNFR2 are 23 and 30 aa 
residues long, respectively. Little is known about their function in signalling so far. 
However, data from erythropoetin receptor/TNFR2 chimaeras showed that the 
transmembrane domain of TNFR2 is essential for signal transduction (Declercq et al., 
1995). 
 
1.3.3 Intracellular domains of TNFR1 and TNFR2 
 
Depending on their intracellular domain, the members of the TNFR superfamily are 
divided into two groups, the death receptors containing a death domain (DD) and the 
gene inductory receptors containing at least one binding domain for TNF receptor-
associated factor (TRAF) family members. The TNFR1 DD (Figure 2) is 85 aa residues 
long and located at the intracellular C-terminus of the receptor (Tartaglia et al., 1993a). 
Furthermore, TNFR1 contains a so called TNFR1 internalisation domain (TRID), which 
is located adjacent to the TM region. Within this domain a YXXW motif has been 
found to essential for ligand-induced receptor internalisation (Schneider-Brachert et al., 
2004).  
Receptor internalisation upon stimulation has also been described for TNFR2. 
Here internalisation was found to be mediated by a di-leucine motif (L319/L320; 
Fischer et al., 2011). In contrast to TNFR1, TNFR2 does not contain a DD but C-
terminal TNF receptor associated factor 2 (TRAF2)-binding domains instead (Rothe et 
al., 1995, Park et al., 1999, Grech et al., 2005). C-terminal of these TRAF2 binding 
domains a 16 aa domain has been described, which interacts with endothelial/epithelial 
tyrosine kinase (Etk). Etk is involved in TNF-mediated angiogenic events in vascular 
endothelial cell migration (Pan et al., 2002). Furthermore, a PEST (proline, glutamic 
acid, serine, threonine) sequence in the cytoplasmic tail of TNFR2 has been identified. 
As PEST sequences are thought to mediate proteasomal degradation, the presence of 
this sequence might affect the half life of the receptor (Carpentier et al., 2004).  
The described cytoplasmic domains of the TNFR do not appear to determine the 
differential responsiveness of the receptors towards sTNF. This could be shown in a 
TNFR-Fas chimaera cellular system, in which the intracellular domains of TNFR1 and 
TNFR2 were replaced with an intracellular Fas domain (Krippner-Heidenreich et al., 
2002). However, although the cytoplasmic domains play a minor role in differential 
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responsiveness of the receptors, they are essential for the transmission of initial signals 
to adaptor proteins and the activation of different signalling pathways. 
 
 
1.4 TNF/TNFR-mediated signalling 
 
Upon binding of TNF to its receptors a wide range of different signalling pathways can 
be activated. Depending on which signalling pathway prevails, the cell either undergoes 
apoptosis or survives through counteracting processes. The signalling events following 
TNFR1 stimulation are better understood than the ones occurring upon TNFR2 
engagement. Due to their complexity, however, only an overview of the three best 
characterised TNFR1 pathways, namely the caspase- and mitogen-activated protein 
kinase-(MAPK) dependent pro-apoptotic and the nuclear factor κB (NF-κB)-dependent 
anti-apoptotic signalling pathways, will be given in the following section.  
While MAPK and NF-κB activation have been described to occur while the 
TNFR1 signalling complex exists at the cell surface, TNFR1-mediated caspase pathway 
activation only occurs after receptor internalisation (Micheau and Tschopp, 2003, 
Schneider-Brachert et al., 2004). These signalling complexes differ not only in their 
cellular localisation but also in their molecular composition. The complex at the plasma 
membrane contains the signalling adapter molecules TNFR-associated death domain 
(TRADD) protein, receptor-interacting protein 1 (RIP1) and TRAF2. Data on the 
signalling complex forming upon TNFR1 internalisation are controversial and two 
different models have been proposed. In the model described by Micheau and Tschopp 
TRADD, RIP1 and TRAF2 dissociate from TNFR1 and form a cytoplasmic complex 
with Fas-associated death domain (FADD) and caspases-8 and -10 (Micheau and 
Tschopp, 2003). In contrast, in the complex proposed by Schneider-Brachert et al. the 
adaptor proteins TRADD, FADD and caspase-8 associate with the internalised TNFR1 
in endosomal compartments which were referred to as TNFR1 receptosomes 
(Schneider-Brachert et al., 2004, Schütze et al., 2008). 
 
  
12 
 
1.4.1 Anti-apoptotic TNFR1 signalling through NF-κB activation  
 
Binding of TNF to TNFR1 can lead to anti-apoptotic signalling through activation of 
NF-κB. In mammalian cells, the five NF-κB family members RelA (p65), RelB, c-Rel, 
p50/p105 (NF-κB1) and p52/p100 (NF-κB2) can form different NF-κB complexes from 
their homo- and heterodimers (reviewed in Hoffmann et al., 2006). In the majority of 
cell types, these NF-κB complexes are retained in the cytoplasm by members of the 
inhibitors of NF-κB (IκB) protein family. In mammalian cells the three principal IκB, 
IκBα, IκBβ and IκBγ, mask NF-κB DNA binding and nuclear translocation sequences 
via their ankyrin repeat domain (reviewed in Basak and Hoffmann, 2008).  
Activation of TNFR1 leads to the activation of NF-κB/p50-p65 dimers through 
the so called canonical pathway (Basak and Hoffmann, 2008). Upon stimulation, 
TRADD and RIP1 are recruited into the TNFR1 signalling complex at the plasma 
membrane (Figure 4). The recruitment of RIP1 is mediated through homotypic 
interactions between the death domains of TRADD and RIP1 (Hsu et al., 1996a). 
However, also TRADD-independent, competitive association of RIP1 with TNFR1 has 
been reported (Zheng et al., 2006, Jin and El-Deiry, 2006). In addition, TRAF2 can be 
recruited to the N-terminus of TRADD via its TRAF2 domain (Hsu et al., 1996b). Upon 
binding to TRADD, TRAF2 can be auto-ubiquitinated and was thought to induce poly-
ubiquitination of RIP1. However, recent studies found the K63-linked poly-
ubiquitination of RIP1 to be mediated by the cellular inhibitor of apoptosis proteins 
(cIAP) 1 and 2 (Varfolomeev et al., 2008), which are associated with TRAF2 via its N-
terminal c-IAP interaction motif (Vince et al., 2009). Once ubiquitinated, RIP1 then 
supports the assembly and activation of a TAK1/TAB (TAK1/TAK1 binding protein) 
complex (Varfolomeev and Vucic, 2008).  
TAK1 is able to phosphorylate and activate the IκB kinase (IKK) complex. The 
activation of IKK1 and IKK2 of the IKK-complex leads to the phosphorylation of IκBα 
at S32 and S36 and the phosphorylation of IκBβ at S19 and S23 (Mercurio et al., 1997, 
Woronicz et al., 1997, Zandi et al., 1997, Wu and Ghosh, 2003). The phosphorylation 
targets IκBα for K48-linked ubiquitination at K21 and K22 and subsequent proteasomal 
degradation (Alkalay et al., 1995, Rodriguez et al., 1996, Perkins, 2006). IKKγ, also 
known as NF-κB essential modulator (NEMO), functions as regulatory subunit in the 
NF-κB activation process (Perkins, 2006) and K63-linked ubiquitination of NEMO has 
been proposed to be essential for IKK1/IKK2 activation (Zhou et al., 2004). 
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Furthermore, recently linear ubiquitination of NEMO by a linear ubiquitin chain 
assembly complex (LUBAC) consisting haem-oxidised IRP2 ubiquitin ligase-1 (HOIL-
1) and HOIL-1-interacting protein (HOIP) has been described (Tokunaga et al., 2009). 
Recruitment of LUBAC to the TNFR1 signalling complex, possibly mediated via 
cIAP1/2 K63-linked ubiquitin chains, has been proposed to stabilise the TNFR1 
signalling complex by acting as a scaffolding platform (Haas et al., 2009). 
Proteasomal degradation of IκBα leads to the release of NF-κB, which can then 
translocate to the nucleus and finally induce transcription of TNF/NF-κB regulated 
genes such as manganese superoxide dismutase (Mn-SOD) and A20 (Figure 4), which 
regulate the JNK pathway negatively at different levels. A20, for example, inhibits the 
activation of JNK by attenuating TRAF2 function (reviewed in Papa et al., 2006). 
Additionally, NF-κB induces the transcription of further anti-apoptotic factors such as 
cellular Fas-associated protein with death domain-like IL-1β-converting enzyme 
inhibitory proteins (cFLIP) and X-chromosome linked inhibitor of apoptosis protein 
(XIAP), thereby promoting cell survival (Kreuz et al., 2001, Micheau et al., 2001, 
Stehlik et al., 1998). 
 
The importance of RIP1 and TRAF proteins in TNFR1 signalling have been highlighted 
by data obtained from mouse knockout models. These indicated that RIP1 is absolutely 
required for NF-κB and JNK activation (Ting et al., 1996). In contrast, TRAF2 was 
found to be only crucial for the activation of JNK but appeared to be dispensable for 
NF-κB responses (Yeh et al., 1997, Tada et al., 2001a). Another member of the TRAF 
protein family, TRAF5, has also been implicated in TNFR1-mediated NF-κB signalling. 
TNF-induced NF-κB nuclear translocation is impaired in traf2-/- traf5-/- double knockout 
but not the corresponding single knockout mice, suggesting both, a critical role and a 
certain redundancy for TRAF2 and TRAF5 (Tada et al., 2001a). TRAF5 was found to 
interact with RIP1 and, like TRAF2, appears to play a role in both, NF-κB and JNK 
activation (Tada et al., 2001a). However, in contrast to data presented by Tada et al. 
(2001a), more recent data indicate that TRAF2 is not dispensable for the activation of 
the canonical NF-κB pathway as it is required for efficient recruitment of cIAP and IKK 
to the TNFR1 signalling complex (Devin et al., 2000, Vince et al., 2009). 
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Figure 4. Schematical representation of TNFR1-mediated anti-apoptotic NF-κB and pro-
apoptotic JNK signalling crosstalk. 
TNFR-associated death domain (TRADD) is recruited to the TNFR1 death domain (DD) and 
can recruit receptor interacting protein 1 (RIP1), TNF receptor associated factor 2 (TRAF2) and 
cellular inhibitor of apoptosis proteins (cIAP1/cIAP2). K63-linked ubiquitination (K63-Ub) of 
RIP1 by cIAP recruits transforming growth factor β activated kinase 1 (TAK1) and TAK1 
binding proteins 2/3 (TAB2/3) to RIP1. Upon recruitment to the TNFR1 signalling complex, 
TAK1 becomes autophosphorylated and phosphorylates inhibitor of NF-kB (I-kB) kinases 
(IKK). Haem-oxidised IRP2 ubiquitin ligase-1 (HOIL-1) and HOIL-1-interacting protein 
(HOIP) mediate linear ubiquitination of NF-κB essential modulator (NEMO), which serves as a 
regulatory compound. The IKK then cause phosphorylation and subsequent proteasomal 
degradation of I-kBα, leading to the release and nuclear translocation of p50/p65.  
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Alternatively, TNF-stimulation can lead to the activation of the JNK signalling 
pathway. Here MAPK kinase kinases (MAPKKK) such as MAP/ERK kinase kinase 1 
(MEKK1), apoptosis-signal regulating kinase (ASK1) or TAK1 are activated, putatively in a 
reactive oxygen species (ROS)-dependent manner by TRAF2 (Dhanasekaran and Reddy, 2008), 
and activate MAPKK such as MKK4 and/or MKK7. The MAPKK then phosphorylate JNK, 
which translocates to the nucleus and activates AP-1-regulated genes. 
NF-κB regulated gene products such as A20, ferritin heavy chain (FHC), manganese 
superoxide dismutase (Mn-SOD) and growth arrest and DNA damage protein 45β (Gadd45β) 
function as negative regulators at various levels of the JNK pathway by, for example, 
counteracting the production of ROS (diagram was adopted from Papa et al., 2006, 
Varfolomeev and Vucic, 2008, Haas et al., 2009, and modified). 
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1.4.2 Pro-apoptotic signalling of TNFR1 
 
1.4.2.1 Mitogen-activated protein kinase cascade  
 
Stimulation of TNFR1 with TNF can alternatively lead to MAPK pathway-mediated 
cell death. Prominent MAPK kinase kinases (MAPKKK) of the c-Jun N-terminal kinase 
(JNK) cascade comprise apoptosis-signal regulating kinase 1 (ASK-1), MAP/ERK 
(extracellular signal-regulated kinase) kinase kinases (MEKK) and TAK1. As depicted 
in Figure 4, these MAPKKK activate MAP kinase kinases (MKK) 4 and/or MKK7, 
which in turn activate JNK (Derijard et al., 1995, Moriguchi et al., 1997, Tournier et al., 
1997, Wu et al., 1997, Yao et al., 1997). Subsequently, the activated JNK translocates 
to the cell nucleus where it phosphorylates and transactivates c-Jun. c-Jun 
phosphorylation then leads to the formation of activator protein 1 (AP-1) and 
transcription of pro-apoptotic AP-1 target genes (reviewed in Dhanasekaran and Reddy, 
2008). As reported by Fan et al. (2010), K63-linked poly-ubiquitination of TAK1 seems 
to play a pivotal role in this JNK-mediated activation of AP-1. 
Reactive oxygen species (ROS) have been found to function as important 
mediators in the JNK cascade. The exact mechanism by which ROS trigger TNF 
induced apoptosis is not clear, but they possibly prolong activation of the JNK cascade 
(reviewed in Papa et al., 2006) and ROS-dependent activation of ASK1 by TRAF2 
appears to play a role (Dhanasekaran and Reddy, 2008). 
JNK signalling has been reported to promote apoptosis via the mitochondria-
dependent pathway of type II cells (see following section) by inactivating anti-apoptotic 
and activating pro-apoptotic members of the B-cell lymphoma protein-2 (Bcl-2) family 
of proteins. UV-induced phosphorylation of JNK was described to lead to release of the 
pro-apoptotic Bcl2 proteins Bim and Bmf, which link JNK signalling to the Bax/Bak-
dependent mitochondrial apoptosis pathway (Lei and Davis, 2003). In addition, JNK 
can induce an alternative, caspase-8 independent cleavage of Bid to a variant termed j-
Bid (Deng et al., 2003). j-Bid leads to the release of Smac (second mitochondrial 
activator of caspases) from the mitochondria and it has been proposed by Deng et al. 
(2003) that Smac then causes disruption of the TRAF2/cIAP complex and subsequent 
activation of caspase-8 and induction of apoptosis.  
However, activation of the JNK pathway has also been found to be associated 
with anti-apoptotic functions, such as the deactivation of pro-apoptotic Bcl-2 family 
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proteins. These controversial findings have been ascribed to the fact, that TNF 
stimulation does not only induce JNK signalling but also the anti-apoptotic NF-κB 
pathway (see section 1.4.1 and Figure 4) and that crosstalk between these two signalling 
pathways ultimately affects whether cells survive or undergo apoptosis. In this context 
MKK4 and TAK1 have been proposed to represent nodal points between pro-apoptotic 
JNK-signalling and activation of the NF-κB signalling pathway via, for example, 
Akt/PKB kinases (Sethi et al., 2007, Fan et al., 2010). 
 
Another member of the MAPK family which can be activated by TNF is p38 MAPK. 
Data obtained from Mkk3
−/−
/Mkk6
−/−
 fibroblasts suggest that this TNF-mediated 
activation requires MKK3 and MKK6 as p38 MAPK activation occurs only in wild type 
but not the knockout cells (Brancho et al., 2003). p38-mediated activation of 
transcription factors such as activating transcription factors (ATF) 1, 2 and 6, p53 and 
myocyte enhance factor 2 C (MEF2C) has been reported and p38 also indirectly 
regulates AP-1 activity (reviewed in Zarubin and Han, 2005, Nakano et al., 2006). 
 
1.4.2.2 Caspase-dependent pathways 
 
As mentioned above, upon TNF-binding TRADD protein, TRAF2 and RIP1 are 
recruited to the death domain of TNFR1 and this complex can signal via the NF-κB and 
MAPK pathways, respectively (sections 1.4.1 and 1.4.2.1). However, upon subsequent 
internalisation of the TNFR1 signalling complex the TRADD/TRAF2/RIP1 complex is 
disrupted (Schütze et al., 2008) and the adaptor proteins FADD (Micheau and Tschopp, 
2003) and procaspase-8 (Boldin et al., 1996, Muzio et al., 1996) are recruited to 
TRADD. TNFR1 and the recruited proteins together constitute the death-inducing 
signalling complex (DISC, Figure 5). DISC formation has already been described for 
Fas (Kischkel et al., 1995). However, while Fas-mediated caspase activation can also 
occur in signalling complexes still located at the plasma membrane, formation of the 
TNFR1 DISC was found to depend upon the internalisation of TNFR1 after ligand 
binding (Schneider-Brachert et al., 2004, Schütze et al., 2008). 
Caspase-8, a member of a family of cysteine proteases, is expressed as the 
precursor procaspase-8. As proposed by Chang et al. (2003), procaspase-8 becomes 
auto-proteolytically activated by interdimer processing upon recruitment into the DISC. 
Caspase-8 then serves as an initiator caspase, which proteolytically cleaves and thereby 
activates effector caspases (reviewed in Riedl and Shi, 2004). Depending on the cell 
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type, caspase-8 leads to activation of different signalling pathways (Scaffidi et al., 
1998). In type I cells, such as the B-lymphoblastoid SKW6.4 cell line (Algeciras-
Schimnich et al., 2003), the high level of caspase-8 directly mediates activation of 
procaspase-3 to caspase-3, which then leads the proteolytical cleavage of cellular 
components and eventually to the induction of apoptosis. In contrast, the caspase-8 level 
in type II cells, such as the T-lymphoblastoid Jurkat cell line (Algeciras-Schimnich et 
al., 2003) is low and requires an amplification of the signal via the mitochondria. Type 
II signalling involves cleavage of the Bcl-2 family protein Bid (BH3 interacting domain 
death agonist) to its truncated form t-Bid by caspase-8 (Li et al., 1998). t-Bid is 
translocated to the mitochondria where it is thought to directly or indirectly activate the 
pro-apoptotic Bcl-2 proteins Bax and Bak (Letai et al., 2002, Willis and Adams, 2005, 
Willis et al., 2005, Willis et al., 2007). This activation leads to the release of 
cytochrome C from the mitochondria. Cytochrome C can bind to the WD40 region of 
apoptotic protease activating factor 1 (Apaf-1), thereby releasing Apaf-1 from its auto-
inhibited state. Seven of the Apaf-1 molecules, which have bound cytochrome C, can 
then assemble into a wheel-like structure termed the apoptosome (Riedl and Salvesen, 
2007). Caspase-9 becomes activated within the apoptosome and in turn activates 
caspase-3 and caspase-7, which then, as described for type I cells, can initiate apoptosis 
(reviewed in Riedl and Salvesen, 2007, Schütze et al., 2008).  
 
Both, the type I and type II signalling pathways can be regulated at the level of DISC 
formation by cFLIP. The three cFLIP isoforms, cFLIPL, cFLIPS and cFLIPR, have been 
reported to inhibit death receptor mediated apoptosis by modulating caspase-8 
activation, although also pro-apoptotic functions of cFLIPL have been described (Yu 
and Shi, 2008). XIAP can directly inhibit the activation of caspase-9 (Eckelman et al., 
2006) while this appears not to be the case for cellular inhibitor of apoptosis proteins 
(cIAP) 1 and 2, which rather counteract apoptosis via their E3 ubiquitin ligase activity. 
cIAP1-mediated proteasomal degradation of caspase-3 and caspase-7 has been reported 
(Choi et al., 2009) and data from IAP inhibitor experiments indicate that cIAP1 also 
controls the non-canonical NF-κB pathway at the level of NF-kB-inducing kinase 
stability (NIK; Varfolomeev et al., 2007, Vince et al., 2007). Furthermore, cIAP1 and 
cIAP2 mediate K63-linked ubiquitination of RIP1, which is in turn required for binding 
of transforming growth factor-β activated kinase 1 (TAK1) and activation of anti-
apoptotic pathways (Bertrand et al., 2008).  
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Figure 5. DISC formation and caspase-dependent signalling of TNFR1. 
Upon TNF-mediated receptor endocytosis TNFR1 receptosomes are formed, in which the death 
inducing signalling complex (DISC) is assembled. The DISC consists of TNFR1, TNFR-
associated death domain (TRADD) and Fas-associated death domain (FADD), which all three 
contain a DD, and caspase-8. In both, type I cells and type II cells, DISC formation leads to the 
activation of caspases and apoptosis. Caspase activation in type II cells, however, does require 
an amplification of the signal via the mitochondrial pathway with apoptotic protease activating 
factor 1 (Apaf-1) and truncated Bid (tBid) being important components. X-chromosome linked 
inhibitor of apoptosis protein (XIAP), cellular inhibitor of apoptosis protein (cIAP), cellular 
FLICE inhibitor protein (cFLIP), B-cell lymphoma protein-2 (Bcl-2) and B-cell lymphoma-
extra large protein (Bcl-xL) regulate the apoptotic pathway negatively (Graphic was adopted 
from Schneider-Brachert et al., 2004, Schütze et al., 2008). 
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1.5 TNFR2-mediated signalling and crosstalk between TNFR1 and 
TNFR2 
 
Similar to TNFR1, for TNFR2 TRAF2-dependent activation of the NF-κB and JNK 
pathways has been described (Rothe et al., 1995, Reinhard et al., 1997) and, 
furthermore, data from tnfr1
-/-
 knockout murine fibroblasts revealed TNFR2-mediated 
activation of ERK1/ERK2 (Kalb et al., 1996, Reinhard et al., 1997). In TNFR2-
mediated MAPK signalling c-IAP1 appears to play an important role. c-IAP1 gets 
activated upon stimulation of TNFR2 and mediates ubiquitination and degradation of 
TRAF2 (Li et al., 2002). In addition, TNFR2 stimulation leads to degradation of ASK1 
in Jurkat cells as well as B-cells from c-iap1
-/-
 knockout mice, further showcasing 
TNFR2-mediated activation of the MAPK pathways (Zhao et al., 2007).  
Recent evidence emerged, that the ability of TNFR2 to induce the JNK 
signalling pathway might be affected by its ubiquitination through the E3 ubiquitin 
ligase Smurf2 (Carpentier et al., 2008). In an overexpression system, Smurf2-mediated  
ubiquitination was found to cause a redistribution of the receptor within the membrane 
to detergent-insoluble cell fractions and this redistribution seemed to effect the selective 
activation of the JNK pathway.  
Furthermore, TNFR2 is capable of facilitating or inducing apoptosis indirectly 
and two possible mechanisms have been described so far. Firstly, TNFR2 was described 
to exert its apoptotic action via the induction of endogenous TNF, which then 
subsequently activates TNFR1 (Vercammen et al., 1995, Grell et al., 1999). Secondly, a 
TRAF2-dependent intracellular mechanism, which is independent of endogenous TNF 
but also enhances TNFR1-mediated signalling for apoptosis, has been described 
(Declercq et al., 1998, Chan and Lenardo, 2000). Fotin-Mleczek et al. (2002) showed 
that co- and pre-stimulation of TNFR2 enhanced TNFR1-induced caspase-8 activation 
and proposed that this is due to a TNFR2-mediated depletion of TRAF2. In several 
publications TRAF2 recruitment to detergent-insoluble membrane compartments upon 
TNFR2 stimulation has been described (Li et al., 2002, Wu et al., 2005, Wicovsky et 
al., 2009). TRAF2 recruitment to TNFR2 would consequently lead to a decreased 
availability of the TRAF2-cIAP complex for TNFR1. As this complex is required for 
efficient induction of anti-apoptotic NF-κB activation of the latter (section 1.4.1), this 
decreased availability promotes the caspase-dependent TNFR1 signalling pathways. A 
TRAF family member which has recently been described to antagonise the recruitment-
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dependent depletion and subsequent proteasomal degradation of TRAF2 is TRAF1. 
TRAF1 can rescue TNFR1-mediated activation of NF-κB and JNK in TNFR2-
prestimulated Colo205 cells to at least some extent (Wicovsky et al., 2009). 
 
In contrast to TNFR1, for TNFR2 in addition to activation of the canonical NF-κB 
pathway (Rothe et al., 1995, Krippner-Heidenreich et al., 2002, Marchetti et al., 2004, 
Fischer et al., 2011) also TNFR2-mediated signalling via the non-canonical NF-κB 
pathway has been reported. Stimulation with oligomerised TNFR2-selective TNF has 
been proposed to result in the accumulation of NIK by preventing 
TRAF2/cIAP1/cIAP2-mediated NIK degradation in HeLa cells expressing exogenous 
TNFR2 (NIK; Rauert et al., 2010). This accumulation of NIK was further described to 
lead to NEMO-mediated processing of the NF-κB subunit p100 to p52 and to the 
nuclear translocation of the latter.  
 
 
1.6 TNF and TNFR in health and disease  
1.6.1 Physiological implications for sTNF and membrane-bound TNF 
 
As mentioned in section 1.2, TNF can exert its biological functions as both soluble and 
membrane-bound ligand. However, depending on which form TNF exists in these 
functions can differ. TNF has, for example, been implicated to be an important regulator 
of the micro-architecture and function of secondary lymphoid tissues. Studies from tnf
-/-
 
mice showed that TNF is required for the formation of germinal centres as well as 
development and organisation of lymph nodes and spleen (Marino et al., 1997, Körner 
et al., 1997). Like tnf
–/–
 mice, transgenic mice which only express membrane-bound 
TNF fail to form organised germinal centres and follicular dendritic cell networks, 
highlighting not only an important role for sTNF in lymphoid tissue development 
(Alexopoulou et al., 2006) but also the divergent biological functions of the soluble and 
membrane-bound forms of the ligand. 
Moreover, the divergent roles for sTNF and membrane-bound TNF become 
apparent in the context of host defence against pathogens. Transmembrane TNF was 
found to be sufficient to mediate immunity and resistance to infections with Bacillus 
Calmette-Guérin (BCG), a strain of the attenuated Mycobacterium bovis (Olleros et al., 
2002). In the absence of sTNF, membrane-bound TNF was capable of sufficiently 
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controlling acute but not chronic infections with Mycobacterium tuberculosis (Saunders 
et al., 2005). Furthermore, studies on D-galactosamine/LPS-induced and BCG/LPS-
induced liver injury in transgenic mice together with TNF inhibitor data support a role 
for sTNF but not membrane-bound TNF in liver granuloma formation and hepatitis 
(Nowak et al., 2000, Olleros et al., 2010). Similarly, membrane-bound TNF was able to 
confer immunity against low doses of Listeria monocytogene , but sTNF was found to 
be required for a full protective inflammatory response to the pathogen (Torres et al., 
2005, Musicki et al., 2006).  
While these data demonstrate the diversity of sTNF and membrane-bound TNF 
functions, the underlying mechanisms for these differences are not very well understood 
to date. 
 
1.6.2 Divergent roles of TNFR1 and TNFR2 in health and disease 
 
As already indicated above, TNF and its receptors play important roles in the immune 
system. In animal studies it was shown that TNF, TNFR1 and TNFR2 are involved in 
the development of germinal centres and Peyer‟s patches (Marino et al., 1997, 
Neumann et al., 1996) and important roles in the proliferation and migration of immune 
cells have been described. While some of the biological functions of TNF are mediated 
by both of its receptors, also divergent roles have been reported for TNFR1 and TNFR2.  
 
1.6.2.1   Modulation of immune tolerance by TNFR2  
 
Given that cells of the immune system represent one of the few cellular subsets where 
TNFR2 expression can be observed (reviewed in Faustman and Davis, 2010), it is not 
surprising that this receptor exerts specific functions in immunity. Results from mouse 
knockout models, for example, indicate a role for TNFR2 but not TNFR1 in the 
promotion of thymocyte proliferation (Tartaglia et al., 1991, Tartaglia et al., 1993b, 
Grell et al., 1998a) and TNFR2 has been described to function as an important co-
stimulator during antigen-driven differentiation and expansion of CD4
+
 and CD8
+
 T-
cells (Kim and Teh, 2001, Aspalter et al., 2003, Kim et al., 2006). Kim et al. (2006) 
propose an anti-apoptotic role for TNFR2 and suggest that this receptor controls T-cell 
survival after T-cell expansion is initiated.   
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Furthermore, involvement of TNFR2 in the maintenance and balance of immune 
tolerance has been reported. Forkhead box P3 (FoxP3) protein positive CD4
+
CD25
+
 
regulatory T-cells (Treg) constitute the major Treg population in the human immune 
system, which controls maintenance of self-tolerance and immune homeostasis. Studies 
on FoxP3
+
-deficient mice and humans who carry mutations in the foxp3
 
gene, 
respectively, showed that the absence of functional FoxP3
+
CD4
+
CD25
+
 Treg results in 
immune system dysregulation and the development of autoimmunity. This 
autoimmunity has been proposed to arise as a result of an imbalance in the control of 
pathogenic auto-reactive T-cells by FoxP3
+
CD4
+
CD25
+
 Treg (reviewed in Miyara and 
Sakaguchi, 2011). In the context of regulatory and auto-reactive T-cells divergent roles 
have been proposed for TNFR2. Valencia et al. (2006) found TNF- and TNFR2-
agonistic antibody-mediated stimulation of TNFR2 to down-regulate FoxP3 expression 
and inhibit the suppressive function of human FoxP3
+
CD4
+
CD25
+
 Treg, thereby 
modulating immune reactivity. This down-regulation of the suppressive 
FoxP3
+
CD4
+
CD25
+
 Treg function appears to result from TNFR2-mediated activation of 
the canonical NF-κB pathway and can be inhibited through co-treatment with anti-
TNFR2 blocking antibodies (Nagar et al., 2010). In contrast, TNFR2 was described to 
be a cell surface marker for a more suppressive subset of the FoxP3
+
CD4
+
CD25
+
 Treg 
population in a murine model of lung carcinoma (Chen et al., 2008). In this model, 
TNFR2 cell surface expression on a CD4
+
FoxP3
-
 subset of conventional T-cells (Tconv) 
was described to lead to an increased resistance of these Tconv cells towards suppression 
by Treg cells. This resistance could, however, be overcome by the aforementioned 
TNFR2-positive subset of FoxP3
+
CD4
+
CD25
+
 Treg cells (Chen et al., 2010). How the 
different findings from these studies relate to each other remains yet to be determined. 
However, together with data from Ban et al. (2008), who observed TNFR2-mediated 
killing of insulin-specific auto-reactive CD8
+
 T-cells of type I diabetes patients, these 
studies highlight the role of TNFR2 as an important regulatory modulator in immunity 
and suggest that TNFR2 might be a promising target in the therapy of autoimmune 
diseases and cancer. 
 
1.6.2.2   Involvement of TNFR1 and TNFR2 in host defence 
 
In addition to its well described function as a pro-inflammatory cytokine, TNF has been 
found to be involved in mediating resistance against various bacterial infections (see 
also section 1.6.1). Studies on mice deficient in TNFR1 revealed that this receptor is 
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required to clear infections with intracellular pathogens such as Listeria monocytogenes, 
Mycobacterium tuberculosis, Leishmania major and Trypanosoma cruzi (Rothe et al., 
1993, Pfeffer et al., 1993, Nashleanas et al., 1998, Castanos-Velez et al., 1998).  
Granuloma formation, which is important for modulating the growth of 
Mycobacterium and clearing the infection, was found to be impaired in tnfr1
-/-
 mice 
(Ehlers et al., 2000). As shown recently by Clay and co-workers (2008), similar 
protective effects of TNF in early infection with Mycobacterium tuberculosis, involving 
modulation of bacterial growth and macrophage death, also hold true in a zebra fish 
tuberculosis model. Unfortunately, it has not yet been described, whether these 
functions involve TNFR1, TNFR2 or are mediated by both TNFR. Increased severity of 
inflammatory lesions has been reported in tnfr1
-/-
 mice after infection with 
Trypanosoma cruzi and Legionella pneumophila, respectively (Fujita et al., 2008, 
Nashleanas et al., 1998). The lesions upon infection with Legionella pneumophila have 
been proposed to be a result of a delayed clearance of the pathogens from the lung 
leading to severe inflammation (Fujita et al., 2008). Therefore, in these studies TNFR1 
was proposed to play an important role in the control of the infection (Castanos-Velez et 
al., 1998, Fujita et al., 2008). In contrast, corresponding experiments with tnfr2-/- mice 
indicated that TNFR2 is required to control inflammation and appears to rather have an 
anti-inflammatory function during infections with Legionella pneumophila (Fujita et al., 
2008).  
While TNF is helping to contain and remove local infections, its actions have, 
however, been found to be detrimental when infections become systemic as the cytokine 
was discovered to trigger septic shock (Beutler et al., 1985, Tracey et al., 1987). Studies 
on tnfr1
-/-
 mice showed that it is TNFR1 which is critically involved in mediating septic 
shock (Pfeffer et al., 1993, Rothe et al., 1993).  
 
1.6.3 TNFR1 and TNFR2 in the central nervous system 
 
In the central nervous system (CNS), TNF regulates physiological processes such as 
neuronal development, cell survival and synaptic transmission and, furthermore, 
represents an important mediator of inflammation (reviewed in Park and Bowers, 2010). 
It is produced in response to various insults to the CNS, including bacterial and viral 
infections, physical damage and oxygen-glucose deprivation, the latter occurring during 
ischaemic conditions associated with stroke. Dysregulation of inflammatory responses 
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in the CNS has been proposed to underlie the pathogenesis of neuronal diseases (Park 
and Bowers, 2010). 
Primary demyelination is a hallmark of several inflammatory diseases of the 
CNS, such as multiple sclerosis (MS). It involves the destruction and phagocytosis of 
myelin by activated microglia/macrophages (Martin et al., 1992) and can be 
accompanied by apoptosis of the myelin sheath-forming oligodendrocytes. Earlier 
studies had shown that the expression of TNF is up-regulated in active MS lesions 
(Hofman et al., 1989) and, that TNF levels in the cerebrospinal fluid of patients 
correlated with MS disease severity (Sharief and Hentges, 1991). Using transgenic mice 
which were deficient in TNFR1 and expressed human membrane-bound TNF on 
astrocytes, Akassoglou et al. (1998) could show that it is TNFR1 which mediates 
oligodendrocyte apoptosis, primary inflammatory demyelination and the generation of 
MS-type plaques. Moreover, in a humanised model, in which membrane-bound human 
TNF was also expressed by astrocytes, Akassoglou et al. (2003) went on to show that 
the inflammation is mediated through both, TNFR1 and TNFR2. The activation of 
TNFR2 expressed by endothelial cells was described to cause inflammation and 
development of neuropathology. In contrast, using mice which were deficient in TNFR1
 
but expressed human TNFR2 together with the non-cleavable membrane-bound TNF 
variant on astrocytes, the exclusive role for TNFR1 in TNF-mediated apoptosis of 
oligodendrocytes and primary demyelination could be further confirmed (Akassoglou et 
al., 2003). In line with these findings, data from a murine experimental autoimmune 
encephalomyelitis model indicate that rather sTNF than membrane-bound TNF 
determines MS pathology (Alexopoulou et al., 2006). Exclusive expression of 
membrane-bound TNF was found to suppress disease onset and progression while TNF-
mediated suppression of autoimmunity and resistance to infections with intracellular 
pathogens was sustained. 
In contrast to the inflammatory diseases affecting the CNS, inflammation has 
been reported to play a positive role in ischaemia-induced neurogenesis and increased 
neurogenesis has been described for several models of inflammation (reviewed in 
Whitney et al., 2009). An involvement of TNF in neuroregeneration after ischaemic 
injury has been suggested as treatment with anti-TNF antibodies two weeks after the 
ischaemic insult was shown to abolish hippocampal neurogenis in a rat model for stroke 
(Heldmann et al., 2005). Based on experiments with tnfr1
-/-
/tnfr2
-/-
 mice, TNFR had 
already been implicated in providing protection of neurons during brain injury (Bruce et 
al., 1996) and TNFR1 and TNFR2 have both been described to be up-regulated in 
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response to ischaemic insults (Botchkina et al., 1997). However, the roles of the two 
TNFR in ischaemia appear to be opposing. In a retina ischaemia-reperfusion mouse 
model TNFR2 was found to promote neuroprotection, whereas TNFR1 aggravated 
neuronal damage (Fontaine et al., 2002).  
Further evidence supporting a neuroprotective role for TNFR2 was provided by 
a study on neurons from tnfr1
-/- 
mice expressing moderate levels of TNF in the cortex 
and hippocampus (Marchetti et al., 2004). Here, TNFR2 was found to counteract 
excitotoxicity, i.e. killing of neurons through excessive stimulation by neurotransmitters 
such as glutamate, through a NF-κB dependent signalling mechanism. Furthermore, the 
use of TNFR antagonists revealed that the inhibition of excitotoxicity was exclusively 
conferred by TNFR2 but not TNFR1. 
 
1.6.4 Anti-TNF treatment in autoimmune diseases  
 
With TNF being a potent immunostimulatory agent, defects in the production and 
regulation of this cytokine and its receptors can cause severe problems. TNF has been 
reported to play an important role in a large number of autoimmune diseases such as 
rheumatoid arthritis (RA), Crohn‟s inflammatory bowel disease (IBD), type I diabetes, 
psoriasis and SLE (reviewed in Bradley, 2008, Faustman and Davis, 2010). Together 
with many other pro-inflammatory cytokines, TNF is produced in the inflamed joints of 
RA patients and was reported to play a dominant role in this disease (Bradley, 2008).  
Neutralisation of TNF with recombinant soluble TNFR or anti-TNF antibodies 
ameliorated joint disease in a mouse model of collagen induced arthritis (Piguet et al., 
1992, Thorbecke et al., 1992, Williams et al., 1992). After these promising results, a 
pilot study was performed in which RA patients were treated with a monoclonal, 
neutralising, mouse/human chimaeric anti-TNF antibody that today is known as 
infliximab (Elliott et al., 1993). A multi-centre study with infliximab confirmed the 
ameliorating effect of the antibody on disease activity and symptoms (Elliott et al., 
1994). Since then, four more TNF antagonists have been authorised for the treatment of 
RA: etanercept, adalimumab, golimumab and certolizumab. Etanercept is a fusion 
protein of the TNFR2 Fc region and human IgG1, whereas adalimumab and golimumab 
are fully human IgG1 monoclonal anti-TNF antibodies. Finally, certolizumab is a 
polyethylene glycol-coupled Fab fragment of a humanised IgG1 monoclonal anti-TNF 
antibody (reviewed in Caminero et al., 2011). Randomised controlled trials found anti-
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TNF therapeutics to be efficient in the treatment of RA and demonstrated that a long-
term treatment in combination with the anti-folate drug methotrexate is feasible 
(Bradley, 2008). Hence, anti-TNF treatment has been one of the major successes in the 
treatment of RA and has, in addition, been successfully applied in various other 
autoimmune diseases such as psoriasis or IBD. 
The above-mentioned TNF antagonists have been shown to bind sTNF with high 
affinity (Tracey et al., 2008) but can also bind membrane-bound TNF. As a 
consequence of the latter, these therapeutic agents have been reported to not only 
function as TNF-antagonist by neutralising TNF, but also show agonistic effects by 
causing so-called reverse signalling (reviewed in Caminero et al., 2011). Reverse 
signalling through TNF occurs when membrane-bound TNF binds either endogenous 
soluble and membrane-bound TNFR or exogenous soluble TNFR, such as etanercept, 
and anti-TNF antibodies. The function of TNF as a receptor has been demonstrated in 
T-cells, monocytes/macrophages and natural killer cells (reviewed in Horiuchi et al., 
2010). Interaction of membrane-bound TNF expressed on monocytes with TNFR2 
expressed on T-cells, for example, was shown to lead to phosphorylation of 
ERK1/ERK2 and to upregulate TNF production in the monocytes via reverse signalling 
(Rossol et al., 2007). As mentioned above, reverse signalling can also be induced by 
TNF antagonists. Infliximab was found to induce apoptosis in membrane-bound TNF-
expressing Jurkat T-cells and monocytes of RA patients, respectively (Mitoma et al., 
2005, Meusch et al., 2009). However, no such effect could be detected for etanercept 
and it has been proposed that this difference in reverse signalling induction is 
determined by the ability of the TNF antagonist to form oligomers/multimers with the 
membrane-bound ligand (reviewed in Horiuchi et al., 2010). 
 
Alexopoulou et al. (2006) suggested, based on data obtained from mice which only 
expressed a membrane-bound TNF variant, that it is rather sTNF than membrane-bound 
TNF which plays a role in the development of arthritis. This idea is further supported by 
observations made in a mouse model of collagen-induced arthritis, in which dominant-
negative TNF (DN-TNF) was able to neutralise sTNF but not membrane-bound TNF 
(Steed et al., 2003). This neutralising effect of DN-TNF was based on the formation of 
heterotrimers from DN-TNF and endogenous sTNF. These heterotrimers exhibited a 
strongly reduced affinity to the TNFR. Another advantage of this therapeutic approach 
was that, while the neutralisation of sTNF did ameliorate the disease symptoms of 
experimental arthritis, it did not impair the TNF-mediated resistance to infections 
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(Zalevsky et al., 2007). Similar observations have been made in an LPS-induced 
hepatitis model, where DN-TNF was also capable to protect mice from liver injury 
(Olleros et al., 2010). However, Olleros et al. (2010) also demonstrated that the 
inhibitory effect of DN-TNF biologics wears off quicker than the one seen with 
etanercept. 
 
Given their involvement in immune defence and regulation of the immune system (see 
section 1.6.2) it is not surprising that TNFR1 and TNFR2 have been reported to play 
certain roles in several autoimmune diseases. In addition to their involvement in the 
pathogenesis of MS and type I diabetes (sections 1.6.2.1 and 1.6.3), distinct roles have 
been suggested for the two TNFR in RA and IBD. Data from a collagen-induced 
arthritis mouse model of tnfr1
-/-
 mice suggested a pro-inflammatory role for TNFR1 
(Mori et al., 1996) and opposing roles for TNFR2 (Tada et al., 2001b). TNFR2 was 
found to accelerate the induction of arthritis during the early stage of the disease, while 
suppressing it at the late stage and in transplantation experiments with bone marrow 
from tnfr1
-/-
, tnfr2
-/-
 and tnfr1
-/-
/tnfr2
-/-
 mice also an anti-inflammatory role was 
observed for TNFR2 (Blüml et al., 2010). Moreover, in myofibroblasts from IBD 
patients TNFR2 seems to be involved in mediating TNF-induced collagen accumulation 
through induction of tissue inhibitor of matrix metalloproteinase-1 (TIMP-1) and 
ERK1/ERK2 mediated proliferation (Theiss et al., 2005).  
This highlights not only the opposing functions of TNFR1 and TNFR2 further 
but also implies that it may not always be beneficial to abrogate TNF-mediated 
signalling altogether. Indeed anti-TNF treatment with anti-TNF antibodies and 
etanercept has been found to be occasionally associated with certain adverse effects 
such as serious bacterial infections (including tuberculosis), demyelinating syndromes 
and SLE-like reactions  (reviewed in Bradley, 2008) and the development of cancer. 
These adverse effects, together with the fact that not all patients respond to anti-TNF 
treatment, suggest that different approaches are required in the treatment of autoimmune 
diseases. A TNFR-selective therapy could be superior to an overall blockage of TNF. 
Findings by Ban et al. (2008) support such an approach. Here, in in vitro experiments 
with selective agonistic TNFR-antibodies a TNFR2-specific killing of auto-reactive 
CD8
+
 T-cells could be achieved not only in cells from type I diabetes patients, but also 
in CD8
+
 T-cells of patients suffering from SLE, psoriasis, MS and Graves‟ disease.  
An alternative way, which has been considered to specifically target TNFR1 and 
TNFR2, respectively, is the use of soluble PLAD protein. A soluble version of the 
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TNFR1 PLAD was found to have an inhibitory effect on disease development in mouse 
models of TNF-, CpG-DNA- and collagen-induced of arthritis, while no such effect 
could be observed when a soluble version of the TNFR2 PLAD was used (Deng et al., 
2005). Since both PLAD proteins used in this study were capable to block TNF-
mediated signalling Deng et al. (2005) proposed that soluble TNFR PLAD could serve 
as TNFR-selective therapeutics. However, this would require the design of more stable 
versions of these proteins as their half-life was measured to be only 5 h in the blood. 
Moreover, more recent evidence emerged which suggested the use of PLAD proteins 
might not always be beneficial. In an SLE mouse model TNFR1 PLAD protein was 
found to improve facial skin lesions and to prevent infiltration by inflammatory cells 
(Deng et al., 2010). However, a trend towards increased levels of IgG and auto-
antibodies against double-stranded DNA could be observed in animals treated with 
either TNFR1 or TNFR2 PLAD protein, indicating that the overall systemic auto-
immunity got rather worse upon treatment. In addition, treatment with TNFR1 PLAD 
protein aggravated SLE kidney pathology, further highlighting the limitations of PLAD 
protein use in the treatment of autoimmune diseases.  
 
Taken together, the anti-inflammatory functions of TNFR2 as outlined above together 
with the described pro-inflammatory functions of TNFR1 indicate that selectively 
blocking TNFR1 while specifically activating TNFR2 may be a promising approach in 
the treatment of autoimmune diseases and could be superior to an overall blockage of 
TNF. However, a more profound understanding of the TNF-mediated receptor 
activation seems to be required as mere interruption of TNFR signalling with, for 
example, PLAD protein has not proven to be suitable for the treatment of all 
autoimmune diseases. 
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1.7 Scope of this thesis 
 
Membrane-bound TNF and sTNF play different roles in immunity and data from mouse 
models indicate that rather the soluble than the membrane-bound form plays a role in 
the development of autoimmune diseases such as RA and MS (Steed et al., 2003, 
Alexopoulou et al., 2006). Therapy with biological antagonists of TNF action has 
proven to be a successful way of treating various autoimmune diseases (Caminero et al., 
2011). In addition, a role for sTNF in autoimmunity has been highlighted by findings 
that especially neutralisation of this soluble form of TNF can ameliorate disease 
symptoms in experimental arthritis (Steed et al., 2003).  
Like its membrane-bound form sTNF can bind both TNFR with high affinity 
(Grell et al., 1998b). However, while TNFR1 and TNFR2 are both efficiently activated 
by membrane-bound TNF, sTNF only fully activates TNFR1 (Grell et al., 1995). This 
differential receptor responsiveness to sTNF, together with the opposing functions 
described for TNFR1 and TNFR2 in immunity (section 1.6.2), suggests that selective 
targeting of the TNFR could be a promising therapeutic approach in the treatment of 
autoimmune diseases and may help to avoid the anti-TNF treatment-associated adverse 
effects which have been reported in some patients (reviewed in Bradley, 2008). 
However, the development of TNFR selective drugs requires a profound understanding 
of the molecular basis of functional differences between TNFR1 and TNFR2.  
 
A cellular system, which comprises immortalised embryonic fibroblasts from tnfr1
-/-
/tnfr2
-/-
 mice stably expressing TNFR-Fas chimaeras (consisting of the extracellular part 
of the TNFR and the cytoplasmic part of Fas), has been established in our group 
previously. By using these cells in combination with sTNF and a membrane-bound TNF 
mimic, respectively, differential responsiveness of TNFR1 and TNFR2 towards sTNF 
can be investigated in the absence of TNFR1/TNFR2 crosstalk. Data generated with the 
help of this cellular system indicated that differential responsiveness to sTNF is not 
controlled by the cytoplasmic part of the receptors (Krippner-Heidenreich et al., 2002) 
and is only to a minor extent determined by the CRD1 (Branschädel et al., 2010) and 
the TM region (Dr Anja Krippner-Heidenreich, personal communication). In contrast, 
preliminary data suggest that rather the TNFR stalk region, potentially in combination 
with the TM region, controls receptor responsiveness to sTNF (Dr Anja Krippner-
Heidenreich, personal communication).  
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Furthermore, it has been observed that efficient activation of TNFR by sTNF 
correlates with the strength of ligand-independent receptor pre-assembly (Branschädel 
et al., 2010, Boschert et al., 2010) and the ability of the receptors to form higher 
molecular TNF/TNFR clusters (Krippner-Heidenreich et al., 2002). These observations, 
together with the aforementioned preliminary data on sTNF responsiveness, raised the 
question whether the TNFR stalk region could influence cluster formation and receptor 
pre-assembly in the plasma membrane. Taken together, we hypothesise that the TNFR 
stalk region is the major determinant for sTNF responsiveness by controlling signalling 
complex formation at the level of receptor pre-assembly and cluster formation. 
 
Moreover, investigations into the potential control of TNFR responsiveness towards 
sTNF by the TNFR stalk region will help elucidate whether this region represents a 
potential target for the design of TNFR-selective therapeutics. 
In the absence of functional FoxP3
+
CD4
+
CD25
+
 Treg cells immune system 
dysregulation and development of autoimmunity have been demonstrated to arise as a 
result of insufficient suppression of pathogenic auto-reactive T-cells (reviewed in 
Miyara and Sakaguchi, 2011). In the murine system TNFR2 signalling has been shown 
to promote the expansion of Treg cells (Chen and Oppenheim, 2010) and in the human 
system TNFR2 has been also been implicated in the control of Treg cell survival and 
function under inflammatory conditions (reviewed in Chen and Oppenheim, 2011). 
However, as mentioned above, despite its ability to bind sTNF with high affinity, 
TNFR2 is only efficiently activated upon the engagement with membrane-bound TNF 
(Grell et al., 1995). Therefore, it is conceivable that at the high sTNF concentrations 
present in acute and chronic inflammatory diseases membrane-bound TNF competes 
with sTNF for TNFR2 binding. This in turn would lead to insufficient activation of 
TNFR2 on Treg cells and, consequently, the aggravation of the disease. Hence, targeting 
the TNFR2 stalk region with, for example, stabilising antibodies or small stabilising 
molecules which help to overcome its inhibitory effect on sTNF responsiveness may 
enhance TNFR2 signalling and promote suppressive Treg cell function. 
In addition, differential responsiveness towards soluble and membrane-bound 
ligands is a characteristic which can also be observed for other TNFR superfamily 
members such as Fas (Suda et al., 1997, Schneider et al., 1998), TRAILR2 (Wajant et 
al., 2001), TACI (Bossen et al., 2008), CD27 (Wyzgol et al., 2009) and OX40 (Müller 
et al., 2008). With the exception of Fas, all of these receptors contain relatively long 
proline-rich stalk regions (Figure 3). Therefore, understanding the mechanisms by 
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which the TNFR2 stalk region determines sTNF responsiveness may also provide 
insight into how the differential responsiveness of other TNFR superfamily members is 
controlled.  
 
 
Therefore, the aims of this project are to:  
 Determine whether the stalk region, alone or in combination with the TM region, 
determines differential receptor responsiveness to sTNF; 
 Identify the molecular feature(s) in the TNFR stalk region controlling sTNF 
responsiveness; 
 Determine whether ligand-independent pre-assembly and multimerisation/cluster 
formation of the receptors are determined by the TNFR stalk region; 
 Investigate whether observations made using the TNFR-Fas cell system are also 
valid for wild type TNFR2 and, hopefully, to provide new insights into the 
control of TNFR signalling initiation. 
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CHAPTER 2 
Materials and methods 
2 nfvierafg 
2.1 Materials  
 
2.1.1 Chemicals and reagents 
 
Overall, chemicals and biochemicals used for this PhD project were commercially 
available analytical grade reagents obtained from Sigma-Aldrich Company Ltd. (Poole, 
UK), Fisher Scientific (Loughborough, UK), Life Technologies (Paisley, UK) or BDH 
(Poole, UK). Chemicals and reagents obtained elsewhere are listed in Table 1 together 
with the appropriate suppliers. 
 
Table 1. Chemicals and reagents 
 
Chemical/reagent Supplier 
40 % (w/v) Acrylamide/bis-acrylamide 
(37.5:1) solution 
Anachem (Luton, UK) 
Agarose (electrophoretic grade) Invitrogen Ltd. (Paisley, UK) 
Ammonium peroxodisulphate (APS)  BDH (Poole, UK) 
BactoAgar Difco
TM
 (West Molesey, UK) 
BactoTryptone Difco
TM
 (West Molesey, UK) 
Benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside  
(Benzyl-α-GalNAc) 
Calbiochem (San Francisco, USA) 
Bis[sulfosuccinimidyl]suberate (BS
3
) Perbio (Erembodegem, Belgium) 
BradfordUltra reagent Expedeon (Harston Cambridgeshire,UK) 
Broad range prestained protein marker  New England Biolabs Inc. (Hertfordshire, 
UK) 
Complete, Mini, EDTA-free protease 
inhibitor cocktail tablets 
Roche Applied Science (Burgess Hill, UK) 
Deoxynucleotide mix (10 mM dNTP 
mix) 
New England Biolabs Inc. (Hertfordshire, 
UK) 
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Fluoromount G Southern Biotech (Birmingham Alabama, 
USA) 
Recombinant protein G-sepharose 4B 
conjugate 
Invitrogen Ltd. (Paisley, UK) 
PROTRAN nitrocellulose transfer 
membrane 
Whatman International Ltd. (Maidstone, 
UK) 
Oregon Green-conjugated wheat germ 
agglutinin (WGA) 
Invitrogen Ltd. (Paisley, UK) 
QIAprep Spin Miniprep kit Qiagen (Crawley, UK) 
Qiagen HiSpeed Plasmid Midiprep kit Qiagen (Crawley, UK) 
QIAquick Gel Extraction kit Qiagen (Crawley, UK) 
Sodium dodecyl sulphate (SDS) BDH (Poole, UK) 
SuperSignal® West Pico 
chemiluminescent substrate 
Thermo Scientific/Pierce (Loughborough, 
UK) 
SuperSignal® West Dura extended 
duration chemiluminescent substrate 
Thermo Scientific/Pierce (Loughborough, 
UK) 
Vectashield® mounting medium with 
DAPI 
Vector Laboratories Ltd. (Peterborough, 
UK) 
Z-Val-Ala-DL-Asp-fluoromethylketone 
(zVADfmk) 
Bachem Ltd. (St. Helens, UK) 
 
 
2.1.2 Cell culture media and reagents  
 
75 cm
2
 vented cell culture flasks were obtained from Greiner Bio-One Ltd. 
(Stonehouse, Gloucestershire, UK). Cryo vials, 96-well tissue culture plates and 6-well 
tissue culture plates were obtained from Corning/Costar UK Ltd. (High Wycombe, 
UK). Cell culture reagents and media used are listed in Table 2 together with the 
appropriate suppliers.  
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Table 2. Cell culture reagents and media 
 
Reagent/medium Supplier 
Blasticidin S Invitrogen Ltd. (Paisley, UK) 
Dimethyl Sulfoxide (DMSO) Hybri-
Max™ 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Dulbecco's Modified Eagle Medium 
(DMEM) 
Invitrogen Ltd. (Paisley, UK) 
Dulbeccos‟s phosphate buffered saline 
(DPBS) 
Lonza (Workingham, UK) 
Doxycycline Sigma-Aldrich Company Ltd. (Poole, UK) 
Effectene® transfection reagent Qiagen (Hilden, Germany) 
Foetal calf serum (FCS) Gibco BRL (Paisley, UK) 
200 mM L-glutamine solution Sigma-Aldrich Company Ltd. (Poole, UK) 
HiPerFect transfection reagent Qiagen (Hilden, Germany) 
Hygromycin B Invitrogen Ltd. (Paisley, UK) 
Lipofectamine
TM
2000 transfection 
reagent 
Invitrogen Ltd. (Paisley, UK) 
MycoAlert® Mycoplasma Detection Kit Lonza (Workingham, UK) 
Opti-MEM 1 reduced serum medium 
with L-glutamine 
Invitrogen Ltd. (Paisley, UK) 
10x Penicillin-streptomycin solution 
(10
4
 units (U) per ml penicillin, 10 
mg/ml streptomycin) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Poly-L-lysine (MW : 70000 – 150000) Sigma-Aldrich Company Ltd. (Poole, UK) 
Puromycin A Calbiochem (San Francisco, USA) 
RPMI-1640 medium Sigma-Aldrich Company Ltd. (Poole, UK) 
TransIt®-293 transfection reagent Mirus Bio Corporation (Madison, USA) 
0.4 %  (w/v) Trypan Blue solution Sigma-Aldrich Company Ltd. (Poole, UK) 
10x Trypsin-EDTA solution (0.5 % 
(w/v) trypsin, 0.2 % (w/v) EDTA) 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Zeocin Invitrogen Ltd. (Paisley, UK) 
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2.1.3 Molecular biology enzymes 
 
Antarctic Phosphatase, Phusion deoxyribonucleic acid (DNA)-polymerase, Thermus 
aquaticus (Taq) DNA polymerase, T4 DNA ligase, T4 polynucleotide kinase and all 
restriction endonucleases were obtained from New England Biolabs Inc. (Hertfordshire, 
UK).  
 
2.1.4 Antibodies  
 
Antibodies and antibody conjugates used are listed in Table 3 together with the 
appropriate suppliers. 
 
Table 3. Antibodies 
 
Antibody Supplier 
Biotin-conjugated rat anti-mouse 
immunoglobulin G (IgG) (H+L) 
eBioscience Ltd. (Hatfield, UK) 
Monoclonal mouse anti-human β-actin 
antibodies AC-15 
Abcam (Cambridge, UK) 
Monoclonal mouse anti-human 
cytoplasmic-Fas antibody clone B10 
Santa Cruz Biotechnology Inc. (Santa Cruz, 
USA) 
Polyclonal rabbit anti-human p65 
antibodies C-20 
Santa Cruz Biotechnology Inc. (Santa Cruz, 
USA) 
Monoclonal mouse anti-human TRAF2 
clone C90–481 
BD/Pharmingen (Oxford, UK) 
Monoclonal mouse anti-human TNFR1 
antibody clone H398 
Institute of Cell Biology and Immunology, 
University of Stuttgart (Stuttgart, Germany) 
Polyclonal goat anti-soluble human 
TNFR2 antibodies 
R&D Systems Europe Ltd. (Abingdon, UK) 
Monoclonal mouse anti-human TNFR2 
antibody clone 80M2 
Institute of Cell Biology and Immunology, 
University of Stuttgart (Stuttgart, Germany) 
Monoclonal mouse anti-human TNFR2 
antibody clone MR2-1 
Hbt HyCult (Uden, Netherlands) 
Phycoerythrin-conjugated monoclonal R&D Systems Europe Ltd. (Abingdon, UK) 
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mouse anti-human TNFR2 antibody 
clone # 22235 
FITC-conjugated goat anti-mouse IgG 
+ IgM (H+L) antibody 
Jackson ImmunoResearch Laboratories Inc. 
(West Grove, USA) 
Goat anti-mouse IgG-HRP antibody Dianova (Hamburg, Germany) 
Alexa594-conjugated goat anti-rabbit 
IgG (H+L) antibody  
Molecular Probes/Invitrogen Ltd. (Paisley, 
UK) 
Rabbit anti-goat IgG (whole molecule)-
HRP antibody 
Sigma-Aldrich Company Ltd. (Poole, UK) 
Streptavidin-phycoerythrin BD/Pharmingen (Oxford, UK) 
 
2.1.5 Ligands 
 
Recombinant soluble TNF (sTNF; 2 x 10
7
 U/mg) was obtained from Knoll AG 
(Ludwigshafen, Germany). The cloning, expression and purification of recombinant, 
endotoxin-free Cysteine-TNF (CysTNF) has been described previously (Bryde et al., 
2005). CysTNF contains an N-terminal histidine tag and a free cysteine residue, which 
leads to the preferential oligomerisation into TNF hexamers. It was produced at the 
University of Stuttgart‟s institute of natural sciences, Germany, by bacterial expression 
and subsequent purification via a nickel column. Stock solutions of sTNF and CysTNF 
were stored at -80 °C; aliquots for the day to day use were stored at 4 °C. Recombinant 
human sTNF had been labelled with AlexaFluor546 (Molecular Probes Inc., Eugene, 
Oregon, USA) at the Institute of Cell Biology and Immunology of the University of 
Stuttgart, Germany, according to the manufacturer‟s instructions and was stored at -80 
°C. Flag-tagged TNFR2-selective sTNF (Flag-sTNF(143N/145R)) and Flag-tagged 
TNFR2-selective single-chain TNF containing the trimerisation domain of chicken 
tenascin-C (Flag-TNC-scTNF(143N/145R)) have been described previously (Rauert et 
al., 2010) and were kindly gifted by Prof. Dr. Harald Wajant, University of Würzburg, 
Germany.  
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2.1.6 Plasmids 
 
The bacterial plasmid pBlueScript SK (+) (pBS SK (+)) from Stratagene was used as a 
subcloning vector. Receptor constructs and chimaeras were cloned into the mammalian 
expression vector pEF-pGK/puro polyA (Huang et al., 1997). For the generation of 
inducible cells the expression plasmid pcDNA/FRT/TO and the Flp recombinase 
encoding pOG44 vector of the Flp-IN T-Rex system from Invitrogen Ltd (Paisley, UK) 
were used. For plasmid maps please see appendix. 
 
2.1.7 Oligonucleotides 
 
Desalted or poly-acrylamide gel electrophoresis (PAGE)-purified oligonucleotides were 
obtained from Sigma-Aldrich Company Ltd. (Poole, UK) and resuspended in ddH2O to 
a final concentration of 100 μM unless stated otherwise. Oligonucleotides that served as 
sequencing primers are listed in Table 4. 
 
Table 4. Sequencing primers 
 
Number Nucleotide sequence (5’→ 3’) 
#O-213 CAA CAC GAC TTC ATC CAC GG 
#O-231 TTT TTC TTC CAT TTC AGG TGT C 
#O-500 GAA AAC GAG TGT GTC TCC TGT AG 
#O-501 AAT TAA CCC TCA CTA AAG GG 
#O-502 GTA ATA CGA CTC ACT ATA GGG C 
CMV fw CGC AAA TGG GCG GTA GGC GTG 
 
2.1.8 Competent cells 
 
Subcloning Efficiency
TM
 DH5α chemically competent Escherichia coli (E. coli) cells 
were obtained from Invitrogen Ltd. (Paisley, UK). 
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2.1.9 Small interfering RNA 
 
ON-TARGETplus SMARTpool TNFRSF1A small interfering RNA (siRNA) was 
obtained from Dharmacon (Lafayette, CO, USA). The four pooled target siRNA strands 
are depicted below. Lyophilised siRNA was dissolved in RNase-free siRNA buffer 
(Dharmacon) to receive a 100 μM stock solution. Non-specific siRNA (5‟-AGG UAG 
UGU AAU CGC CUU GTT-3‟) was purchased from MWG-Biotech AG (Ebersberg, 
Germany). 
 
Table 5: ON-TARGETplus SMARTpool TNFRSF1A siRNA strands 
 
No. Sense strand (5‟→ 3‟) Antisense strand (5‟→ 3‟) 
1 CAA AGG AAC CUA CUU GUA 
CUU 
pGUA CAA GUA GGU UCC UUU 
GUU  
2 GAG CUU GAA GGA ACU ACU 
AUU 
pUAG UAG UUC CUU CAA GCU 
CUU 
3 AAG CUC UAC UCC AUU GUU 
UUU 
pAAA CAA UGG AGU AGA GCU 
UUU 
4 CCC UUG CGC UGG AAG GAA 
UUU 
pAUU CCU UCC AGC GCA ACG 
GUU 
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2.1.10 Software 
Sequence similarity searches were carried out using ClustalW (based on the algorithms 
described in Wilbur and Lipman, 1983, Myers and Miller, 1988). OLIGO primer 
analysis software (Molecular Biology Insights Inc.; Cascade, USA) was used to ensure 
optimal oligonucleotide design. The online sequence alignment tool LALIGN (based on 
the algorithm described in Myers and Miller, 1988) was used to compare DNA 
sequences of parental and mutated receptor constructs. Plasmid maps were created using 
the Clone Manager 9 software (Scientific & Educational Software; Cary, USA). 
Photographs were formatted and figures created with the help of the Corel DRAW 
Graphics Suite X4. Chemical structures were drawn using the ACD/Labs Software 
version 12.0 (Advanced Chemistry Development Inc., Toronto, Canada).  
 Statistical difference between non-parametric samples was assessed by Mann-
Whitney U test. The GraphPad Prism 5 software (GraphPad Software, Inc.; La Jolla, 
USA) was used in all instances. Significance levels were indicated as * = p ≤ 0.05, ** p 
≤ 0.01 and *** = p ≤ 0.001. 
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2.2 Molecular biology methods  
 
To obtain TNFR2-Fas chimaeras with point mutations in the stalk region, inserts were 
constructed via two-step site-directed mutagenesis. TNFR-Fas chimaeras, in which parts 
of the stalk region had been replaced with artificial glycine-serine-linkers, were also 
constructed via two-step site-directed mutagenesis.  
For complete replacement of the stalk region with artificial linkers of different 
lengths, oligonucleotides with complementary 3‟-ends were heat-denatured, annealed 
and the resulting 5‟-overhangs were filled in using Phusion DNA polymerase. The 
plasmid pBS SK (+) was used in subcloning steps for the construction of chimaeras 
with GSL of different lengths. All constructs were finally cloned into the mammalian 
expression vector pEF-PGK/puro polyA. pEF-PGK/puro polyA contains an elongation 
factor 1 promoter, a puromycin A resistance gene and a poly adenosine (polyA) 
sequence.  
 
2.2.1 Determination of DNA concentrations 
 
Concentrations of plasmid and insert DNA were determined by measuring the 
absorbance at 260 nm (A260nm) using a ND1000 spectrophotometer (Nanodrop, USA). The 
ratio A260nm/ A280nm was used to determine DNA purity. 
 
2.2.2 Agarose gel electrophoresis 
 
6x Sample buffer 
30 % (v/v)  Glycerol 
0.25 % (w/v)  Bromophenol blue 
 
10x Tris-boric acid-EDTA buffer (TBE) pH 8.0 
900 mM  Tris base 
900 mM  Boric acid 
20 mM  Na2-EDTA  
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50x Tris-acetate-EDTA buffer (TAE) pH 8.0  
2 M   Tris base 
1 M   Glacial acetic acid 
50 mM  Na2-EDTA (from 0.5 M stock solution pH 8.0)  
 
Vector DNA and insert DNA for cloning were separated by 1 - 3 % horizontal agarose 
gel electrophoresis. TBE buffer was used for gels containing 2 % (w/v) agarose or more, 
TAE was used for gels containing up to 2 % (w/v) agarose. Samples were mixed with 
sample buffer, loaded onto the gels containing 0.1 µg/ml of ethidium bromide and 
electrophoresis was performed at constant 80 V for 1 - 2.5 h. For DNA detection a 
ChemiGenius
2
 bioimaging system (Syngene, Cambridge, UK) was used.  
 
2.2.3 Agarose gel extraction 
 
For the extraction of plasmid and insert DNA from agarose gels buffers are used that 
contain guanidine thiocyanate. Guanidine thiocyanate is a chaotropic salt which creates 
a hydrophobic environment in which the DNA can bind to silica membranes via cation-
bridges.  
DNA in agarose gels was visualised with UV300nm light and cut out of the gel 
using a sharp, clean scalpel blade. DNA was extracted using the QIAquick Gel 
Extraction kit as decribed by the supplier. Briefly, the gel slice was dissolved in three 
gel slice volumes of the guanidine thiocyanate-containing buffer QG. DNA was 
precipitated by adding one gel slice volume of propan-2-ol to the mixture and was then 
allowed to bind to the silica membrane. Columns were washed with buffer PE and DNA 
was eluted in 30-50 μl ddH2O. 
 
2.2.4 Enzymatic modifications of DNA 
 
2.2.4.1 Restriction digests and dephosphorylation of vector DNA 
 
Unless stated otherwise, restriction digests were performed as 40 μl reactions in 1.5 ml 
Eppendorf reaction tubes in a 37 °C water bath for 2 h. For 0.7 pmol of double-stranded 
DNA (dsDNA) 5 U of restriction enzyme were used in the buffer recommended by the 
supplier. For partial restrictions, 1-2 U per 0.7 pmol of dsDNA were used.  
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Restriction samples of vector DNA were supplemented with 1x Antarctic 
Phosphatase reaction buffer and de-phosphorylation of the 3‟- and 5‟-ends of the DNA 
was performed using 5 U of Antarctic Phosphatase. Samples were incubated at 37 °C 
for 30 min and were then purified via agarose gel extraction. 
 
2.2.4.2 Ligation of vector and insert DNA 
 
Approximately 14 fmol of vector DNA and a 5-fold excess of insert DNA were ligated 
using 20 U of T4 DNA ligase in 1x T4 DNA ligase reaction buffer for 3 h or over night 
in a 16 °C water bath. 
 
2.2.5 Heat shock transformation of chemically competent E. coli DH5α cells 
 
SOC++ medium 
2 % (w/v)  BactoTryptone 
0.5 % (w/v)  Yeast extract 
10 mM  Sodium chloride (NaCl) 
2.5 mM  KCl 
200 mM  Glucose (sterile filtered) 
10 mM  MgCl2 (sterile filtered) 
pH adjusted to 7.0 
 
Lysogeny broth medium (LB)  
1 % (w/v)  BactoTryptone 
0.5 % (w/v)  Yeast extract 
0.5 % (w/v)  NaCl 
pH adjusted to 7.5 
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LB ampicillin agar plates 
1 % (w/v)  BactoTryptone 
0.5 % (w/v)  Yeast extract 
0.5 % (w/v)  NaCl 
1.5 % (w/v)  Bacto agar 
100 µg/ml  Ampicillin 
 
LB ampicillin medium 
1 % (w/v)  BactoTryptone 
0.5 % (w/v)  Yeast extract 
0.5 % (w/v)  NaCl 
100 µg/ml  Ampicillin 
 
Heat shock transformation in the presence of calcium chloride (CaCl2) is a commonly 
used method to deliver DNA into E. coli cells. CaCl2 is believed to facilitate DNA 
binding to the cell surface. The bacteria are subjected to a heat-pulse (transfer from 0 ºC 
to 42 ºC) followed by a cold-shock (transfer from 42 ºC to 0 ºC). The heat-pulse has 
been reported to lead to the formation of pores in the outer cell membrane and a 
decrease in membrane potential of the inner cell membrane, while the cold-shock 
decreases the inner cell membrane potential further. Both, pore formation and reduction 
of membrane potential, facilitate the DNA to cross the E. coli cell membranes (Panja et 
al., 2006, Panja et al., 2008). 
 
50 µl of chemically competent Subcloning Efficiency
TM
 DH5α chemically competent E. 
coli cells were incubated with 5 µl of ligation reaction sample on ice for 30 min. Cells 
were then transferred to a 42 °C water bath for 45 sec and afterwards immediately 
placed on ice for 2 min. 550 µl of pre-warmed SOC ++ medium were added to each 
sample and samples were incubated at 37 °C under vigorous shaking for 1 h. Bacteria 
were pelleted in an Eppendorf microcentrifuge 5418 at 2500 x g for 3 min. The 
supernatant was discarded; bacteria were resuspended in 100 μl of SOC++ medium and 
plated onto LB ampicillin plates. Plates were incubated at 37 °C over night. The next 
day, single colonies were used to inoculate 5 ml of LB ampicillin medium for mini 
plasmid DNA preparations. 
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2.2.6 Preparation of plasmid DNA from E. coli DH5α cells 
 
Preparation of plasmid DNA for cloning, DNA sequencing and transfection of 
mammalian cells was performed using kits obtained from Qiagen. Plasmid preparation 
with these kits is based on the principle of alkaline lysis (as described in Birnboim and 
Doly, 1979) using three different buffers: a resuspension buffer (P1), a lysis buffer (P2) 
and a neutralisation buffer (P3). 
The EDTA in buffer P1 destabilises the cell membrane and inhibits DNases by 
chelating bivalent cations. Buffer P2 contains sodium dodecyl sulphate (SDS), which 
breaks up the cell membranes, and sodium hydroxide (NaOH), which denatures the 
chromosomal DNA in the lysates. In contrast, the covalently closed circular plasmid 
DNA remains intact at pH 12-12.5. Buffer P3 contains potassium acetate (KAc) and 
stops the cell lysis. KAc neutralises the sample and causes renaturation and aggregation 
of chromosomal DNA. Addition of KAc also allows the formation of water-insoluble 
potassium dodecyl sulphate and, therefore, leads to the precipitation of SDS/protein 
complexes and high molecular weight RNA. Precipitated chromosomal DNA, protein 
and RNA can then be removed via a centrifugation step and plasmid DNA can be 
purified from the supernatant with the help of a silica column. 
 
2.2.6.1   Mini plasmid preparation 
 
The Qiagen Mini Plasmid Kit was used for the preparation of up to 20 μg of plasmid 
DNA from E. coli DH5α cells. 5 ml of LB ampicillin medium (see section 2.2.5) were 
inoculated and bacteria were grown over night. The next day, bacteria from 4 ml of the 
cell suspension were pelleted at 7000 x g for 3 min and the supernatant was discarded. 
The bacterial pellet was resuspended in 250 μl of buffer P1. In order to lyse the bacteria, 
250 μl of buffer P2 were added to the resuspended cells. Finally, 350 μl buffer P3 were 
added to the lysates. Samples were applied to Qiagen columns, columns were washed as 
recommended by the supplier and DNA was eluted in 50 μl ddH2O. 
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2.2.6.2   Midi plasmid preparation 
 
Buffer TE (Qiagen) 
10 mM Tris-HCl pH 8.0 
0.1 mM  EDTA 
 
The Qiagen HiSpeed Plasmid Midiprep kit was used for preparation of plasmids for 
transfections of mammalian cells. 120 ml of LB ampicillin medium (see section 2.2.5) 
were inoculated with 1 ml of a 5 ml pre-culture of E. coli DH5α cells and bacteria were 
grown at 37 ºC over night. The next day, bacteria were pelleted at 4 ºC at 6000 x g for 
15 min in a Sorvall RC 5C PLUS centrifuge using a SLA-1500 Superlite rotor. 
Afterwards, the supernatant was discarded and the bacterial pellet was resuspended in 6 
ml buffer P1. The bacteria were lysed by adding 6 ml of buffer P2 and incubation at 
room temperature for 5 min. 6 ml of buffer P3 were added to the lysates and samples 
were applied to equilibrated Qiagen columns. Washing steps and DNA precipitation 
were carried out as recommended by the supplier. Plasmid DNA was eluted in 600 μl of 
endotoxin-free buffer TE. 
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2.2.7 Replacement of the complete stalk region with glycine-serine-linkers  
 
The stalk region of TNFR1 is 15 aa long whereas the stalk region of TNFR2 consists of 
56 aa. In order to assess whether the length of the stalk region could account for the 
difference in receptor responsiveness towards sTNF, the stalk regions of TNFR1-Fas 
and TNFR2-Fas chimaeras were replaced with artificial linkers. These linkers (SGSL) 
were 15 and 56 aa residues long, respectively, and consisted of glycine and serine 
residues (for aa sequences see Table 6). Glycine-serine-linkers were chosen as they are 
predicted to adopt no distinct secondary structure but a random coil fold (Evers et al., 
2006), thereby ensuring that changes in sTNF responsiveness are not due to the 
introduction of any secondary structures.  
 
For the generation of short linkers (SGSL15) for TNFR1 and TNFR2, two pairs of 
overlapping oligonucleotides were used. Their sequences were designed so they 
encoded the linker itself, (parts of) the TM, an Acc65I restriction site, an XbaI 
restriction site as well as a BglII restriction site. Due to the required length and the 
limitation in possible codons, overlapping oligonucleotides were chosen instead of full-
length oligonucleotides to reduce their tendency to self-anneal and/or form strong 
secondary structure.  
The sequences of the used oligonucleotide pairs were complementary in their 3‟-
ends and, after the annealing step, the 5‟-overhangs could be filled in using PhusionTM 
High-Fidelity DNA Polymerase. The resulting dsDNA was cut with the restriction 
enzymes XbaI and Acc65I and was cloned into the plasmid pBS SK (+), which had been 
cut with XbaI and Acc65I (Figure 6).  
In order to subsequently generate longer SGSL, two more combinations of 
overlapping oligonucleotides were used. dsDNA was generated by fill-in reactions and 
was then cut with the restriction enzymes BamHI and XbaI and cloned into the 
previously generated pBS SK (+) plasmid, which had been cut with XbaI and BglII 
(Figure 7).  
Being isocaudamers, BamHI and BglII differ slightly in their recognition sites 
but create DNA 5‟-overhangs which are compatible which each other. This permits the 
ligation of vector DNA cut with BglII and oligonucleotide dsDNA cut with BamHI and, 
eventually, leads to the loss of both restriction sites. 
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Figure 6. Construction of the 15 aa glycine-serine-linker for TNFR.  
Two DNA oligonucleotides, which overlap in their 3‟-ends, were annealed and the 5‟-overhangs 
were filled in using PhusionTM High-Fidelity DNA polymerase. This dsDNA oligonucleotide 
encoded for the transmembrane domain (tm) of the receptor and the linker sequence (linker 1). 
The TM/linker sequence was cloned into a pBS SK (+) plasmid using the restriction enzymes 
XbaI and Acc65I. 
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Figure 7. Subsequent cloning of glycine-serine-linker sequences for TNFR.  
Linker 1 generated earlier (Figure 6) was extended by inserting a further linker sequence (linker 
2). Vector DNA was cut with BglII and XbaI, dsDNA oligonucleotides were cut with BamHI 
and XbaI. Ligation of the vector and fragment DNA led to the loss of the BamHI and BglII 
restriction sites, allowing the introduction of another linker 2 fragment applying the same 
technique. Finally, using the same approach the linker 3 fragment could be introduced resulting 
in the full-length 56 aa artificial linker sequence. 
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Once generated, the SGSL sequences could be cut out of the pBS SK (+) subcloning 
vectors and be cloned into the TNFR sequences using the restriction enzymes BamHI 
and BstBI. The resulting, modified TNFR sequences could then be transferred into pEF 
PGKpuro polyA expression plasmids. Table 6 shows the aa compositions of the 
different SGSL for TNFR1 and TNFR2. 
 
Table 6. Amino acid composition of SGSL for TNFR1 and TNFR2  
 
Insert 
combinations 
SGSL aa sequence SGSL 
for TNFR1 
aa sequence SGSL for 
TNFR2 
linker1 SGSL15 PGS[GGGS]3 GSG[GGGS]3 
linker1/2 SGSL31 PGS[GGGS]7 GS[GGGS]4G[GGGS]3 
linker1/2/2 SGSL47 PGS[GGGS]11 GS[GGGS]8G[GGGS]3 
linker1/2/2/3 SGSL56 PGSG[GGGS]13 GSG[GGGS]10G[GGGS]3 
 
2.2.7.1 Subcloning of linker sequences 
 
Fill-in reaction of linker inserts for the generation of SGSL 
For the subcloning of SGSL sequences pairs of PAGE-purified oligonucleotides were 
used. The oligonucleotides of these pairs (see Table 7) were complementary in their 3‟-
ends. Annealing of the oligonucleotides of the respective pairs resulted in 5‟-overhangs 
which could be filled in using Phusion
TM
 High-Fidelity DNA Polymerase. 
Oligonucleotides were dissolved in ddH2O to a final concentration of 50 μM. 
For fill-in reactions, 50 µl reaction samples containing 50 pmol of each of the two 
oligonucleotides, 1x Phusion reaction buffer HF and 200 µM of dNTPs (10 mM 
deoxynucleotide mix, NEB) were prepared. The reaction was performed in a TaKaRa 
polymerase chain reaction (PCR) Thermal Cycler Dice™ TP600. After a 3 min 
denaturing step at 98 °C, the samples were gradually cooled down (respective annealing 
temperatures see Table 8) to allow annealing of the oligonucleotides. After the 
annealing step 1 U of Phusion
TM
 High-Fidelity DNA Polymerase was added per 
reaction tube and the 3‟-ends were extended at 72 °C for 10 sec. Afterwards, the 
samples were cooled down to 4 °C.  
Four different linker inserts were generated via fill-in reactions: linker 1 for TNFR1 and 
linker 1 for TNFR2 as well as linker 2 and linker 3, which were compatible for both 
TNFR.  
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Table 7. Oligonucleotides for the replacement of the complete stalk region with 
SGSL 
 
 Number Nucleotide sequence (5’→ 3’) 
linker 1 
for 
TNFR1 
#O-505 
CTT CAG GTA CCG ATA CAT TAA ACC AAT GAA 
GAG GAG GGA TAA AAG GCA AAG ACC AAA GAA 
AAT GAC CAG GGG CAA CAG CAC 
#O-506 
TTG GGC TCT AGA CTG CAG AGA TCT GGC GGT 
GGT TCC GGA GGT GGA AGT GGA GGA GGC AGC 
GTG CTG TTG CCC CTG GTC ATT TTC TTT GGT C 
linker 1 
for 
TNFR2 
#O-507 
GTT CAC GGT ACC TAT TAT TAG TAG ACC CAA 
GGC TGT CAC ACC CAC AAT CAG TCC AAC TGG 
AAG AGC GAA GC 
#O-508 
GGC TCT AGA CTG CAG AGA TCT GGG GGC GGT 
GGT TCC GGA GGT GGA AGT GGA GGA GGC AGC 
TTC GCT CTT CCA GTT GGA CTG ATT GTG 
linker 2 
for 
TNFR1 
and 
TNFR2 
#O-509 
GTT CAC GGT ACC CAC AAT CAG TCC AAC TGG 
AAG AGC GAA GG 
#O-510 
GCT CTA GAG TTC TGC AGA GAT CTG GCG GCG 
GTT CCG GTG GTG GAA GTG GCG GAG GTA GCG 
GCG GAG GAT CCT TCG CTC TTC CAG TTG GAC 
TGA TTG 
linker 3 
for 
TNFR1 
and 
TNFR2  
#O-509 
GTT CAC GGT ACC CAC AAT CAG TCC AAC TGG 
AAG AGC GAA GG 
#O-511 
GCT CTA GAG TTG GCG GCG GTT CCG GTG GTC 
TGC AGA GAT CTG GAG GTG GAG GAA GTG GAG 
GTG GAT CCT TCG CTC TTC CAG TTG GAC TGA 
TTG 
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Table 8. Oligonucleotide annealing temperatures for complete stalk region 
replacement with SGSL 
 
 Oligonucleotide Annealing temperature and 
times 
Insert generated 
Pair 1 
#O-505 and  
#O-506 
72.4 °C for 5 min, 
67.4 °C for 5 min, 
66.1 °C for 6 min; 
linker 1 for TNFR1 
Pair 2 
#O-507 and  
#O-508 
73.0 °C for 5 min, 
68.0 °C for 5 min, 
59.4 °C for 6 min; 
linker 1 for TNFR2 
Pair 3 
#O-509 and  
#O-510 
70.6 °C for 5 min, 
65.6 °C for 5 min, 
60.6 °C for 6 min; 
linker 2 
Pair 4 
#O-509 and  
#O-511 
70.6 °C for 5 min, 
65.6 °C for 5 min, 
60.6 °C for 6 min; 
linker 3 
 
 
Cloning of the linker sequences into pBS SK (+) 
The linker 1 sequences for TNFR1 and TNFR2 were introduced into the subcloning 
vector pBS SK(+) (internally referred to as plasmid #86) and the resulting plasmids 
were used for the introduction of further linker sequences (see Figure 7). Restriction 
digests of the pBS SK(+) plasmids were performed with XbaI and Acc65I. The cut 
vector DNA was then de-phosphorylated with Antarctic Phosphatase and purified by 
agarose gel extraction. 
65 pmol of the linker 1, linker 2 and linker 3 fill-in products, respectively, were 
used in 60 µl restriction samples containing 26 U XbaI and 20 U BamHI. After 
purification via agarose gel extraction, insert DNA was ligated into the pBS SK(+) 
plasmids. The resulting plasmids were transformed into E. coli DH5α via heat shock 
transformation. The DNA sequence was verified by sequencing at GATC (Konstanz, 
Germany) using the sequencing primer #O-501 (Table 4). Generated plasmids are listed 
in Table 9. 
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Table 9. Subcloning plasmids generated for SGSL introduction into TNFR1 and 
TNFR2  
 
Subcloning vector 
generated 
Linkers inserted Resulting SGSL Subcloning 
vector for 
#501 linker1 SGSL15 TNFR2 
#502 linker1 SGSL15 TNFR1 
#507 linker1/2 SGSL31 TNFR2 
#508 linker1/2 SGSL31 TNFR1 
#513 linker1/2/2 SGSL47 TNFR2 
#514 linker1/2/2 SGSL47 TNFR1 
#519 linker1/2/2/3 SGSL56 TNFR2 
#520 linker1/2/2/3 SGSL56 TNFR1 
 
2.2.7.2 Cloning of SGSL sequences into pBS SK (+) TNFR-BamHI-Fas 
 
In order to exchange the stalk region in TNFR2-Fas with the artificial SGSL15 and SGSL56 
sequences, which had been subcloned previously, the SGSL inserts of plasmids #501, 
#502, #519 and #520 were cut out and transferred into plasmid pBS SK(+) TNFR1-
BamHI-Fas -KpnI (#500) and pBS SK(+) TNFR2-BamHI-Fas (#345), respectively. 
Plasmid #345 had been generated previously by Krippner-Heidenreich et al. (2002). 
For the introduction of the SGSL into TNFR1-Fas, the plasmids #502 and #520 
were cut using the restriction enzymes BglII and Acc65I and the insert DNA was 
purified via agarose gel extraction. A partial restriction digest of 0.7 pmol vector DNA 
(#500) was performed in a 40 µl restriction sample using 12.5 U Acc65I and 1.4 U 
BamHI. The vector DNA was dephosphorylated and purified using agarose gel 
extraction.  
For the introduction of the SGSL into TNFR2-Fas, the plasmids #501 and #519 
were sequentially cut using the restriction enzymes BglII and AccI. 7.7 pmol of plasmid 
DNA was fully digested with BglII and, after 2 h of incubation at 37 ºC, ethanol-
precipitated and subjected to another restriction digest with AccI. The insert DNA was 
purified via agarose gel extraction. A partial restriction with 5 U AccI and 1.4 U BamHI 
was performed with 0.7 pmol of vector DNA (#345) in a 40 µl restriction sample. The 
vector DNA was dephosphorylated and purified using agarose gel extraction. Insert and 
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vector DNA were ligated and transformed into E. coli DH5α. The resulting plasmids are 
listed in Table 10. 
 
Table 10. pBS SK(+) TNFR-SGSL-Fas plasmids  
 
plasmid plasmid name linker 
#503 pBS SK(+) TNFR1-SGSL15-Fas SGSL15 
#504 pBS SK(+) TNFR2-SGSL15-Fas SGSL15 
#521 pBS SK(+) TNFR1-SGSL56-Fas SGSL56 
#522 pBS SK(+) TNFR2-SGSL56-Fas SGSL56 
 
2.2.7.3 Cloning of SGSL sequences into pEF-PGK/puro polyA TNFR-Fas 
 
The TNFR-SGSL-Fas constructs, generated as described in section 2.2.7.2, were 
transferred from the pBS SK(+) plasmids into the mammalian expression plasmids pEF- 
PGK/puro polyA TNFR1-Fas (#113) and pEF-PGK/puro polyA TNFR2-Fas (#114), 
respectively. The generation of plasmids #113 and #114 has been described previously 
(Krippner-Heidenreich et al., 2002). 
 
Restriction digests of plasmids #113, #114, #503, #504, #521 and #522 with the 
restriction enzymes BamHI and BstBI were performed as described in section 2.2.4.1. 
The plasmid DNA of plasmids #113 and #114 was treated with Antarctic Phosphatase 
and purified by gel extraction. The insert DNA of plasmids #503, #504, #521 and #522 
was purified via gel extraction.  
The ligation of the insert DNA of plasmids #503 and #521 into the purified 
vector DNA #113 resulted in the plasmids pEF-PGK/puro polyA TNFR1-SGSL15-Fas 
(#505) and pEF-PGK/puro polyA TNFR1-SGSL56-Fas (#523), respectively. The ligation 
of the insert DNA of plasmids #504 and #522 into the purified plasmid #114 resulted in 
the plasmids pEF-PGK/puro polyA TNFR2-SGSL15-Fas (#506) and pEF-PGK/puro 
polyA TNFR2-SGSL56-Fas (#524), respectively. DNA sequences were verified via 
sequencing at GATC (Konstanz, Germany) using the sequencing primers #O-213, #O-
231 and #O-500, respectively.  
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2.2.8 Partial replacement of the TNFR2 stalk region with glycine-serine-linkers  
 
In order to locate which part of the TNFR2 stalk region could account for the lack of 
sTNF responsiveness of TNFR2, the stalk region of TNFR2-Fas chimaeras was partially 
replaced with glycine-serine-linkers. Four different exchange mutants, TNFR2-(SExaa202-
219/TM)R2-Fas, TNFR2-(SExaa215-232/TM)R2-Fas, TNFR2-(SExaa228-249/TM)R2-Fas and 
TNFR2-(SExaa241-257/TM)R2-Fas), were generated by a two step site directed mutagenesis 
approach. The aa sequences for the stalk regions of wild type TNFR2 (wt; aa 202-257) 
and the four exchange mutants (Exaa202-219, Exaa215-232, Exaa228-249 and Exaa241-257) are 
depicted in Table 11.   
 
Table 11. Amino acid sequences of the wild type and partially replaced TNFR2 
stalk regions 
 
 
wt:   STSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGD 
Exaa202-219: GSGGSGGSGGSGGSGGSGVSTRSQHTQPTPEPSTAPSTSFLLPMGPSPPAEGSTGD 
Exaa215-232: STSPTRSMAPGAVGSGGSGGSGGSGGSGGSGPSTAPSTSFLLPMGPSPPAEGSTGD 
Exaa228-249: STSPTRSMAPGAVHLPQPVSTRSQHTGSGGSGGSGGSGGSGGSGGSGGPAEGSTGD 
Exaa241-257: STSPTRSMAPGAVHLPQPVSTRSQHTQPTPEPSTAPSTSGSGGSGGSGGSGGSGGS 
 
 
Pairs of PAGE-purified oligonucleotides were used, in which the 3‟-ends were 
complementary to the sequences flanking the region which was to be replaced (for pairs 
see Table 12). The remaining bases encoded the glycine-serine-linker sequence and 
were complementary between the oligonucleotides of the respective oligonucleotide 
pair (Table 12, bold letters). 
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Table 12. Oligonucleotides for partial stalk replacements in TNFR2-Fas 
 
 Number Nucleotide sequence (5’→ 3’) 
Forward 
primer 1 
#O-524 GT GAG GAA TTC TAG GAT CCC CCA GCT TCT AGA 
GAT C 
Forward 
primer 2 
#O-525 GAT CTC ATC TAT TTT GGC TTC ATT GAC ACC ATT 
CTT TCG 
Pair 1 for 
TNFR2-
(SExaa202-
219/TM)R2-
Fas 
#O-526 GAA GCG GGG GAA GCG GAG GAT CAG GCG 
GCA GCG GAG TGT CCA CAC GAT CCC AAC ACA 
CG 
#O-527 CGC TGC CGC CTG ATC CTC CGC TTC CCC CGC 
TTC CAC CAG AAC CAC CAC TTC CCG TGC AGA 
CCG CAT CCA TGC TTG CAT TCC CAG 
Pair 2 for 
TNFR2-
(SExaa215-
232/TM)R2-
Fas 
#O-528 GGT GGT TCT GGT GGA AGC GGT GGA AGC GGC 
GGA TCA GGC GGT AGC GGA CCC AGC ACT GCT 
CCA AGT ACC TCC TTC CTG CT 
#O-529 CTG ATC CGC CGC TTC CAC CGC TTC CAC CAG 
AAC CAC CGG AAC CTA CTG CTC CTG GGG CCA 
TAC TCC 
Pair 3 for 
TNFR2-
(SExaa228-
249/TM)R2-
Fas 
#O-530 GGA GGA TCA GGC GGC AGC GGA GGC AGT 
GGA GGT CCA GCT GAA GGG AGC ACT GGC GAC 
TTC 
#O-531 GAC CTC CAC TGC CTC CGC TGC CGC CTG ATC 
CTC CGC TTC CCC CGC TTC CAC CAG AAC CTC 
CAG AAC CGG TGT GTT GGG ATC GTG TGG ACA 
CTG 
Pair 4 for 
TNFR2-
(SExaa241-
257/TM)R2-
Fas 
#O-532 TCA GGT GGA AGC GGT GGA AGT GGA GGA TCT 
GGA GGC AGC TTC GCT CTT CCA GTT GGA CTG 
ATT G 
#O-533 CAG ATC CTC CAC TTC CAC CGC TTC CAC CTG 
ATC CGC CGG AGC CAG AGG TGC TTG GAG CAG 
TGC TGG GTT CTG 
Reverse 
primer 
#O-534 CTT GGT TCA TTC TCA AGC CTC AGA CAG TGG 
TTC AAA G 
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As a first step in the mutagenesis procedure, two separate PCR were performed. For one 
of these PCR an oligonucleotide of the oligonucleotide pair in combination with a 
forward primer (primers #O-524 and #O-534, respectively), while for the other PCR the 
second oligonucleotide of the pair and the reverse primer #O-525 were used (see Figure 
8 A). A summary of the appropriate oligonucleotide combinations and annealing 
temperatures is given in Table 13. 
Each of the 25 μl PCR samples contained 200 μM dNTPs, 0.4 μM forward 
primer, 0.4 μM reverse primer, 1.8 fmol template DNA (#114) and 0.5 U PhusionTM 
High-Fidelity DNA Polymerase in 1x Phusion reaction buffer HF. Cycling conditions 
were as follows: 30 sec at 98 ºC; 30 cycles of 10 sec 98 ºC, 20 sec 55.8-64.7 ºC 
(appropriate annealing temperatures see Table 13) and 15 sec at 72 ºC; 5 min 72 ºC; 
hold 4 ºC. Resulting PCR products were purified via agarose gel extraction and 
resuspended in 30 μl ddH2O. 
 
Table 13. Oligonucleotide combinations and annealing temperatures for partial 
stalk replacements 
 
 Oligonucleotides Annealing temperature 
PCR 1 #O-526 and #O-525 58.2 ºC 
PCR 2 #O-527 and #O-534 64.7 ºC 
PCR 3 #O-528 and #O-525 58.9 ºC 
PCR 4 #O-529 and #O-524 62.5 ºC 
PCR 5 #O-530 and #O-525 57.6 ºC 
PCR 6 #O-531 and #O-524 61.2 ºC 
PCR 7 #O-532 and #O-525 55.8 ºC 
PCR 8 #O-533 and #O-534 64.5 ºC 
 
In the second part of the mutagenesis procedure, the purified PCR products were 
combined in four parallel PCR as follows: products PCR1 and PCR2; products PCR3 
and PCR4; products PCR5 and PCR6; products PCR7 and PCR8.  
The 25 μl PCR samples contained 3 μl of each of the respective purified PCR 
products, 200 μM dNTPs and 0.5 U PhusionTM High-Fidelity DNA Polymerase in 1x 
Phusion reaction buffer HF. As depicted in Figure 8 D, the 3‟-ends of the PCR products 
are complementary and, therefore, could act as primers for each other. The resulting 5‟-
overhangs were filled-in by the Phusion
TM
 High-Fidelity DNA polymerase and one long 
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product, which contained the desired mutation in the middle, was generated. This PCR 
product could then be amplified by addition of primers which were complementary to 
the 3‟-ends of the full PCR product (Figure 8 E). The cycling conditions for the fill-in 
reaction and amplification were as follows: 30 sec 98 ºC; 10 cycles of 10 sec 98 ºC, 20 
sec 58.8 ºC, 20 sec 72 ºC; cool down to 4 ºC for 6 min and addition of primers #O-524 
and #O-525 to a final concentration of 0.4 μM; 20 sec 98 ºC; 30 cycles of 10 sec 98 ºC, 
20 sec 55.0 ºC, 20 sec 72 ºC; 5 min 72 ºC; cool down to 4 ºC. 
The resulting PCR products were purified using the Qiagen gel extraction kit. 
Briefly, 600 μl buffer QC and 200 μl propan-2-ol were added to the PCR samples and 
the mixture was applied to a silica column. The following steps were identical to the gel 
extraction procedure described in section 2.2.3. Samples were eluted in 30 μl ddH2O. 
The primers used to generate the PCR products contained a BamHI and a BstBI 
restriction site, respectively. Therefore, after the purification the PCR products could be 
cut with these restriction enzymes and could, after purification via gel extraction, be 
cloned into the mammalian expression plasmid pEF-PGK/puro polyA. DNA sequences 
were verified via sequencing at Genome Enterprise Ltd. (Norwich, UK) using the 
sequencing primers #O-213 and #O-231 (Table 4), respectively. A summary of the 
generated plasmids is given in Table 14. 
 
Table 14. Mammalian expression vectors encoding for partial stalk exchange 
mutants of TNFR2-Fas 
 
Number Plasmid name 
#532 pEF-PGK/puro polyA TNFR2-(SExaa202-219/TM)R2-Fas 
#533 pEF-PGK/puro polyA TNFR2-(SExaa215-232/TM)R2-Fas 
#534 pEF-PGK/puro polyA TNFR2-(SExaa228-249/TM)R2-Fas 
#535 pEF-PGK/puro polyA TNFR2-(SExaa241-257/TM)R2-Fas 
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Figure 8. Schematic representation of the partial replacement of the TNFR2 stalk region 
with an artificial glycine-serine linker (Exaa 202-219).  
PCR were performed using oligonucleotides complementary to the region A) upstream of the 
TNFR2-Fas insert (#O-534) and B) downstream of the TNFR2-Fas insert (#O-525), 
respectively. These were combined with oligonucleotides of which the 5‟-part encoded a 
glycine-serine-linker and the 3‟-part was complementary to either the region A) upstream (#O-
527) or B) downstream (#O-526) of the part which was to be replaced. C) Amplification 
resulted in two PCR products which carried the glycine-serine-linker sequence at the 3‟-end and 
5‟-end, respectively. D) In a fill-in reaction the 3‟-ends of the PCR products could be annealed 
and extended. This resulted in a product in which the desired part of the TNFR2 stalk region 
was replaced with a glycine-serine-linker sequence. E) The filled-in product could be amplified 
via PCR using the primers #O-534 and #O-525 and cloned into pEF-PGK/puro polyA via 
BamHI and BstBI.  
A 
B 
C 
D 
E 
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2.2.9 Mutagenesis of conserved proline residues in the TNFR2 stalk region 
 
Sequence alignment of the TNFR2 from different mammalian species (homo sapiens, 
macaca mulatta, mus musculus, rattus norvegicus, canis familiaris and equus caballus) 
revealed seven conserved proline residues in the TNFR2 stalk region: P205, P211, 
P219, P231, P233, P237 and P249. To assess the role of these prolines in sTNF 
responsiveness of TNFR2, the proline residues were mutated to alanines via two step 
site directed mutagenensis.   
The mutagenesis approach was similar to the one described in section 2.2.8. 
Here pairs of desalted oligonucleotides were used which were complementary to each 
other (for pairs see Table 15). These oligonucleotides encoded proline to alanine 
mutations (Table 15, bold letters). Where necessary, silent mutations where introduced 
for cloning purposes (Table 15, underlined). 
 
Table 15. Oligonucleotides for proline mutants of TNFR2-Fas 
 
 Number Nucleotide sequence (5‟→ 3‟) 
Pair 1 
#O-512 C ACG TCC ACG TCT GCC ACC CGG AGT ATG G 
#O-513 C CAT ACT CCG GGT GGC AGA CGT GGA CGT G 
Pair 2 
#O-514 G AGT ATG GCA GCA GGG GCA GTA CAC TTA C 
#O-515 G TAA GTG TAC TGC CCC TGC TGC CAT ACT C 
Pair 3 
#O-516 GTA CAC TTA CCC CAG GCA GTT TCC ACA CGA  
#O-517 TCG TGT GGA AAC TGC CTG GGG TAA GTG TAC 
Pair 4 
#O-518 ACA CAG CCA ACT GCA GAA GCT AGC ACG GCT CCA 
#O-519 TGG AGC CGT GCT AGC TTC TGC AGT TGG CTG TGT 
Pair 5 
#O-520 GAA CCC AGT ACT GCT GCA AGC ACC TCC TTC C 
#O-521 G GAA GGA GGT GCT TGC AGC AGT ACT GGG TTC 
Pair 6 
#O-522 A ATG GGC CCC AGC GCA CCA GCA GAA GGG AGC A 
#O-523 T GCT CCC TTC TGC TGG TGC GCT GGG GCC CAT T 
 
As a first step, two separate PCR were performed. With one oligonucleotide of the 
oligonucleotide pair a PCR was performed in combination with the forward primer #O-
524, while for the other PCR the second oligonucleotide of the pair and the reverse 
primer #O-525 were used. A summary of the appropriate oligonucleotide combinations 
and annealing temperatures is given in Table 16.  
  
61 
 
The 25 μl reaction samples contained 200 μM dNTPs, 0.4 μM forward primer, 0.4 μM 
reverse primer, 1.8 fmol template DNA (#114) and 0.5 U Phusion
TM
 High-Fidelity 
DNA Polymerase in 1x Phusion reaction buffer HF. Cycling conditions were as follows: 
30 sec at 98 ºC; 30 cycles of 10 sec 98 ºC, 15 sec 58.2-65 ºC (appropriate annealing 
temperatures see Table 16) and 15 sec at 72 ºC; 5 min 72 ºC; hold 4 ºC. Resulting PCR 
products were purified via agarose gel extraction and resuspended in 40 μl ddH2O. 
 
Table 16. Two step site directed mutagenesis of conserved proline residues in the 
TNFR2 stalk region - oligonucleotide combinations and annealing temperatures 
 
 Oligonucleotides Annealing temperature 
PCR 1 #O-512 and #O-525 61.1 ºC 
PCR 2 #O-513 and #O-524 64.9 ºC 
PCR 3 #O-514 and #O-525 58.9 ºC 
PCR 4 #O-515 and #O-524 63.5 ºC 
PCR 5 #O-516 and #O-525 59.6 ºC 
PCR 6 #O-517 and #O-524 64.5 ºC 
PCR 7 #O-518 and #O-525 64.9 ºC 
PCR 8 #O-519 and #O-524 59.0 ºC 
PCR 9 #O-520 and #O-525 58.8 ºC 
PCR 10 #O-521 and #O-524 64.9 ºC 
PCR 11 #O-522 and #O-525 58.2 ºC 
PCR 12 #O-523 and #O-524 65.0 ºC 
 
In the second part of the mutagenesis procedure, the purified PCR products were 
combined in six parallel PCR as follows: products PCR1 and PCR2; products PCR3 and 
PCR4; products PCR5 and PCR6; products PCR7 and PCR8; products PCR9 and 
PCR10; products PCR11 and PCR12.  
The 25 μl PCR samples contained 3 μl of each of the respective purified PCR 
products, 200 μM dNTPs and 0.5 U PhusionTM High-Fidelity DNA Polymerase in 1x 
Phusion reaction buffer HF. The same principle was applied to generate the full-length 
inserts as has been described in section 2.2.8. The cycling conditions for the fill-in 
reaction and amplification were as follows: 30 sec 98 ºC; 10 cycles of 10 sec 98 ºC, 20 
sec 58.0 ºC, 20 sec 72 ºC; cool down to 4 ºC for 6 min and addition of primers #O-524 
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and #O-525; 20 sec 98 ºC; 30 cycles of 10 sec 98 ºC, 20 sec 55.0 ºC, 20 sec 72 ºC; 5 
min 72 ºC; cool down to 4 ºC. 
 
The PCR products were purified using the Qiagen gel extraction kit. 600 μl buffer QC 
and 200 μl propan-2-ol were added to the PCR samples and the mixture was applied to a 
silica column. The following steps were identical to the gel extraction procedure 
described in section 2.2.3. Samples were eluted in 30 μl ddH2O. 
The PCR products could be cloned into the mammalian expression plasmid pEF-
PGK/puro polyA via BamHI and BstBI as described previously. DNA sequences were 
verified via sequencing at Genome Enterprise Ltd. (Norwich, UK) using the sequencing 
primers #O-213 and #O-231 (Table 4), respectively. A summary of the generated 
plasmids is given in Table 17. 
 
Table 17. Mammalian expression vectors encoding for proline mutants of TNFR2-
Fas 
 
Number Plasmid name 
#525 pEF-PGK/puro polyA TNFR2-Fas P205A 
#526 pEF-PGK/puro polyA TNFR2-Fas P211A 
#527 pEF-PGK/puro polyA TNFR2-Fas P219A 
#528 pEF-PGK/puro polyA TNFR2-Fas P231A/P233A 
#529 pEF-PGK/puro polyA TNFR2-Fas P237A 
#530 pEF-PGK/puro polyA TNFR2-Fas P249A 
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2.2.10 Generation of TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 constructs  
 
To create a TNFR2 variant, in which 42 aa residues of the stalk region are deleted 
(TNFR2-(SΔ42/TM)R2-R2), the sequences encoding the extracellular portion and 
transmembrane region of the corresponding TNFR2-Fas chimaera (TNFR2-
(SΔ42/TM)R2-Fas) were cloned from plasmid #436 (generated by Dr Andrea Zappe, 
University of Stuttgart, Germany) into plasmid pEF-PGK/puro polyA TNFR2 + KpnI 
(#81). For this purpose a partial restriction with Acc65I and a full restriction with 
EcoRV were performed with these plasmids. The products were ligated to receive 
plasmid pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-R2 (#450).  
 
The expression plasmid for TNFR2 with the stalk and transmembrane regions of 
TNFR1 (pEF-PGK/puro polyA TNFR2-(S/TM)R1-R2, #451) was generated by using a 
set of three primers: #O-564 (PAGE-purified), #O-562 and #O-563 (sequences see 
Table 18).  
Primer #O-562 is complementary to the sequence around the KpnI restriction 
site of the intracellular portion of TNFR2 and primer #O-563 encodes for the plasmid 
#81 sequence downstream of the TNFR2 stop codon. Therefore, with #O-564 as 
forward primer and #O-563 as reverse primer the DNA sequence encoding aa 293-461 
of TNFR2, the Stop codon and the 59 DNA base pairs downstream of the Stop codon 
could be amplified from plasmid #81.  
Primer #O-564 is complementary to the plasmid sequence encoding for the 12 
membrane-proximal aa of the intracellular portion of TNFR2 (Table 18 bold letters) and 
parts of the TNFR1 TM region. Using plasmid pEF-PGK/puro polyA TNFR2-
(S/TM)R1-Fas (#449), primer #O-564 as reverse primer and the forward primer #O-524 
(Table 12) a PCR product could be generated which comprised the extracellular portion 
of TNFR2, the stalk and TM regions of TNFR1 and the 12 membrane-proximal 
intracellular aa of TNFR2.  
The 25 μl reaction samples contained 200 μM dNTPs, 0.4 μM of each primer, 
1.8 fmol template DNA and 0.5 U Phusion
TM
 High-Fidelity DNA Polymerase in 1x 
Phusion reaction buffer HF. Cycling conditions were as follows: 30 sec at 98 ºC; 30 
cycles of 10 sec 98 ºC, 15 sec 64 ºC and 15 sec at 72 ºC; 5 min 72 ºC; hold 4 ºC. PCR 
products were gel purified as described in section 2.2.8. 
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Table 18. Oligonucleotides for the generation of TNFR2-(S/TM)R1-R2 
 
Number Nucleotide sequence (5‟→ 3‟) 
#O-562 GTG CCT GCA GAG AGA AGC CAA GGT ACC 
#O-563 GGG TCA TCC TGC CAG GGC TCA G 
#O-564 CCT TGG CTT CTC TCT GCA GGC ACA AGG GCT TCT TTT 
TCC GAT ACA TTA AAC CAA TGA AGA GG 
 
The two PCR products generated from plasmids #81 and #449, respectively, could then 
be used in a third PCR. 23 bases of the 3‟-regions of these PCR products were 
complementary to each other, could be annealed with each other and the 5‟-overhangs 
could be filled-in with the help of the Phusion
TM
 High-Fidelity DNA Polymerase. The 
resulting full-length TNFR2 constructs carried the stalk and transmembrane regions of 
TNR1 and the intracellular portion of wild type TNFR2.  
For this third PCR, 3 μl of each of the purified PCR products, 200 μM dNTPs 
and 0.5 U Phusion
TM
 High-Fidelity DNA Polymerase in 1x Phusion reaction buffer HF 
were used. The cycling conditions for the fill-in reaction and amplification were as 
follows: 30 sec 98 ºC; 10 cycles of 10 sec 98 ºC, 15 sec 53.6 ºC, 40 sec 72 ºC; cool-
down to 4 ºC for 5 min and addition of primers #O-524 and #O-563 to a final 
concentration of 0.4 μM; 10 sec 98 ºC; 30 cycles of 10 sec 98 ºC, 15 sec 55.0 ºC, 40 sec 
72 ºC; 5 min 72 ºC; cool down to 4 ºC. The following steps were identical to the gel 
extraction procedure described in section 2.2.3. Samples were eluted in 50 μl ddH2O. 
The PCR products were cloned into the mammalian expression plasmid pEF-
PGK/puro polyA via BamHI and EcoRV. DNA sequences were verified via sequencing 
at Genome Enterprise Ltd. (Norwich, UK) using the sequencing primers #O-213 and 
#O-231 (Table 4), respectively. 
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2.2.11 Generation of vectors for inducible HEK 293 Flp-IN T-Rex cells 
 
For the generation of inducible HEK 293 Flp-IN T-Rex cells cloning of the construct of 
interest into the pcDNA5/FRT/TO vector of the Flp-IN T-Rex system (Invitrogen) was 
required. The pcDNA5/FRT/TO plasmid encodes for a CMV/TetO2 promoter, which is 
located upstream of the insert DNA and ensures doxycycline-inducible expression of 
the insert DNA. The CMV/TetO2 promoter and insert DNA in the pcDNA5/FRT/TO 
vector are flanked by FRT sites of recombination at the 3‟- and 5‟-ends, which allows 
site-specific recombination in HEK 293 Flp-IN T-Rex cells by Flp recombinase. 
A pcDNA5/FRT/TO vector carrying the TNFR1-Fas chimaera as insert (plasmid 
# 358) had been generated previously (Branschädel et al., 2010). This vector was used 
to generate pcDNA5/FRT/TO vectors encoding for TNFR2, TNFR2-(S/TM)R1-R2, 
TNFR2-(SΔ42/TM)R2-R2 and TNFR2-(SΔ42/TM)R2-Fas. For this purpose, the TNFR1-
Fas insert was removed from plasmid #358 by cutting the vector DNA with the 
restriction enzymes BamHI and EcoRV, dephosphorylating with Antarctic Phosphatase 
(section 2.2.4.1) and purifying it via gel extraction (section 2.2.3).  
A full restriction digest with these enzymes was performed with plasmid pEF-
PGK/puro polyA TNFR2 + KpnI (plasmid #81). With the plasmids pEF-PGK/puro 
polyA TNFR2-(S/TM)R1-R2 (# 451), pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-R2 (# 
450) and pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-Fas (#436) a partial restriction 
with BamHI and full restriction with EcoRV were performed. Full-length inserts were 
purified by gel extraction (section 2.2.3) and were ligated into plasmid #358 (section 
2.2.4.2). DNA sequences were verified via sequencing at Genome Enterprise Ltd. 
(Norwich, UK) using the sequencing primers #O-213 and CMV fw (Table 4), 
respectively. A summary of the generated plasmids is given in Table 19. 
 
Table 19. pcDNA5/FRT/TO vectors for the generation of HEK 293 Flp-IN T-Rex 
cells 
 
Number Plasmid name 
#539 pcDNA5/FRT/TO TNFR2 
#540 pcDNA5/FRT/TO TNFR2-(S/TM)R1-R2 
#541 pcDNA5/FRT/TO TNFR2-(SΔ42/TM)R2-R2 
#546 pcDNA5/FRT/TO TNFR2-(SΔ42/TM)R2-Fas 
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2.3 Cell culture  
 
Cell lines 
HeLa cells (human cervix carcinoma cell line; ATCC, Manassas, USA);  
SV40 large T immortalised tnfr1
-/-
/tnfr2
-/-
 murine embryonic fibroblasts (MF)(kindly 
provided by Daniela Maennel, University of Regensburg, Germany);  
Human embryonic kidney (HEK) 293 Flp-IN T-Rex cells (Invitrogen Ltd., Paisley, UK) 
 
Cell culture medium 
2 mM   L-glutamine  
5 % (v/v)  Foetal calf serum 
in RPMI-1640  
  
HEK 293 Flp-IN T-Rex cell culture medium 
10 % (v/v)  Foetal calf serum  
in DMEM  
 
Mammalian cell lines were cultivated at 37 °C in 5 % CO2 humidified air. For 
harvesting, adherent cells were washed with DPBS and detached with 1x trypsin-EDTA 
(diluted in DPBS from 10x stock solution,). Trypsin was inactivated by the addition of 
cell culture medium. Cells were then pelleted at 400 x g for 5 min and resuspended in 
buffer or cell culture medium. To determine the cell concentration, 0.4 % (w/v) Trypan-
Blue solution was added to the cells in a 1:1 ratio and cells were counted in a Neubauer 
counting chamber. 
Mycoplasma infection of cell cultures can alter cell proliferation and cellular 
responses. Therefore, the cell lines were routinely tested for contamination with 
Mycoplasma using the MycoAlert® mycoplasma detection kit. In the presence of 
Mycoplasma, mycoplasmal enzymes react with the MycoAlert substrate and ATP is 
produced. ATP levels can then be meassured via the ATP-dependent conversion of 
luciferin to oxyluciferin by luciferase and the resulting luminescence could be detected 
on a Berthold Microlumat Plus LB96V luminometer. 
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2.4 Transfection of mammalian cells 
 
Four different transfection reagents were used for the transfection of mammalian cells. 
TransIT®-293 (Mirus), HiPerFect (Qiagen) and Lipofectamine
TM
2000 (Invitrogen) are 
all cationic, lipid-based transfection reagents. These reagents form liposomes which 
carry a positively charged head group. This head group interacts with negatively 
charged DNA leading to the condensation of the DNA and the formation of 
DNA:liposome complexes. The positive charge of the liposomes allows them to interact 
with the cell membrane and the uptake of the DNA:liposome complex into the cell is 
believed to happen via endocytosis (reviewed in Chesnoy and Huang, 2000). 
In contrast, transfection with the reagent Effectene® (Qiagen) is based on the 
formation of positively charged micelles. At first, the DNA is condensed using an 
enhancer and is then coated with the cationic Effectene micelle. Similar to the 
liposomes, the DNA-loaded micelles can then bind to the cell membrane and are also 
believed to be taken up into the cell via endocytosis. 
  
2.4.1 Transfection of mammalian cells with mammalian expression plasmids 
 
Transfection of HEK 293 Flp-IN T-Rex cells 
 
HEK 293 Flp-IN T-Rex selection medium A 
2 mM   L-glutamine  
10 % (v/v)  Foetal calf serum 
100 μg/ml  Zeocin 
15 μg/ml  Blasticidin S 
in DMEM  
 
HEK 293 Flp-IN T-Rex selection medium B 
2 mM   L-glutamine  
10 % (v/v)  Tetracycline-free foetal calf serum 
100 μg/ml Hygromycin B 
15 μg/ml  Blasticidin S 
in DMEM  
 
Opti-MEM 1 reduced serum medium with L-glutamine (Invitrogen) 
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Doxycycline-inducible stable HEK 293 Flp-IN T-Rex cells expressing TNFR2 variants 
were generated using the Flp-IN T-Rex system (Invitrogen). Cells were grown in HEK 
293 Flp-IN T-Rex selection medium A for 10 days prior to transfection to ensure cells 
carried the FRT recombination site and were expressing the Tet repressor. After this 
first selection, for each construct 8 x 10
5
 cells/flask were seeded in 7 ml of HEK 293 
Flp-IN T-Rex cell culture medium into three parallel 75 cm
2
 vented cell culture flasks 
and grown for 48 h. Cells were then co-transfected on day 3 with pcDNA5/FRT/TO 
(containing the insert of interest) and the pOG44 vector (encoding the Flp recombinase) 
in a 1:11 ratio. Briefly, 500 μl of Opti-MEM 1 reduced serum medium with L-glutamine 
were mixed with 25 μl of TransIT®-293 transfection reagent and 11 μg of total plasmid 
DNA and incubated at room temperature for 15 min. Cells were washed once with pre-
warmed DPBS and 180 μl of the transfection sample were added to each of the 75 cm2 
flasks. Cells were selected the next day with HEK 293 Flp-In T-Rex selection medium 
B. Cell culture medium was changed every 2-3 days and, in general, it took about 10 
days until stable cell clones were obtained. 
 
Transfection of HeLa cells using Effectene 
 
For transient and stable transfections of HeLa cells with expression plasmids the 
Effectene® transfection reagent kit was used.  2.5 x 10
5
 HeLa cells/well were seeded in 
2.5 ml of cell culture medium into a 6-well plate. The next day, 86 µl of buffer EC were 
combined with 750 ng of plasmid DNA and 6 µl of enhancer in a 1.5 ml reaction tube 
and incubated at room temperature for 5 min. After addition of 7.5 µl Effectene, the 
sample was mixed briefly and incubated at room temperature for 10 min. After the 
incubation, 261 µl of cell culture medium were added. Meanwhile, cells were washed 
once with pre-warmed DPBS and 670 µl of cell culture medium were added per well. 
The transfection sample was added to the cells drop by drop and cells were cultivated 
over night. The next day, cells were either harvested or, for stably transfected HeLa 
cells, selected with 3 µg/ml puromycin A. Cell culture medium was changed every 2-3 
days and, in general, it took about 7 days until stable cell clones were obtained. 
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Transfection of MF using Lipofectamine 
 
Transfection medium 
2 mM   L-Glutamine  
in RPMI-1640 
 
Simian virus 40 large T immortalised mouse embryonic fibroblasts (MF) generated 
from TNFR1/TNFR2 double-knockout mice were kindly provided by Prof. Daniela 
Männel (University of Regensburg, Germany). The generation of MF stably expressing 
TNFR-Fas chimaeric receptors using the Lipofectamine
TM
 method has been described 
previously (Krippner-Heidenreich et al., 2002).  
Briefly, 2.5 x 10
5
 cells/well were seeded in 6-well plates. The following day, 2.0 
μg of DNA were combined with 100 μl of transfection medium. In a separate reaction 
tube 6.0 μl of Lipofectamine reagent were added to 100 μl of transfection medium. 
After 15 min of incubation at room temperature, both samples were combined and 
incubated at room temperature for another 15 min. In the meantime, cells were washed 
with pre-warmed DPBS and covered with 800 µl of transfection medium. The 
transfection mixture was added to the cells drop by drop and cells were cultivated for 6 
h. The transfection mixture was then replaced with normal cell culture medium. The 
medium was changed the next day and puromycin A was added to a final concentration 
of 3 µg/ml. The cell culture medium was changed every 2-3 days and, in general, it took 
about 7 days until stable cell clones were obtained. 
 
2.4.2 Transfection of HeLa cells with siRNA  
 
HeLa cells were transfected with siRNA using the Qiagen transfection reagent 
HiPerFect. 3 x 10
5 
cells/well were seeded in 2.3 ml of cell culture medium into a 6-well 
plate and grown over night. The next day, 12 μl of HiPerFect transfection reagent were 
added to 100 μl of serum-free medium. 3 μl of 20 μM siRNA were added to this 
mixture and samples were incubated at room temperature for 10 min. Afterwards, the 
transfection samples were added to the cells drop by drop, resulting in a final siRNA 
concentration of 25 nM, and cells were cultivated over night. After 24 h and 48 h, 
respectively, HeLa cells were harvested for flow cytometry analysis (see section 2.5.2) 
or were used for co-immunoprecipitation (co-IP) experiments. 
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2.5 Cell sorting and flow cytometry 
 
PBS-BSA-sodium azide buffer (PBA) 
0.025 % (w/v)  Bovine serum albumine (BSA)  
0.02 % (w/v)   Sodium azide (NaN3) 
DPBS 
sterile filtered 
 
Antibodies 
Biotin rat anti-mouse IgG (H+L) (eBioscience); 
Mouse anti-human TNFR1 antibody clone H398 (Institute of Cell Biology and 
Immunology, University of Stuttgart, Germany); 
Mouse anti-human TNFR2 antibody clone MR2-1 (Hycult); 
Goat anti-mouse IgG + IgM (H + L)-FITC (Dianova); 
Streptavidin-phycoerythrin (BD); 
 
2.5.1 Cell sorting 
 
Previously transfected and puromycin A-selected cells were harvested (at least 5 x 10
6
), 
washed once with ice-cold PBA and resuspended in 500 µl of ice-cold PBA containing 
the primary antibodies mouse anti-human TNFR1 clone H398 (5 μg/ml) and mouse 
anti-human TNFR2 clone MR2-1 (2 µg/ml), respectively. After one hour of incubation 
on ice, the cells were washed once more and resuspended in ice-cold PBA containing 
the fluorescein isothiocyanate (FITC)-labelled secondary antibodies (goat anti-mouse 
IgG + IgM (H + L)-FITC, 1:200). After 45 min of incubation in the dark, the cells were 
washed once and were resuspended in ice-cold PBA to a concentration of approximately 
3 x 10
6
 cells/ml. 40,000 cells were sorted into sterile FACS-tubes containing 3 ml cell 
culture medium. The cell culture medium was supplemented with 20 µM zVADfmk, a 
pan caspase-inhibitor, to prevent induction of cell apoptosis by the antibody staining 
and/or sorting process. Cells were then transferred to a 6-well plate and selected with 3 
µg/ml puromycin A the next day. The selection medium was changed every 2-3 days 
and after approximately 10 days cells could be used for further analyses. 
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2.5.2 Flow cytometry 
 
For the detection of exogenously expressed TNFR2, TNFR2 variants and TNFR-Fas 
chimaeras on the cell surface 5 x 10
5
 cells were harvested, washed once with ice-cold 
PBA and transferred into V-bottom 96-well plates. Cells were incubated in 100 µl PBA 
containing 2 µg/ml of TNFR2 specific antibodies (mouse anti-human TNFR2 clone 
MR2-1) or 5 μg/ml of TNFR1 specific antibodies (mouse anti-human TNFR1 clone 
H398) on ice for 1 h. After washing with 200 µl PBA, cells were incubated on ice with 
FITC-labelled secondary antibodies (goat anti-mouse IgG + IgM (H + L)-FITC, 1:200) 
for 1 h, washed again with ice-cold PBA and analysed by flow cytometry on a Becton 
Dickinson FACScan or FACSCanto II. Cells incubated with PBA or secondary 
antibodies only served as controls.  
 
For the detection of endogenously expressed TNFR1 on HeLa cells, the protocol 
described above with the following changes was used: Cells were resuspended in 100 μl 
PBA containing 2 μg/ml human IgG and 5 μg/ml primary mouse anti-human TNFR1 
antibodies H398. Cells were incubated on ice for 1 h and were then washed twice with 
150 μl of ice-cold PBA. Cells were resuspended in ice-cold 50 μl PBA containing 2 % 
(v/v) rat serum and incubated on ice for 15 min. 1 μl of biotin rat anti-mouse IgG (H+L) 
(1:50) was added to each well and samples were incubated on ice for 30 min. Cells were 
washed twice with 100 μl PBA and resuspended in 70 μl PBA containing 5 μl of 
streptavidin-phycoerythrin. After a 20 min incubation on ice in the dark, cells were 
washed twice with ice-cold PBA, resuspended in PBA and analysed on a Becton 
Dickinson FACSCanto II flow cytometer. 
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2.6 Cell viability assay using crystal violet staining  
 
10x Phosphate buffered saline (PBS) 
160.8 mM Na2HPO4 
39.5 mM NaH2PO4 
1.2 M  NaCl 
pH adjusted to 7.2 
 
Crystal violet solution 
0.5 % (w/v)  Crystal violet powder 
20 % (v/v)  Methanol  
ddH2O 
 
For cell viability assays of MF TNFR-Fas, 1 x 10
4
 cells/well were seeded in 100 µl of 
cell culture medium into a flat bottom 96 well plate. The next morning, cells were 
treated with serial dilutions of sTNF and CysTNF (0.015-100 ng/ml), respectively. 
After 8 h of cultivation, the medium was removed and cells were washed three times 
with 1x PBS. Cells were then stained with 70 µl/well of crystal violet solution for 20 
min at room temperature. After removing the crystal violet solution, plates were washed 
with ddH2O and left to air-dry over night. 100 µl of 100 % methanol were added per 
well and the absorbance at 550 nm was determined using a TECAN sunrise basic 
microplate reader. 
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2.7 Bradford protein assay 
 
The determination of protein concentrations with the Bradford protein assay is based on 
the shift in absorbance (465 nm to 595 nm) the Coomassie Brilliant Blue G-250 dye 
undergoes upon binding to proteins. The protein-dye complex formation stabilises the 
negatively charged, blue form of the dye in acidic solution. The protein concentration 
correlates with the absorbance and can be determined via comparison with a solution of 
a protein, such as BSA, of known concentration. 
Cell lysates were prepared using solubilisation buffers as described in sections 
2.10 and 2.12. 20 μl of the cell lysates were transferred into the wells of a flat-bottom 
96-well plate and 300 μl of room temperature BradfordUltra reagent were added to each 
well. The plate was incubated at room temperature for 5 min and then the absorbance at 
595 nm was determined on a TECAN sunrise basic microplate reader. Samples were 
prepared in duplicates or triplicates. 
 
2.8 SDS-polyacrylamide gel electrophoresis 
 
4x Resolving gel buffer 
1.5 M   Tris-HCl pH 8.8 
0.4 % (w/v)  SDS 
 
10 % SDS polyacrylamide gel solution 
1x  Resolving gel buffer 
10 % (w/v) Acrylamide/bis-acrylamide (37.5:1) 
0.1 % (w/v)  Ammonium persulphate (APS)  
0.17 % (w/v)  N,N,N‟N‟-tetramethylenediamine (TEMED) 
 
4x Stacking gel buffer 
0.5 M   Tris-HCl pH 6.8 
0.4 % (w/v)  SDS 
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4.5 % Stacking gel solution 
1x  Stacking gel buffer 
4.5 % (w/v) Acrylamide/bis-acrylamide (37.5:1) 
0.1 % (w/v)  Ammonium persulphate (APS)  
0.17 % (w/v)  N,N,N‟N‟-tetramethylenediamine (TEMED) 
 
4x Sample buffer 
0.25 M  Tris-HCl pH 6.8 
0.28 M  SDS 
0.4 % (w/v)  Bromophenol blue 
40 % (v/v)  Glycerol 
20 % (v/v)  β-mercaptoethanol (added just before use) 
 
10x Running buffer 
250 mM Tris 
2 M  Glycine 
10 % (w/v)  SDS 
 
Sealing agarose 
0.5 % (w/v)  Agarose  
ddH2O 
 
SDS-PAGE gels consist of a fine mesh of acrylamide and bisacrylamide, which is 
generated in a co-polymerisation reaction. TEMED accelerates formation of free 
radicals from APS. APS radicals in turn catalyse the polymerisation of acrylamide and 
bisacrylamide. SDS present in the SDS-PAGE gels and buffers provides denaturing 
conditions during electrophoresis and, furthermore, ensures that all proteins are 
negatively charged and can be resolved in the gel solely according to their molecular 
weight irrespective of their other electrochemical properties. 
The stacking gel has a lower pH of 6.8 at which glycine exists as zwitterion. 
During electrophoresis, proteins are concentrated into a thin band between the neutrally 
charged glycine zwitterions and the negatively charged chloride ions in the stacking gel. 
Entering into the resolving gel, the pH increases to 8.8. Glycine becomes negatively 
charged and overtakes the proteins in the resolving gel, leading to a further concentration of 
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the protein bands. In the resolving gel proteins are separated based on their molecular 
weight. 
 
Discontinuous Tris/glycine SDS-PAGE was performed using a vertical PROT-
RESOLV MAXI-LC gel electrophoresis chamber (Phase GmbH, Lübeck) with 1.5 mm 
spacers and combs (immunoprecipitation samples) or 1.0 mm spacers and combs (all 
other samples). Glass plates and spacers were assembled and sealing agarose was 
applied to prevent leakage of the gel solution during pouring. For the resolving gel, 10 
% SDS polyacrylamide gel solution was poured between the plates and overlaid with 
propan-2-ol to exclude oxygen. The gel was allowed to polymerise. After the gel had 
set, the propan-2-ol was removed, a 4.5 % stacking gel was poured on top and the comb 
was inserted. After the stacking gel had set, the comb was removed and the gel kit was 
assembled into the device. Both gel chambers were filled with 1x running buffer. 
Cell lysates supplemented with 1x sample buffer were denatured at 105 °C for 3 
min. Samples were then loaded onto the gel together with a broad range prestained 
protein marker (NEB). For the stacking of the proteins electrophoresis was performed at 
constant 90 V and for the separation at constant 180 V. The gel run was stopped when 
the bromophenol blue front had reached the bottom of the gel and the gel was analysed 
using Western Blot analysis. 
 
2.9 Western Blot analysis 
 
Transfer buffer 
192 mM Glycine 
25 mM  Tris-HCl pH 8.3 
20 % (v/v)  Methanol 
ddH2O 
 
1x phosphate buffered saline-Tween 20 (PBS-T) 
16.08 mM Na2HPO4 
3.95 mM NaH2PO4 
120 mM NaCl 
0.05 % (v/v)  Tween 20 
pH adjusted to 7.2 
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Blocking solution 
5 % (w/v)  Non-fat milk powder 
PBS-T 
 
PBA 
0.025 % (w/v) BSA  
0.02 % (w/v)  NaN3  
DPBS 
 
Proteins were transferred from SDS-polyacrylamide gels onto PVDF membranes 
(immunoprecipitation samples) or nitrocellulose membranes (all other samples) using a 
Pegasus S semi-dry blotting chamber (Phase, Lübeck).  
The blotting chamber was assembled as follows: a layer of three 1.0 mm thick 
Whatman papers soaked in transfer buffer was placed on the cathode plate and the gel 
was placed on top of the Whatman papers, followed by the nitrocellulose membrane, 
which had been bathed briefly in transfer buffer. When PVDF membranes were used, 
the membrane was briefly soaked in methanol, was washed in ddH2O and a finally 
soaked in transfer buffer. Another layer of three soaked Whatman papers was placed on 
top of the membrane.  
The anode plate was placed on top of the second Whatman paper layer and protein 
transfer was performed for 80 min at 1.4 mA/cm
2
. After the transfer, the membrane was 
incubated in blocking buffer on a rocking table at room temperature for 1 h. Then the 
membrane was washed four times for 10 min with PBS-T and incubated with the 
primary antibodies at 4 °C over night. The next day, the membrane was washed four 
times for 10 min with PBS-T and incubated with the secondary antibodies for 2 h at 
room temperature on a rocking table. The membrane was washed again and overlaid 
with SuperSignal® West Pico or SuperSignal® West Dura chemiluminescence 
substrate (Thermo Scientific/Pierce) and transferred between two layers of clear-
transparent plastic film. The secondary antibodies were labelled with horseradish 
peroxidise (HRP). This enzyme cleaved the West Pico and West Dura substrates, 
respectively, and the resulting chemiluminescence was captured on Kodak® BioMax
TM
 
MR autoradiography films (Sigma-Aldrich) or detected using a Syngene G:Box and the 
GeneSnap V7.09 aquisition software (Syngene UK, Cambridge). Western Blot band 
quantification was performed using the GeneTools V4.01 analysis software (Syngene 
UK, Cambridge).  
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2.10 Protein crosslinking with bis[sulfosuccinimidyl]suberate 
 
Solubilisation buffer  
20 mM Tris-HCl pH 7.4 
150 mM  NaCl 
1 mM  EDTA 
1 % (v/v)  Triton X-100 
1x  Complete, Mini, EDTA-free protease inhibitor cocktail tablets (Roche 
Applied Science, Burgess Hill, UK; added just before use) 
 
Bis[sulfosuccinimidyl]suberate (BS
3
) stock solution 
500 μM  Bis[sulfosuccinimidyl]suberate 
in DPBS 
 
10x Tris-buffered saline (TBS) 
200 mM Tris-HCl pH 7.6 
1.37 M NaCl 
in ddH2O 
 
3 x 10
5 
cells/well of MF TNFR-Fas were seeded into 6-well plates and grown over 
night. For each concentration of the chemical crosslinking reagent 
bis[sulfosuccinimidyl]suberate (BS
3
) two parallel wells were seeded. The next day, cells 
were transferred onto ice and washed once with ice-cold DPBS. Afterwards, cells were 
incubated with 0.8 ml/well of freshly prepared dilutions of BS
3
 (0 μM, 33 μM, 64 μM, 
125 μM, 250 μM and 500 μM, respectively) for 30 min on ice. The crosslinking 
reaction was stopped by addition of Tris-HCl pH 7.2 to a final concentration of 10 mM 
and incubation at room temperature for 15 min. Cells were washed once with 1 ml of 
ice-cold 1x TBS and harvested on ice using a rubber cell scraper. Cells were pelleted at 
400 x g at 4 ºC for 5 min and resuspended in 200 μl of solubilisation buffer. Samples 
were vortexed for 30 sec and incubated on ice for 5 min afterwards. This step was 
repeated six times. Finally, the samples were centrifuged at 13000 x g at 4 ºC for 10 
min. Supernatants were transferred to new 1.5 ml reaction tubes and protein 
concentrations were determined via Bradford analysis. Samples were normalised for 
protein concentrations and receptor cell surface expression as determined by parallel 
FACS analyses. Chimaeric receptors were detected using the mouse anti-human 
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cytoplasmic Fas antibody clone B10 (Santa Cruz; 1:2000) and goat anti-mouse IgG-
HRP antibodies (Dianova; 1:20000). 
 
2.11 Inhibition of core 1 and core 2 O-glycosylation in MF TNFR-Fas 
cells 
 
Mucin-type O-glycosylation is initiated by the addition of an N-acetyl-galactosamine 
(GalNAc) residue to the hydroxyl group of a serine or threonine residue of the protein 
substrate. Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside (Benzyl-α-GalNAc) is a 
structural analog of GalNAc (Figure 9) and can function as a competitive inhibitor for β-
1,3-galactosyltransferase-dependent core 1 and core 2 O-glycosylation (Kuan et al., 
1989). 
MF TNFR1-Fas and MF TNFR2-Fas were cultivated in cell culture medium 
containing 3.5 mM Benzyl-α-GalNAc until day 3 or day 4. TNFR2-SL56-Fas were 
cultivated in cell culture medium containing 3.5 mM Benzyl-α-GalNAc until day 4. The 
cell culture medium was replaced with fresh medium containing 3.5 mM Benzyl-α-
GalNAc on day 2. 
For flow cytometry and Western Blot experiments 2.5 x 10
5
 cells/well were 
seeded into a 6-well plate on day 3 and 4, respectively. For cell viability assays 1 x 10
5
 
cells/well were seeded into a 96-well plate on day 3 and day 4. The cell culture medium 
was supplemented with 3.5 mM Benzyl-α-GalNAc. 0.55 % (v/v) DMSO served as 
solvent control. Chimaeric receptors were detected using the mouse anti-human 
cytoplasmic Fas antibody clone B10 (Santa Cruz; 1:2000) and goat anti-mouse IgG-
HRP antibodies (Dianova; 1:20000). 
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GalNAc Benzyl-α-GalNAc
A B
 
 
Figure 9. Chemical Structure of Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside. 
Shown are the chemical structures of A) 2-Acetamido-2-deoxy-D-galactose (GalNAc) and B) 
Benzyl-2-acetamido-2-deoxy-α-D-galactopyranoside (Benzyl-α-GalNAc). Both, GalNAc and 
Benzyl-α-GalNAc can act as substrates for β-1,3-galactosyltransferase.  
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2.12 TNFR2/TRAF2 co-immunoprecipitation from HeLa cell lysates 
 
Solubilisation buffer Shu 
20 mM Tris-HCl pH 7.5 
150 mM  NaCl 
1 mM  EDTA 
1 % (v/v)  Triton X-100 
30 mM NaF  
1x   Complete, Mini, EDTA-free protease inhibitor cocktail tablets (Roche 
Applied Science, Burgess Hill, UK; added just before use) 
0.5 mM  PMSF (added just before use) 
 
Antibodies 
Mouse anti-human TRAF2 antibody clone C90–481 (BD/Pharmingen, Oxford, UK) 
Polyclonal goat anti-human soluble TNFR2 antibodies (R&D Systems Europe Ltd., 
Abingdon, UK) 
Goat anti-mouse IgG-HRP antibody (Dianova, Hamburg, Germany) 
Rabbit anti-goat IgG-HRP antibody (Sigma-Aldrich Company Ltd., Poole, UK) 
 
Co-immunoprecipitation allows the purification of intact protein complexes from cell 
lysates. Antibodies against a specific protein are coupled to a solid matrix and can bind 
their target protein from cell lysates. The matrix, here protein G sepharose beads, can 
then be pelleted together with the protein of interest. Associated proteins present in the 
target protein complex will be precipitated together with the protein of interest and can 
be analysed, e.g. by Western Blotting. 
For each immunoprecipitation sample 2.5 x 10
5
 HeLa cells/well were seeded 
into 6-well plates. The next day, the medium was replaced with 1 ml of pre-warmed cell 
culture medium containing 10 ng/ml of sTNF and CysTNF, respectively. Cells were 
stimulated at 37 ºC for 5 min, 10 min or 15 min. After stimulation the cells were 
transferred onto ice and washed with 3 ml of ice-cold DPBS. Cells were harvested in 
750 μl of ice-cold DPBS using a cell scraper and pelleted at 400 x g at 4 ºC for 5 min. 
The cell pellets were resuspended in 300 μl of solubilisation buffer Shu. The resulting 
lysates were vortexed three times for 45 sec with 5 min incubations on ice in between. 
Cell lysates were centrifuged at 13000 x g at 4 ºC for 10 min and the supernatants were 
transferred into fresh 1.5 ml Eppendorf reaction tubes. For each immunoprecipitation 
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sample an equivalent of 5 x 10
5
 cells was used. The use of equal amounts of protein was 
ensured by Bradford analysis. 2 μg of monoclonal goat anti-human soluble TNFR2 
antibodies (R&D) were added to each lysate and samples were incubated on a rotary 
mix at 4 ºC for 2 h. The lysates were then added to 10 μl of equilibrated slurry (1:1) 
protein G sepharose beads and incubated at 4 ºC on the rotary mix for 1 h. Beads were 
washed three times with 1 ml of solubilisation buffer Shu and pelleted at 14000 x g. 50 
μl of 1x SDS PAGE sample buffer were added to the pelleted beads and the mixture 
was vortexed briefly. The samples were denatured at 105 ºC for 3 min, the beads were 
pelleted and supernatants were loaded onto a 10 % SDS gel. TRAF2 was detected using 
mouse anti-human TRAF2 antibodies (BD/Pharmingen; 1:2000) and goat anti-mouse 
IgG-HRP antibodies (Dianova; 1:20000).  
Precipitated TNFR2 was detected using polyclonal goat anti-human soluble 
TNFR2 antibodies (R&D; 1:2000) and rabbit anti-goat IgG-HRP antibodies (Sigma-
Aldrich; 1:20000). β-actin from the supernatants of the co-immunoprecipitation samples 
was detected on a separate gel using mouse anti-human β-actin antibodies AC-15 
(Abcam; 1:50000) and goat anti-mouse IgG-HRP antibodies (Dianova; 1:20000). 
 
2.13 Analysis of p65 translocation in MF via immunofluorescence 
 
Antibodies 
Polyclonal rabbit anti-human p65 antibody clone C-20 (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA)  
Alexa594-conjugated goat anti-rabbit IgG (H+L) antibody (Molecular 
Probes/Invitrogen Ltd., Paisley, UK) 
 
5 x 10
4
 MF were seeded onto ethanol-sterilised glass cover slips in a 24-well plate. The 
next day, some of the cells were pre-treated with 1.25 μg/ml mouse anti-human TNFR2 
antibody clone 80M2 for 30 min prior to stimulation. Cells were then stimulated by 
adding sTNF and CysTNF, respectively, to a final concentration of 100 ng/ml. Cells 
were stimulated for 30 min or 60 min and then transferred onto ice. The medium was 
removed using an aspirator, cells were washed once with ice-cold DPBS and fixed with 
300 μl/well of 3.7 % formaldehyde for 10 min at room temperature. Cells were washed 
once with DPBS and permeabilised for 10 min at room temperature using 1 ml 0.1 % 
(w/v) saponin/0.5 % (w/v) BSA/DPBS per cover slip. The saponin solution was 
removed and the cells were blocked with 3 % (w/v) BSA/DPBS for 45 min at room 
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temperature. Each cover slip was stained with 75 μl of primary antibody solution 
(polyclonal rabbit anti-human p65 IgG (C-20) sc-372 1:100 in 1 % (w/v) BSA/DPBS) 
in a wet chamber for 2 h at room temperature. Cover slips were washed three times with 
DPBS and were then incubated in 75 μl of secondary antibody solution (Alexa594-
conjugated goat anti-rabbit IgG (H+L) 1:100 in 1 % (w/v) BSA/DPBS) in a wet 
chamber for 1 h at room temperature in the dark. Cover slips were washed three times 
with DPBS and then mounted onto microscope slides with Vectashield® DAPI-
containing mounting medium (Vector Laboratories Ltd., Peterborough, UK). Images 
were acquired on a Zeiss Axio Imager 2 fluorescence microscope using the AxioVision 
4.7.2 software. 
 
2.14 Confocal microscopy of HEK FlpIN T-Rex cells over-expressing 
TNFR2 and TNFR2 variants 
 
Distribution of the TNFR on the cell surface was investigated by confocal microscopy 
of doxycycline-induced HEK Flp-IN T-Rex cells, which had been stained with either 
AlexaFluor546-labelled recombinant human sTNF or phycoerythrin-conjugated 
TNFR2-specific antibodies clone # 22235 (R&D Systems Europe Ltd., Abingdon, UK). 
Ethanol-sterilised glass cover slips were coated with poly-L-lysine. Briefly, cover slips 
were incubated with the 0.01% (w/v) poly-L-lysine solution (MW: 70 - 150 kDa; 
Sigma-Aldrich Company Ltd. (Poole, UK)) for 5 min and the excess solution was 
removed. Cover slips were left to air-dry at room temperature in a laminar flow.  
8 x 10
4
 HEK Flp-In T-Rex cells/well were seeded onto the poly-L-lysine coated 
cover slips in 12-well plates. After 6 h, TNFR expression was induced by additing 
doxycycline to a final concentration of 6 ng/ml. After 18 h of induction cells were 
transferred onto ice and washed three times with ice-cold DPBS. Cover slips were then 
stained with 50 μl 1.7 μg/ml AlexaFluor546-labelled recombinant human sTNF diluted 
in HEK cell culture medium on ice for 5 min. Cells were washed three times with ice-
cold DPBS and were fixed with 4 % formaldehyde at room temperature for 20 min. 
Cover slips were washed three times with DPBS and incubated with 200 μl of 1 μg/ml 
DAPI/1 % (w/v) BSA/DPBS at room temperature for 30 min. Cover slips were washed 
three times with DPBS, mounted onto glass microscope slides using Fluoromount G 
mounting medium and sealed with clear nail varnish. Images were acquired on an 
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Andor Revolution XD confocal microscope using the Andor iQ 1.9.1 software 
(Welcome Trust Grant reference number 087961). 
 
For the staining with the phycoerythrin-conjugated TNFR2-specific antibodies (clone # 
22235), cells were seeded as described above and fixed with 4 % formaldehyde at room 
temperature for 20 min. TNFR2-specific antibodies were diluted 1:75 in HEK Flp-IN T-
Rex cell culture medium. Cells were stained with of 50 μl of this dilution for 1 h at 
room temperature in a wet chamber. Afterwards, cells were washed three times with 
DPBS and mounted onto glass microscope slides and analysed as described above. 
 
To demonstrate cell membrane localisation of the TNFR, co-localisation with Oregon 
Green-conjugated wheat germ agglutinin (WGA) staining was assessed. The lectin 
WGA selectively recognises sialic acid and N-acetylglucosaminyl sugars, which are 
predominantly found in the cell membrane. Cells were stained as described above and 
the DAPI staining solution was supplemented with 5 μg/ml of Oregon Green-
conjugated wheat germ agglutinin. 
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CHAPTER 3 
Results I: Control of sTNF responsiveness by the TNFR1 and 
TNFR2 stalk regions 
 
3.1 Introduction 
 
TNFR1 and TNFR2 can bind membrane-bound TNF and sTNF with high affinity (Grell 
et al., 1998b). However, while TNFR1 can be efficiently activated by both forms of 
TNF, efficient activation of TNFR2 only occurs upon stimulation with membrane-
bound TNF (Grell et al., 1995). A cellular system to investigate differential 
responsiveness of TNFR1 and TNFR2 has been described previously (Krippner-
Heidenreich et al., 2002). Krippner-Heidenreich et al. (2002) stably transfected 
embryonic fibroblasts from tnfr1
-/-
/tnfr2
-/- 
double knockout mice (MF) with TNFR-Fas 
chimaeras, which consisted of the extracellular and transmembrane part of the TNFR 
and the cytoplasmic part of Fas (a potent inducer of apoptosis in MF)(Figure 10). The 
intracellular domain of Fas ensures that the signalling outcome upon activation is 
identical between TNFR-Fas chimaeras. Therefore, this cellular system allows 
comparing activation of TNFR1 and TNFR2 while it also eliminates the major technical 
problem that TNFR1 tends to induce ligand-independent toxicity when expressed 
exogenously.  
MF TNFR-Fas can be stimulated with sTNF or CysTNF, a mutant variant of 
sTNF which forms oligomers via an N-terminal cysteine residue and displays activity 
similar to membrane-bound TNF (Bryde et al., 2005). Cell viability can then be 
determined by crystal violet staining and reflects the responsiveness of TNFR-Fas 
chimaeras towards the respective ligand. Pilot data obtained with this cellular system 
showed that responsiveness to sTNF is not determined by the intracellular portion of 
either TNFR (Krippner-Heidenreich et al., 2002)(see also Figure 11 A and D).  
 
Preliminary data from MF transfected with TNFR-Fas chimaeras in which stalk (S) and 
transmembrane (TM) regions had been exchanged between receptors (TNFR1-
(S/TM)R2-Fas and TNFR2-(S/TM)R1-Fas, Figure 10) suggest a role for these regions in 
determining the differential responsiveness to sTNF (Figure 11 B and E, obtained in our 
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group previously). Analysis of chimaeras, in which only the TM had been exchanged 
between TNFR1-Fas and TNFR2-Fas, indicates that the TM regions play only a minor 
role in differential responsiveness towards sTNF (data not shown, diploma thesis 
Gerlinde Holeiter 2005, Stuttgart University, Germany). This implies that the stalk 
region plays a major role in determining sTNF responsiveness. 
 
The stalk regions of TNFR1 and TNFR2 do not only differ in their aa composition but, 
with 15 aa for TNFR1 and 56 aa for TNFR2, also in their length. To investigate whether 
a component within the stalk region determines responsiveness towards sTNF, the 
TNFR2 stalk region in the TNFR1-(S/TM)R2-Fas chimaeras was shortened by 42 amino 
acids (TNFR1-(SΔ42/TM)R2-Fas, Figure 10). These chimaeras, in which the stalk length 
is comparable to the one of TNFR1, were responsive to sTNF (Figure 11 C), supporting 
a role for the stalk regions of TNFR1 and TNFR2 in differential sTNF responsiveness. 
 
Therefore, the aims in this chapter were to: 
 Investigate whether the TNFR2 stalk region has an inhibitory effect on the sTNF 
responsiveness of TNFR2-Fas chimaeras; 
 Determine whether the TNFR2 stalk region controls sTNF responsiveness of 
wild type TNFR2; 
 Establish a read-out system for sTNF-mediated downstream signalling of wild 
type TNFR2. 
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Figure 10. Schematic representation of TNFR-Fas chimaeras. 
Wild type TNFR1 and TNFR2, chimaeric receptors TNFR1-Fas and TNFR2-Fas as well as four 
TNFR-Fas variants are shown schematically. TNFR-Fas chimaeras consist of the extracellular 
and transmembrane (TM) domain of TNFR1 (aa 1-236, light blue) and TNFR2 (aa 1-301, 
orange), respectively, and the intracellular portion of Fas (aa 191-335, dark blue)(Krippner-
Heidenreich et al., 2002). The TM and stalk regions (S, shaded) are indicated. Exchange of aa 
197-236 of TNFR1 and aa 202-301 of TNFR2 between TNFR-Fas resulted in the TNFR1-
(S/TM)R2-Fas and TNFR2-(S/TM)R1-Fas chimaeras. TNFR1-(SΔ42/TM)R2-Fas and TNFR2-
(SΔ42/TM)R2-Fas represent chimaeras in which the TNFR2 stalk region had been shortened to the 
same length as the TNFR1 stalk region. The deletion comprised aa 202-243 of TNFR2. 
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Figure 11. Preliminary data suggest a role for stalk and/or TM regions of TNFR in sTNF responsiveness.  
MF were stably transfected with A) TNFR1-Fas, B) TNFR1-(S/TM)R2-Fas, C) TNFR1-(SΔ42/TM)R2-Fas, D) TNFR2-Fas or E) TNFR2-(S/TM)R1-Fas. Cells remained 
untreated or were stimulated with increasing concentrations (0.015-100 ng/ml) of sTNF and CysTNF, a TNF variant that mimics membrane-bound TNF (Bryde et 
al., 2005). Data shown represent more than three independent experiments and were kindly provided by Dr Anja Krippner-Heidenreich, Newcastle University, UK.
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3.2 The TNFR2 stalk region inhibits sTNF responsiveness in 
TNFR2-Fas chimaeras 
 
Preliminary data obtained from MF stably transfected with the TNFR1-(S/TM)R2-Fas 
and TNFR1-(SΔ42/TM)R2-Fas chimaeras suggested that the TNFR stalk regions are 
determining receptor responsiveness to sTNF (Figure 11 B and C). In order to elucidate 
whether the TNFR2 stalk region also controls sTNF responsiveness of the TNFR2-Fas 
chimaera, the stalk region of this construct was shortened by the same 42 aa residues as 
in TNFR1-(SΔ42/TM)R2-Fas. The aa sequence of the stalk region of the resulting 
TNFR2-(SΔ42/TM)R2-Fas construct is depicted in Figure 12. The two N-terminal aa 
residues of the TNFR2-(SΔ42/TM)R2-Fas stalk region (GS) represent the BamHI 
restriction site used for the generation of this construct. MF stably transfected with this 
chimaera (MF TNFR2-(SΔ42/TM)R2-Fas) were generated by Dr Andrea Zappe, 
University of Stuttgart, Germany, and were analysed at Newcastle University.   
 
MF TNFR2-(SΔ42/TM)R2-Fas were characterised by FACS analysis (Figure 13 A) and 
Western Blotting (Figure 13 B). The TNFR2-(SΔ42/TM)R2-Fas chimaera was expressed 
on the cell surface of MF with a mean fluorescence intensity (MnX) of 187. 80 % of the 
cells could be gated positive for the construct (Figure 13 A).  
The correct molecular weight of the stably transfected constructs was confirmed 
via Western Blot analysis using whole cell lysates from both transiently transfected 
HeLa cells and stably transfected MF (Figure 13 B). The predicted molecular weight for 
the TNFR2-Fas construct is 48 kDa whereas the one for TNFR2-(SΔ42/TM)R2-Fas is 44 
kDa (both determined using the ProtParam tool on the ExPaSy proteomics 
server)(Gasteiger et al., 2005). For both constructs two bands could be observed in 
Western Blot analysis, of which the faster migrating bands correlated with the predicted 
molecular weights for the constructs (Figure 13 B).  
As whole cell lysates were used in this Western Blot, the faster migrating protein 
bands presumably represent receptors which had been translated but had not undergone 
any post-translational modification yet, whereas the slower migrating bands probably 
represent the mature form of the receptor. This assumption is supported by the fact that 
more of the putatively un-modified forms of the TNFR-Fas chimaeras can be found in 
lysates from transiently transfected HeLa cells than in lysates from stably transfected 
MF (Figure 13 B). 
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Figure 12. The aa sequences of the TNFR1, TNFR2 and TNFR2-(SΔ42/TM)R2-Fas stalk regions.  
Shown are the aa sequences of the stalk regions of TNFR1 (aa 197-211) and TNFR2 (aa 202-257). The aa sequence of the TNFR2 stalk region, in which aa 202-243 
had been deleted, is also shown (TNFR2-(SΔ42/TM)R2-Fas). The two N-terminal aa residues of the TNFR2-(SΔ42/TM)R2-Fas stalk region (GS) represent the BamHI 
restriction site used for the generation of this construct.  
8
9
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Figure 13. Characterisation of TNFR2-Fas chimaeras with a shortened stalk region.  
MF had been stably transfected with the TNFR2-(SΔ42/TM)R2-Fas chimaera. After selection with 
puromycin A the cells were characterised by FACS and Western Blot analyses. A) FACS 
analysis of MF TNFR2-(SΔ42/TM)R2-Fas. Chimaeras were stained on the cell surface using 
mouse anti-human TNFR2 antibodies (clone MR2-1) and goat anti-mouse IgG-FITC antibodies 
(black line). Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC 
antibodies (grey). 80 % of the MF were gated positive for TNFR2-(SΔ42/TM)R2-Fas. Acquisition 
was performed on a Becton Dickinson FACScan flow cytometer. B) Western Blot analysis of 
MF TNFR2-(SΔ42/TM)R2-Fas. Whole cell lysates from 1 x 10
5
 cells were subjected to SDS-
PAGE and Western Blot analysis. Mouse anti-human Fas antibodies (clone B10, 1:2000) were 
used as primary and goat anti-mouse-IgG-HRP (1:20000) as secondary antibodies. HeLa cells 
transiently transfected with indicated TNFR-Fas chimaeras, untransfected MF, MF TNFR1-Fas 
and MF TNFR2-Fas served as controls. Data shown represent one experiment.  
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To determine the effect the shortening of the TNFR2 stalk region had on sTNF 
responsiveness of TNFR2-Fas, cell viability assays were performed with MF TNFR2-
(SΔ42/TM)R2-Fas. For this purpose MF TNFR2-(SΔ42/TM)R2-Fas were treated with 
increasing concentrations of CysTNF and sTNF, respectively, and cell viability was 
determined using crystal violet staining. About 75 % of the cells were responsive 
towards CysTNF (Figure 14 A and B), which correlated with the receptor positive cell 
population determined by FACS analysis (Figure 13 A). The responsiveness towards 
CysTNF with a half-maximal effective dose (ED50) of 0.3 ng/ml was comparable to that 
of MF TNFR2-Fas cells (ED50 = 0.2 ng/ml, Figure 11 D). This indicates that CysTNF-
mediated activation of this chimaera is not compromised by the deletion of the 42 aa in 
the TNFR2 stalk region.  
In contrast to TNFR2-Fas, TNFR2-(SΔ42/TM)R2-Fas was activated by sTNF, 
although the responsiveness towards sTNF was somewhat reduced (ED50 = 3 ng/ml) 
compared to the one seen for CysTNF (ED50 = 0.3 ng/ml). This, together with the data 
from the TNFR1-(SΔ42/TM)R2-Fas chimaera, shows that the inhibitory effect of the 
TNFR2 stalk region on sTNF responsiveness can be overcome when this stalk region is 
shortened by 42 aa residues (see Figure 11 C and Figure 14 C). Therefore, one or more 
feature(s) that is (are) encoded by these 42 aa appears to inhibit sTNF responsiveness of 
TNFR2. 
 
Interestingly, only about 50 % of the cells were responsive to saturating concentrations 
of sTNF (Figure 14 A and B), suggesting that a subpopulation of the cells was resistant 
to sTNF. When cells were treated with 100 ng/ml sTNF for 8 h and the surviving cells 
were challenged again after 2 days of cultivation, no difference in receptor cell surface 
expression (Figure 15 A and C) and responsiveness to TNF (Figure 15 B and D) 
between pretreated and non-pretreated cells could be detected. Therefore, we could 
exclude the possibility that during the selection process of this cell line an sTNF-
resistant sub-population had been generated. Our observations rather suggest that an 
unknown intrinsic mechanism leads to a certain percentage of sTNF-unresponsive cells. 
However, this mechanism has not been further investigated in this project and remains 
as future work.   
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Figure 14. MF TNFR2-(SΔ42/TM)R2-Fas are responsive to sTNF. 
MF stably transfected with TNFR2-(SΔ42/TM)R2-Fas remained untreated or were stimulated with 
increasing concentrations of sTNF and CysTNF (0.015-100 ng/ml) for 8 h. Adherent cells were 
stained using crystal violet solution. A) Photograph of a 96-well plate after crystal violet 
staining; B) Corresponding absorbances at 550 nm were determined for quantitative analysis of 
cell viability. Data shown represent five independent experiments.   
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Figure 15. Partial responsiveness of MF TNFR2-(SΔ42/TM)R2-Fas to sTNF is an 
intrinsically regulated phenomenon.  
MF stably transfected with TNFR2-(SΔ42/TM)R2-Fas were A and B) left untreated or C and D) 
pre-selected with sTNF. Cells were analysed 48 h post pre-selection.  A and C) FACS analysis; 
chimaeras were stained on the cell surface using mouse anti-human TNFR2 antibodies (clone 
MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). Cells only incubated with goat 
anti-mouse IgG-FITC antibodies are depicted in grey. 98 % of the MF were gated positive for 
TNFR2-(SΔ42/TM)R2-Fas. Acquisition was performed on a Becton Dickinson FACSCanto II 
flow cytometer. B and D) Cell viability assay; cells remained unstimulated or were stimulated 
with increasing concentrations of sTNF and CysTNF (0.015-100 ng/ml), respectively, and 
viable cells were stained using crystal violet. Data shown represent three independent 
experiments.  
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3.3 Influence of the stalk region on sTNF-mediated TNFR2 complex 
formation 
 
Data obtained from the MF TNFR-Fas cell system suggest an important role for the 
TNFR stalk regions in the control of receptor responsiveness to sTNF (see sections 3.1 
and 3.2). However, while the use of this cell system allowed us to assess TNFR-Fas 
activation in an easy and reproducible manner, the question remained how these data 
would apply to wild type receptors. Therefore, the aim was to investigate whether an 
inhibitory effect of the stalk region could also be observed when TNFR2 wild type 
constructs were used instead of TNFR-Fas chimaeras. Unfortunately, to date the 
downstream signalling of TNFR2 in MF is not very well understood and data on 
TNFR2-mediated IL-6 production, IκBα degradation, p65 phosphorylation and real-
time PCR analysis for potential NF-κB downstream target genes, which had been 
generated in our group, were inconclusive (Dr Anja Krippner-Heidenreich, personal 
communication).  
Furthermore, I wanted to investigate whether the TNFR stalk region would also 
control differential responsiveness when different cell types were used. This was of 
particular importance as we used mouse cells to investigate signalling of human 
receptors and, despite the high homology between murine and human TNFR, processes 
in receptor activation might differ between species.  
 
3.3.1 The TNFR2 stalk region inhibits sTNF-mediated TRAF2 recruitment  
 
TRAF2 recruitment to the TNF/TNFR2 signalling complex occurs as an early event 
during TNFR2 activation. The TNF-mediated recruitment of TRAF2 to TNFR2 and the 
subsequent poly-ubiquitination of TRAF2 have already been described for HeLa cells 
stably transfected with TNFR2 (Krippner-Heidenreich et al., 2002, Habelhah et al., 
2004). These interactions are required for the activation of both, the NF-κB and JNK 
signalling pathways (Rothe et al., 1995, Reinhard et al., 1997). Furthermore, in 
agreement with observations made in the MF TNFR-Fas system, sTNF-induced 
recruitment of TRAF2 to wild type TNFR2 was found to be markedly reduced 
compared to recruitment upon stimulation with a TNFR2-selective CysTNF variant 
(Krippner-Heidenreich et al., 2002). Therefore, HeLa cells stably transfected with 
expression constructs of TNFR2 variants, which contained different stalk and/or 
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transmembrane regions and the intracellular portion of wild type TNFR2, represented a 
system to investigate the role of the stalk region in differential sTNF responsiveness of 
wild type TNFR2.  
 
HeLa cells stably transfected with wild type TNFR2 have been generated previously by 
Regina Pfeiffer (University of Stuttgart, Germany). HeLa transfectants stably 
expressing the mutants TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2, respectively, 
have been generated. These TNFR2 constructs contain either the stalk and 
transmembrane regions (aa 197-236) of TNFR1 (TNFR2-(S/TM)R1-R2) or the TNFR2 
stalk region shortened by 42 aa residues (aa 244-257; TNFR2-(SΔ42/TM)R2-R2). TNFR2 
and variants thereof were expressed on the cell surface (Figure 16) with a comparable 
MnX (MnX = 7816 for TNFR2, MnX = 9037 for TNFR2-(S/TM)R1-R2 and MnX = 
5843 for TNFR2-(SΔ42/TM)R2-R2). All three cell lines showed homogenous cell 
populations which could be gated positive for the respective TNFR2 variants (94 % for 
TNFR2 (Figure 16 A), 98 % for TNFR2-(S/TM)R1-R2 (Figure 16 B) and 88 % for  
TNFR2-(SΔ42/TM)R2-R2 (Figure 16 C)). 
 
In addition the correct molecular size of the TNFR2 variants was confirmed via Western 
Blot analysis using whole cell lysates from both transiently and stably transfected HeLa 
cells (Figure 16 D). The predicted molecular weight for wild type TNFR2 is 48 kDa, 
whereas TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 are predicted to be 
approximately 44 kDa in size (determined using the ProtParam tool on the ExPaSy 
proteomics server)(Gasteiger et al., 2005). For all constructs two bands in the range of 
the predicted molecular weight could be observed in the Western Blot (approximately 
70 kDa and 50 kDa for TNFR2 and approximately 50 kDa and 48 kDa for TNFR2-
(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 (Figure 16 D)). Similar to the TNFR-Fas 
constructs analysed in results section 3.2, the faster migrating protein bands are likely to 
represent receptors which had been translated but not post-translationally modified yet, 
whereas the slower migrating bands probably represent the mature forms of the 
receptors.  
 
To ensure that any differences in TRAF2 recruitment of the three HeLa cell lines, HeLa 
TNFR2, HeLa TNFR2-(S/TM)R1-R2 and HeLa TNFR2-(SΔ42/TM)R2-R2, would not be 
due to differences in the levels of endogenous TRAF2, TRAF2 expression of the cells 
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was determined via Western Blotting. For this purpose whole cell lysates were prepared 
and subjected to SDS-PAGE and Western Blot analysis. 
As seen in Figure 17, there are no apparent differences in TRAF2 levels between 
untransfected HeLa cells, HeLa TNFR2, HeLa TNFR2-(S/TM)R1-R2 and HeLa TNFR2-
(SΔ42/TM)R2-R2 cells. The Western Blot membrane was reprobed with antibodies 
against human β-actin to ensure equal loading for all samples (Figure 17, as indicated). 
Therefore, differences in endogenous TRAF2 levels would not account for any 
differences observed in TNF-mediated TRAF2 recruitment to the receptor constructs 
during co-IP experiments. 
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Figure 16. Characterisation of HeLa cells stably expressing TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2. 
9
7
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Figure 16 continued:  
Hela cells had been stably transfected with TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-
(SΔ42/TM)R2-R2, respectively. FACS analysis of A) TNFR2, B) TNFR2-(S/TM)R1-R2 and C) 
TNFR2-(SΔ42/TM)R2-R2 is shown. Receptors were stained on the cell surface using mouse anti-
human TNFR2 antibodies (clone MR2-1) and goat anti-mouse IgG-FITC antibodies (black 
line). Cells only incubated with goat anti-mouse IgG-FITC antibodies are depicted in grey. 94 
%, 98 %  and 88 % of the cells were gated positive for TNFR2, TNFR2-(S/TM)R1-R2 and 
TNFR2-(SΔ42/TM)R2-R2, respectively. Data shown represent three independent experiments. D) 
Western Blot analysis of TNFR2 variants.Whole cell lysates were prepared from 6 x 10
4
 stably 
transfected cells (s) and subjected to SDS-PAGE and Western Blot analysis. Untransfected 
HeLa cells (-) served as control. Lysates from 4 x 10
4
 HeLa cells, which had been transiently 
transfected with indicated TNFR2 variants (t) served as positive control. Goat anti-human 
TNFR2 antibodies (1:2000) were used as primary and rabbit anti-goat-IgG-HRP (1:20000) as 
secondary antibodies. Acquisition was performed on a Becton Dickinson FACSCanto II flow 
cytometer. Data shown represent one experiment. 
 
 
 
 
 
 
Figure 17. Endogenous TRAF2 levels in HeLa cells expressing different TNFR2 variants.  
Hela cells had been stably transfected with TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-
(SΔ42/TM)R2-R2, respectively and Western Blot analysis of endogenous TRAF2 was performed. 
An equivalent of 4 x 10
4
 cells was used. Untransfected HeLa cells (-) served as control. TRAF2 
was detected using mouse anti-human TRAF2 antibodies (1:2000) were as primary and goat 
anti-mouse-IgG-HRP (1:20000) as secondary antibodies (top). Human β-actin (bottom) served 
as loading control. All bands shown are from the same exposure. Data shown represent one 
experiment.  
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To investigate the potential of sTNF to recruit TRAF2 to TNFR2, TNFR2-(S/TM)R1-R2 
and TNFR2-(SΔ42/TM)R2-R2, HeLa cells stably expressing these constructs were 
stimulated with sTNF and CysTNF, respectively, and TRAF2 recruitment at different 
time points was analysed by TNFR2/TRAF2 co-IP.  
When CysTNF was used, TRAF2 recruitment to TNFR2, TNFR2-(S/TM)R1-R2 
and TNFR2-(SΔ42/TM)R2-R2 could already be observed 5 min past stimulation (Figure 
18 A, bottom). The TRAF2 signal persisted 10 min and 15 min after stimulation, but a 
trend towards a decrease in signal strength could be observed (Figure 18 A, bottom, and 
Figure 19).  
In line with observations made by Krippner-Heidenreich et al. (2002), 
stimulation with sTNF led to a markedly reduced TRAF2 recruitment in HeLa TNFR2 
cells. For HeLa TNFR2, after 5 min and 10 min (Figure 18 A, bottom) of sTNF 
stimulation approximately 70 % less TRAF2 were recruited compared to the amount 
recruited upon 5 min of stimulation with CysTNF (Figure 19). For the chosen 
timepoints, sTNF-mediated TRAF2 recruitment to TNFR2 was maximal at 15 min post 
stimulation but did not exceed 50 % of the recruitment seen after stimulation with 
CysTNF for 5 min (Figure 19).  
In contrast, the stimulation of HeLa TNFR2-(S/TM)R1-R2 and HeLa TNFR2-
(SΔ42/TM)R2-R2 with sTNF resulted in an increased TRAF2 recruitment for all three 
time points when compared to sTNF-treated HeLa TNFR2 (Figure 18 A, bottom). 
While after 5 min only approximately 25 % of TRAF2 were recruited in HeLa TNFR2, 
a recruitment of approximately 44 % and 63 % could be observed for HeLa TNFR2-
(S/TM)R1-R2 and HeLa TNFR2-(SΔ42/TM)R2-R2, respectively (Figure 19). After 10 
min, 56 % of TRAF2 were recruited to TNFR2-(S/TM)R1-R2 and 61 % to TNFR2-
(SΔ42/TM)R2-R2 opposed to 27 % of TRAF2 that were recruited to TNFR2 (Figure 19). 
When a Mann-Whitney U-test was performed, the differences between the TRAF2 
recruitment to TNFR2 and TNFR2-(SΔ42/TM)R2-R2 upon 5 min and 10 min of sTNF 
stimulation were found to be statistically significant (p = 0.0286). The highest values for 
sTNF-induced TRAF2 recruitment were observed 15 min post stimulation (41 % for 
HeLa TNFR2, 65 % for HeLa TNFR2-(S/TM)R1-R2 and 74 % for HeLa TNFR2-
(SΔ42/TM)R2-R2; Figure 19). However, while more TRAF2 was recruited to TNFR2-
(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 than to TNFR2, these differences were not 
statistically significant. 
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As the cell surface expression of mutant TNFR2 was comparable or even lower than the 
one observed for wild type TNFR2 (Figure 16) and basal TRAF2 recruitment to all 
three TNFR2 variants was comparable (5 % for TNFR2 and TNFR2-(S/TM)R1-R2 and 3 
% for TNFR2-(SΔ42/TM)R2-R2; Figure 19), the observed differences in sTNF-mediated 
TRAF2 recruitment were not due to higher basal activation of the receptors but were 
rather determined by the different stalk regions.  
 
To exclude the possibility that different amounts of TNF/TNFR2 complexes were 
precipitated, the Western Blot membranes of the co-IP experiments were reprobed with 
the same polyclonal TNFR2-specific antibodies which had been used to precipitate the 
signalling complexes. Stronger signals were detected for HeLa TNFR2-(S/TM)R1-R2 
cells, while the signals obtained for HeLa TNFR2-(SΔ42/TM)R2-R2 were so weak that 
they could unfortunately not be distinguished from background (Figure 18 A, top). 
These results correlated with the corresponding cell surface staining of the receptors 
(Figure 16). As the amount of detected TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-
(SΔ42/TM)R2-R2 did not correlate with the amount of co-immunoprecipitated TRAF2 
(Figure 18 A), the differences seen in TRAF2 recruitment are unlikely to be a result of 
differences in the pull-down of the signalling complexes.  
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Figure 18. The TNFR2 stalk region counteracts sTNF-mediated recruitment of endogenous TRAF2 to TNFR2 in HeLa cells.  
HeLa cells stably transfected with TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2, respectively, remained untreated (0) or were stimulated with 10 ng/ml 
sTNF or wild type CysTNF for 5, 10 and 15 min (5, 10, 15). For each treatment, TNFR signalling complexes from approximately 5 x 10
5
 HeLa cells were 
immunoprecipitated using 2 μg goat anti-human TNFR2 antibodies. Immunoprecipitation samples were subjected to SDS-PAGE and Western Blot analysis. A) 
TRAF2 (bottom) was detected using mouse anti-human TRAF2 antibodies (1:2000) as primary and goat anti-mouse-IgG-HRP (1:20000) as secondary antibodies. 
Afterwards, Western Blot membranes were reprobed with goat anti-human TNFR2 antibodies (1:2000) and rabbit anti-goat-IgG-HRP (1:20000) antibodies (top). 
Unspecific bands are highlighted with an asterisk. A whole cell lysate from HeLa cells transiently transfected with a human TRAF2 construct (t) served as positive 
control, while 2 μg goat anti-human TNFR2 antibodies (Ab) were loaded as negative control. B) Using mouse anti-human β-actin antibodies (1:50000) and goat anti-
mouse-IgG-HRP (1:20000), immunoprecipitation supernatants were analysed for their β-actin content which served as a loading control. Data shown represent three 
independent experiments for TNFR2-(S/TM)R1-R2 and four independent experiments for TNFR2 and TNFR2-(SΔ42/TM)R2-R2. 
1
0
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Figure 19. Quantitative analysis of TNF-mediated TRAF2 recruitment to TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2. 
Band intensities of TRAF2 Western Blots from TNFR2/TRAF2 co-IP experiments depicted in Figure 18 were quantified on a Syngene G:Box using the GeneTools 
V4.01 analysis software. Values were corrected for background levels and normalised to endogenous β-actin. Shown is the relative TRAF2 recruitment, expressed as 
a percentage of the TRAF2 recruitment to the respective TNFR construct after 5 min of CysTNF stimulation. Results are expressed as mean ± standard deviation and 
are representative of three (TNFR2-(S/TM)R1-R2) and four (TNFR2 and TNFR2-(SΔ42/TM)R2-R2) independent experiments. * = p < 0.05  
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In comparison to CysTNF-mediated TRAF2 recruitment, neither TNFR2-(S/TM)R1-R2 
nor TNFR2-(SΔ42/TM)R2-R2 were fully responsive towards sTNF.  
For MF TNFR2-(S/TM)R1-Fas the responsiveness towards sTNF and CysTNF had been 
very similar (Figure 11 E). Therefore, it was somewhat surprising that TNFR2-
(S/TM)R1-R2 did not prove to be more potent in sTNF-mediated TRAF2 recruitment. In 
contrast, the partial sTNF responsivness of TNFR2-(SΔ42/TM)R2-R2 reflected the partial 
sTNF responsiveness that had been observed for TNFR2-(SΔ42/TM)R2-Fas chimaeras 
previously very well (section 3.2).  
 
In conclusion, a significant increase in sTNF-mediated TRAF2 recruitment could be 
observed for TNFR2 constructs in which the stalk region had been shortened by 42 aa 
residues. For TNFR2 in which the stalk and transmembrane regions had been replaced 
with the ones of TNFR1 also a trend towards an increased sTNF-mediated TRAF2 
recruitment could be observed. However, further experiments would be required to 
assess whether this increase is statistically significant.  
Our findings indicate that the TNFR stalk regions do not only determine sTNF 
responsiveness of TNFR-Fas chimaeras but also control sTNF responsiveness of wild 
type TNFR2. Furthermore, our data provide evidence that sTNF responsiveness of wild 
type TNFR2 is also inhibited by 42 aa in the TNFR2 stalk region.  
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3.3.2 Suitability of soluble and oligomerised TNFR2-selective TNF to study 
differential responsiveness of TNFR 
 
Expression of endogenous TNFR2 is observed in only a few cell types and occurs upon 
cellular activation. In contrast, most cell types commonly show a basal expression of 
TNFR1. When these cells are expressing exogenous TNFR2, any TNF-mediated 
response will potentially reflect the crosstalk between TNFR1 and TNFR2. Therefore, 
we wanted to assess whether TNFR1 signalling was in any way contributing to the 
differences we had been observing for sTNF-mediated TRAF2 recruitment to TNFR2, 
TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 (Figure 18 and Figure 19). For this 
purpose it was required to establish a system in which TNFR2-mediated signalling 
could be investigated without simultaneous activation of TNFR1. 
 
Rauert et al. (2010) developed a soluble and an oligomerised TNF variant, which were 
TNFR2-selective due to the introduction of two point mutations (Loetscher et al., 1993). 
Rauert et al. found wild type TNFR2 to be only activated upon stimulation with the 
oligomerised but not the soluble TNFR2-selective TNF variant. Therefore, these 
muteins represented ligands which were potentially suitable to compare responsiveness 
of TNFR2 to sTNF and membrane-bound TNF in cell lines other than MF, while 
avoiding potential simultaneous sTNF-mediated TNFR1 signalling. Both, the soluble 
(FLAG-sTNF(143N/145R)) and the oligomerised (FLAG-TNC-scTNF(143N/145R)) 
TNFR2-selective ligands described in Rauert et al. (2010) were kindly provided by 
Prof. Harald Wajant (Würzburg University, Germany).   
 
To determine the suitability of FLAG-sTNF(143N/145R) and FLAG-TNC-
scTNF(143N/145R) for investigating responsiveness of TNFR2 variants towards sTNF 
and membrane-bound TNF in a TNFR2-selective manner, we stimulated MF TNFR2-
(S/TM)R1-Fas and MF TNFR2-(SΔ42/TM)R2-Fas with these ligands. The cell lines were 
chosen as they both show responsiveness towards sTNF and CysTNF (Figure 11 and 
Figure 14). When MF TNFR2-(S/TM)R1-Fas (Figure 20 A) and MF TNFR2-
(SΔ42/TM)R2-Fas (Figure 20 B) were treated with the aforementioned ligands, the 
responsiveness towards CysTNF and FLAG-TNC-scTNF(143N/145R) was comparable 
in these cell lines (ED50 = 0.5-0.7 ng/ml for FLAG-TNC-scTNF(143N/145R) and ED50 
= 0.9 ng/ml for wild type CysTNF). In contrast, neither MF TNFR2-(S/TM)R1-Fas nor 
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MF TNFR2-(SΔ42/TM)R2-Fas were activated by the soluble variant of TNFR2-specific 
TNF, FLAG-sTNF(143N/145R), up to a concentration of 200 ng/ml (Figure 20 A and 
B).  
 
It has been described previously that the introduction of the D143N/Al45R mutations in 
TNF leads to a 100-fold reduced affinity to TNFR2 (Loetscher et al., 1993). 
Furthermore, Krippner-Heidenreich et al. (2002) showed that the responsiveness of 
TNFR2-Fas towards a CysTNF variant carrying these mutations is 100-fold reduced 
(ED50 = 30 ng/ml) compared to CysTNF (ED50 = 0.2 ng/ml; Figure 11 D).  
If the introduction of the D143N/Al45R mutations in FLAG-sTNF(143N/145R) 
would similarly lead to a 100-fold reduction in activity compared to sTNF, we would, 
however, expect to see half-maximal responsiveness of MF TNFR2-(S/TM)R1-Fas 
(ED50 = 0.4 ng/ml for sTNF; Figure 11 E) and MF TNFR2-(SΔ42/TM)R2-Fas (ED50 = 3 
ng/ml for sTNF; Figure 14 B) at 40 ng/ml and 300 ng/ml, respectively. 
To ensure that the observed lack of responsiveness to FLAG-sTNF(143N/145R) 
is not caused by a lack of bioactivity of the ligand, cells were pre-incubated with 1 
μg/ml of the monoclonal TNFR2 antibody 80M2, which has been described to stabilise 
ligand binding by prolonging the half-life of the TNF-TNFR2-complex (Grell et al., 
1995). With the help of this antibody, the responsiveness of MF TNFR2-Fas towards a 
TNFR2-selective CysTNF variant can be increased up to levels comparable to wild type 
CysTNF (Dr. Anja Krippner-Heidenreich, personal communication). When MF 
TNFR2-(SΔ42/TM)R2-Fas were stimulated with sTNF in combination with the TNFR2 
antibody 80M2 (ED50 = 4 ng/ml), responsiveness was almost comparable to CysTNF 
(ED50 = 1 ng/ml; Figure 20 C). In contrast, for FLAG-sTNF(143N/145R) in 
combination with the TNFR2 antibody 80M2 only very few apoptotic cells could be 
observed under the microscope even at concentrations of 300 ng/ml (Figure 20 C). 
Unfortunately, the observed effect was so marginal that it could not be depicted using 
crystal violet staining. 
Taken together, this indicates that FLAG-sTNF(143N/145R), despite showing 
bioactivity to some extent, is not a suitable ligand to investigate differential sTNF 
responsiveness of TNFR2. Other means, such as the use of small interfering RNA 
(siRNA), were required to eliminate TNFR1 crosstalk (section 3.3.3).  
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Figure 20. Evaluation of the activity of the TNFR2-selective ligands FLAG-
sTNF(143N/145R) and FLAG-TNC-scTNF(143N/145R)   
MF were stimulated with increasing concentrations of soluble TNFR2-selective TNF (FLAG-
sTNF(143N/145R)), oligomerised TNFR2-specific TNF (FLAG-TNC-scTNF(143N/145R)), 
CysTNF and sTNF, respectively. Cell viability was assessed using crystal violet staining. 
Results are expressed as mean values of duplicates. Responsiveness of A) MF TNFR2-
(S/TM)R1-Fas and B) MF TNFR2-(SΔ42/TM)R2-Fas to 0.03-200 ng/ml of FLAG-
sTNF(143N/145R), FLAG-TNC-scTNF(143N/145R) and CysTNF was determined. C) Shown 
is the responsiveness of MF TNFR2-(SΔ42/TM)R2-Fas to 0.09-300 ng/ml of CysTNF, FLAG-
sTNF(143N/145R) and sTNF, respectively. FLAG-sTNF(143N/145R) and sTNF-treated cells 
had been pre-incubated with 1 μg/ml of the stabilising TNFR2 antibody 80M2 for 30 min prior 
to stimulation. Data shown represent A and C) one experiment and B) two independent 
experiments. 
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3.3.3 TNFR1 activation does not affect TNF-mediated TRAF2 recruitment to 
TNFR2 
 
The TRAF2 experiments described in section 3.3.1 were performed with HeLa cells 
stably expressing TNFR2 and TNFR2 stalk mutants, respectively. These cells also 
expressed endogenous TNFR1, which was also stimulated by sTNF and CysTNF in 
these experiments. Therefore, to assess whether sTNF-mediated recruitment of TRAF2 
to the receptor was affected by TNFR1 crosstalk, the co-IP experiments were repeated 
with HeLa cells which had been treated with TNFR1-specific siRNA (siRNATNFR1) 
prior to stimulation.   
 
As a first step, the amount of siRNA and incubation time required for an efficient 
downregulation of TNFR1 cell surface expression had to be determined. Experiments 
with HeLa cells overexpressing a non-cytotoxic TNFR1 variant, which had been 
performed in our group previously, indicated that a treatment with 50 nM siRNATNFR1 
for 48 h could reduce cell surface expression of this variant by about 50 % (determined 
as part of the Master of Research project of Rosanna Keegan, Newcastle University, 
2008). As in this PhD project HeLa cells were used which only expressed low levels of 
endogenous TNFR1, 50 nM siRNATNFR1 as well as a lower siRNATNFR1 concentration 
(25 nM) and two different incubation times (24 h and 48 h) were tested. Non-specific 
siRNA (further referred to as siRNAnonsense) served as a control.  
After 24 h of treatment 78 % of HeLa TNFR2 cells treated with 25 nM 
siRNATNFR1  and 75 % of cells treated with 50 nM siRNATNFR1 were gated positive for 
TNFR1 (Figure 21 C and D), while the corresponding percentages for the untreated 
cells and the cells treated with siRNAnonsense were 91 % and 94 %, respectively (Figure 
21 A and B). After 48 h of treatment with both, 25 nM and 50 nM siRNATNFR1, the 
percentage of cells gated positive for TNFR1 cell surface expression was reduced even 
further (36 %; Figure 21 G and H) compared to the untreated and siRNAnonsense treated 
cells (approximately 93 %; Figure 21 F and G).  
In comparison with untreated cells and cells treated with siRNAnonsense (MnX = 
952-1204; Figure 21 A, B, E and F), for the cells treated with 25 nM and 50 nM 
siRNATNFR1 a decrease in MnX could be observed after 24 h (MnX = 782-810;  Figure 
21 C and D), which was even stronger after 48 h (MnX = 530-570; Figure 21 G and H).  
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In conclusion, a reduction up to 58 % in the number of TNFR1 positive cells as well as 
a decrease in overall TNFR1 cell surface expression could be observed when cells were 
treated with 50 nM siRNATNFR1 for 48 h. However, as treatment with 25 nM 
siRNATNFR1 gave similarly good results, treatment of the cells with this lower siRNA 
concentration was chosen for the following co-IP experiments to minimise potential off-
target effects of the siRNA.        
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Figure 21. Optimisation for the reduction of TNFR1 cell surface expression by RNA interference.  
HeLa TNFR2 cells were analysed for cell surface expression of endogenous TNFR1 after treatment with TNFR1-specific siRNA (siRNATNFR1) and non-specific 
siRNA (siRNAnonsense). Shown are FACS analyses of HeLa TNFR2 cells which had been left untreated for A) 24 h and F) 48 h; treated with 50 nM siRNAnonsense for 
B) 24 h and F) 48 h; treated with 25 nM siRNATNFR1 for C) 24 h and D) 48 h; treated with 50 nM siRNATNFR1 for G) 24 h and H) 48 h, respectively. TNFR1 was 
stained on the cell surface using mouse anti-human TNFR1 antibody clone H398, biotin rat anti-mouse IgG (H+L) and PE-conjugated streptavidin (black line) Cells 
were analysed on a Becton Dickinson FACSCanto II flow cytometer. Cells only incubated with biotin rat anti-mouse IgG (H+L) and PE-conjugated streptavidin 
(grey). Percentages of cells gated positive for TNFR1 and MnX are indicated. Data shown represent one experiment. 
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After the conditions for an efficient reduction of TNFR1 cell surface expression by 
RNA interference had been established, the co-IP experiments decribed in section 3.3.1 
were repeated with HeLa TNFR2 and HeLa TNFR2-(SΔ42/TM)R2-R2 cells, which had 
both been treated with siRNATNFR1. HeLa TNFR2-(SΔ42/TM)R2-R2 were chosen here 
because they had shown a more pronounced increase in sTNF-mediated TRAF2 
recruitment than HeLa TNFR2-(S/TM)R1-R2 cells (Figure 18 and Figure 19). Cells 
treated with siRNAnonsense served as negative control.  
 
For each of these co-IP experiments FACS analysis of the cells was performed in 
parallel to ensure that the siRNATNFR1 treatment led to reduced TNFR1 expression while 
the cell surface expression of the respective TNFR2 construct remained unaffected.  
Cell surface expression of TNFR2 and TNFR2-(SΔ42/TM)R2-R2 was assessed for cells 
which had been left untreated, treated with siRNAnonsense or treated with siRNATNFR1. 
The number of cells gated positive for TNFR2 and TNFR2-(SΔ42/TM)R2-R2, 
respectively, was comparable between all treatment groups (91-93 % for TNFR2, 
Figure 22 A, B and C; 86-88 % for TNFR2-(SΔ42/TM)R2-R2, Figure 22 D, E and F). 
Furthermore, between untreated  and siRNATNFR1 treated HeLa TNFR2 cells no drastic 
changes in TNFR2 cell surface expression could be detected (MnX = 2528-2637; Figure 
22 A and C). The cell surface expression of TNFR2 was slightly reduced when these 
cells were treated with siRNAnonsense (MnX = 1983, Figure 22 B). For TNFR2-
(SΔ42/TM)R2-R2 the cell surface expression in untreated cells (MnX = 2921, Figure 22 
D) was higher compared to the treated cells but was comparable between siRNAnonsense 
treated  and siRNATNFR1 treated cells (MnX = 2229-2433; Figure 22 D and E).  
In addition, the cell surface expression of endogenously expressed TNFR1 was 
assessed. The MnX for TNFR1 was almost identical in untreated and siRNAnonsense 
treated HeLa TNFR2 cells (MnX = 912 versus MnX = 922; Figure 23 A and B, 
respectively) and HeLa TNFR2-(SΔ42/TM)R2-R2 cells (MnX = 1011 versus MnX = 993; 
Figure 23 D and E, respectively). In contrast, the TNFR1 cell surface expression was 
markedly reduced in siRNATNFR1 treated HeLa TNFR2 cells (MnX = 430, Figure 23 C) 
and HeLa TNFR2-(SΔ42/TM)R2-R2 cells (MnX = 451, Figure 23 F).  
While 97 % of untreated and 95 % of siRNAnonsense treated HeLa TNFR2 cells 
and HeLa TNFR2-(SΔ42/TM)R2-R2 cells were positive for TNFR1, respectively, only 44 
% of siRNATNFR1 treated HeLa TNFR2 cells and 39 % of siRNATNFR1 treated HeLa 
TNFR2-(SΔ42/TM)R2-R2 cells were gated positive for TNFR1 (Figure 23).  
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In conclusion, treatment of HeLa cells with TNFR1-specific siRNA did not alter the cell 
surface expression of TNFR2 and TNFR2-(SΔ42/TM)R2-R2 (Figure 22) but efficiently 
reduced TNFR1 cell surface expression by more than 50 % (Figure 23). 
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Figure 22. Reduction of TNFR1 levels by RNA interference does not alter TNFR2 cell 
surface expression of HeLa cells.  
Cell surface expression of TNFR2 and TNFR2-(SΔ42/TM)R2-R2 stably expressed by HeLa cells. 
FACS analysis of A) untreated HeLa TNFR2 cells; B) untreated HeLa TNFR2-(SΔ42/TM)R2-R2 
cells. FACS analysis of C) HeLa TNFR2 cells and D) HeLa TNFR2-(SΔ42/TM)R2-R2 cells, 
which had been treated with 25 nM siRNAnonsense for 48 h. FACS analysis of E) HeLa TNFR2 
cells and F) HeLa TNFR2-(SΔ42/TM)R2-R2 cells, which had been treated with 25 nM 
siRNATNFR1 for 48 h. TNFR2 variants were stained on the cell surface using mouse anti-human 
TNFR2 antibody clone MR2-1 and FITC-conjugated goat anti-mouse IgG + IgM (H+L) 
antibody (black line). Cells only incubated with FITC-conjugated goat anti-mouse IgG + IgM 
(H+L) antibody (grey). Acquisition was performed on a Becton Dickinson FACSCanto II flow 
cytometer. Percentages of cells gated positive for TNFR2 and MnX are indicated. Data shown 
represent three independent experiments.  
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Figure 23. TNFR1 cell surface expression in HeLa cells overexpressing TNFR2 constructs 
after treatment with TNFR1-specific siRNA.  
Cell surface expression of endogenous TNFR1 in HeLa TNFR2 and HeLa TNFR2-(SΔ42/TM)R2-
R2 cells. FACS analysis of A) untreated HeLa TNFR2 cells; B) untreated HeLa TNFR2-
(SΔ42/TM)R2-R2 cells. FACS analysis of C) HeLa TNFR2 cells and D) HeLa TNFR2-
(SΔ42/TM)R2-R2 cells, which had been treated with 25 nM siRNAnonsense for 48 h. FACS analysis 
of E) HeLa TNFR2 cells and F) HeLa TNFR2-(SΔ42/TM)R2-R2 cells, which had been treated 
with 25 nM siRNATNFR1 for 48 h. TNFR1 was stained on the cell surface using mouse anti-
human TNFR1 antibody clone H398, biotin rat anti-mouse IgG (H+L) and PE-conjugated 
streptavidin (black line). Cells only incubated with biotin rat anti-mouse IgG (H+L) and PE-
conjugated streptavidin (grey). Acquisition was performed on a Becton Dickinson FACSCanto 
II flow cytometer. Percentages of cells gated positive for TNFR1 and MnX are indicated. Data 
shown represent three independent experiments. 
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TNFR2/TRAF2 co-IP were then performed with cells which had been treated with 25 
nM siRNAnonsense and siRNATNFR1 for 48 h, respectively. Similar to the experiments in 
section 3.3.1, the siRNATNFR1 treated HeLa TNFR2 cells and HeLa R2-(SΔ42/TM)R2-R2 
cells were stimulated with 10 ng/ml sTNF and CysTNF respectively for 5 min, 10 min 
and 15 min. Due to experimental limitations, however, only the 5 min and 10 min 
timepoints could be included for the siRNAnonsense treatment group. 
When siRNAnonsense treated HeLa TNFR2 and HeLa R2-(SΔ42/TM)R2-R2 cells 
were stimulated with CysTNF, efficient recruitment of TRAF2 to the respective TNFR2 
variants could be observed after 5 min and 10 min of stimulation (Figure 24). 
Stimulation with CysTNF also led to efficient TRAF2 recruitment in siRNATNFR1 
treated HeLa TNFR2 and HeLa R2-(SΔ42/TM)R2-R2 cells after 5 min, 10 min and 15 
min (Figure 24). In contrast, the TRAF2 recruitment efficiency differed between HeLa 
TNFR2 and HeLa TNFR2-(SΔ42/TM)R2-R2 when cells were stimulated with sTNF. In 
line with findings described in section 3.3.1 (Figure 18 and Figure 19), sTNF-mediated 
TRAF2 recruitment was increased in HeLa TNFR2-(SΔ42/TM)R2-R2 cells compared to 
HeLa TNFR2 cells. Compared to CysTNF-stimulated cells, siRNAnonsense and 
siRNATNFR1 treated HeLa TNFR2 cells showed relatively weak TRAF2 recruitment 
upon 5 min, 10 min and 15 min sTNF stimulation (Figure 24). This difference was 
smaller in both siRNAnonsense treated and siRNATNFR1 treated HeLa TNFR2-
(SΔ42/TM)R2-R2 cells 5 min, 10 and 15 min after stimulation, respectively (Figure 24).  
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Figure 24. sTNF-mediated recruitment of TRAF2 to TNFR2 constructs is independent of TNFR1 signalling.  
HeLa cells stably transfected with TNFR2 and TNFR2-(SΔ42/TM)R2-R2, respectively, were treated with 25 nM nonsense siRNA or 25 nM TNFR1-specific siRNA 
for 48 h. These cells remained untreated (0) or were stimulated as indicated with 10 ng/ml sTNF or wild type CysTNF for 5, 10 and 15 min (5, 10, 15). Lysates were 
prepared from these cells and equal amounts of protein were used in co-IP. For each co-IP sample an equivalent of approximately 5 x 10
5
 HeLa cells and 2 μg goat 
anti-human TNFR2 antibodies were used. Co-immunoprecipitated TRAF2 was detected using mouse anti-human TRAF2 antibodies (1:2000) as primary and goat 
anti-mouse-IgG-HRP (1:20000) as secondary antibodies. 2 μg goat anti-human TNFR2 antibodies (Ab) were loaded as negative control. Data shown represent three 
independent experiments. 
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TRAF2 signal intensities were determined for the co-IP experiments depicted in using 
the Syngene G:Box and the GeneTools V4.01 analysis software. TRAF2 recruitment 
was expressed as a percentage of recruitment observed for siRNAnonsense treated cells 
after 5 min of CysTNF stimulation.  
In siRNAnonsense treated HeLa TNFR2 and HeLa TNFR2-(SΔ42/TM)R2-R2 cells, 
CysTNF led to a strong TRAF2 recruitment after 5 min and 10 min of stimulation (100 
% and 111 % for HeLa TNFR2, 100 % and 143 % for HeLa TNFR2-(SΔ42/TM)R2-R2;  
Figure 25). Similarly, strong TRAF2 recruitment could be observed when the 
corresponding siRNATNFR1 treated cells were stimulated with CysTNF for 5 min, 10 
min and 15 min, respectively (123 %, 130 % and 132 % for HeLa TNFR2, 127 %, 135 
% and 136 % for HeLa TNFR2-(SΔ42/TM)R2-R2; Figure 25).  
In line with observations made in section 3.3.1 (Figure 19), only relatively weak 
TRAF2 recruitment to the receptor could be observed in siRNAnonsense treated HeLa 
TNFR2 cells upon stimulation with sTNF for 5 min and 10 min (11 % and 23 %, 
respectively; Figure 25). While the percentages for the siRNATNFR1 treated HeLa 
TNFR2 cells after stimulation with sTNF for 5 min, 10 min and 15 min were slightly 
higher (18 %, 31 % and 36 %, respectively; Figure 25), they were still markedly lower 
than the ones observed in the corresponding CysTNF-treated samples. In contrast, 
sTNF-mediated TRAF2 recruitment was increased in both siRNAnonsense and 
siRNATNFR1 treated HeLa TNFR2-(SΔ42/TM)R2-R2 cells for all time points (46 % and 65 
% for siRNAnonsense treated and 51 %, 72 % and 81 % for siRNATNFR1 treated cells, 
respectively; Figure 25) when compared with the corresponding HeLa TNFR2 samples. 
This indicates that the differences observed in sTNF-mediated TRAF2 recruitment of 
TNFR2 and TNFR2-(SΔ42/TM)R2-R2 are determined by the TNFR2 stalk region and are 
not affected by crosstalk of the receptor variants with TNFR1. 
Furthermore, basal levels of TRAF2 recruitment were low in both, siRNAnonsense 
and siRNATNFR1 treated HeLa TNFR2 and HeLa TNFR2-(SΔ42/TM)R2-R2 cells (1-3 % 
for siRNAnonsense and 3-5 % for siRNATNFR1; Figure 25), so that differences in basal 
TRAF2 recruitment could be excluded as a determining factor for the observed 
differences in sTNF responsiveness of these contructs. 
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Figure 25. TNF-mediated TRAF2 recruitment to TNFR2 constructs in HeLa cells after 
treatment with TNFR1-specific siRNA. 
Band intensities of TRAF2 Western Blots from TNFR2/TRAF2 co-IP experiments depicted in 
Figure 24 were quantified on a Syngene G:Box using the GeneTools V4.01 analysis software. 
Values were corrected for background levels. Shown is the relative TRAF2 recruitment, 
expressed as a percentage of the TRAF2 recruitment in nonsense RNA treated cells after 5 min 
of CysTNF stimulation. Results are expressed as mean ± SD and are representative of three 
independent experiments.  
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As seen in Figure 25, all samples from siRNATNFR1 treated cells showed higher 
percentages for TRAF2 recruitment than did the corresponding siRNAnonsense samples. 
We, therefore, determined whether the ratios of CysTNF-mediated to sTNF-mediated 
TRAF2 recruitment were still comparable between the treatment groups.   
In siRNAnonsense treated HeLa TNFR2 cells, 5 min of CysTNF stimulation led to 
9x more TRAF2 recruitment than the corresponding stimulation with sTNF, while at 10 
min of stimulation CysTNF-mediated TRAF2 recruitment was 5x higher than the one 
for sTNF. For siRNATNFR1 treated HeLa TNFR2 cells the factor was 7x at 5 min of 
stimulation and 4x at 10 min of stimulation. In contrast, the ratio of CysTNF-mediated 
to sTNF-mediated TRAF2 recruitment was approximately 2x for both siRNAnonsense and 
siRNATNFR1 treated HeLa TNFR2-(SΔ42/TM)R2-R2 cells for both stimualtion time points 
(2x for 5 min and 10 min siRNAnonsense treated HeLa cells , 2x for 5 min siRNATNFR1 
treated HeLa cells, 2.5x for 10 min siRNATNFR1 treated HeLa cells). 
With the exception of the 5 min timepoint for HeLa TNFR2 cells, where a 
slightly bigger difference in recruitment efficiency (9x versus 7x) could be detected, the 
ratios of CysTNF-mediated TRAF2 recruitment to sTNF-mediated TRAF2 recruitment 
were comparable in siRNAnonsense and siRNATNFR1 treated cells. An increased sTNF 
responsiveness in TNFR2 with a shortened stalk region could be observed which was 
similar to the one described in section 3.3.1. However, for statistical analysis further 
repeats of this experiment would be required. 
 
Taken together, our data suggest that the differences observed in sTNF-mediated 
TRAF2 recruitment to TNFR2 and TNFR2-(SΔ42/TM)R2-R2 are determined by the stalk 
region and are not caused by altered crosstalk with TNFR1. In addition, these data 
further support the conclusions drawn in section 3.3.1 that the stalk region inhibits 
sTNF responsiveness of wild type TNFR2. 
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3.4 Preliminary experiments on the role of the TNFR2 stalk region 
in sTNF-mediated p65 translocation 
 
Data from TNFR2/TRAF2 co-IP experiments support a role for the TNFR2 stalk region 
in the control of TNFR2 responsiveness to sTNF at the level of early receptor 
activation. To be able to determine whether the differences seen in the recruitment of 
TRAF2 would be reflected at the downstream signalling level, the TNF-induced 
translocation of the NF-κB p65 subunit from the cytoplasm to the nucleus was 
investigated. However, due to timely limitations of this PhD project only preliminary 
results can be presented here. 
Electrophoretic mobility shift assays (Krippner-Heidenreich et al., 2002) and 
translocation experiments (Fischer et al., 2011) had shown that upon stimulation of wild 
type TNFR2 the NF-κB p65 signalling pathway is activated in MF. Therefore, we chose 
p65 translocation in MF stably transfected with TNFR2 and TNFR2 variants as a read-
out system to investigate the role of the TNFR2 stalk region in sTNF-mediated 
downstream signalling. MF TNFR2 had been generated previously by Regina Pfeiffer, 
University of Stuttgart, Germany. The same TNFR2-(S/TM)R1-R2 and TNFR2-
(SΔ42/TM)R2-R2 constructs, which had been used for the stable transfection of HeLa 
cells (section 3.3.1), were stably transfected in MF as part of this PhD project.  
 
Cell surface expression and correct molecular weight of the transfected TNFR2, 
TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 variants were ensured by FACS and 
Western Blot analysis. All three variants were expressed on the cell surface and 91-96 
% of MF could be gated positive for the receptors (MnX = 12327 for TNFR2, MnX = 
10328 for TNFR2-(S/TM)R1-R2 and MnX = 5500 for TNFR2-(SΔ42/TM)R2-R2, 
respectively; Figure 26 A, B and C). 
For the Western Blot analysis whole cell lysates from transiently transfected 
HeLa cells and stably transfected MF were used (Figure 26 D). As seen before for HeLa 
cells stably expressing these constructs (Figure 16), for TNFR2-(S/TM)R1-R2 and 
TNFR2-(SΔ42/TM)R2-R2 two bands could be observed in the Western Blot (Figure 26 
D), of which the faster migrating bands correlated more or less with the predicted 
molecular weight. The slower migrating bands were approximately 50 kDa in size. 
Similar to the TNFR-Fas constructs analysed in results section 3.2, the faster migrating 
protein bands probably represent receptors which had been translated but not post-
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translationally modified, whereas the slower migrating bands presumably represent the 
mature forms of the receptors. Importantly, the receptors from stably transfected MF co-
migrated with the transiently expressed variants (Figure 26 D), excluding the possibility 
that, during the selection process for the stable cell lines, MF expressing receptors with 
larger deletions had been accumulated. 
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Figure 26. Characterisation of MF stably expressing TNFR2,  TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2.  
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Figure 26 continued: MF had been stably transfected with TNFR2, TNFR2-(S/TM)R1-R2 and 
TNFR2-(SΔ42/TM)R2-R2, respectively. FACS analysis of A) TNFR2, B) TNFR2-(S/TM)R1-R2 
and C) TNFR2-(SΔ42/TM)R2-R2; receptors were stained on the cell surface using mouse anti-
human TNFR2 antibodies (clone MR2-1) and goat anti-mouse IgG-FITC antibodies (black 
line). Cells only incubated with goat anti-mouse IgG-FITC antibodies are depicted in grey. 96 
%, 92 % and 91 % of the cells were gated positive for TNFR2, TNFR2-(S/TM)R1-R2 and 
TNFR2-(SΔ42/TM)R2-R2, respectively. Data shown represent four independent experiments. D) 
Western Blot analysis of TNFR2 variants. Whole cell lysates were prepared from 4 x 10
4
 (s) and 
6 x 10
4
 (s„) stably transfected MF, respectively, and subjected to SDS-PAGE and Western Blot 
analysis. Untransfected MF (-/-) served as control. Lysates from 4 x 10
4
 HeLa cells, which had 
been transiently transfected with indicated TNFR2 variants (t) served as positive control. Goat 
anti-human TNFR2 antibodies (1:2000) were used as primary and rabbit anti-goat IgG-HRP 
(1:20000) as secondary antibodies. Acquisition was performed on a Becton Dickinson 
FACSCanto II flow cytometer. Data shown represent one experiment. 
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After characterisation of the MF TNFR2-(S/TM)R1-R2 and MF TNFR2-(SΔ42/TM)R2-R2 
cell lines, these cells were used for preliminary p65 translocation experiments. Cells 
were stimulated with 100 ng/ml sTNF and CysTNF, respectively, for 30 min and 
endogenous p65 was visualised via immunofluorescence. In addition, cells were stained 
with the DNA dye DAPI to visualise the cell nucleus (Figure 27 A, E and I and Figure 
28 A, E and I).  
When cells remained untreated, p65 was mostly detected in the cytoplasm of MF 
TNFR2-(S/TM)R1-R2 and MF TNFR2-(SΔ42/TM)R2-R2 (Figure 27 C and Figure 28 C, 
respectively). Hardly any co-localisation with the nuclear staining could be detected 
(Figure 27 D and Figure 28 D). In contrast, nuclear translocation of p65 could be 
observed in MF TNFR2-(S/TM)R1-R2 and MF TNFR2-(SΔ42/TM)R2-R2 when cells were 
stimulated with sTNF (Figure 27 G and Figure 28 G, respectively). Stimulation with 
CysTNF also led to p65 translocation from the cytoplasm to the nucleus in MF TNFR2-
(S/TM)R1-R2 (Figure 27 K).  
The stabilising anti-human TNFR2 antibody 80M2 has been described to 
enhance the stimulation capacities of sTNF and CysTNF (Krippner-Heidenreich et al., 
2002, Bryde et al., 2005) and increased the responsiveness of MF TNFR2-(SΔ42/TM)R2-
Fas towards sTNF (Figure 20 C). Therefore, we included MF TNFR2-(SΔ42/TM)R2-R2, 
which had been pre-treated with 2 μg/ml of this antibody and subsequently stimulated 
with 100 ng/ml CysTNF, as a control for maximal stimulation of the receptor variant. 
p65 translocation could also be observed in these 80M2/CysTNF-treated MF TNFR2-
(SΔ42/TM)R2-R2 (Figure 28 K). The co-localisation of p65 with the nuclei after the 
various stimuli is shown in the corresponding overlay pictures (Figure 27 H and L and 
Figure 28 H and L).  
 
A profound number of cells positive for nuclear p65 could be observed not only upon 
treatment with CysTNF but also when cells were stimulated with sTNF.  This indicates 
that both sTNF and CysTNF are potent inducer of downstream signalling pathways in 
MF TNFR2-(S/TM)R1-R2 and MF TNFR2-(SΔ42/TM)R2-R2. However, whether the 
TNFR2 stalk region has an inhibitory effect on sTNF-mediated translocation of p65 
similar to the one observed for sTNF-mediated TRAF2 recruitment (Figure 18 and 
Figure 19), still needs to be determined by comparing these cells with MF TNFR2. A 
quantitative analysis of sTNF- and CysTNF-mediated p65 nuclear translocation was 
unfortunately not possible during this PhD project.  
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Figure 27. TNF-mediated nuclear translocation of p65 in MF TNFR2-(S/TM)R1-R2 (preliminary data). 
As indicated, MF TNFR2-(S/TM)R1-R2 were left untreated or were stimulated with sTNF and CysTNF (100 ng/ml), respectively, for 30 min. Cell nuclei were 
visualised with DAPI. Additionally, cells were stained for endogenous p65 using rabbit anti-human p65 (clone C-20; 1:100) and Alexa594-conjugated goat anti-
rabbit IgG (H+L) antibodies (1:100). Cells were analysed on a Zeiss Axio Imager 2 fluorescence microscope (40x magnification). Shown are A, E and I) 
Differential interference contrast (DIC) images of MF TNFR2-(S/TM)R1-R2; B, F and J) nuclear staining with DAPI; C, G and K) staining for endogenous p65; D, 
H and L) overlay of DAPI and p65 images. Pink colour indicates co-localisation. Data shown represent one experiment.  
1
2
3
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Figure 28. TNF-mediated nuclear translocation of p65 in MF TNFR2-(SΔ42/TM)R2-R2 (preliminary data). 
MF TNFR2-(SΔ42/TM)R2-R2 were left untreated, stimulated with 100 ng/ml sTNF for 30 min or pre-incubated with 2 μg/ml mouse anti-human TNFR2 antibody 
80M2 and then stimulated with 100 ng/ml CysTNF for 30 min (CysTNF + 80M2). Cell nuclei were visualised with DAPI and cells were stained for endogenous p65 
using rabbit anti-human p65 (clone C-20; 1:100) and Alexa594-conjugated goat anti-rabbit IgG (H+L) antibodies (1:100). Cells were analysed on a Zeiss Axio 
Imager 2 fluorescence microscope (40x magnification). A, E and I) Differential interference contrast (DIC) images; B, F and J) nuclear staining with DAPI; C, G 
and K) staining for endogenous p65; D, H and L) overlay DAPI and p65 images. Pink colour indicates co-localisation. Data shown represent one experiment. 
1
2
4
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3.5 Discussion 
 
3.5.1 The TNFR2 stalk region determines sTNF responsiveness in TNFR2-Fas 
chimaeras 
 
Preliminary data by Dr Anja Krippner-Heidenreich‟s group obtained using the MF 
TNFR-Fas cell system suggested a critical role for the TNFR1 and TNFR2 stalk regions 
in the control of differential responsiveness to sTNF (Figure 11). The data presented 
here confirm that the TNFR stalk region is a major determinant for this differential 
responsiveness and show that 42 aa in the TNFR2 stalk region inhibit receptor 
responsiveness towards sTNF.  
For MF stably transfected with the TNFR2-(SΔ42/TM)R2-Fas chimaera 
responsiveness  towards CysTNF (ED50 = 0.3 ng/ml) could be observed in 75 % of the 
cells (Figure 14 B). The population of CysTNF-responsive cells correlated with the 
TNFR2-(SΔ42/TM)R2-Fas positive population of the cell pool (Figure 13 A), arguing for 
a full CysTNF susceptibility in all receptor positive MF. In contrast, only approximately 
50 % of MF TNFR2-(SΔ42/TM)R2-Fas were responsive towards sTNF with an ED50 of 3 
ng/ml (Figure 14 B). The cause of the discrepancy between the number of cells positive 
for TNFR2-(SΔ42/TM)R2-Fas cell surface expression and the number of cells responsive 
towards sTNF is not known to date. sTNF is not capable of inducing cytotoxicity in MF 
TNFR2-Fas, even at concentrations of up to 1 μg/ml (Dr Krippner-Heidenreich, 
personal communication). Therefore, the deletion of 42 aa in the stalk region of 
TNFR2-Fas chimaeras leads to a more than 100-fold increase in sTNF responsiveness 
compared to the parental chimaeric receptor.  
However, shortening of the TNFR2 stalk region did not result in a receptor fully 
responsive to sTNF as MF TNFR2-(SΔ42/TM)R2-Fas were still 10-fold less sensitive 
towards sTNF when compared to CysTNF stimulated cells. This is in line with previous 
experiments, which showed that susceptibility towards sTNF was decreased when either 
the TM (Dr Anja Krippner-Heidenreich, personal communication) or CRD1 
(Branschädel et al., 2010) had been exchanged between TNFR1 and TNFR2. This 
suggests that sTNF responsiveness is controlled at a minimum of three levels: CRD1, 
transmembrane domain and stalk region. Therefore, full responsiveness of TNFR2-
(SΔ42/TM)R2-Fas towards sTNF could not be expected. However, our results show that 
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out of the three determinants the stalk region has the strongest impact on sTNF 
responsiveness. 
 
Furthermore, our data indicate that some molecular feature(s) encoded by the 42 aa, 
which had been deleted in the TNFR2 stalk region, inhibits responsiveness to sTNF. 
Post-translational modifications of the stalk region, such as glycosylation, could 
represent such a feature. It has been reported previously that TNFR2 is N- and O-
glycosylated (Hohmann et al., 1989) and specifically in the membrane proximal region 
of the receptor O-glycosylation has been described (Pennica et al., 1993). By shortening 
the TNFR2 stalk region more than 10 of 12 putative O-glycosylation sites predicted by 
the bioinformatics programme NetOglyc (Julenius et al., 2005) were deleted. This 
became apparent in the Western Blot analysis of TNFR2-Fas and TNFR2-(SΔ42/TM)R2-
Fas, where both chimaeras showed two bands of which only the faster migrating one 
correlated with the predicted molecular mass (Figure 13). For wild type TNFR2 it has 
been described that N-glycosylation contributes 2-4 kDa and O-glycosylation 
contributes 6-10 kDa, so that in total glycosylation of the receptor adds about 10-15 kDa 
to its molecular mass (Hohmann et al., 1989). As glycosylation takes place in the 
endoplasmic reticulum and/or Golgi apparatus (reviewed in Spiro, 2002), the faster 
migrating bands of TNFR2-Fas, therefore, presumably represent chimaeras which have 
been translated but not been glycosylated yet. In contrast the slower migrating bands 
have a molecular mass which is about 10 kDa greater and, therefore, are most likely 
representing the mature, glycosylated form of the receptor.  
The difference in molecular mass of the mature TNFR2-Fas chimaeras and the 
mature TNFR2-(SΔ42/TM)R2-Fas chimaeras is approximately 8 kDa (Figure 13 B). 4 
kDa of this difference can be attributed to the fact that TNFR2-(SΔ42/TM)R2-Fas is 
lacking the 42 amino acid residues. The remaining difference is likely to be due to the 
fact that O-glycosylation sites have been deleted. In contrast, N-glycosylation of the 
receptor constructs should not be affected by the deletion as it has been reported to take 
place at two asparagine residues in CRD4 (Pennica et al., 1993). Indeed we could still 
detect two bands for TNFR2-(SΔ42/TM)R2-Fas constructs, of which the slower migrating 
one presumably represents the N-glycosylated but not O-glycosylated mature form of 
the chimaera. Thus, O-glycosylation of the stalk region represents a feature which 
potentially could influence the responsiveness of TNFR2 to sTNF. 
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3.5.2 The stalk region determines sTNF responsiveness of wild type TNFR2 
 
The chimaeric TNFR-Fas system indicated that the TNFR stalk region is a major 
determinant for differential receptor responsiveness to sTNF. The results presented in 
sections 3.3.1 and 3.3.3 show that this is also the case in wild type TNFR2 and that the 
stalk region inhibits sTNF responsiveness at the level of TRAF2 recruitment.  
Differential responsiveness to sTNF has already been described for HeLa TNFR2 cells. 
In these cells, only weak sTNF-mediated recruitment of TRAF2 to TNFR2 could be 
detected while stimulation with oligomerised TNFR2-selective CysTNF led to an 
efficient TRAF2 recruitment (Krippner-Heidenreich et al., 2002). Using HeLa cells 
which stably expressed the TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 variants, 
we could show that sTNF-mediated TRAF2 recruitment to TNFR2 is inhibited by the 
TNFR2 stalk region and, furthermore, that 42 aa in this region determine this inhibition 
(Figure 18 and Figure 19). In comparison with wild type TNFR2, sTNF-mediated 
TRAF2 recruitment was significantly increased for TNFR2-(SΔ42/TM)R2-R2. 
TNFR1 overexpression leads to the self-association of the TNFR1 death 
domains and induces ligand-independent apoptosis (Boldin et al., 1995). This 
overexpression-induced apoptotic effect of TNFR1 has also been observed in murine 
embryonic fibroblasts from wild type (Yeh et al., 1998) and tnfr1
-/-
/tnfr2
-/-
 double 
knockout mice (Dr Anja Krippner-Heidenreich, personal communication). Therefore, 
we were unfortunately not able to determine whether the TNFR2 stalk region would 
have a similar inhibitory effect on sTNF responsiveness in wild type TNFR1 as we had 
observed for TNFR2.  
 
Upon engagement of TNFR2 TRAF2 recruitment can be observed within 3 min of 
stimulation (Wicovsky et al., 2009) and is sustained for more than 30 min (Krippner-
Heidenreich et al., 2002, Wicovsky et al., 2009). Furthermore, TNFR2-mediated 
TRAF2 translocation to detergent-insoluble cell membrane compartments and its 
subsequent polyubiquitination have been reported (Li et al., 2002, Habelhah et al., 
2004, Wu et al., 2005). 20-30 min after stimulation proteasomal degradation of TRAF2 
is initiated (Wu et al., 2005, Fischer et al., 2011), which was found to be mediated by 
cIAP1 (Li et al., 2002). In agreement with observations made by Wicovsky et al. 
(2009), we could also detect TRAF2 recruitment to TNFR2 variants as early as 5 min 
post stimulation with CysTNF (Figure 18). 10 min and 15 min after stimulation with 
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CysTNF a trend towards a decrease in TRAF2 signal strength could be observed (Figure 
19) which is likely to be caused by a decreased solubility of the TNF/TNFR signalling 
complexes. The buffer used for the solubilisation of the signalling complexes from the 
cell membrane contains 1 % (v/v) Triton X-100. Whether the decreased solubility of the 
signalling complexes is due to their translocation to detergent-resistant membrane 
compartments as suggested by Li et al. (2002), Habelhah et al. (2004) and Wu et al. 
(2005) is not known to date. In addition, the formation of larger ligand/receptor clusters 
as described by Krippner-Heidenreich et al. (2002), which occurs just within 5 min of 
stimulation, might play a role here. Formation of these clusters might render signalling 
complexes inacessible to the detergent.  
Furthermore, reduced solubility of the TNF/TNFR2 signalling complexes could 
be the reason why the signal strength of the precipitated TNFR2 constructs did not 
always correlate with the one observed for the co-immunoprecipitated TRAF2. As 
CysTNF is a potent inducer of TNFR2 signalling and cluster formation (Krippner-
Heidenreich et al., 2002), this would explain the trend that less precipitation of TNFR2 
constructs occured in CysTNF stimulated samples compared to samples from sTNF 
stimulated and untreated cells.  
 
In contrast, the amount of TRAF2 recruited to the TNFR2 variants was still increasing 
at 10 min and 15 min post stimulation with sTNF compared to the 5 min timepoint 
(Figure 19). This delayed recruitment could be caused by differences in the stability of 
the receptor/ligand complexes. With a half-life of only 1.1 min, sTNF was found to bind 
to TNFR2 in a relatively transient manner (Grell et al., 1995). Stabilising the 
sTNF/TNFR2 complexes through pre-treating the cells with the TNFR2 antibody 80M2 
could increase this half-life by factor 10 (Grell et al., 1995). In addition, the stabilising 
capacity of oligomerised TNF has been described as an important component of 
efficient TNFR2 activation previously (Krippner-Heidenreich et al., 2002, Rauert et al., 
2010). Therefore, the different kinetics of sTNF-mediated and CysTNF-mediated 
TRAF2 recruitment in the three HeLa cell lines could be explained by this difference in 
stabilisation potential between the two ligands.  
In contrast, the differences between the sTNF-mediated TRAF2 recruitment in 
HeLa TNFR2 and HeLa TNFR2-(S/TM)R1-R2 and HeLa TNFR2-(SΔ42/TM)R2-R2 are 
most likely not due to different sTNF affinities of the TNFR2 variants. Equilibrium 
binding studies with 
125
I-labelled sTNF had revealed that sTNF binding affinities to 
TNFR2-Fas, TNFR2-(S/TM)R1-Fas and TNFR2-(SΔ42/TM)R2-Fas were comparable in 
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MF (data obtained by Verena Boschert, University of Stuttgart, Germany; Dr Krippner-
Heidenreich, personal communication). 
 
In co-IP experiments Shu et al. (1996) found TRAF2 to be recruited to both TNFR and 
observed recruitment to TNFR1 within 2 min after stimulation. In cells which express 
both TNFR, stimulation of TNFR2 has been described to enhance TNFR1-mediated cell 
death in a TRAF2-dependent manner (Vandenabeele et al., 1995, Weiss et al., 1997, 
Declercq et al., 1998, Chan and Lenardo, 2000) and Fotin-Mleczek et al. (2002) 
postulated this to be caused by competition of the two TNFR for TRAF2-mediated 
recruitment of the anti-apoptotic proteins cIAP1 and cIAP2. Furthermore, the affinity 
between TRAF2 and TRADD is significantly higher than the affinity between TRAF2 
and a TNFR2 peptide, which indicates that TRADD acts as a stronger inducer of 
TRAF2 signalling (Park et al., 2000, Tsao et al., 2000). In addition, this suggests that 
activation of TNFR1 influences recruitment of TRAF2 recruited to TNFR2 and, 
therefore, TRAF2-dependent signalling of TNFR2. 
In this project TNF-mediated TRAF2 recruitment in HeLa cells expressing 
endogenous TNFR1 and exogenous TNFR2 was investigated. By using TNFR1-specific 
siRNA, we were able to exclude the possibility that the observed differences in sTNF-
induced TRAF2 recruitment to TNFR2 and TNFR2-(SΔ42/TM)R2-R2 resulted from 
altered TNFR1-TNFR2 crosstalk (Figure 24). However, in comparison to the 
siRNAnonsense treated cells, we observed an increase in TRAF2 recruitment in 
siRNATNFR1 treated cells after stimulation with both, sTNF and CysTNF. TNFR2 
variants are approximately three times higher expressed on the cell surface of HeLa 
cells than TNFR1 (Figure 22 A and D and Figure 23 A and D). However, the higher 
affinity of the TNFR1/TRADD complexes for TRAF2 described by Park et al. (2000) 
and Tsao et al. (2000) suggests that after siRNATNFR1-treatment more TRAF2 would be 
available for recruitment to the TNFR2 variants. Therefore, the stronger TRAF2 signals 
observed for the siRNATNFR1 treated samples would reflect the decrease in the above 
mentioned competition for TRAF2 between TNFR1 and TNFR2 (Vandenabeele et al., 
1995, Weiss et al., 1997, Declercq et al., 1998, Chan and Lenardo, 2000, Fotin-Mleczek 
et al., 2002). 
 
Recently, Fischer et al. (2011) demonstrated in co-IP experiments that stimulation with 
TNF also leads to TRAF2 recruitment to TNFR2 in MF. These experiments were 
performed with TNFR2-selective CysTNF in combination with the anti-human TNFR2 
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antibody 80M2. Therefore, it remains to be determined whether this cell system would 
also be suitable to investigate differential responsiveness of TNFR2 towards sTNF at 
the level of TRAF2 recruitment.  
 
3.5.3 sTNF-mediated downstream signalling of TNFR2 variants 
 
TNFR2 is a known activator of the NF-κB signalling pathway (Rothe et al., 1995). 
CysTNF-mediated activation of this pathway in HeLa TNFR2 cells was demonstrated 
by Krippner-Heidenreich et al. (2002) in electrophoretic mobility shift assays and TNF-
mediated nuclear translocation of the NF-κB subunit p65 has been described in primary 
cortical neurons (Marchetti et al., 2004). Furthermore, TNFR2-selective CysTNF in 
combination with the anti-human TNFR2 antibody 80M2 was capable of inducing 
translocation of p65 from the cytoplasm to the nucleus in MF TNFR2 (Fischer et al., 
2011). This p65 translocation occurred in MF TNFR2 within 10 min of stimulation. 
However, the p65 translocation potential of sTNF in these cells in not known. Here it 
was shown that p65 translocates to the nucleus in MF TNFR2-(S/TM)R1-R2 and MF 
TNFR2-(SΔ42/TM)R2-R2 within 30 min of stimulation with sTNF and CysTNF (Figure 
27 and Figure 28), respectively. This is in good agreement with the data obtained by 
Fischer et al. (2011). Future work will comprise quantification of cells which are 
positive for nuclear p65 after stimulation with sTNF and CysTNF. Comparison with MF 
expressing the wild type TNFR2 will then show whether the stalk region proves to be a 
determinant of differential responsiveness at the level of NF-κB activation. 
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3.6 Conclusion 
 
 The TNFR2 stalk region inhibits receptor responsiveness to sTNF but not 
membrane-bound TNF in TNFR-Fas chimaeras and wild type TNFR2. 
 The TNFR2 stalk region inhibits sTNF responsiveness at the level of 
receptor signalling complex formation; this effect is independent of TNFR1 
signalling. 
 Analysis of TNF-mediated nuclear translocation of the NF-κB p65 subunit 
is promising method to investigate the influence of the TNFR2 stalk region 
on sTNF responsiveness downstream of TNF/TNFR signalling complex 
formation. 
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CHAPTER 4 
Results II: Investigations into molecular mechanisms by 
which the TNFR2 stalk region controls sTNF 
responsiveness 
4 bfag ff 
4.1 Introduction 
 
Data presented in chapter 3 identified the stalk region of TNFR as a major determinant 
of differential responsiveness to sTNF. When the length of the TNFR2 stalk region (56 
aa) was reduced to that of the TNFR1 stalk region (15 aa), the TNFR2-Fas chimaera 
and TNFR2 showed a more than 100-fold increase in responsiveness towards sTNF 
(Figure 14). This suggests that sTNF responsiveness is inhibited by something which is 
encoded by the 42 deleted aa residues in the stalk region (Please note, that a BamHI 
restriction site was introduced into the TNFR2 stalk region, which accounts for the 
substitution of an additional aa residue (Figure 29)).  
A comparison of the TNFR1 and TNFR2 stalk regions reveals that these regions 
differ in their length (15 aa for TNFR1 as opposed to 56 aa for TNFR2), their content in 
proline residues (one proline in TNFR1, 12 prolines in TNFR2) and their O-
glycosylation status (no O-glycosylation is present in TNFR1, TNFR2 is highly O-
glycosylated (Pennica et al., 1993)). When 42 aa were deleted in the TNFR2 stalk 
region this changed not only its length but also led to the deletion of eight of the proline 
residues and the deletion of more than 10 potential O-glycosylation sites (see Figure 
29).  
 
Therefore, the aims in this chapter were to: 
 investigate whether the length of the TNFR stalk region determines sTNF 
responsiveness; 
 determine whether proline residues in the TNFR2 stalk region influence receptor 
responsiveness towards sTNF; 
 identify O-glycosylation sites in the TNFR2 stalk region and to study their role 
in determining sTNF responsiveness of TNFR2. 
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Figure 29. Shortening of the TNFR2 stalk region leads to the loss of conserved proline 
residues and potential O-glycosylation sites. 
Shown are the aa sequences of the stalk regions of human TNFR1 and TNFR2. The aa sequence 
of the TNFR2 stalk region after deletion of 42 aa residues is also shown (TNFR2-(SΔ42/TM)R2-
Fas). Putative O-glycosylation sites, as predicted by two different O-glycosylation prediction 
programmes, are marked with black stars and/or red stars. The two N-terminal aa residues of the 
TNFR2-(SΔ42/TM)R2-Fas stalk region (GS) represent the BamHI restriction site used for the 
generation of this construct. 
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4.2 Length of the stalk region does not control TNFR2 
responsiveness towards sTNF 
 
The difference in stalk region length between TNFR1 and TNFR2 could potentially 
influence the responsiveness of the receptor to sTNF (Dr Anja Krippner-Heidenreich, 
personal communication). To determine whether the length of the stalk region does 
indeed affect sTNF responsiveness, artificial glycine-serine linkers of 15 aa or 56 aa in 
length were constructed and cloned into TNFR-Fas chimaeras as described in section 
2.2.7. The aa sequences of these linkers are depicted in Figure 30.  
 
MF stably expressing the constructs with 15 aa long linkers (TNFR1-SGSL15-TMR1-Fas 
and TNFR2-SGSL15-TMR2-Fas) and 56 aa long linkers (TNFR1-SGSL56-TMR1-Fas and 
TNFR2-SGSL56-TMR2-Fas), respectively, were characterised by Western Blot analysis. 
For this purpose, whole cell lysates from transiently transfected HeLa cells and stably 
transfected MF were analysed (Figure 31). The predicted molecular weights were as 
follows: 42 kDa for TNFR1-SGSL15-TMR1-Fas, 45 kDa for TNFR1-SGSL56-TMR1-Fas, 44 
kDa for TNFR2-SGSL15-TMR2-Fas and 46 kDa for TNFR2-SGSL56-TMR2-Fas (determined 
using the ProtParam tool on the ExPaSy proteomics server)(Gasteiger et al., 2005).  
For all transiently transfected constructs two bands could be detected, of which 
the faster migrating bands correlated with the respective predicted molecular weights. 
The slower migrating bands of TNFR1-SGSL15-TMR1-Fas and TNFR2-SGSL15-TMR2-Fas 
had a molecular weight of approximately 46 kDa and the molecular weight of the 
slower migrating bands of TNFR1-SGSL56-TMR1-Fas and TNFR2-SGSL56-TMR2-Fas was 
approximately 48 kDa (Figure 31). The faster migrating protein bands presumably 
represent intracellular receptors which had not been post-translationally modified while 
the slower migrating bands probably represent the mature form of the receptor as it 
exists on the cell surface. For samples from stably transfected MF only one band could 
be detected which correlated in molecular weight with the slower migrating band of the 
corresponding transiently transfected HeLa cell samples (Figure 31). 
 
In addition, the mouse anti-human Fas antibodies also recognised two proteins of 
approximately 55 kDa in size. As these protein bands are present in all of the MF 
samples regardless of the transfected construct and can also be seen for HeLa samples 
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after longer exposures, these bands appear to be unrelated to the exogenously expressed 
receptor chimaeras. The unspecific bands are highlighted Figure 31 by an asterisk.  
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Figure 30. Composition of artificial stalk regions for TNFR-Fas chimaeras.  
Shown are the aa sequences of the stalk regions of TNFR1 and TNFR2 as well as the aa sequences for the 15 aa (TNFR1-SGSL15-TMR1-Fas and TNFR2-SGSL15-TMR2-
Fas) and 56 aa (TNFR1-SGSL56-TMR1-Fas and TNFR2-SGSL56-TMR2-Fas) long artificial linkers of the indicated chimaeras. Repetitive glycine-serine motifs are shown 
in brackets ([GGGS]). Subscript numbers indicate the number of motif repeats.  
  
1
3
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Figure 31. Western Blot analysis of TNFR-Fas chimaeras containing 15 aa and 56 aa long 
artificial stalk regions. 
The stalk regions of TNFR1-Fas and TNFR2-Fas chimaeras were replaced with either 15 aa 
(TNFR1-SGSL15-TMR1-Fas and TNFR2-SGSL15-TMR2-Fas) or 56 aa (TNFR1-SGSL56-TMR1-Fas and 
TNFR2-SGSL56-TMR2-Fas) long artificial linkers and the resulting constructs were stably 
transfected into MF. Whole cell lysates were prepared from 1 x 10
5
 cells and were subjected to 
SDS-PAGE and Western Blot analysis. Mouse anti-human Fas antibodies clone B10 (1:2000) 
were used as primary and goat anti-mouse IgG-HRP (1:20000) as secondary antibodies. 
Transiently transfected HeLa cells (t) served as controls. Unspecific bands are highlighted with 
an asterisk. Due to low construct expression, for transiently transfected TNFR2-SGSL15-TMR2-
Fas a longer exposure time was chosen (rectangle). Data shown represent one experiment. 
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FACS analysis of the MF was performed to ensure that the different TNFR-Fas 
chimaeras were expressed on the cell surface. TNFR1-SGSL15-TMR1-Fas (MnX = 244, 
Figure 32 A), TNFR1-SGSL56-TMR1-Fas (MnX = 255, Figure 32 C), TNFR2-SGSL15-
TMR2-Fas (MnX = 128, Figure 33 A) and TNFR2-SGSL56-TMR2-Fas (MnX = 183, 
Figure 33 C) were all expressed on the cell surface of MF and between 90 % and 99 % 
of the cells could be gated positive for the respective chimaeras (Figure 32 A and C and 
Figure 33 A and C).  
 
In order to investigate whether stalk region length influences sTNF responsiveness of 
TNFR-Fas chimaeras, stably transfected MF were treated with increasing concentrations 
of the CysTNF or sTNF and cell viability was determined using crystal violet staining. 
For MF TNFR1-SGSL15-TMR1-Fas (Figure 32 B) and MF TNFR1-SGSL56-TMR1-Fas 
(Figure 32 D) full responsiveness towards both ligands with very similar ED50 between 
0.04 ng/ml and 0.06 ng/ml could be observed. The responsiveness correlated well with 
the percentages of positive cells that had been determined for these chimaeras (Figure 
32 A and C) and was comparable to that of TNFR1-Fas (0.04 ng/ml; see also Figure 11 
A).  
Approximately 80 % of MF TNFR2-SGSL15-TMR2-Fas (Figure 33 B) and 90 % of 
MF TNFR2-SGSL56-TMR2-Fas (Figure 33 D) treated were responsive towards CysTNF, 
which correlated with the receptor cell surface stainings (Figure 33 A and C, 
respectively). With an ED50 of 0.3-0.4 ng/ml this responsiveness towards CysTNF was 
comparable to that of MF TNFR2-Fas cells (ED50 = 0.2 ng/ml; see also Figure 11 D). In 
contrast to MF TNFR2-Fas, both TNFR2-SGSL15-TMR2-Fas and TNFR2-SGSL56-TMR2-
Fas were responsive towards sTNF, but with an ED50 of 1.5-2.0 ng/ml this 
responsiveness to sTNF was approximately 5-fold reduced compared to CysTNF. 
Similar to MF TNFR2-(SΔ42/TM)R2-Fas cells described in section 3.2, only about 50 – 
60 % of the cells were responsive to saturating concentrations of sTNF (Figure 33 B and 
D), indicating that here also a sub-population of the cells is resistant to sTNF. The cause 
of the partial unresponsiveness to sTNF remains elusive. 
 
The sTNF responsiveness of TNFR1-SGSL15-TMR1-Fas and TNFR2-SGSL15-TMR2-Fas 
was comparable to the one observed for the corresponding chimaeras containing the 
shortened stalk region of TNFR2, TNFR1-(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-
Fas (Figure 11 C and Figure 14 B). This sTNF responsiveness, however, did not change 
when the stalk regions of TNFR1-Fas chimaeras and TNFR2-Fas chimaeras were 
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replaced with 56 aa long artificial linkers. Therefore, these data indicate that the length 
of the stalk region does not determine differential responsiveness to sTNF. 
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Figure 32. Characterisation of cell surface expression and TNF responsiveness of MF 
overexpressing TNFR1-Fas chimaeras with artificial stalk regions.  
MF were stably transfected with TNFR1-Fas chimaeras containing a 15 aa long glycine/serine 
linker (MF TNFR1-SGSL15-TMR1-Fas) and a 56 aa long glycine/serine linker (MF TNFR1-
SGSL56-TMR1-Fas), respectively. A and C) Histograms of MF TNFR1-SGSL15-TMR1-Fas and MF 
TNFR1-SGSL56-TMR1-Fas. TNFR1-Fas chimaeras were stained on the cell surface using mouse 
anti-human TNFR1 antibodies (H398) and goat anti-mouse IgG-FITC antibodies (black line). 
Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC antibodies 
(grey). Approximately 99 % of the MF were gated positive for TNFR1-SGSL15-TMR1-Fas and 
TNFR1-SGSL56-TMR1-Fas, respectively. Acquisition was performed on a Becton Dickinson 
FACScan flow cytometer. B and D) MF TNFR1-SGSL15-TMR1-Fas and MF TNFR1-SGSL56-
TMR1-Fas remained untreated or were stimulated with different concentrations of sTNF and 
CysTNF (0.015-100 ng/ml). Viable cells were stained using crystal violet after 8 h of treatment. 
Data shown represent three independent experiments.  
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Figure 33. Characterisation of cell surface expression and TNF responsiveness of MF 
overexpressing TNFR2-Fas chimaeras with artificial stalk regions.  
MF were stably transfected with TNFR2-Fas chimaeras containing a 15 aa long glycine/serine 
linker (MF TNFR2-SGSL15-TMR2-Fas) and a 56 aa long glycine/serine linker (MF TNFR2-
SGSL56-TMR2-Fas), respectively. A and C) Histograms of MF TNFR2-SGSL15-TMR2-Fas and MF 
TNFR2-SGSL56-TMR2-Fas. TNFR2-Fas chimaeras were stained on the cell surface using mouse 
anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). 
Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC antibodies 
(grey). 90.4 % of the MF were gated positive for TNFR2-SGSL15-TMR2-Fas and 98.5 % were 
gated positive for TNFR2-SGSL56-TMR2-Fas. Acquisition was performed on a Becton Dickinson 
FACScan flow cytometer. B and D) MF TNFR2-SGSL15-TMR2-Fas and MF TNFR2-SGSL56-
TMR2-Fas remained untreated or were stimulated with different concentrations of sTNF and 
CysTNF (0.015-100 ng/ml). Viable cells were stained using crystal violet after 8 h of treatment. 
Data shown represent three independent experiments.  
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4.3 Mutagenesis of individual conserved proline residues in the 
TNFR2 stalk region does not alter responsiveness to sTNF 
 
Sequence alignment of TNFR2 from different mammalian species (homo sapiens, 
macaca mulatta, mus musculus, rattus norvegicus, canis familiaris and equus caballus) 
revealed seven conserved proline residues in the TNFR2 stalk region (determined by 
ClustalW sequence alignment (Chenna et al., 2003)). The conserved proline residues, 
P205, P211, P219, P231, P233, P237 and P249, are highlighted in Figure 34 A. 
In proteins, prolines can adopt two distinct conformations, cis and trans. The 
conversion of one of these forms into the other can be catalysed by peptidyl prolyl cis-
trans isomerases and has been found to function as a molecular switch during some 
signalling events (reviewed in Lu et al., 2007, Shaw, 2007). Importantly, a member of 
the cyclophilin family of peptidyl prolyl cis-trans isomerases, cyclophilin B, has been 
found to be localised not only in the endoplasmic reticulum but also in the plasma 
membrane (Bukrinsky, 2002, Stumpf et al., 2008), suggesting that prolyl cis-trans 
isomeration could potentially play a role in plasma membrane receptor activation. 
In addition, O-glycosylation of the TNFR2 stalk region has been described 
(Pennica et al., 1993) and proline residues are found at positions -1, +1 and +3 relative 
to the site of O-glycosylation in the majority of proteins with mucin-type O-linked 
glycosylation (Wilson et al., 1991, Hansen et al., 1995). Therefore, proline residues in 
the stalk region could also play a role in determining the O-glycosylation status of the 
stalk region, which in turn might influence the responsiveness towards sTNF. 
 
In order to investigate the role of conserved proline residues of the TNFR2 stalk region 
in determining sTNF responsiveness, these prolines were exchanged for alanines via 
two step site directed mutagenesis. Prolines P205, P211, P219, P237 and P249 were 
each exchanged separately while, for cloning reasons, prolines P231 and P233 were 
exchanged together. The resulting TNFR2-Fas P205A, TNFR2-Fas P211A, TNFR2-Fas 
P219A, TNFR2-Fas P231A/P233A, TNFR2-Fas P237A and TNFR2-Fas P249A 
chimaeras were stably transfected into MF. Whole cell lysates prepared from these cells 
were analysed via Western Blotting (Figure 34 B). Similar to TNFR2-Fas, the predicted 
molecular weight for these constructs was approximately 48 kDa (determined using the 
ProtParam tool on the ExPaSy proteomics server)(Gasteiger et al., 2005).  
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In Western Blot analysis, for all constructs, except TNFR2-Fas P205A, three bands 
could be observed, of which the fastest migrating one correlated with the respective 
predicted molecular weight and represented the putatively not post-translationally 
modified form of the receptors (Figure 34 B, as indicated). The two slower migrating 
bands of the TNFR2-Fas variants were approximately 58 kDa - 60 kDa in size (Figure 
34 B) and presumably represent the mature forms of the receptors. For the samples from 
MF TNFR2-Fas P205A only two bands could be observed of which the faster migrating 
one correlated in size with the predicted molecular weight. The slower migrating band 
co-migrated with the faster of the two slow migrating bands of the other constructs 
(Figure 34 B, compare lane 3 with lanes 4 – 8). This indicates that mutation of proline 
residue P205 affects post-translational modification of TNFR2-Fas. However, these 
findings would have to be confirmed by comparing lysates from stably and transiently 
transfected cells.  
 
Using the mouse anti-human Fas antibodies clone B10, which recognises the 
intracellular portion of Fas, a band of approximately 90 kDa and two 55 kDa protein 
bands could be detected (Figure 34 B, highlighted by an asterisk). As these protein 
bands are present in all of the MF whole cell lysates regardless of the receptor mutant, 
these bands appear to be non-specific for the TNFR2-Fas variants. The 90 kDa band 
might represent endogenous murine Fas which is recognised by the mouse anti-human 
Fas antibodies. 
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Figure 34. Western Blot analysis of TNFR2-Fas chimaeras in which conserved proline residues of the stalk region had beed mutated.  
A) Shown is the aa sequence of the TNFR2 stalk region (aa 202–257) and the C-terminal aa residue of CRD4 (T, aa 201). Conserved Proline residues are highlighted 
in bold letters. B) Analysis of conserved proline residues in the TNFR2 stalk region. MF were stably transfected with TNFR2-Fas chimaeras in which the indicated 
proline residues of the TNFR2 stalk region had been exchanged for alanines. Whole cell lysates from 3.3 x 10
4
 cells were prepared and subjected to SDS-PAGE and 
Western Blot analysis. Mouse anti-human Fas antibodies (clone B10, 1:2000) were used as primary and goat anti-mouse IgG-HRP (1:20000) as secondary 
antibodies. Untransfected MF and MF TNFR2-Fas served as controls. As indicated, the slower migrating protein bands represent mature receptor chimaeras, 
whereas the faster migrating protein bands represent putatively not post-translationally modified chimaeric receptors. Unspecific bands are highlighted with an 
asterisk. Data shown represent one experiment.  
1
4
3
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Cell surface expression of the various TNFR2-Fas chimaeras, in which conserved 
proline residues had been exchanged for alanines, was measured by FACS analysis. All 
six chimaeras were expressed on the cell surface of MF. 89-93 % of the cells could be 
gated positive for TNFR2-Fas P205A (MnX = 46; Figure 35 A), TNFR2-Fas P211A 
(MnX = 50; Figure 35 C), TNFR2-Fas P219A (MnX = 115; Figure 35 E), TNFR2-Fas 
P231A/P233A (MnX = 94; Figure 36 A), TNFR2-Fas P237A (MnX = 122; Figure 36 
C) and TNFR2-Fas P249A (MnX = 115; Figure 36 E), respectively. The cell surface 
expressions of the chimaeras were comparable to the ones observed for TNFR2-
(SΔ42/TM)R2-Fas (MnX = 187; Figure 13 A) and TNFR2-SGSL15-TMR2-Fas (MnX = 128; 
Figure 33 A) or even lower. 
 
The role of conserved prolines in the TNFR2 stalk in controlling receptor 
responsiveness towards sTNF was determined by stimulating MF, which stably 
expressed the TNFR2-Fas chimaeras in which the aforementioned prolines had been 
mutated to alanines, with increasing concentrations of CysTNF or sTNF. Cell viability 
was determined using crystal violet staining. 
60-80 % of MF were responsive to CysTNF with an ED50 of approximately 0.3 
ng/ml. This responsiveness towards CysTNF was comparable to that seen in MF 
TNFR2-Fas cells (EC50 = 0.2 ng/ml; see also Figure 11 D). Similar to MF TNFR2-Fas, 
these cells were not responsive towards sTNF, even at concentrations as high as 100 
ng/ml. This suggests that single conserved proline residues do not determine 
responsiveness of TNFR2-Fas to sTNF. However, at this point it cannot be excluded 
that more than one of these conserved proline residues could be involved in controlling 
sTNF responsiveness. Thus, the effect of simultaneous mutation of several conserved 
proline residues on sTNF responsiveness remains to be determined.  
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Figure 35. Replacement of the conserved proline residues P205, P211 and P219 in the 
TNFR2 stalk region does not alter TNF responsiveness.  
MF were stably transfected with TNFR2-Fas chimaeras in which conserved proline residues 
(P205, P211, P219) had been exchanged for alanines via two step site directed mutagenesis. A, 
C, and E) FACS histograms. Chimaeric receptors were stained on the cell surface using mouse 
anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). 
Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC antibodies 
(grey). As indicated, 89-90 % of MF were gated positive for the corresponding TNFR2-Fas 
chimaeras. Acquisition was performed on a Becton Dickinson FACScan flow cytometer. MnX 
are indicated. B, D and F) Cell viability assays. MF remained untreated or were stimulated with 
increasing concentrations of sTNF and CysTNF (0.015-100 ng/ml), respectively, and cell 
viability was determined using crystal violet staining. Data shown represent B and D) two and 
F) three independent experiments, respectively. 
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Figure 36. Replacement of the conserved proline residues P231, P233, P237 and P249 in 
the TNFR2 stalk region does not alter TNF responsiveness.  
MF were stably transfected with TNFR2-Fas chimaeras in which conserved proline residues 
(P231/P233, P237 and P249) had been exchanged for alanines via two step site directed 
mutagenesis. A, C, and E) FACS histograms. Chimaeric receptors were stained on the cell 
surface using mouse anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-FITC 
antibodies (black line). Unstained cells (dotted line); cells only incubated with goat anti-mouse 
IgG-FITC antibodies (grey). As indicated, 88.5-90.4 % of MF were gated positive for the 
corresponding TNFR2-Fas chimaeras. Acquisition was performed on a Becton Dickinson 
FACScan flow cytometer. MnX are indicated. B, D and F) Cell viability assays. MF remained 
untreated or were stimulated with increasing concentrations of sTNF and CysTNF (0.015-100 
ng/ml), respectively, and cell viability was determined using crystal violet staining. Data shown 
represent three independent experiments. 
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4.4 Influence of the O-glycosylation status of the TNFR2 stalk region 
on responsiveness towards sTNF 
 
In addition to its high proline residue content, the TNFR2 stalk region is also rich in 
serine and threonine residues, of which several could be identified as potential sites of 
mucin-type O-glycosylation using the bioinformatic tool NetOglyc (Julenius et al., 
2005) and a supported vector machine (SVM) programme (Li et al., 2006)(see Figure 
37 A). O-glycosylation occurs on serine or threonine residues, which are generally 
found in clusters with a β-turn near proline and at a distance from charged aa residues 
(Elhammer et al., 1993). 
O-glycosylation has been reported to be involved in protein trafficking, delivery 
and stabilisation at the cell surface (reviewed in Tian and Ten Hagen, 2009). Park and 
Tenner (2003), for example, described O-glycosylation of the C1qRP/CD93 receptor to 
be required for its stable cell surface expression.   
O-glycosylation of the stalk region of TRAIL receptor 2, another member of the 
TNF receptor superfamily, has been found to influence the sensitivity of the receptor to 
its ligand and the ability of the receptor to signal for apoptosis (Wagner et al., 2007). O-
glycosylation has also been described in the stalk region of TNFR2 (Pennica et al., 
1993), but whether it plays a role in sTNF responsiveness is not known to date. 
Therefore, the aim was to identify sites of O-glycosylation in the TNFR2 stalk region 
and to investigate the role of stalk region O-glycosylation in sTNF responsiveness 
 
4.4.1 sTNF responsiveness of TNFR2-Fas chimaeras after site-directed 
mutagenesis of predicted O-glycosylation sites  
 
The role of O-glycosylation of the stalk region in TNFR2 responsiveness towards sTNF 
was investigated using TNFR2-Fas chimaeras with point mutations in putative O-
glycosylation sites. For this purpose several expression vectors containing TNFR2-Fas 
chimaeras in which potential O-glycosylation sites were mutated to alanines or, in the 
case of T235, to an arginine had been generated previously (Dr Andrea Zappe/Dr Anja 
Krippner-Heidenreich, University of Stuttgart, Germany). Due to the large number of 
potential O-glycosylation sites, six potential O-glycosylation motifs had been defined 
(motifs 1-6, Figure 37 A). Expression vectors containing TNFR2-Fas chimaeras, in 
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which potential glycosylation sites of the following motifs and/or motif combinations 
were mutated, had been created: motif 1 (TNFR2-Fas mot. 1), motif 1 and 2 (TNFR2-
Fas mot. 1/2), motifs 1, 2 and 3 (TNFR2-Fas mot. 1/2/3), motifs 1 and 4 (TNFR2-Fas 
mot. 1/4) and motifs 1 and 5 (TNFR2-Fas mot. 1/5).  
 
As a quick and easy screening method for the effect of the mutation of potential O-
glycosylation sites the resulting chimaeras were transiently transfected into HeLa cells 
as described in section 2.4.1 and whole cell lysates were prepared and resceptors were 
analysed for their migration properties by Western Blotting (Figure 37 B). The plain 
expression vector pEF-PGK/puroA and the stalk region deletion mutant TNFR2-
(SΔ42/TM)R2-Fas served as negative controls, while the TNFR2-Fas chimaera served as 
positive control. All chimaeric receptors mutated in the potential O-glycosylation motifs 
(Figure 37 B, lanes 4 - 8) showed an intermediate phenotype for their molecular weight, 
migrating between the fully glycosylated and the putatively non-glycosylated forms of 
TNFR2-Fas (Figure 37 B, lane 2). Again, as mentioned in section 3.2, the faster 
migrating protein band might represent receptors which had been translated but not 
undergone any post-translational modifications yet. 
As TNFR2-Fas motif 1 and motifs 1/4 represent receptor mutants with minimal 
mutations but greatest mobility, residues mutated in motif 1 and motif 4 are most likely 
to be sites of O-glycosylation. Furthermore, the Western Blot analysis revealed 
decreased molecular weights for chimaeras, in which motifs 1, 2 and 3 and motifs 1 and 
5, respectively, had been mutated, suggesting that these motifs are likely to be also O-
glycosylated in TNFR2-Fas. 
 
 
 
 
 
 
 
  
149 
 
B
A
 
Figure 37. Characterisation of putative O-glycosylation sites within the TNFR2 stalk 
region.  
A) Shown is the aa sequence of the TNFR2 stalk region (aa 202–257) and the C-terminal aa of 
CRD4 (T, aa 201). Putative O-glycosylation sites are marked with black stars (predicted by 
NetOGlyc) and/or purple stars (predicted by SVM programme). B) Analysis of putative O-
glycosylation motifs in the TNFR2 stalk region. Hela cells were transiently transfected with 
TNFR2-Fas chimaeras in which serine and threonine residues of indicated potential O-
glycosylation clusters (motifs 1-5) in the TNFR2 stalk region had been mutated to alanines. In 
motif 1 T235 had been exchanged for an arginine. Whole cell lysates were prepared from these 
cells and an equivalent of 3.3 x 10
4
 cells was used for SDS-PAGE and Western Blot analysis. 
Mouse anti-human Fas antibodies (clone B10, 1:2000) were used as primary and goat anti-
mouse IgG-HRP (1:20000) as secondary antibodies. HeLa cells transiently transfected with 
TNFR2-(SΔ42/TM)R2-Fas, TNFR2-Fas or the plain expression vector (pEF-PGKpuroA) served 
as controls. As indicated, the slower migrating protein bands represent fully and partially 
glycosylated receptor chimaeras, respectively, whereas the faster migrating protein bands 
represent putatively un-O-glycosylated chimaeric receptors. Data shown are representative of 
three independent experiments.  
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MF stably transfected with chimaeras, in which the serine and threonine residues of 
motifs 1, 2 and 3 (MF TNFR2-Fas mot. 1/2/3) were exchanged for alanines, had been 
generated by Dr Andrea Zappe. In addition, MF stably transfected with chimaeras, in 
which all serine and threonine residues of motifs 1 and 5 (MF TNFR2-Fas mot. 1/5) 
were exchanged for alanines, have been generated as part of this PhD project. Both, 
TNFR2-Fas mot. 1/2/3 (MnX = 18; Figure 38 A) and TNFR2-Fas mot. 1/5 (MnX = 90; 
Figure 38 C) were expressed on the cell surface and were fully responsive to CysTNF 
with an ED50 = 0.15 ng/ml for TNFR2-Fas mot. 1/2/3 (Figure 38 B) and an ED50 = 0.09 
ng/ml for TNFR2-Fas mot. 1/5 (Figure 38 D). However, no responsiveness towards 
sTNF could be observed for either construct (Figure 38 B and D, respectively), 
indicating that these motifs are involved in determining O-glycosylation but not sTNF 
responsiveness of TNFR2.  
Despite high intracellular protein expression of the TNFR2-Fas mot. 1/4 
chimaera, cell surface expression of this construct could be detected neither for 
transiently transfected HeLa cells nor for stably transfected MF (data not shown). 
Therefore, an analysis of the sTNF responsiveness of the TNFR2-Fas mot. 1/4 variant 
was not possible.  
 
Taken together, these experiments did not reveal single O-glycosylation motifs 
inhibiting sTNF responsiveness of TNFR2. However, further combinations of mutated 
O-glycosylation motifs have yet to be tested. 
  
151 
 
 
 
 
 
 
0.0
0.5
1.0
1.5
0.01 0.1 1 10 100
CysTNF
sTNF
TNF [ng/ml]
v
ia
b
le
 c
e
lls
 (
O
D
5
5
0
 n
m
)
TNFR2-Fas mot. 1/2/3B
C TNFR2-Fas mot. 1/5
A TNFR2-Fas mot. 1/2/3
D
100 101 102 103 104
0
20
40
60
80
100
65.3
MnX =
18
65.3 %
fluorescence intensity
%
 o
f 
M
a
x
0.0
0.5
1.0
1.5
0.01 0.1 1 10 100
Cys TNF
sTNF
TNF [ng/ml]
v
ia
b
le
 c
e
lls
 (
O
D
5
5
0
 n
m
)
100 101 102 103 104
fluorescence intensity
0
20
40
60
80
100
%
 o
f 
M
a
x
78.2 %
MnX =
90
TNFR2-Fas mot. 1/5
 
Figure 38. Characterisation of cell surface expression and TNF responsiveness of MF 
TNFR2-Fas with reduced O-glycosylation.  
A and C) FACS Histograms of MF stably transfected with TNFR2-Fas mot. 1/2/3 (MF TNFR2-
Fas mot. 1/2/3) and TNFR2-Fas mot. 1/5 (MF TNFR2-Fas mot. 1/5) expression constructs. 
TNFR2-Fas chimaeras were stained on the cell surface using mouse anti-human TNFR2 
antibodies (MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). Unstained cells 
(dotted line); cells only incubated with goat anti-mouse IgG-FITC antibodies (grey). 65 % of the 
MF were gated positive for TNFR2-Fas mot. 1/2/3 and 91 % were gated positive for TNFR2-
Fas mot. 1/5. Acquisition was performed on a Becton Dickinson FACScan flow cytometer. B 
and D) MF TNFR2-Fas mot. 1/2/3 and MF TNFR2-Fas mot. 1/5 remained untreated or were 
stimulated with different concentrations of sTNF and CysTNF (0.015-100 ng/ml), respectively, 
and cell viability was determined using crystal violet staining. Data shown represent three 
independent experiments. 
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4.4.2 sTNF responsiveness of TNFR-Fas chimaeras upon inhibition of core 1/core 
2 O-glycosylation 
 
The mutation of putative O-glycosylation sites in the TNFR2 stalk region did not reveal 
a role for TNFR2 stalk region O-glycosylation in the control of receptor responsiveness 
towards sTNF so far. However, we were not able to analyse all putative O-glycosylation 
sites yet and Western Blot analysis data suggest that the tested O-glycosylation mutants 
are not fully un-O-glycosylated (Figure 37 B). Therefore, to complement our data, we 
used an O-glycosylation inhibitor to shed light onto the potential role of mucin-type O-
glycosylation in sTNF responsiveness. 
Mucin-type O-glycosylation is initiated by the addition of a GalNAc residue to 
the hydroxyl group of a serine or threonine residue of the protein substrate. The 
formation of core 1 and core 2 O-glycosylation, two of the early steps during the O-
glycosylation of most proteins with mucin-type O-glycosylation, is then dependent on 
the addition of another GalNAc residue by β-l,3-N-galactosyltransferase (reviewed in 
Tian and Ten Hagen, 2009). Benzyl-α-GalNAc is a structural analog of GalNAc (see 
Figure 9) and, therefore, can function as a competitive inhibitor for β-1,3-
galactosyltransferase-dependent core 1 and core 2 O-glycosylation (Kuan et al., 1989). 
 
To address the question whether overall core 1/core 2 O-glycosylation affects the 
responsiveness of TNFR towards sTNF, MF stably transfected with TNFR1-Fas and 
TNFR2-Fas were cultivated in the presence of 3.5 mM Benzyl-α-GalNAc for three days 
and four days, respectively. MF TNFR2-SGSL56-TMR2-Fas were cultivated in the 
presence 3.5 mM Benzyl-α-GalNAc for four days and served as negative control. 
Western Blot analysis and cell viability assays were performed on days 4 and 5. Cells 
incubated with 0.55 % (v/v) DMSO served as solvent control (see also section 2.11).  
For the Benzyl-α-GalNAc treated cells Western Blot analysis revealed a much 
stronger decrease in molecular weight for TNFR2-Fas than for TNFR1-Fas in 
comparison to the corresponding solvent controls on both, day 4 and day 5 (Figure 39). 
No comparable decrease in molecular weight could be observed after Benzyl-α-GalNAc 
treatment of MF TNFR2-SGSL56-TMR2-Fas, in which the stalk region had been replaced 
by a 56 amino acid long artificial linker. These data indicate that the Benzyl-α-GalNAc 
treatment did not only lead to an overall reduction in O-glycosylation, but also that it is 
indeed the stalk region of the parental TNFR2-Fas chimaera which is O-glycosylated. 
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Figure 39. O-glycosylation in the TNFR2-Fas stalk region can be inhibited by Benzyl-2-
acetamido-2-deoxy-α-D-galactopyranoside. 
MF stably transfected with TNFR2-Fas, TNFR1-Fas and TNFR2-SGSL56-TMR2-Fas were 
cultivated in the presence of 0.55 % (v/v) DMSO or 3.5 mM Benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside (Benzyl-α-GalNAc) for 3 days and 4 days, respectively. Cells were re-seeded 
and whole cell lysates were prepared on days 4 and 5. An equivalent of approximately 3.3 x 10
4
 
cells was used for SDS-PAGE and Western Blot analysis. Mouse anti-human Fas antibodies 
(clone B10, 1:2000) were used as primary and goat anti-mouse IgG-HRP (1:20000) as 
secondary antibodies. Untransfected MF -/- served as negative control. As indicated, the faster 
migrating protein bands represent receptor chimaeras with reduced O-glycosylation, whereas 
the slower migrating protein bands represent chimaeric receptors in which O-glycosylation is 
not reduced. Unspecific bands are highlighted with an asterisk. Data shown represent two 
independent experiments. 
 
 
 
The cell surface expression of both, TNFR1-Fas and TNFR2-Fas chimaeras remained 
comparable between untreated cells, solvent control and Benzyl-α-GalNAc treated cells 
(MnX = 104-152 for TNFR1-Fas; Figure 40 A, C and E; MnX = 213-247 for TNFR2-
Fas; Figure 41 A, C and E). Responsiveness towards TNF was not affected by Benzyl-
α-GalNAc treatment in MF TNFR1-Fas (Figure 40 B, D and F) and MF TNFR2-Fas 
(Figure 41 B, D and F). TNFR1-Fas remained responsive to both, CysTNF (ED50 = 
0.03-0.04 ng/ml) and sTNF (ED50 = 0.04-0.08 ng/ml), while TNFR2-Fas was only 
responsive towards CysTNF (ED50 = 0.3-0.5 ng/ml) but not sTNF. These data indicate 
that core 1 and core 2 dependent O-glycosylation is unlikely to be a determining factor 
for the differential responsiveness of TNFR2 to sTNF. 
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Figure 40. Inhibition of core 1/2 O-glycosylation does not alter sTNF responsiveness in MF 
TNFR1-Fas.  
MF stably transfected with TNFR1-Fas were cultivated in the presence of 0.55 % (v/v) DMSO 
for 5 days (A and B) or in the presence of 3.5 mM Benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside (Benzyl-α-GalNAc) for 4 days (C and D) and 5 days (E and F), respectively. 
A, C and E) FACS Histogram. TNFR1-Fas chimaeras were stained on the cell surface using 
mouse anti-human TNFR1 antibodies (H398) and goat anti-mouse IgG-FITC antibodies (black 
line). Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC 
antibodies (grey). 85-86 % of the MF were gated positive for TNFR1-Fas. Acquisition was 
performed on a Becton Dickinson FACScan flow cytometer. B, D and F) Responsiveness to 
CysTNF and sTNF. Cells remained untreated or were stimulated with different concentrations 
of sTNF and CysTNF (0.015-100 ng/ml), respectively, and cell viability was determined using 
crystal violet staining. Data shown represent two independent experiments.  
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Figure 41. Inhibition of core 1/2 O-glycosylation does not alter TNF responsiveness in MF 
TNFR2-Fas. 
MF stably transfected with TNFR2-Fas were cultivated in the presence of 0.55 % (v/v) DMSO 
for 5 days (A and B) or in the presence of 3.5 mM Benzyl-2-acetamido-2-deoxy-α-D-
galactopyranoside (Benzyl-α-GalNAc) for 4 days (C and D) and 5 days (E and F), respectively. 
A, C and E) FACS Histogram. TNFR2-Fas chimaeras were stained on the cell surface using 
mouse anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-FITC antibodies 
(black line). Unstained cells (dotted line); cells only incubated with goat anti-mouse IgG-FITC 
antibodies (grey). 90 % of the MF were gated positive for TNFR2-Fas. Acquisition was 
performed on a Becton Dickinson FACScan flow cytometer. B, D and F) Responsiveness to 
CysTNF and sTNF. Cells remained untreated or were stimulated with different concentrations 
of sTNF and CysTNF (0.015-100 ng/ml), respectively, and cell viability was determined using 
crystal violet staining. Data shown represent two independent experiments. 
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4.5 Effect of partial replacement of the TNFR2 stalk region on sTNF 
responsiveness 
 
The data described in sections 4.2, 4.3 and 4.4, further confirmed a critical role for the 
TNFR2 stalk region in determining responsiveness towards sTNF. However, so far this 
effect could not be assigned to one specific molecular feature of this region. Therefore, 
to narrow down which section of the stalk region controls sTNF responsiveness, the 
stalk region of TNFR2-Fas chimaeras was partly replaced with artificial glycine-serine-
linkers. These linkers were between 17 aa and 22 aa in length and were overlapping by 
five to nine aa residues (see Table 11). Four different TNFR2-Fas chimaeras were 
generated, in which the following aa residues were substituted: aa 202-219 in TNFR2-
(SExaa202-219/TM)R2-Fas, aa 215-232 in TNFR2-(SExaa215-232/TM)R2-Fas, aa 228-249 in 
TNFR2-(SExaa228-249/TM)R2-Fas and aa 241-257 in TNFR2-(SExaa241-257/TM)R2-Fas. 
These constructs were generated as described in section 2.2.8 and stably transfected into 
MF.  
 
The correct molecular weight of the constructs was confirmed via Western Blot analysis 
using whole cell lysates from transiently transfected HeLa cells and stably transfected 
MF (Figure 42). For the HeLa cell lysates two protein bands could be observed for all 
partial stalk replacement mutants. Again, the faster migrating protein bands presumably 
represented receptors which had not been post-translationally modified while the slower 
migrating bands most likely represented the mature forms of the constructs (Figure 42). 
For the stably transfected MF only the presumably post-translationally modified 
band could be observed which co-migrated with the slower migrating band of the 
corresponding transiently transfected HeLa cell samples (Figure 41). Unspecific bands, 
which were also recognised by the mouse anti-human Fas antibodies, are highlighted by 
an asterisk (Figure 41).  
 
 
  
  
157 
 
 
 
 
 
 
 
 
Figure 42. Western Blot analysis of TNFR2-Fas chimaeras with partially substituted stalk 
regions.  
The receptor constructs TNFR2-(SExaa202-219/TM)R2-Fas, TNFR2-(SExaa215-232/TM)R2-Fas, 
TNFR2-(SExaa228-249/TM)R2-Fas and TNFR2-(SExaa241-257/TM)R2-Fas were transiently 
transfected into HeLa cells or stably transfected into MF. Whole cell lysates were prepared from 
these cells. For HeLa cells an equivalent of approximately 2.5 x 10
4
 cells and for MF an 
equivalent of approximately 5 x 10
4
 cells were used for SDS-PAGE and Western Blot analysis. 
Mouse anti-human Fas antibodies (clone B10, 1:2000) were used as primary and goat anti-
mouse IgG-HRP (1:20000) as secondary antibodies. TNFR2-(SΔ42/TM)R2-Fas, TNFR2-Fas and 
the plain expression vector (pEF-PGKpuro) served as controls. As indicated, the slower 
migrating protein bands represent the mature receptor chimaeras, whereas the faster migrating 
protein bands represent putatively not post-translationally modified chimaeric receptors. Shown 
are re-arranged Western Blot data from the same exposure. Data shown represent one 
experiment. 
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As a next step, cell surface expression of the chimaeras was confirmed by FACS 
analysis. All four TNFR2-Fas chimaeras, in which the stalk region had been partly 
substituted with glycine and serine residues, were expressed on the cell surface of stably 
transfected MF (Figure 43 A and C). 76 % of the cells showed cell surface expression of 
TNFR2-(SExaa202-219/TM)R2-Fas (Figure 43 A) and 91 % of the cells were gated positive 
for TNFR2-(SExaa215-232/TM)R2-Fas (Figure 43 C). 92 % of the cells were gated positive 
for TNFR2-(SExaa228-249/TM)R2-Fas (Figure 43 E) and 77 % of the cells were gated 
positive for TNFR2-(SExaa241-257/TM)R2-Fas (Figure 43 G). With the exception of the 
data for TNFR2-(SExaa202-219/TM)R2-Fas, which were acquired on a FACScan flow 
cytometer, acquisition of the flow cytometric data was performed on a Becton 
Dickinson FACSCanto II flow cytometer. A comparison of data acquired on these two 
flow cytometers showed that MnX were approximately 10-fold higher when the Becton 
Dickinson FACSCanto II flow cytometer was used as opposed to the FACScan flow 
cytometer (data not shown). Therefore, the MnX of TNFR2-(SExaa202-219/TM)R2-Fas and 
TNFR2-(SExaa215-232/TM)R2-Fas were comparable (MnX = 1504 for   TNFR2-(SExaa202-
219/TM)R2-Fas and MnX = 137 TNFR2-(SExaa215-232/TM)R2-Fas; Figure 43 A and C), 
while with MnX of 3096 and 11609, respectively, MF TNFR2-(SExaa228-249/TM)R2-Fas 
and MF TNFR2-(SExaa241-257/TM)R2-Fas showed both higher cell surface expression of 
the respective chimaeras (Figure 43 E and G). 
 
MF stably expressing these partial stalk replacement variants were treated with 
increasing concentrations of CysTNF or sTNF and cell viability was determined using 
crystal violet staining. Approximately 50 % of MF TNFR2-(SExaa202-219/TM)R2-Fas 
treated were responsive to CysTNF while about 70 % of MF TNFR2-(SExaa215-
232/TM)R2-Fas and MF TNFR2-(SExaa228-249/TM)R2-Fas showed responsiveness towards 
this ligand at high concentrations. For MF TNFR2-(SExaa241-257/TM)R2-Fas only about 45 
% of the treated cells were responsive to 100 ng/ml CysTNF. With ED50 values between 
0.1 ng/ml and 0.3 ng/ml, the responsiveness towards CysTNF was comparable to that 
seen in MF TNFR2-Fas cells (ED50 = 0.2 ng/ml; see also Figure 11 D). Importantly, 
similar to the parental TNFR2-Fas chimaera, neither of these receptor chimaera variants 
was responsive towards sTNF, indicating that potentially more than one molecular 
feature in the TNFR2 stalk region controls responsiveness towards sTNF.   
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In conclusion, we were not able to narrow down which part of the TNFR2 stalk region 
encodes the inhibitory capacity this region has on receptor responsiveness towards 
sTNF.  
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Figure 43. Partial replacement of the TNFR2 stalk region does not alter TNF 
responsiveness.  
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MF were stably transfected with expression constructs encoding for TNFR2-(SExaa202-
219/TM)R2-Fas, TNFR2-(SExaa215-232/TM)R2-Fas TNFR2-(SExaa228-249/TM)R2-Fas and TNFR2-
(SExaa241-257/TM)R2-Fas chimaeras. A, C, E and G) FACS histograms of MF stably transfected 
with indicated TNFR2-Fas variants. Cell surface expression of the chimaeric receptors was 
verified using mouse anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse-IgG-FITC 
antibodies (black line). Unstained cells (dotted line); cells only incubated with goat anti-mouse 
IgG-FITC antibodies (grey). As indicated, between 76 % and 91 % of MF were gated positive 
for the respective chimaeras. Acquisition was performed on a Becton Dickinson FACSCanto II 
(C) or a Becton Dickinson FACScan (A, E and G) flow cytometer. B, D, F and H) MF stably 
transfected with indicated TNFR2-Fas chimaeras remained untreated or were stimulated with 
different concentrations of sTNF and CysTNF (0.015-100 ng/ml) and cell viability was 
determined using crystal violet staining. Data shown represent three independent experiments.  
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4.6 Discussion 
 
As described below, for the stalk regions of cell surface receptors various different 
functions, such as the control of cell surface expression and stabilisation, involvement 
in ligand binding and/or activation of the receptors have been reported. These functions 
have often been linked to special features of these stalk regions such as the O-
glycosylation status and length or certain conformations these regions adopt.  
The length of the stalk region of the α-subunit of the Fc-epsilon receptor (FcεR) 
I, for example, was described to be important for the receptor stability on the cell 
surface (Kubota et al., 2006), while the flexibility of the FcεRII stalk region was 
suggested to control receptor orientation and high affinity binding to its ligand, 
immunoglobulin E (Kilmon et al., 2004). An involvement in ligand binding has also 
been reported for the stalk regions of the CD8 beta-chain (CD8β)(Moody et al., 2001, 
Moody et al., 2003, Rettig et al., 2009) and the murine Ly49 receptors (Ito et al., 2009, 
Back et al., 2009), with O-glycosylation and conformation of the stalk region being of 
importance, respectively. Interestingly, a potential role for the stalk region in signal 
transduction has already been suggested for another TNFR superfamily member, 
TRAILR2 (Wagner et al., 2007). Preliminary data of our group together with data 
presented here showed that the stalk regions of TNFR1 and TNFR2 control sTNF-
mediated signalling initiation. In contrast to the TRAILR2 stalk region, the stalk region 
of TNFR2 was found to prevent sTNF-mediated but not CysTNF-mediated signal 
transduction (see chapter 3). Therefore, the aim of this chapter was to investigate the 
role of different stalk region features, including length, proline-richness and O-
glycosylation, in the control of sTNF responsiveness of TNFR2. 
 
4.6.1 Stalk region length does not determine responsiveness towards sTNF 
 
Relatively little is known about the influence of stalk region length on receptor 
functions. Kubota et al. (2006) found that elongation of the stalk region led to an 
increased half-life of the α-subunit of FcεRI (FcεRIα) on the cell surface. This effect 
was independent of the aa sequence of the FcεRIα stalk region and, therefore, it was 
proposed that the stalk region length was the determining factor for this increased half-
life.  
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In this PhD project, the stalk regions of TNFR1-Fas and TNFR2-Fas were 
replaced with 15 aa and 56 aa long artificial linkers, respectively. While the receptor 
numbers on the cell surface were not determined experimentally, the comparable cell 
surface expression of the TNFR-Fas chimaeras with 15 aa artificial stalk regions and the 
corresponding constructs with a 56 aa artificial stalk region suggests that stalk region 
length does not determine the overall TNFR stability on the cell surface.  
No differences in sTNF responsiveness between chimaeras with short and long 
artificial stalk regions could be observed for both, TNFR1-Fas and TNFR2-Fas (see 
Figure 32 and Figure 33). In contrast to the parental TNFR2-Fas chimaera, however, 
TNFR2-Fas chimaeras in which the stalk regions had been replaced with 15 aa and 56 
aa long artificial linkers, respectively, did show an increased responsiveness to sTNF. 
The sTNF responsiveness of TNFR1-Fas and TNFR2-Fas chimaeras containing 
artificial 56 aa linkers (Figure 32 D and Figure 33 D, respectively) also differed 
markedly from the one of TNFR2-Fas and TNFR1-(S/TM)R2-Fas (Figure 11), which 
both contain the wild type TNFR2 stalk region. While the artificial 56 aa stalk regions 
and the wild type TNFR2 stalk region have the same length their aa composition is 
different. Therefore, while our data further support an inhibitory role for the TNFR2 
stalk region in receptor responsiveness to sTNF, they also suggest that this is not 
controlled by stalk region length. Instead sTNF responsiveness appears rather to be 
encoded by an intrinsic motif or feature of this region. 
 
4.6.2 The influence of conserved proline residues in the TNFR2 stalk region on 
sTNF responsiveness 
 
In contrast to the TNFR1 stalk region, the TNFR2 stalk region is rich in proline 
residues, of which seven are well conserved between species (Figure 34 A). Due to their 
bulky side chain and incapability to act as hydrogen-bond donors, proline residues 
function in proteins as helix- and β-sheet breakers, respectively, and proline-rich 
sequences are often found in extended structures and flexible regions (reviewed in 
Williamson, 1994). Furthermore, cis-trans isomerisation of proline residues has been 
found to function as a molecular switch during some signalling events of, for example, 
the interleukin-2-inducible T-cell kinase pathway (Brazin et al., 2002, Mallis et al., 
2002) and the NF-κB pathway (Ryo et al., 2003, Jiang et al., 2008). For one of the 
enzymes catalysing cis-trans isomerisation, namely the peptidyl prolyl cis-trans 
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isomerase cyclophilin B, localisation at the plasma membrane has been reported, 
suggesting a potential role of this enzyme during the initiation of signal transduction 
events (Bukrinsky, 2002, Stumpf et al., 2008). 
To investigate whether single conserved proline residues in the TNFR2 stalk 
region could potentially act as molecular switches in TNFR2 signalling initiation site-
directed mutagenesis of the seven conserved proline residues in this region was 
performed. No difference in sTNF responsiveness could be observed between parental 
TNFR2-Fas chimaeras and chimaeras in which proline residues had been mutated 
(Figure 11, Figure 35 and Figure 36). Therefore, in contrast to cis-trans isomerisation 
events occurring during NF-κB signalling (Ryo et al., 2003) or histone methylation 
(Nelson et al., 2006), a single proline acting as a molecular switch controlling sTNF 
responsiveness of TNFR2 could not be identified.  
However, it is possible that a combination of several proline residues in the 
TNFR2 stalk region could determine sTNF responsiveness of this receptor. In several 
proteins proline-rich sequences have been reported to adopt folds which can confer 
both, flexibility and stability (reviewed in Williamson, 1994). A prominent example of 
such a secondary structure is the left handed collagen helix, in which proline residues 
and their hydroxylated form, hydroxyproline, occur as part of a regular pattern 
(reviewed in Bhattacharjee and Bansal, 2005). The TNFR2 stalk region does not display 
an equally even distribution of proline residues, but it is conceivable that with their 
abundance in the stalk region these aa residues could contribute to stalk region 
conformation and orientation to a large extent while also providing a certain degree of 
flexibility. 
In addition, proline residues are found at positions -1, +1 and +3 relative to the 
site of O-glycosylation in the majority of proteins with mucin-type O-linked 
glycosylation (Wilson et al., 1991, Hansen et al., 1995). Thus, the proline residues in 
the TNFR2 stalk region will be involved in defining sites of O-glycosylation. Indeed for 
the TNFR2-Fas P205A chimaera a decreased molecular weight compared to the 
parental receptor chimaera could be observed, which indicates that P205 might be 
defining such an O-glycosylation site (Figure 34). However, this would have to be 
further confirmed by comparing lysates from stably and transiently transfected cells. 
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4.6.3 O-glycosylation of the TNFR2 stalk region does not determine 
responsiveness to sTNF  
 
The stalk region of TNFR2 has been described to be O-glycosylated (Pennica et al., 
1993) and several potential sites of O-glycosylation were predicted by the 
bioinformatics tool NetOglyc (Julenius et al., 2005) and a supported vector machine 
(SVM) programme (Li et al., 2006)(see Figure 37 A). O-glycosylation of the stalk 
region of the TNFR superfamily member TRAILR2 has been reported to play a role in 
the sensitivity of the receptor to its ligand and its ability to signal for apoptosis (Wagner 
et al., 2007). To address whether O-glycosylation in the stalk region also affects sTNF-
mediated activation of TNFR2 the responsiveness of TNFR2-Fas chimaeras, in which 
either O-glycosylation sites had been mutated or O-glycosylation had been reduced 
using the inhibitor Benzyl-α-Gal-NAc, were analysed as part of this PhD project. 
  
Five predicted O-glycosylation motifs in the TNFR2 stalk region were analysed for 
their effect on sTNF responsiveness. Mutation of motif 1 in combination with motif 4 
identified these two motifs as major O-glycosylation sites, but also motifs 2, 3 and 5 
appeared to be involved in stalk region O-glycosylation (Figure 37 B). However, for 
none of the analysed variants an increase in sTNF responsiveness could be observed, 
indicating that O-glycosylation of the serine and threonine residues of motifs 1, 2, 3 and 
5 does not inhibit responsiveness of TNFR2-Fas chimaeras towards sTNF (Figure 38 B 
and D). Unfortunately, it was not possible to determine whether O-glycosylation of 
motif 4 controls sTNF responsiveness of TNFR2-Fas. Despite its high intracellular 
protein expression (Figure 37 B), the TNFR2-Fas mot. 1/4 chimaera was not expressed 
on the cell surface. This suggests that O-glycosylation of motif 4, possibly in 
combination with O-glycosylation of motif 1, could be essential for exporting TNFR2-
Fas chimaeras from the endoplasmic reticulum and localising them at cell surface. For 
example, site-specific O-glycosylation of the membrane-proximal part of the 
extracellular portion of the neurotrophin receptor has already been reported to be 
required for apical sorting of this receptor (Breuza et al., 2002).  
In conclusion, O-glycosylation of motifs 1, 2, 3 and 5 does not appear to 
critically control sTNF responsiveness of TNFR2-Fas, while the role of O-glycosylation 
of motif 4 in determining sTNF responsiveness remains elusive. 
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Experiments with Benzyl-α-Gal-NAc, a substrate for β-l,3-N-galactosyltransferase 
(Brockhausen et al., 1983) and competitive inhibitor for core 1 and core 2 mucin-type 
O-glycosylation (Kuan et al., 1989) underlined our findings from the O-glycosylation 
mutants. The data obtained using this inhibitor highlight that it is rather unlikely that O-
glycosylation of the TNFR2 stalk region is a determinant critical for receptor 
responsiveness towards sTNF. While O-glycosylation was reduced by the Benzyl-α-
Gal-NAc treatment, no effect on the responsiveness of TNFR-Fas chimaeras towards 
sTNF could be detected when compared with solvent control (Figure 40 B, D and F and 
Figure 41 B, D and F). Importantly, comparison of Benzyl-α-Gal-NAc-treated TNFR2-
Fas and TNFR2-SGSL56-TMR2-Fas, in which the stalk region is replaced by a 56 aa long 
artificial linker, indicates that the decrease in molecular weight of TNFR2-Fas 
chimaeras is indeed caused by reduced O-glycosylation in the TNFR2 stalk region 
(Figure 39).  
With a concentration of 3.5 mM, Benzyl-α-Gal-NAc was added at a 
concentration which was above the one that had been used to fully inhibit O-
glycosylation in a human colonic adenocarcinoma cell line (2 mM; Kuan et al., 1989), 
but just below the 4 mM used by Wagner et al. (2007) to inhibit O-glycosylation of 
TRAILR2 in HEK 293 cells. As a substrate which is competing for βl,3-N-
galactosyltransferase, Benzyl-α-Gal-NAc leads to the accumulation of aryl-glycans in 
the cell, affects the sialylation of N-linked glycans (Zanetta et al., 2000) and has even 
been described to cause apoptosis and growth inhibition (Patsos et al., 2009). Therefore, 
Benzyl-α-Gal-NAc was used at a sensible concentration sufficient to inhibit core 1 and 
core 2 O-glycosylation efficiently while not being so high as to cause problems with 
cell growth and viability (Figure 39, Figure 40 and Figure 41).  
Taken together, our data indicate that the TNFR2 stalk region carries core 1 
and/or core 2 mucin-type O-glycosylation but this type of glycosylation does not control 
sTNF responsiveness of the TNFR.  
 
As mentioned above, core 1 and core 2 O-glycosylation represent the most common 
forms of mucin-type O-glycosylation. In addition, six more types of mucin-type O-
glycosylation structures (core 3-8) have been described in mammals. However, while β-
l,3-N-galactosyltransferase is expressed in all cell types throughout all developmental 
stages (Tian and Ten Hagen, 2009), core 3 and core 4 structures have only been 
observed in secreted mucins and occurrence of core 5-8 mucins is very restricted 
(Brockhausen et al., 2009). Therefore, while we cannot entirely exclude the possibility 
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that alternative O-glycosylation affects sTNF responsiveness in other cell types or 
tissues, it is, however, very unlikely to play a role in our TNFR-Fas cellular system. A 
full analysis of the O-glycosylation types in the TNFR2 stalk region by mass 
spectrometry would allow a more selective inhibition of stalk region O-glycosylation 
for example through the use of glycosyltransferase-specific siRNA. However, this was 
not possible due to timely limitations of this project and remains as future work. 
 
4.6.4 Partial replacement of the TNFR2 stalk region suggests a more complex 
regulation of sTNF responsiveness by the stalk region 
 
Data obtained using MF stably transfected with TNFR-Fas chimaeras, in which the stalk 
regions had been replaced with 15 aa and 56 aa long artificial linkers, suggested that 
sTNF responsiveness is rather determined by the aa composition than the length of the 
stalk region (section 4.2). To further investigate which part of the TNFR2 stalk region 
in particular controls responsiveness towards sTNF we exchanged this region partly 
with artificial linkers of 17-22 aa in length and determined sTNF responsiveness of the 
resulting TNFR2-Fas chimaeras. While all four partial exchange mutants were 
expressed on the cell surface, for none an effect of the partial stalk region replacement 
on the responsiveness to the soluble ligand could be observed (Figure 43). This suggests 
that either the region as a whole or more than one feature within this region determine 
responsiveness towards sTNF. Therefore, control of sTNF responsiveness by the 
TNFR2 stalk region appears to be determined through a more complex mechanism 
which remains yet to be elucidated. 
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4.7 Conclusion 
 
 Single conserved proline residues in the TNFR2 stalk region do not control 
sTNF responsiveness of TNFR2-Fas chimaeras. However, the role of 
combinations of these conserved proline residues in sTNF responsiveness 
remains yet to be determined. 
 O-glycosylation of the TNFR2 stalk region is most likely no critical 
determinant for the differential responsiveness of TNFR2 as mutation of 
putative O-glycosylation sites and inhibition of core 1 and core 2 mucin-
type O-glycosylation do not alter responsiveness of TNFR2-Fas towards 
sTNF.  
 The length of the TNFR2 stalk region does not determine receptor 
responsiveness to sTNF. However, the aa composition of the TNFR2 stalk 
region appears to play an important role in differential responsiveness of 
TNFR. 
 Partial replacement of the TNFR2 stalk region suggests that a more complex 
mechanism is underlying sTNF responsiveness and that either the region as 
a whole or more than one feature encoded by this region control differential 
responsiveness. 
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CHAPTER 5 
Results III: Influence of the TNF receptor stalk regions on 
ligand-independent receptor homodimerisation and formation 
of larger receptor clusters 
5 chagkgey 
5.1 Introduction 
 
Formation of receptor clusters has been postulated to enhance signal transduction of 
transmembrane receptors in various ways, for example by increasing their sensitivity 
and specificity and enhancing response simultaneity, respectively (reviewed in Duke 
and Graham, 2009). Formation of such receptor clusters has already been observed for 
Fas (Algeciras-Schimnich et al., 2002, Siegel et al., 2004). These clusters were 
described as “signaling protein oligomeric transduction structures” (SPOTS) and were 
found to be formed as an early event during Fas signalling (Siegel et al., 2004). The 
extracellular region of Fas has been reported to be sufficient for cluster formation 
induced by membrane-bound FasL (Henkler et al., 2005). In contrast, Fas cluster 
formation upon stimulation with soluble FasL was found to be dependent on 
interactions of the intracellular portion of Fas and required localisation to cholesterol-
rich plasma membrane microdomains. Based on crystallographic data, Scott et al. 
(2009) recently proposed that FasL binding stabilises the signalling-competent form of 
Fas. Furthermore, it results in linkage of the Fas DD, leading to rapid processive Fas 
cluster formation and binding of FADD, which in turn further promotes receptor cluster 
and DISC formation. In addition, electron microscopy data suggest that the minimal 
cluster-forming Fas/FADD complexes show a hexameric arrangement (Scott et al., 
2009).  
Similarly, ligand-induced cluster formation of TNFR1, which had already been 
proposed by Naismith et al. (1995), could be demonstrated in confocal microscopy 
experiments by Schneider-Brachert et al. (2004). In line with these findings, Krippner-
Heidenreich et al. (2002) observed that efficient TNF-mediated recruitment of FADD 
and TRAF2 to TNFR1-Fas chimaeras coincided with the formation of large receptor 
clusters. The exact composition of these receptor clusters and the mechanism by which 
they are formed are largely unknown. However, the so-called pre-ligand binding 
  
170 
 
assembly domains (PLAD) of the receptors and the localisation of the TNFR in 
microdomains of the plasma membrane have already been described as possible 
determinants for the formation of these receptor clusters (see below).  
 
Ligand-independent homotypic dimerisation and/or trimerisation of TNFR1, TNFR2 
(Chan et al., 2000) and Fas (Papoff et al., 1996, Papoff et al., 1999, Siegel et al., 2000) 
via their PLAD in CRD1 have been described previously. CRD1 has been proposed to 
be required for high affinity ligand binding of the receptor by mediating homotypic 
receptor oligomerisation (Chan et al., 2000) and/or conformationally stabilising CRD2, 
which is directly involved in TNF binding (Branschädel et al., 2010). Moreover, CRD1 
was found to be, to some extent, a potential determining co-factor for conferring sTNF 
responsiveness to TNFR1 (Branschädel et al., 2010). 
Furthermore, upon stimulation with sTNF simultaneous receptor activation and 
receptor cluster formation can be observed for TNFR1-Fas (Krippner-Heidenreich et al., 
2002). In contrast, TNFR2-Fas receptor cluster formation can only be detected in MF 
when cells are incubated with the stabilising monoclonal mouse anti-human TNFR2 
antibody Mab 80M2 prior to sTNF stimulation (Krippner-Heidenreich et al., 2002). 
Therefore, the inability of TNFR2-Fas to form sTNF-induced receptor clusters 
correlates with its lacking responsiveness to sTNF. Currently, it is not known how 
cluster formation of TNFR2 is controlled. Fluorescence correlation spectroscopy data 
suggest that, in contrast to TNFR1-Fas, TNFR2-Fas chimaeras do not localise in 
cholesterol-rich microdomains of the plasma membrane in the absence of the ligand 
(Gerken et al., 2010). Branschädel et al. (2010) found the homotypic interactions of the 
TNFR2 PLAD to be weaker than those seen for TNFR1. The latter accounted to some 
extent for the reduced sTNF responsiveness of TNFR2-Fas. However, this region is not 
exclusively controlling differential sTNF responsiveness as exchange of CRD1 of 
TNFR1 with the one of TNFR2 did not render TNFR1-Fas completely un-responsive to 
sTNF (Branschädel et al., 2010).  
 
As described in sections 3.2 and 3.3.1, the TNFR2 stalk region has a strong inhibitory 
effect on the responsiveness of TNFR2 towards sTNF. Preliminary data from chemical 
protein crosslinking experiments indicated a potential role for the TM and/or stalk 
regions of TNFR1 and TNFR2 in ligand-independent homotypic pre-assembly of the 
receptors (Dr Anja Krippner-Heidenreich, personal communication). Therefore, here the 
influence of the stalk region on ligand-idependent receptor-receptor interactions was 
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further investigated by using stalk region deletion mutants. In addition, the influence of 
the stalk region on the potential of TNFR2 to form larger receptor clusters was 
determined as part of this PhD project. 
 
Therefore, the aims in this chapter were to: 
 determine whether TNFR2 stalk region affects ligand independent interactions 
of TNFR-Fas chimaeras; 
 investigate whether the TNFR2 stalk region controls receptor cluster formation 
in TNFR-Fas chimaeras and TNFR2 variants; 
 
5.2 The stalk region of TNF receptor type 2 counteracts ligand-
independent receptor homo-dimerisation 
 
TNFR1 and TNFR2 have been reported to self-associate prior to ligand binding via their 
PLAD, which are located in CRD1 (Chan et al., 2000, Branschädel et al., 2010). This is 
in line with the parallel crystal structure of the extracellular domain of TNFR1, which 
shows contacts between the CRD1 of two receptor chains (Naismith et al., 1996a). 
Recent data obtained in our group linked these homotypic receptor-receptor interactions 
for the first time to sTNF responsiveness of TNFR (Branschädel et al., 2010). In 
addition, preliminary protein crosslinking data from MF TNFR1-(S/TM)R2-Fas and MF 
TNFR2-(S/TM)R1-Fas indicated that the TNFR stalk regions are also potential 
determinants controlling receptor self-association (Dr Anja Krippner-Heidenereich, 
personal communication). Therefore, my aim was to investigate the role of the TNFR2 
stalk region in ligand-independent TNFR pre-assembly. 
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Figure 44. Schematic representation of chemical crosslinking of primary amino groups 
with bis-(sulfosuccinimidyl)-suberate. 
The membrane-impermeable chemical crosslinker bis-(sulfosuccinimidyl)-suberate (BS
3
) can 
react with primary amino groups of proteins and peptides, i.e. lysine and arginine residues and 
N-terminal amino groups. A) The two reactive N-hydroxysulfosuccinimide ester groups of BS
3
 
are linked by a 1.14 nm spacer and react with the amino groups of proteins (-NH2) of proteins 
R
1 
and R
2
, thereby B) covalently linking the two proteins. Chemical structures were adopted 
from the Thermo Scientific/Pierce Crosslinking Technical Handbook (Thermo 
Scientific/Pierc, Loughborough, UK) and drawn using the ACD/Labs Software version 12.0 
(Advanced Chemistry Development Inc., Toronto, Canada). 
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To address this question the homo-bifunctional membrane-impermeable NH2-reactive 
crosslinker bis-(sulfosuccinimidyl)-suberate (BS
3
), which allows detection of weak and 
transient protein-protein interactions on the cell surface, was used. The chemical 
structure of BS
3
 and a schematic representation of the crosslinking reaction are depicted 
in Figure 44. Chemical protein crosslinking experiments with 33-500 μM BS3 were 
performed using MF stably transfected with TNFR-Fas chimaeras as described in 
section 2.10.  
To ensure that differences between the chimaeric receptors in crosslinking 
experiments were not due to differences in cell surface expression, FACS analysis was 
performed in parallel to the crosslinking experiments. The results of these analyses were 
used to correct protein loading for Western Blotting for receptor cell surface expression 
and percentage of positive cells. Generally, minimal adjustments had to be made as the 
more than 90 % of the cells could be gated positive for cell surface expression of the 
chimaeras and MnX were also comparable (MnX = 285 for TNFR2-Fas and MnX = 298 
for TNFR2-(SΔ42/TM)R2-Fas; Figure 45 A and B and MnX = 303 for TNFR1-Fas and 
MnX = 290 for TNFR1-(SΔ42/TM)R2-Fas; Figure 46 A and B).  
 
Only a relatively weak signal could be detected for crosslinked oligomers of TNFR2-
Fas at a BS
3
 concentration of 66 μM (Figure 45 C). In contrast, a strong signal for 
crosslinked TNFR2-(SΔ42/TM)R2-Fas could already be observed at 33 μM BS
3
 (Figure 
45 C), suggesting that the full length TNFR2 stalk region decreases ligand-independent 
receptor-receptor interactions of TNFR2-Fas. In agreement with previous analyses 
(Branschädel et al., 2010, Boschert et al., 2010), the molecular size of the bands 
indicates that the TNFR1-Fas and TNFR2-Fas variants exist as homodimers in the 
plasma membrane. It is likely that the homodimers detected in chemical protein 
crosslinking experiments originate from PLAD-PLAD interactions of the chimaeras. 
However, it is currently unknown how the TNFR stalk regions could affect such 
interactions. It is likely that this also applies to wild type TNFR2 but verification would 
be required. 
In contrast to TNFR2-Fas and in line with observations made by Branschädel et 
al. (2010), for the parental TNFR1-Fas chimaeras strong receptor-receptor interactions 
could already be observed at a BS
3
 concentration of 33 μM. These interactions are 
markedly reduced when the TNFR1 stalk and TM regions are replaced with the ones of 
TNFR2 (Dr Anja Krippner-Heidenreich, personal communication). While deletion of 
the 42 aa in the TNFR2 stalk region of TNFR2-Fas enhances receptor-receptor 
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interactions, deletion of these aa apparently cannot restore ligand-independent receptor 
pre-assembly of TNFR1-(S/TM)R2-Fas, as crosslinked species of TNFR1-(SΔ42/TM)R2-
Fas chimaeras could only be detected at higher BS
3
 concentrations (125 μM; Figure 46 
C). 
 
Taken together, the data presented here suggest that 42 aa in the TNFR2 stalk region 
counteract receptor homodimerisation of TNFR2-Fas in the absence of a ligand. 
However, in the case of TNFR1-Fas, parameters such as the TM region and/or adjacent 
intracellular sequences appear to mask the potential effects of the stalk region in ligand-
independent pre-assembly. 
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Figure 45. Shortening of the TNFR2 stalk region increases ligand-independent receptor-
receptor interactions in TNFR2-Fas chimaeras.  
MF were stably transfected with TNFR2-Fas and TNFR2-(SΔ42/TM)R2-Fas expression 
constructs, respectively. A and B) FACS analysis; chimaeric receptors were stained on the cell 
surface using mouse anti-human TNFR2 antibodies clone MR2-1 and goat anti-mouse IgG-
FITC antibodies (black line). Unstained cells (dotted line); cells only incubated with goat anti-
mouse IgG-FITC antibodies (grey). 91 % and 99 % of the cells were gated positive for TNFR2-
Fas and TNFR2-(SΔ42/TM)R2-Fas, respectively. MnX were as indicated. C) Chemical protein-
crosslinking and Western Blot analysis; cells were incubated with PBS or increasing amounts 
(33 µM, 66 µM, 125 µM, 250 µM and 500 µM) of the chemical crosslinker 
bis(Sulfosuccinimidyl)-suberate (BS
3
). Cells were harvested and membrane proteins were 
extracted using 1 % (v/v) TritonX-100. Membrane extracts from approximately 1 x 10
5
 cells 
were subjected to SDS-PAGE and Western Blot analysis. Protein concentrations were corrected 
for cell surface expression of the receptor chimaeras and percentages of positive cells. Mouse 
anti-human Fas antibodies (clone B10, 1:2000) were used as primary and goat anti-mouse IgG-
HRP (1:20000) as secondary antibodies. As indicated, the faster migrating protein bands 
represent monomers of the receptor chimaeras, whereas the slower migrating protein bands 
represent dimers and multimers of chimaeric receptors, respectively (Branschädel et al., 2010, 
Boschert et al., 2010). β-actin levels served as loading control. All bands shown are from the 
same exposure. Data shown represent three independent experiments.  
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Figure 46. Ligand-independent receptor-receptor interactions of TNFR1-Fas chimaeras 
containing the TM and shortened stalk region of TNFR2.  
MF were stably transfected with TNFR1-Fas and TNFR1-(SΔ42/TM)R2-Fas expression 
constructs, respectively. A and B) FACS analysis; chimaeric receptors were stained on the cell 
surface using mouse anti-human TNFR1 antibodies clone H398 and goat anti-mouse IgG-FITC 
antibodies (black line). Unstained cells (dotted line); cells only incubated with goat anti-mouse 
IgG-FITC antibodies (grey). 95 % and 90 % of the cells were gated positive for TNFR1-Fas and 
TNFR1-(SΔ42/TM)R2-Fas, respectively. MnX were as indicated. C) Chemical protein-
crosslinking and Western Blot analysis; cells were incubated with PBS or increasing amounts 
(33 µM, 66 µM, 125 µM, 250 µM and 500 µM) of the chemical crosslinker 
bis(Sulfosuccinimidyl)-suberate (BS
3
). Cells were harvested and membrane proteins were 
extracted using 1 % (v/v) TritonX-100. Membrane extracts from approximately 1 x 10
5
 cells 
were subjected to SDS-PAGE and Western Blot analysis. Protein concentrations were corrected 
for cell surface expression of the receptor chimaeras and percentages of positive cells. Mouse 
anti-human Fas antibodies (clone B10, 1:2000) were used as primary and goat anti-mouse IgG-
HRP (1:20000) as secondary antibodies. As indicated, the faster migrating protein bands 
represent monomers of the receptor chimaeras, whereas the slower migrating protein bands 
represent dimers of chimaeric receptors, respectively (Branschädel et al., 2010, Boschert et al., 
2010). β-actin levels served as loading control. Data shown represent three independent 
experiments.  
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5.3 The stalk region of TNFR2 abrogates efficient cluster formation 
of TNFR2-Fas and wild type TNFR2 
 
As shown in section 5.2, the TNFR2 stalk region has an inhibitory effect on ligand-
independent receptor-receptor interactions. This could potentially also extend to the 
inhibition of the formation of larger receptor clusters, which has previously been 
proposed to be a potential prerequisite for efficient activation of TNFR1 and TNFR2 
(Krippner-Heidenreich et al., 2002).  
To investigate whether the TNFR2 stalk region influences the ability of TNFR to 
form receptor clusters, we used the doxycycline-inducible HEK 293 FlpIN T-Rex cell 
system. HEK 293 Flp-IN T-Rex cells, which overexpress TNFR1-Fas, TNFR2-Fas and 
TNFR2-(S/TM)R1-Fas upon induction with doxycycline have been generated and 
characterised in our group previously (Branschädel et al., 2010). HEK 293 Flp-IN T-
Rex cells inducibly overexpressing TNFR2-(SΔ42/TM)R2-Fas, TNFR2, TNFR2-
(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2, respectively, have been generated as part of 
this PhD project.  
 
For the HEK 293 FlpIN T-Rex cell system induction with 0.1-1.0 μg/ml of tetracycline 
or doxyxycline for 24 h has been suggested (Invitrogen). Therefore, HEK 293 FlpIN T-
Rex TNFR2 cells were induced with increasing concentrations of doxycycline (0.5- 2.5 
ng/ml) for 18 h and TNFR2 expression was determined by FACS analysis and Western 
Blotting (Figure 47). A dose-dependent induction of overall and cell surface TNFR2 
expression could be observed. While uninduced cells showed only low TNFR2 
expression (MnX = 1266; Figure 47 A, black) a marked increase could be observed for 
induction with 0.5 ng/ml (MnX = 5964; Figure 47 A, blue), 1 ng/ml (MnX = 7654; 
Figure 47 A, green) and 1.5 ng/ml (MnX = 9752; Figure 47 A, orange) of doxycycline. 
At 2 ng/ml and 2.5 ng/ml doxycycline TNFR2 cell surface expression was comparable 
(MnX = 11080 and MnX = 11307, respectively; Figure 47 A, red and margenta), 
suggesting that maximal induction of TNFR2 expression was reached at these 
concentrations. Higher doxycyline concentrations of up to 5 ng/ml increased cell surface 
expression of TNFR2 only marginally (data not shown). Therefore, a saturating 
doxycycline concentration of  6 ng/ml was chosen for the induction of HEK 293 FlpIN 
T-Rex cells in the following experiments.  
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Figure 47. Dose-dependent doxycycline-induced expression of TNFR2 in HEK 293 FlpIN 
T-Rex cells.  
Doxycycline-inducible HEK 293 FlpIN T-Rex cells expressing TNFR2 (HEK TNFR2) were left 
untreated or were induced with increasing concentrations of doxycycline ([dox]; 0.5 ng/ml, 1 
ng/ml, 1.5 ng/ml, 2 ng/ml and 2.5 ng/ml) for 18 h. A) FACS analysis. TNFR2 was stained on 
the cell surface using mouse anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-
FITC antibodies. Cells only incubated with goat anti-mouse IgG-FITC antibodies (grey); 
uninduced cells (black), cells induced with 0.5 ng/ml (blue), 1 ng/ml (green), 1.5 ng/ml 
(orange), 2 ng/ml (red) and 2.5 ng/ml (margenta) of doxycycline, respectively. Acquisition was 
performed on a FACSCanto II flow cytometer. Percentages indicate cells positive for TNFR2 
cell surface expression at the highest doxycycline concentration. B) Western Blot analysis. 
Whole cell lysates were prepared from an equivalent of 5 x 10
4
 cells and were subjected to 
SDS-PAGE and Western Blot analysis. Polyclonal goat anti-human TNFR2 antibodies (1:2000) 
were used as primary and rabbit anti-goat IgG-HRP (1:20000) as secondary antibodies. β-actin 
levels served as loading control. Data shown represent one experiment. 
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5.3.1 The TNFR2 stalk region inhibits formation of larger TNFR2-Fas clusters 
 
Preliminary data obtained from HEK 293 Flp-IN T-Rex cells overexpressing TNFR-Fas 
chimaeras suggested a potential role for the TNFR stalk regions in controlling receptor 
cluster formation. To investigate whether the 42 aa in the TNFR2 stalk region, which 
have been shown have an inhibitory effect on ligand-independent receptor-receptor 
interactions and sTNF responsiveness (sections 3.2 and 3.3.1), also affect the potential 
of TNFR2-Fas to form larger receptor clusters, inducible HEK 293 Flp-IN T-Rex 
TNFR2-(SΔ42/TM)R2-Fas cells were generated and analysed by confocal microscopy. 
 
As a first characterisation step, cell surface expression of TNFR2-(SΔ42/TM)R2-Fas on 
the HEK 293 FlpIN T-Rex cells was determined for various induction times using 
FACS analysis. While only low cell surface expression could be detected for un-
induced cells (MnX = 965; Figure 48 A), TNFR2-(SΔ42/TM)R2-Fas was expressed at 
comparably high levels 9 h, 12 h, 18 h and 24 h after induction (MnX = 15380 – 16538; 
Figure 48 B – E). Similar results were obtained when overall TNFR2-(SΔ42/TM)R2-Fas 
expression was analysed by Western Blotting (Figure 48 F). Furthermore, TNFR2-
(SΔ42/TM)R2-Fas expressed by HEK 293 Flp-IN T-Rex cells upon induction with 
doxycycline co-migrated with the TNFR2-(SΔ42/TM)R2-Fas chimaera transiently 
expressed in HeLa cells. This indicates that TNFR2-(SΔ42/TM)R2-Fas is expressed as the 
full length protein in HEK cells.  
As TNFR2-(SΔ42/TM)R2-Fas was expressed at high levels after 12 h and 18 h of 
induction, respectively, for experimental set-up reasons an induction time of 18 h was 
chosen for the following experiments. 
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Figure 48. Kinetics of doxycycline induced expression of TNFR2-(SΔ42/TM)R2-Fas in HEK 
293 Flp-IN T-Rex cells.  
HEK 293 FlpIN T-Rex TNFR2-(SΔ42/TM)R2-Fas cells were left untreated (-) or were induced 
with 6 ng/ml doxycycline for 9 h, 12 h, 18 h and 24 h, respectively. Shown are FACS analyses 
of A) uninduced cells and B, C, D and E) cells which had been induced with doxycycline for 
the indicated times. TNFR2-(SΔ42/TM)R2-Fas was stained on the cell surface using mouse anti-
human TNFR2 (MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). Cells only 
incubated with goat anti-mouse IgG-FITC antibodies (grey). Acquisition was performed on a 
FACSCanto II flow cytometer. Percentages indicate cells gated positive for TNFR2-
(SΔ42/TM)R2-Fas and MnX are indicated. F) Western Blot analysis. Whole cell lysates were 
prepared from 5 x 10
4
 of uninduced cells and cells, which had been induced for the indicated 
times, respectively, and subjected to SDS-PAGE and Western Blot analysis. Polyclonal goat 
anti-human TNFR2 antibodies (1:2000) were used as primary and rabbit anti-goat-IgG-HRP 
(1:20000) as secondary antibodies. HeLa cells transiently transfected with the expression vector 
pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-Fas (t) served as positive control. Data shown 
represent two independent experiments.  
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To investigate the role of the TNFR2 stalk region in receptor cluster formation, HEK 
293 FlpIN T-Rex cells expressing the parental chimaeras TNFR1-Fas and TNFR2-Fas, 
the stalk/TM exchange mutant TNFR2-(S/TM)R1-Fas and the stalk region deletion 
mutant TNFR2-(SΔ42/TM)R2-Fas, respectively, were induced with 6 ng/ml doxycycline 
for 18 h. Cells were then stained with AlexaFluor546-labelled sTNF on ice for 5 min, 
fixed with formaldehyde and analysed via confocal microscopy.   
For TNFR1-Fas a clear tendency towards formation of few but large receptor 
clusters could be observed (Figure 49 A – D). In contrast, for TNFR2-Fas mainly 
homogenous distribution on the cell surface with only occasional, relatively weak 
cluster formation could be detected (Figure 49 E – H). This difference in cluster 
formation was not due to higher cell surface expression, as FACS analysis revealed 
higher relative expression levels for TNFR2-Fas than for TNFR1-Fas (MnX = 8911 for 
TNFR1-Fas and MnX = 18873 for TNFR2-Fas; Dr Anja-Krippner-Heidenreich, 
personal communication). When the stalk and TM regions of TNFR2 were exchanged 
for the ones of TNFR1, a strong increase in number and size of TNFR2-Fas clusters 
could be observed (TNFR2-(S/TM)R1-Fas; Figure 49 I – L). Similar results were 
obtained when the TNFR2 stalk region was shortened by 42 aa (TNFR2-(SΔ42/TM)R2-
Fas; Figure 49 M – P). This increase in receptor cluster formation of TNFR2-(S/TM)R1-
Fas and TNFR2-(SΔ42/TM)R2-Fas was again not caused by a stronger cell surface 
expression of these chimaeras as the relative expression levels of these chimaeras were 
comparable to parental TNFR2-Fas (MnX = 17305 for TNFR2-(S/TM)R1-Fas (Dr Anja-
Krippner-Heidenreich, personal communication) and MnX = 16067 for TNFR2-
(SΔ42/TM)R2-Fas (Figure 48)). 
The analysis of cluster formation described above was performed on cells which 
had been fixed after the incubation with AlexaFluor546-labelled sTNF. Despite working 
at low temperatures, the short incubation with TNF and the subsequent incubation at 
room temperature during the fixing of the cells may have sufficed to induce ligand-
mediated receptor clusters. Therefore, HEK 293 FlpIN T-Rex cells overexpressing 
TNFR2-Fas and TNFR2-(SΔ42/TM)R2-Fas, respectively, were fixed and then stained 
with a phycoerythrin-conjugated mouse anti-human TNFR2 antibody (clone # 22235) to 
determine whether the observed cluster formation was ligand-independent. While for 
TNFR2-Fas similar results were obtained with labelled TNF and antibody (Figure 49 I – 
L and Figure 50 A), a clear yet less pronounced cluster formation was observed for 
antibody staining of TNFR2-(SΔ42/TM)R2-Fas in comparison to cells which had been 
stained with AlexaFluor546-labelled sTNF (Figure 49 M – P and Figure 50 B). This 
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suggests that the TNFR2-(SΔ42/TM)R2-Fas cluster formation described above is only 
partly ligand-indepent. However, our data indicate that 42 aa in the TNFR2 stalk region 
have an inhibitory effect on TNFR2-Fas receptor cluster formation and that this is the 
case in both, the absence and the presence of the ligand.  
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Figure 49. Control of receptor cluster formation by the TNFR2 stalk region in TNFR2-Fas 
chimaeras.  
HEK 293 FlpIN T-Rex cells were induced with 6 ng/ml doxycycline for 18 h. Cells were then 
stained with Alexa546-labelled sTNF on ice for 5 min and fixed with formaldehyde. Images 
were acquired as z-series on an Andor Revolution XD confocal microscope. Shown are serial 
sections of HEK 293 FlpIN T-Rex cells overexpressing A, B and C) TNFR1-Fas; E, F and G) 
TNFR2-Fas; I, J and K) TNFR2-(S/TM)R1-Fas and M, N and O) TNFR2-(SΔ42/TM)R2-Fas, 
respectively. The thickness of each single section was 0.37 μm and the distance between the 
sections was 1.48 μm. D, H, L and P) 8.4x magnification of the selected area in A, E, I and M, 
respectively (white box). Larger receptor clusters are highlighted with white arrows. Data 
shown represent three independent experiments.  
 
 
T
N
F
R
1
-F
a
s
 
T
N
F
R
2
-F
a
s
 
T
N
F
R
2
-(
S
/T
M
) R
1
-F
a
s
 
T
N
F
R
2
-(
S
Δ
4
2
/T
M
) R
2
-F
a
s
 
Serial sections 8.4x magnification 
  
184 
 
 
 
 
 
 
 
 
 
 
10 µm 10 µm
A B
 
  
Figure 50. Ligand-independent receptor cluster formation of TNFR2-Fas and TNFR2-
(SΔ42/TM)R2-Fas chimaeras. 
HEK 293 FlpIN T-Rex cells were induced with 6 ng/ml doxycycline for 18 h. Cells were then 
fixed with formaldehyde and stained with phycoerythrin-conjugated mouse anti-human 
TNFR2 antibodies (clone # 22235; 1:75; R&D). Images (0.37 μm sections) were acquired 
on an Andor Revolution XD confocal microscope. Shown are A) HEK 293 FlpIN T-Rex 
TNFR2-Fas and B) HEK 293 FlpIN T-Rex TNFR2-(SΔ42/TM)R2-Fas cells. Data shown represent 
three independent experiments. 
TNFR2-Fas TNFR2-(SΔ42/TM)R2-Fas 
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5.3.2 Cluster formation of wild type TNFR2 is abrogated by the TNFR2 stalk 
region 
 
Overexpression of TNFR-Fas chimaeras in an inducible HEK cell system had revealed 
an inhibitory role for the TNFR2 stalk in TNFR cluster formation (section 5.3.1). To 
address, whether these results also translate to the cluster formation of wild type 
TNFR2, confocal microscopy experiments were repeated with HEK 293 FlpIN T-Rex 
cells expressing TNFR2, TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2, 
respectively.  
 
The inducible HEK 293 FlpIN T-Rex cell lines for TNFR2, TNFR2-(S/TM)R1-R2 and 
TNFR2-(SΔ42/TM)R2-R2 were generated as part of this PhD project. Overall expression 
and cell surface expression of the TNFR2 variants were determined by Western Blot 
and FACS analysis of HEK 293 FlpIN T-Rex cell lines which remained uninduced or 
were induced with 6 ng/ml doxycycline for 9 h, 12 h, 18 h and 24 h.  
For uninduced cells no expression of the TNFR2 variants could be detected in 
Western Blot analyses (Figure 51). Furthermore, only low cell surface expression was 
detectable for all three variants (MnX = 672- 920; Figure 52 A, Figure 53 A and Figure 
54 A, respectively). Upon induction, comparably high expression of TNFR2 and 
TNFR2-(SΔ42/TM)R2-R2 could be determined for all induction time points in both 
Western Blot (Figure 51) and FACS analysis (MnX = 11847-12755 for TNFR2 and 
MnX = 9967-11127 for TNFR2-(SΔ42/TM)R2-R2; Figure 52 B – E and Figure 54 B – E). 
In contrast, overall expression and cell surface expression of TNFR2-(S/TM)R1-R2 was 
higher than the one observed for wild type TNFR2 at all induction time points (MnX = 
15833- 21911; Figure 51 and Figure 52 B – E). For experimental set-up reasons, again 
the 18 h time-point was chosen for analysis of receptor cluster formation. 
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Figure 51. Time-course of doxycycline-induced expression of TNFR2 and variants thereof.  
Doxycycline-inducible HEK 293 FlpIN T-Rex cells expressing TNFR2, TNFR2-(S/TM)R1-R2 
and TNFR2-(SΔ42/TM)R2-R2, respectively, were induced with 6 ng/ml doxycycline for the 9 h 
(9), 12 h (12), 18 h (18) and 24 h (24) or were left untreated (-). Whole cell lysates were 
prepared and an equivalent of 3.3 x 10
4
 cells was used for SDS-PAGE and Western Blot 
analysis. Polyclonal goat anti-human TNFR2 antibodies (1:2000; R&D) were used as primary 
and rabbit anti-goat IgG-HRP (1:20000) as secondary antibodies. β-actin levels served as 
loading control. Data shown represent two independent experiments.  
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Figure 52. Cell surface expression of TNFR2 in HEK 293 Flp-IN T-Rex cells upon 
induction with doxycycline.  
Doxycycline-inducible HEK 293 Flp-IN T-Rex TNFR2 cells were induced with 6 ng/ml 
doxycycline for the 9 h, 12 h, 18 h and 24 h or were left untreated (0 h). Shown are FACS 
analyses of A) uninduced HEK 293 Flp-IN T-Rex TNFR2 cells and B, C, D, E) HEK 293 Flp-
IN T-Rex TNFR2 cells after induction with 6 ng/ml doxycycline for 9 h, 12 h, 18 h and 24 h. 
TNFR2 was stained on the cell surface using mouse anti-human TNFR2 antibodies (MR2-1) 
and goat anti-mouse IgG-FITC antibodies (black line). Cells only incubated with goat anti-
mouse IgG-FITC antibodies (grey). Acquisition was performed on a FACSCanto II flow 
cytometer. Percentages indicate cells gated positive for TNFR2 cell surface expression. MnX 
are indicated. Data shown represent two independent experiments. 
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Figure 53. Cell surface expression of TNFR2-(S/TM)R1-R2 in HEK 293 Flp-IN T-Rex cells 
upon induction with doxycycline.  
Doxycycline-inducible HEK 293 Flp-IN T-Rex TNFR2-(S/TM)R1-R2 cells were induced with 6 
ng/ml doxycycline for the 9 h, 12 h, 18 h and 24 h or were left untreated (0 h). Shown are FACS 
analyses of A) uninduced HEK 293 Flp-IN T-Rex TNFR2-(S/TM)R1-R2 cells and B, C, D, E) 
HEK 293 Flp-IN T-Rex TNFR2-(S/TM)R1-R2 cells after induction with 6 ng/ml doxycycline for 
9 h, 12 h, 18 h and 24 h. TNFR2-(S/TM)R1-R2 was stained on the cell surface using mouse anti-
human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-FITC antibodies (black line). Cells 
only incubated with goat anti-mouse IgG-FITC antibodies (grey). Acquisition was performed on 
a FACSCanto II flow cytometer. Percentages indicate cells gated positive for TNFR2-(S/TM)R1-
R2 cell surface expression. MnX are indicated. Data shown represent two independent 
experiments. 
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Figure 54. Cell surface expression of TNFR2-(SΔ42/TM)R2-R2 in HEK 293 Flp-IN T-Rex 
cells upon induction with doxycycline.  
Doxycycline-inducible HEK 293 FlpIN T-Rex cells expressing TNFR2-(SΔ42/TM)R2-R2 were 
induced with 6 ng/ml doxycycline for 9 h, 12 h, 18 h and 24 h or were left untreated (0 h). 
Shown are FACS analyses of A) uninduced HEK 293 Flp-IN T-Rex TNFR2-(SΔ42/TM)R2-R2 
cells and B, C, D, E) HEK 293 Flp-IN T-Rex TNFR2-(SΔ42/TM)R2-R2 cells after induction with 
6 ng/ml doxycycline for 9 h, 12 h, 18 h and 24 h. TNFR2-(SΔ42/TM)R2-R2 was stained on the 
cell surface using mouse anti-human TNFR2 antibodies (MR2-1) and goat anti-mouse IgG-
FITC antibodies (black line). Cells only incubated with goat anti-mouse IgG-FITC antibodies 
(grey). Acquisition was performed on a FACSCanto II flow cytometer. Percentages indicate 
cells gated positive for TNFR2-(SΔ42/TM)R2-R2 cell surface expression. MnX are indicated. 
Data shown represent two independent experiments.  
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To investigate the role of the TNFR2 stalk region in receptor cluster formation of wild 
type TNFR2, confocal microscopy studies of TNFR2 and variants thereof were 
performed. HEK 293 FlpIN T-Rex cell lines were induced with 6 ng/ml doxycycline for 
18 h, stained with AlexaFluor546-labelled sTNF on ice and fixed with formaldehyde.  
Similar to TNFR2-Fas, an overall homogenous distribution with only very few 
and rather small clusters could be detected for overexpressed wild type TNFR2 (Figure 
55 A – D). In contrast, formation of more and larger receptor clusters was discovered 
for the two TNFR2 variants, TNFR2-(S/TM)R1-R2 and TNFR2-(SΔ42/TM)R2-R2 (Figure 
55 E – L). The differences in the cluster formation potential of TNFR2 and TNFR2-
(SΔ42/TM)R2-R2 were not due to differences in cell surface expression as similar relative 
expression levels were seen at 18 h of induction for these two variants (MnX = 11869 
for TNFR2 and MnX = 10529 for TNFR2-(SΔ42/TM)R2-R2; Figure 52 D and Figure 54 
D). While a higher cell surface expression was determined for TNFR2-(S/TM)R1-R2 at 
18 h of induction (MnX = 19415; Figure 53 D), it is relatively unlikely that this 
accounted for the observed receptor cluster formation as, despite lower cell surface 
expression, a similarly pronounced cluster formation of TNFR2-(S/TM)R1-R2 was 
detected at 6 h of induction (MnX < 15000; data not shown). 
By staining the respective receptor variants with phycoerythrin-conjugated 
mouse anti-human TNFR2 antibodies (clone # 22235) it was assessed whether the 
cluster formation observed for sTNF stained cells was occurring in a ligand-independent 
fashion. Similar to the results obtained with labelled sTNF, the antibody staining 
revealed homogenous distribution and no cluster formation for wild type TNFR2 
(compare Figure 55 A – D and Figure 56 A). For TNFR2-(S/TM)R1-R2 and TNFR2-
(SΔ42/TM)R2-R2, however, where pronounced receptor clusters had been seen for 
AlexaFluor546-labelled sTNF stained cells (Figure 55 E – L), little or no pronounced 
cluster formation was observed when cells were stained with the TNFR2 antibody 
(Figure 56 B and C). In line with results obtained from the TNFR2-Fas and TNFR2-
(SΔ42/TM)R2-Fas chimaeras (Figure 49 and Figure 50), this indicates that the cluster 
formation observed for TNFR2 variants is not (entirely) ligand-indepent and indeed 
controlled by the TNFR2 stalk region.  
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Figure 55. The stalk region prevents cluster formation of wild type TNFR2.  
HEK 293 FlpIN T-Rex cells were induced with 6 ng/ml doxycycline for 18 h. Cells were then 
stained with Alexa546-labelled TNF on ice and fixed with formaldehyde. Images were acquired 
as z-series on an Andor Revolution XD confocal microscope. Shown are serial sections of 
induced HEK 293 FlpIN T-Rex cells expressing A, B and C) TNFR2, E, F and G) TNFR2-
(S/TM)R1-R2 and I, J and K) TNFR2-(SΔ42/TM)R2-R2, respectively. The thickness of each 
single section was 0.37 μm and the distance between the sections was 1.48 μm. D, H and L) 
8.4x magnification of the selected area (white box) in A, E and I, respectively. Larger receptor 
clusters are highlighted with white arrows. Data shown represent three independent 
experiments. 
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Figure 56. Ligand-independent receptor cluster formation of wild type TNFR2 and variants thereof. 
HEK 293 FlpIN T-Rex cells were induced with 6 ng/ml doxycycline for 18 h. Cells were then fixed with formaldehyde and stained with the phycoerythrin-
conjugated mouse anti-human TNFR2 antibody clone # 22235 (1:75; R&D). Images (0.37 μm sections) were acquired on an Andor Revolution XD confocal 
microscope. Shown are A) HEK 293 FlpIN T-Rex TNFR2 B) HEK 293 FlpIN T-Rex TNFR2-(S/TM)R1-R2 and C) HEK 293 FlpIN T-Rex TNFR2-(SΔ42/TM)R2-R2 
cells. Data shown represent three independent experiments. 
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5.4 Discussion 
 
PLAD-mediated ligand-independent receptor-receptor interactions of TNFR1 and 
TNFR2, respectively, have been described previously (Chan et al., 2000) and CRD1 
exchange mutants linked sTNF responsiveness of the receptors to their capacity to form 
homotypic receptor dimers (Branschädel et al., 2010). Furthermore, responsiveness to 
sTNF has been observed to correlate with sTNF-mediated formation of larger receptor 
clusters (Krippner-Heidenreich et al., 2002). As shown in sections 3.2 and 3.3, the 
TNFR2 stalk region inhibits sTNF responsiveness (Figure 14 and Figure 18). Data 
presented in this chapter demonstrate that the TNFR2 stalk region prevents ligand-
independent homotypic dimerisation of TNFR2-Fas chimaeras and inhibits formation of 
larger receptor clusters of TNFR2-Fas chimaeras and wildtype TNFR2. 
 
5.4.1 Control of TNFR2-Fas homo-dimerisation by the TNFR2 stalk region 
 
Pilot data obtained in our group disclosed strong homotypic receptor interactions for 
TNFR1-Fas chimaeras whereas these interactions are only weak for TNFR2-Fas 
(Boschert et al., 2010). This is only partly mediated by CRD1 of the receptors as 
exchange of this region between TNFR1-Fas and TNFR2-Fas did not abrogate sTNF 
responsiveness of TNFR1-Fas completely (Branschädel et al., 2010). Preliminary data 
showed that the strong homotypic interactions of TNFR1-Fas could be abrogated by the 
introduction of the stalk and TM regions of TNFR2 (TNFR1-(S/TM)R2-Fas). 
Furthermore, the relatively weak homotypic interactions of TNFR2-Fas chimaeras 
could be enhanced by replacing stalk and TM regions with the ones of TNFR1 (TNFR2-
(S/TM)R1-Fas; Dr Anja Krippner-Heidenreich, personal communication). All these data 
point to a critical role of the TM and/or stalk region in homotypic receptor dimerisation. 
As sTNF responsiveness was found to be strongly regulated by the stalk region 
of the TNFR, protein crosslinking experiments were performed as part of this PhD 
project to investigate the influence of the TNFR2 stalk region on ligand-independent 
receptor-receptor interactions of TNFR-Fas chimaeras. Deletion of 42 aa residues in the 
TNFR2 stalk region increased the homotypic receptor interactions of TNFR2-Fas, 
indicating that this region inhibits ligand-independent receptor pre-assembly of the 
parental TNFR2-Fas chimaera. In contrast, no such increase could be observed when the 
same 42 aa residues were deleted in the stalk region of TNFR1-(S/TM)R2-Fas, which 
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suggests that the control of ligand-independent receptor-receptor interactions of 
TNFR1-Fas differs from the ones seen for TNFR2-Fas. 
 
For the parental TNFR2-Fas and TNFR1-Fas chimaeras as well as their respective stalk 
deletion mutants a strong decrease in signal strength of the monomeric and 
dimeric/multimeric forms could be observed at high BS
3
 concentrations (250 μM and 
500 μM; Figure 45 C and Figure 46 C). At the same time high molecular weight bands 
appeared in these samples, which presumably represent receptor species which had not 
only been crosslinked with one another but had, due to the high BS
3
 concentrations, also 
been crosslinked unspecifically with other plasma membrane components. Furthermore, 
the decrease in signal intensity observed for β-actin, which is an intracellular protein, 
indicates that at these high concentrations BS
3
 is either no longer membrane-
impermeable or, alternatively, cannot not be quenched efficiently enough to completely 
abrogate the crosslinking reaction (Figure 45 C, bottom). Therefore, crosslinking 
occurring at 250 μM and 500 μM BS3 cannot be regarded as specific and no 
assumptions about homotypic receptor-receptor interactions can be made for these 
samples.  
While samples which did not contain the crosslinking reagent only showed 
bands for the respective monomers, in lysates from BS
3
-treated cells also protein bands 
of higher molecular weight could be detected, which corresponded in their molecular 
weight to dimeric receptors (TNFR1-Fas, TNFR1-(SΔ42/TM)R2-Fas and TNFR2-
(SΔ42/TM)R2-Fas; Figure 45 C as indicated). The observation of dimeric TNFR-Fas 
chimaeras is in good agreement with crystallographic data obtained by Naismith et al. 
(1995, 1996a, 1996b) who depicted wild type TNFR1 to exist as dimers in the absence 
of the ligand. Furthermore, according to Mukai et al. (2010) wild type TNFR2 occurs as 
receptor dimers in the presence of TNF. In contrast to TNFR1-Fas, TNFR1-
(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-Fas, the molecular weight of crosslinked 
TNFR2-Fas cannot definitely be assigned to a TNFR2-Fas dimer but could, due to the 
limited resolution of 10 % SDS-PAGE gels, also represent receptor trimers. The 
occurrence of TNFR2 as trimers has already been proposed by Chan et al. (2000). 
However, previous protein crosslinking experiments with MF TNFR2-Fas rather 
suggest that in the absence of ligand this chimaera exists as a dimer in the plasma 
membrane (Boschert et al., 2010). 
Regardless of whether these chimaeras exist as dimers or trimers, it becomes 
apparent that the homotypic interactions of TNFR2-Fas are relatively weak with only 
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low signal strength for the crosslinked receptors at 64 μM BS3. Importantly, an increase 
in homotypic interactions of TNFR2-Fas could be observed when 42 aa residues were 
deleted in the TNFR2 stalk region (Figure 45 C), highlighting the inhibitory effect of 
the TNFR2 stalk region on ligand-independent homotypic receptor-receptor 
interactions. 
 
Unexpectedly, shortening of the stalk region by the same 42 aa could not restore the 
receptor-receptor interactions of TNFR1-(S/TM)R2-Fas chimaeras to match the ones 
observed for parental TNFR1-Fas (Figure 46 C). While crosslinked species of TNFR1-
Fas could readily be observed at a BS
3
 concentration of 33 μM, only a weak signal 
could be observed for crosslinked TNFR1-(SΔ42/TM)R2-Fas dimers at 125 μM BS
3
. 
Preliminary protein crosslinking data generated by Gerlinde Holeiter (Stuttgart 
University, Germany), showed that the exchange of the TNFR1 TM region with that of 
TNFR2 already leads to a decrease in homotypic receptor-receptor interactions of 
TNFR1-Fas. Therefore, data presented here (Figure 46 C) together with data by 
Gerlinde Holeiter suggest that ligand-independent receptor-receptor interactions of 
TNFR1-Fas are probably rather controlled by the TM region and/or the adjacent 
intracellular aa residues than the TNFR stalk region. Whether this could be associated 
with different requirements of TNFR1 and TNFR2 regarding their plasma membrane 
localisation is discussed in chapter 6.  
 
Importantly, the differences in signal strength for the crosslinked TNFR-Fas chimaeras 
are most probably not caused by a lack of crosslinkable aa residues. BS
3
 interacts with 
the primary amino groups of arginines, lysines and the protein N-terminus (Figure 44). 
Based on the published crystal structures of the soluble TNFR, one or more covalent 
linkages by BS
3
 are possible for TNFR1-Fas and TNFR2-Fas in both, parallel and 
antiparallel arrangement of the receptor dimers (Prof. Richard Lewis, Newcastle 
University, personal communication). Moreover, the two arginine residues amongst the  
deleted 42 aa residues in the TNFR2 stalk region do not appear to qualify as sites for 
potential BS
3
-mediated crosslinking as suggested by the increase in signal strength for 
crosslinked TNFR2-(SΔ42/TM)R2-Fas compared to TNFR2-Fas. 
 
In conclusion, the data presented here together with previously obtained preliminary 
data demonstrate that for TNFR2-Fas the strength of ligand-independent homotypic 
receptor-receptor interactions is determined by its stalk region and correlates with the 
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potential of the TNFR-Fas chimaeras to be activated by sTNF. This suggests that the 
lack of receptor pre-assembly could prevent TNFR2 responsiveness to sTNF. However, 
in case of TNFR1-Fas efficient receptor activation by sTNF seems to be regulated by an 
additional mechanism (or mechanisms) as sTNF responsiveness of TNFR1-
(SΔ42/TM)R2-Fas does show no such correlation with the strength of ligand-independent 
receptor pre-assembly. Therefore, the mechanism(s) underlying efficient sTNF-
mediated activation of TNFR1-(SΔ42/TM)R2-Fas despite chimaera‟s lower degree of 
ligand-independent pre-assembly remains yet to be determined. 
 
MF are deficient for murine TNFR1 and TNFR2 but do express endogenous murine 
TNF. Comparison of murine and human TNF showed that the murine ligand is capable 
of binding both human TNFR almost equally well as the human version of TNF 
(reviewed in Lucas et al., 2005). Therefore, there is the possibility that the differences in 
receptor homodimerisation between the parental chimaeras and the stalk region deletion 
mutants TNFR1-(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-Fas could be caused by 
altered interactions of the receptors with endogenous murine TNF. However, binding 
studies with iodinated human sTNF had revealed that ligand-binding affinities for the 
parental chimaeras and the corresponding stalk region deletion mutants were 
comparable (Dr Anja Krippner-Heidenreich, personal communication). Based on the 
data from the binding study, rather similar results should be expected in the crosslinking 
experiments for both, parental and mutant chimaeras if murine TNF played a role as 
crosslinking mediator here. As this is not the case, it is, therefore, relatively unlikely 
that the differences in homotypic receptor interactions can be attributed to altered 
TNFR-Fas interactions with endogenous murine TNF.  
 
5.4.2 Inhibition of TNFR2 and TNFR2-Fas cluster formation by the TNFR2 stalk 
region 
 
As mentioned above, ligand-independent TNFR-Fas pre-assembly overall correlates 
with the potential of the chimaeras to respond to sTNF. In addition, the ability of TNFR 
to form large receptor clusters upon stimulation with sTNF has been found to correlate 
with receptor responsiveness towards sTNF (Krippner-Heidenreich et al., 2002). Data 
presented here, which were obtained using an inducible cell system, revealed an 
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inhibitory role for the TNFR2 stalk region in the formation of larger clusters of both 
TNFR2-Fas chimaeras and wild type TNFR2.  
 
As a first approach to detect receptor clusters, TNFR-Fas chimaeras and TNFR2 
variants were stained on the cell surface using Alexa546-labelled sTNF. Based on the 
crystal structure published by Mukai et al. (2010), a diameter of approximately 8.5 nm 
was determined for a TNF trimer in complex the extracellular domains of three TNFR2 
molecules. This is also consistent with the crystal structure for the LTα/TNFR1 
complex, which has been described previously (Banner et al., 1993). Consequently, one 
of the trimeric TNF/TNFR complexes presumably occupies a cell surface area of 
roughly 57 nm
2
. As determined from the confocal microscopy images, receptor cluster 
sizes for TNFR-Fas chimaeras and wild type TNFR2 variants ranged from 
approximately 1 x 10
4
 nm
2
 – 8 x 104 nm2 and, therefore, comprise a maximum of 200-
1400 ligand/receptor complexes consisting of trimeric TNF and three receptors.  
For TNFR1-Fas, TNFR2-Fas and wild-type TNFR2 fewer and smaller receptor 
clusters could be observed (200-500 trimeric TNF/TNFR complexes/cluster; Figure 49 
A – H and Figure 55 A – D). An increase in number and size of the receptor clusters 
was seen when stalk and TM regions of TNFR1 were introduced into TNFR2-Fas and 
wild-type TNFR2, respectively (900 – 1400 TNF/TNFR complexes/cluster; Figure 49 I 
– L and Figure 55 E – H). Similarly, deletion of 42 aa residues in the TNFR2 stalk 
region lead to an increase in receptor cluster number and size of both TNFR2-Fas and 
wild-type TNFR2 (300 – 1400 TNF/TNFR complexes/cluster; Figure 49 M – P and 
Figure 55 I – L).  
We cannot exclude that for the TNFR1-(SΔ42/TM)R2-R2 variant its higher cell 
surface expression (MnX = 19415; Figure 53 D) compared to wild-type TNFR2 (MnX 
= 11869; Figure 52 D) causes increased receptor aggregation on the cell surface. 
However, despite equal or even lower cell surface expression compared to the parental 
receptors, enhanced cluster formation could be observed for TNFR1-(SΔ42/TM)R2-Fas 
and TNFR2-(SΔ42/TM)R2-Fas compared to TNFR2-Fas and TNFR2-(SΔ42/TM)R2-R2 
compared to wild type TNFR2. This suggests that indeed the TNFR2 stalk region 
controls TNFR2 cluster formation and that this is independent of receptor cell surface 
expression.  
 
In addition to the staining with Alexa546-labelled sTNF, receptor cluster formation has 
also been investigated using a PE-labelled TNFR2-specific antibody. Again, for 
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TNFR2-Fas and wild type TNFR2 only weak cluster formation could be observed when 
fixed cells were stained with this antibody (Figure 50 A and Figure 56 A). In contrast, 
for both stalk deletion mutants, TNFR2-(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-R2, 
more distinct receptor clusters could be observed. However, the observed clusters were 
less pronounced than the ones seen in the staining with sTNF. As the sTNF staining was 
performed on live cells and followed by a fixing step at room temperature this might 
have been sufficient to allow the ligand to promote formation of receptor clusters. 
Therefore, the size of signalling competent receptor clusters is probably smaller than 
estimated above and the formation of larger receptor clusters appears to be not (entirely) 
ligand-independent but requires the presence of sTNF. 
This also seems to be the case for the TNFR2-(S/TM)R1-R2 variant, which 
clearly shows larger receptor clusters in sTNF stained samples (Figure 55 E – H) but no 
obvious aggregation of the receptors when cells were stained with the antibody (Figure 
56 B). For the corresponding TNFR2-(S/TM)R1-Fas chimaera also enhanced cluster 
formation could be detected on sTNF-stained cells (Figure 49 I – L). However, to what 
extent this cluster formation occurs ligand-independently remains yet to be determined. 
 
It has been shown previously that the formation of signalling competent TNFR-Fas 
complexes can be meassured by the level of apoptosis HEK cells undergo upon 
overexpression of the chimaeras (Branschädel et al., 2010). Experiments recently 
performed by Dr Anja Krippner-Heidenreich showed that the cluster size of the TNFR-
Fas chimaeras investigated in this PhD project correlated with the potential of the 
respective receptor to signal for apoptosis (Dr Anja Krippner-Heidenreich, personal 
communication). While efficient induction of apoptosis could be observed for TNFR1-
Fas, TNFR2-(S/TM)R1-Fas and TNFR2-(SΔ42/TM)R2-Fas, hardly any apoptotic response 
was seen for TNFR2-Fas. Therefore, the TNFR2 stalk region counteracts the formation 
of larger receptor clusters, which is in turn apparently required for efficient receptor 
activation.   
 
Taken together, our data show that by deleting 42 aa residues in the TNFR2 stalk region 
TNFR2-Fas chimaeras and wild type TNFR2 can be converted into receptors which 
form larger aggregates upon incubation with sTNF similar to the ones observed for 
TNFR1 and TNFR1-Fas (Krippner-Heidenreich et al., 2002, Schneider-Brachert et al., 
2004). 
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5.5 Conclusion 
 
 The TNFR2 stalk region prevents ligand-independent, most likely PLAD-
PLAD-mediated homotypic receptor dimerisation of TNFR2-Fas chimaeras. 
 Ligand-independent homotypic receptor interactions of TNFR1 are not 
entirely controlled by the stalk region but rather may be determined by the 
TM region and/or the adjacent membrane-proximal intracellular aa residues 
and CRD1. 
 42 aa residues in the TNFR2 stalk region inhibit formation of larger receptor 
clusters of TNFR2-Fas chimaeras and wildtype TNFR2. Deletion of these 
42 aa facilitates the formation of larger sTNF-induced clusters of both, 
TNFR2-Fas and wildtype TNFR2. 
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CHAPTER 6 
General Discussion 
 
6 hgbgfal 
The aim of this thesis has been to investigate the role of the stalk region in differential 
TNFR responsiveness to sTNF at the level of signalling complex formation and cluster 
formation and to identify the component(s) in this region controlling sTNF 
responsiveness. 
 
6.1 General perspective 
 
TNF is a pro-inflammatory cytokine which plays an important role in the regulation of 
the immune system and, consequently, in the pathogenesis of various autoimmune 
diseases (reviewed in Bradley, 2008, Faustman and Davis, 2010). It exists either as a 
transmembrane homotrimer or, upon protease-mediated cleavage, as its soluble form 
sTNF (Black et al., 1997). The soluble and membrane-bound forms of TNF appear to 
play different roles in immunity and data from mouse models indicate that it is rather 
sTNF than membrane-bound TNF which plays a role in the development of 
autoimmune diseases such as RA and MS (Steed et al., 2003, Alexopoulou et al., 2006). 
In good agreement with these observations, neutralisation of TNF proves to be a 
successful therapy for RA (Bradley, 2008) and neutralisation of sTNF in particular can 
ameliorate disease symptoms in experimental arthritis (Steed et al., 2003). 
In addition to the different roles for the two forms of TNF, divergent biological 
functions have also been described for the two TNFR with, for example, TNFR1 being 
critically involved in host defence and sepsis (Pfeffer et al., 1993, Rothe et al., 1993, 
Castanos-Velez et al., 1998, Fujita et al., 2008) and TNFR2 playing an important role in 
the modulation of immune tolerance (Valencia et al., 2006, Ban et al., 2008, Chen et al., 
2008, Nagar et al., 2010). In addition, data from animal models of RA have implied a 
pro-inflammatory role for TNFR1 and a rather suppressive function for TNFR2 (Mori et 
al., 1996, Tada et al., 2001b).  
 
Both forms of TNF can bind to TNFR1 and TNFR2 with high affinity, but, while the 
membrane-bound variant can fully activate both receptors, sTNF is only capable of 
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activating TNFR1 efficiently (Grell et al., 1995, Grell et al., 1998b). This differential 
responsiveness of TNFR2 towards the soluble and the membrane-bound ligand is a 
characteristic which can also be observed for various other members of the TNFR 
superfamily. For the soluble form of FasL, for example, a strong reduction in its pro-
apoptotic activity compared to membrane-bound FasL has been described (Suda et al., 
1997, Schneider et al., 1998), which was found to be associated with increased 
autoimmunity and enhanced anti-apoptotic, pro-inflammatory signalling (O'Reilly et al., 
2009). Differences in receptor activation potential between the soluble and membrane-
bound forms of TRAIL (Wajant et al., 2001), APRIL (Bossen et al., 2008), OX40 
ligand (Müller et al., 2008) and TWEAK (Roos et al., 2010) have also been described.  
Ligand trimer stabilisation and/or oligomerisation have been reported to be 
important parameters for the efficient activation of some of the TNFR superfamily 
members including TNFR2 (Krippner-Heidenreich et al., 2002, Bryde et al., 2005, 
Müller et al., 2008, Wyzgol et al., 2009, Rauert et al., 2010). In addition, 
responsiveness towards sTNF correlates with the ability of the TNFR1 and TNFR2 to 
form larger sTNF-mediated receptor clusters (Krippner-Heidenreich et al., 2002, 
Schneider-Brachert et al., 2004, Branschädel et al., 2010). While stimulation with sTNF 
leads to the formation of large TNFR1 clusters, the formation of similar TNFR2 clusters 
requires additional stabilisation (Krippner-Heidenreich et al., 2002, Schneider-Brachert 
et al., 2004).  
A domain which mediates homotypic receptor-receptor interaction in the 
absence of the ligand is the PLAD, which is located in CRD1. As already described for 
Fas (Papoff et al., 1996, Papoff et al., 1999, Siegel et al., 2000), this domain mediates 
ligand-independent homotypic interactions of TNFR1 and TNFR2, respectively, (Chan 
et al., 2000) and CRD1, which mediates these interactions, was found to be a potential 
co-factor for conferring sTNF responsiveness to TNFR1 (Branschädel et al., 2010). 
However, CRD1 exchange mutants revealed that this domain is not the sole determinant 
for sTNF responsiveness of the TNFR. 
 
In an attempt to locate the receptor region(s) responsible for controlling TNFR 
responsiveness towards sTNF, different regions were exchanged between TNFR1-Fas 
and TNFR2-Fas. When receptor chimaeras, in which only the TM region had been 
exchanged, were analysed, only a minor role for the TM regions in differential 
responsiveness towards sTNF could be observed (Dr Anja Krippner-Heidenreich, 
personal communication). However, preliminary data from MF transfected with TNFR-
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Fas chimaeras in which both, stalk and TM regions had been exchanged between 
receptors (TNFR1-(S/TM)R2-Fas and TNFR2-(S/TM)R1-Fas) indicated that the stalk 
regions, potentially together with the TM regions, are involved in determining 
differential responsiveness to sTNF (Figure 11 B and E).  
Furthermore, ligand-independent homotypic receptor-receptor interactions and 
formation of receptor clusters of these chimaeras correlated with the observed sTNF 
responsiveness. Chimaeras containing the TM and stalk regions of TNFR2 (TNFR2-Fas 
and TNFR1-(S/TM)R2-Fas) showed weak ligand-independent homotypic interactions 
and no formation of larger receptor clusters. In contrast, for the corresponding 
chimaeras with TNFR1 stalk and TM regions (TNFR1-Fas and TNFR2-(S/TM)R1-Fas) 
stronger homotypic interactions and formation of larger receptor clusters could be 
observed (Dr Anja Krippner-Heidenreich, personal communication). Taken together, 
these data suggest that the TNFR stalk regions, potentially together with the TM 
regions, determine responsiveness towards sTNF and that this may be controlled at the 
level of ligand-independent receptor pre-assembly and cluster formation. Therefore, it 
was the aim of this PhD project to establish the role of the TNFR stalk regions in sTNF 
responsiveness as well as ligand-independent pre-assembly and cluster formation of the 
TNFR and to investigate the underlying molecular mechanism(s). 
 
6.2 The TNFR stalk region and its prominent molecular features in 
the control of receptor responsiveness to sTNF  
 
Preliminary data obtained from the TNFR1-(SΔ42/TM)R2-Fas chimaera, which contains a 
version of the TNFR2 stalk region of the same length as the TNFR1 stalk region, had 
suggested that it is the stalk regions of TNFR1 and TNFR2 in particular which play a 
role in differential responsiveness towards sTNF (Figure 11 C). The data obtained 
during this PhD project demonstrate that the TNFR stalk region is indeed a major 
determinant for this differential responsiveness and show that 42 aa in the TNFR2 stalk 
region inhibit receptor responsiveness towards sTNF. This was found to be the case for 
both, TNFR-Fas chimaeras as well as wild type TNFR2 (sections 3.2 and 3.3).  
 
The sTNF responsiveness of TNFR2-Fas can be increased more than 100-fold by the 
deletion of 42 aa in the TNFR2 stalk region (section 3.2). However, this chimaera is still 
10-fold less responsive towards sTNF compared to CysTNF. This finding is in 
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agreement with data, which showed that susceptibility towards sTNF was decreased 
when either the TM regions (Dr Anja Krippner-Heidenreich, personal communication) 
or CRD1 (Branschädel et al., 2010) had been exchanged between TNFR1 and TNFR2. 
Together these data indicate that sTNF responsiveness is controlled by at least three 
different regions of the receptor: the N-terminal CRD1, the TM region and the stalk 
region.  
Similar results were obtained for wild type TNFR2 when either the stalk and TM 
regions of TNFR2 were exchanged for the ones of TNFR1 (TNFR1-(S/TM)R2-R2) or 
the TNFR2 stalk region was shortened by 42 aa (TNFR2-(SΔ42/TM)R2-R2). A significant 
increase in sTNF responsiveness at the level of TRAF2 recruitment to the TNFR2 
signalling complex could be observed compared to the wild type receptor (Figure 18 
and Figure 19) and this was independent of TNFR1 signalling (Figure 24 and Figure 
25). Moreover, very recently it could be shown that the enhanced sTNF-mediated 
TRAF2 recruitment to TNFR2-(SΔ42/TM)R2-R2 is reflected by an increased activation of 
NF-κB signalling (Dr Anja Krippner-Heidenreich, personal communication). This 
indicates that the 42 aa residues in the TNFR2 stalk region also affect sTNF-mediated 
downstream signalling and that results obtained from the TNFR-Fas cellular system can 
be directly translated into the wild type TNFR2 system. 
  
6.2.1 The role of stalk region O-glycosylation in sTNF responsiveness of TNFR2 
 
The stalk regions of the two TNFR differ in their aa composition and, with 15 aa for 
TNFR1 and 56 aa for TNFR2, also in their length. When 42 aa residues were deleted in 
the TNFR2 stalk region to match its length to the one of the TNFR1 stalk region, this 
also abolished predicted O-glycosylation sites as well as eight proline residues.  
For TNFR1 and TNFR2 post-translational modifications have been reported. 
Both receptors have been described to be N-glycosylated (Hohmann et al., 1989) and 
the membrane proximal region of TNFR2 was also found to be O-glycosylated (Pennica 
et al., 1993). When the TNFR2 stalk region was shortened by 42 aa, more than 10 
putative O-glycosylation sites were deleted (Figure 29). Three lines of evidence support 
O-glycosylation of the stalk region of wild type TNFR2 and TNFR2-Fas variants 
investigated in this thesis. Firstly, in Western Blot analysis a decreased molecular 
weight could be observed for stalk deletion mutants of both wild-type TNFR2 and 
TNFR2-Fas (Figure 13, Figure 16 and Figure 26) and this decrease was greater than the 
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calculated sum of molecular weights of the single deleted aa residues. Secondly, full 
replacement of the TNFR2 stalk region with a 56 aa long artificial linker (TNFR2-
SGSL56-TMR2-Fas) resulted in a chimaera which again showed reduced molecular weight 
compared to TNFR2-Fas (Figure 31). Thirdly, in contrast to parental TNFR2-Fas, the 
molecular weight of TNFR2-SGSL56-TMR2-Fas also remained unaltered when cells were 
treated with the O-glycosylation inhibitor Benzyl-α-GalNAc (Figure 39). Therefore, 
TNFR2-Fas and TNFR2 appear to be O-glycosylated when stably expressed in MF and 
this O-glycosylation seems to be located in the stalk region. This is in agreement with 
data, which have been published for wild type TNFR2 previously (Pennica et al., 1993).   
As mentioned above, TNFR2 has also been reported to be N-glycosylated. N-
glycosylation of any of the TNFR2-Fas and TNFR2 variants should, however, not be 
affected by TNFR2 stalk region deletion or replacement as it has been reported to occur 
not in this region but at two asparagine residues in CRD4 (Pennica et al., 1993). In line 
with this, two bands could be detected for the stalk deletion mutants TNFR2-
(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-R2 as well as the stalk replacement mutants 
TNFR2-SGSL15-TMR2-Fas and TNFR2-SGSL56-TMR2-Fas in Western Blot analyses 
(Figure 13, Figure 16 and Figure 31). Whether these receptor variants are indeed N-
glycosylated similarly to wild type TNFR2 remains, however, yet to be confirmed. 
 
Differential responsiveness to soluble and membrane-bound ligand has also been 
described for two other members of the TNFR-related superfamily, TRAILR1 and 
TRAILR2 (Wajant et al., 2001). While TRAILR1 can be activated by both, the soluble 
and the membrane-bound form of TRAIL, TRAILR2 activation requires membrane-
bound TRAIL. Similar to TNFR1 and TNFR2, the stalk regions of the two TRAILR 
differ in their length (10 aa for TRAILR1, 32 aa for TRAILR2) and their predicted O-
glycosylation sites. Interestingly, O-glycosylation of the stalk region of TRAILR2 has 
been found to influence the receptor sensitivity towards TRAIL and the ability of the 
receptor to signal for apoptosis (Wagner et al., 2007). In contrast to TRAILR2, in which 
the stalk region has an activating function in the induction of apoptosis, the stalk region 
of TNFR2 seems to play rather a inhibitory role in signalling initiation. This inhibitory 
role of the TNFR2 stalk region, however, remained unaltered when putative O-
glycosylation sites were mutated or, alternatively, TNFR2-Fas chimaeras were treated 
with the core 1/core 2 O-glycosylation inhibitor Benzyl-α-GalNAc. Therefore, this type 
of O-glycosylation apparently plays no role in receptor responsiveness towards sTNF 
under the given experimental conditions. 
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While O-glycosylation of the stalk region might not be a prerequisite for TNFR2 
responsiveness to sTNF it might exert other functions. Involvement of O-glycosylation 
has been reported in trafficking, delivery and cell surface stabilisation of proteins 
(reviewed in Tian and Ten Hagen, 2009) and site-specific O-glycosylation of the 
membrane-proximal part of the extracellular portion of the neurotrophin receptor, for 
example, was proposed  to be essential for apical sorting of this receptor (Breuza et al., 
2002). One of the TNFR2-Fas chimaeras with mutated O-glycosylation sites, TNFR2-
Fas mot. 1/4 (Figure 37), was not expressed at the cell surface despite its high 
intracellular expression, suggesting that motif 4 may be required for the export of 
TNFR2-Fas chimaeras from the endoplasmic reticulum and/or plasma membrane 
localisation. However, neither the partial stalk exchange mutant TNFR2-(SExaa202-
219/TM)R2-Fas nor the full stalk exchange mutants TNFR2-SGSL15-TMR2-Fas and 
TNFR2-SGSL56-TMR2-Fas contain O-glycosylation motif 4 but are both expressed on the 
cell surface at high levels. Hence, the role of motif 4 O-glycosylation remains elusive 
and there is the possibility that specifically its mutation in combination with motif 1 
leads to a misfolding of the chimaera which in turn inhibits its membrane localisation. 
Alternatively, the effect of motif 4 could be dependent on other sequences which are not 
present in the full and partial stalk exchange mutants, for which no such inhibitory 
effect on membrane localisation could be observed (Figure 33 and Figure 43). 
The O-glycosylation status of the stalk region does apparently not affect the 
ligand binding affinity of the receptor. In contrast to the CD8β receptor, in which O-
glycosylation/sialylation of the stalk region was proposed to influence its ligand binding 
affinity (Moody et al., 2001, Moody et al., 2003), binding studies indicated that sTNF 
binds with comparably high affinity to TNFR-Fas chimaeras with wild type and 
shortened TNFR2 stalk regions, respectively (Dr Anja Krippner-Heidenreich, personal 
communication).  
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6.2.2 Control of sTNF responsiveness by proline residues in the TNFR2 stalk 
region  
 
In addition to the O-glycosylation of the TNFR2 stalk region we also investigated the 
role of stalk region length and conserved proline residues in this region. Our data show 
that neither the length nor single conserved proline residues of the stalk region control 
TNFR2-Fas responsiveness towards sTNF (sections 4.2 and 4.3).  
While our data indicate that it is unlikely that a single proline residue in the 
TNFR2 stalk region is acting as a molecular switch controlling sTNF responsiveness, 
there is the possibility that a combination of several proline residues in this region could 
determine sTNF responsiveness. This, however, has not been further investigated in this 
PhD project. In proteins, proline-rich sequences are often found in extended structures 
and flexible regions and can confer both, flexibility and stability (reviewed in 
Williamson, 1994). The left handed collagen helix is a prominent example of such a 
secondary structure (reviewed in Bhattacharjee and Bansal, 2005). In comparison to 
collagen, the proline residues in the TNFR2 stalk region are less abundant and do not 
occur in an equally regular pattern, but they may still determine stalk region 
conformation and orientation while also providing a certain degree of flexibility and/or 
rigidity.  
In this context, it is worth noting that, by introducing artificial linkers into 
TNFR-Fas chimaeras, the wild type TNFR2 stalk region was replaced with an aa 
sequence which is postulated to be very flexible and predicted to adopt no distinct 
secondary structure but a random coil fold (Evers et al., 2006). This replacement of the 
wild type TNFR2 stalk region with artificial 56 aa stalk regions turned TNFR2-Fas into 
a receptor which was responsive towards sTNF. Therefore, one might speculate that the 
rigidity of wild type TNFR2 stalk region, which is potentially determined by its proline-
richness, inhibits responsiveness towards sTNF and can only be overcome when either 
the ligand exists in an oligomerised state such as described by Bryde et al. (2005) and 
Rauert et al. (2010) or additional stabilisation is provided by e.g. the mouse anti-human 
TNFR2 antibody 80M2 (Grell et al., 1995, Krippner-Heidenreich et al., 2002). If the 
rigidity of the stalk region as a whole was counteracting sTNF responsiveness of 
TNFR2, partial replacement of this region with flexible linkers might not be sufficient 
to overcome this inhibition. This could explain why the sTNF responsiveness of 
TNFR2-Fas chimaeras, in which the stalk region had been only partly exchanged with 
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artificial linkers, did not differ from the one seen for the parental chimaera (Figure 11 
and Figure 43). 
 
6.3 Inhibition of ligand-independent TNFR interactions and cluster 
formation by the TNFR2 stalk region 
 
Receptor cluster formation is thought to enhance signal transduction of transmembrane 
receptors by, for example, increasing their sensitivity and specificity and enhancing 
response simultaneity, respectively (reviewed in Duke and Graham, 2009). Formation 
of ligand-induced clusters of TNFR1 has been demonstrated previously (Schneider-
Brachert et al., 2004) and Krippner-Heidenreich et al. (2002) observed that TNF-
mediated activation of TNFR1-Fas chimaeras also coincided with the formation large 
receptor clusters. The TNFR PLAD and the localisation of the TNFR in plasma 
membrane microdomains have already been described as two possible determinants for 
the formation of these receptor clusters. CRD1, which contains the PLAD, has been 
proposed to be required for high affinity ligand binding of TNFR1 (Chan et al., 2000). 
The homotypic interactions of the TNFR2 PLAD are weaker than the ones seen for 
TNFR1 and a correlation of the strength of PLAD/PLAD-mediated interactions with 
sTNF responsiveness of TNFR1-Fas has been described recently (Branschädel et al., 
2010). However, these weaker PLAD/PLAD interactions only account to some extent 
for the reduced sTNF responsiveness of TNFR1-Fas as the exchange of the TNFR1 
PLAD with the one of TNFR2 did not render TNFR1-Fas fully unresponsive to sTNF 
(Branschädel et al., 2010).  
 
6.3.1 The TNFR2 stalk region abrogates ligand-independent TNFR interactions  
 
Preliminary data from chemical protein crosslinking experiments indicated a potential 
role for the stalk regions of TNFR1 and TNFR2 in ligand-independent homotypic pre-
assembly of the receptors (Dr Anja Krippner-Heidenreich, personal communication). In 
this PhD project an inhibitory role for the TNFR2 stalk region in the control of 
homotypic interactions of TNFR2-Fas could be confirmed. An increase in homotypic 
interactions of TNFR2-Fas could be observed when 42 aa residues were deleted in the 
TNFR2 stalk region (Figure 45 C). In contrast, shortening of the TNFR2 stalk region by 
42 aa could not restore the homotypic receptor-receptor interactions of TNFR1-
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(S/TM)R2-Fas chimaeras to the same level as seen for the parental TNFR1-Fas chimaera 
(Figure 46 C). As mentioned in section 5.4.1, protein crosslinking data by Gerlinde 
Holeiter indicated that the exchange of the TNFR1 TM region with the one of TNFR2 
already leads to a decrease in homotypic receptor-receptor interactions of TNFR1-Fas. 
Together with the data presented here (Figure 46 C) this suggests that ligand-
independent receptor-receptor interactions of TNFR1-Fas are rather controlled by the 
TM region and/or the adjacent intracellular aa residues, which were exchanged together 
with the TM region, than by the stalk region. 
Interestingly, for TNFR1 the aa sequence YQRW (aa 236-239), which 
comprises four aa of the proposed TM region and two membrane-proximal intracellular 
aa of TNFR1, has been described to be essential for TNFR1 internalisation (Schneider-
Brachert et al., 2004, Schütze et al., 2008). Data on whether these aa residues are 
required for localisation of TNFR1 to cholesterol-rich membrane microdomains are 
conflicting (Schneider-Brachert et al., 2004, D'Alessio et al., 2010), but some of these 
aa are part of a potential cholesterol binding motif. The aa consensus sequence L/V-X(1-
5)-Y-X(1-5)-R/K, where X is any aa, has previously been described for cholesterol 
binding proteins (Li and Papadopoulos, 1998). In the case of TNFR1 a potential 
cholesterol binding motif is represented by the aa sequence LMYRYQR (aa 232 – 238). 
Variations of this potential cholesterol binding motif are maintained in the TNFR1-Fas 
and TNFR2-(S/TM)R1-Fas chimaeras with the aa sequence LMYRYLK and in the 
TNFR2 variant TNFR2-(S/TM)R1-R2 with the aa sequence LMYRKKK. In contrast, 
wild type TNFR2 and (chimaeric) variants thereof, which include the TNFR2 TM 
region and the 14 membrane-proximal intracellular aa residues, do not contain such a 
potential cholesterol binding motif. The presence of this motif may be required for the 
localisation of TNFR1 to cholesterol-rich plasma membrane compartments, which 
would be in agreement with data describing different localisation of the two TNFR in 
the plasma membrane (Ranzinger et al., 2009, Gerken et al., 2010). It is conceivable 
that this different membrane localisation could be a determining factor for homotypic 
interactions of the TNFR-Fas chimaeras (see also following section).  
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6.3.2 The TNFR2 stalk region counteracts TNFR2 cluster formation 
 
While receptor activation and cluster formation of TNFR1-Fas chimaeras occur 
simultaneously upon stimulation with sTNF, sTNF-mediated cluster formation of 
TNFR2 (Dr Anja Krippner-Heidenreich personal communication) and TNFR2-Fas 
(Krippner-Heidenreich et al., 2002) only occurs in the presence of the stabilising mouse 
anti-human TNFR2 antibody 80M2. Therefore, the ability of TNFR2 and TNFR2-Fas to 
form sTNF-induced receptor clusters correlates with their responsiveness to sTNF.  
The role of formation of receptor clusters is not quite clear to date as recent 
evidence emerged that the formation of larger receptor clusters might be dispensable for 
efficient TNFR1-Fas activation (Ranzinger et al., 2009). Studies with nanoscale 
arranged TNF rather suggest that a confinement of TNFR1-Fas to membrane 
microdomains of approximately 200 nm in diameter is required for apoptosis induction 
(Ranzinger et al., 2009). While this apoptosis induction appears to be largely cholesterol 
independent (Ranzinger et al., 2009), cholesterol depletion increases the diffusion 
constant of TNFR1-Fas on the MF cell surface (Gerken et al., 2010), indicating that 
TNFR1-Fas chimaeras are localised in cholesterol-rich membrane domains. Moreover, 
co-IP of caveolin-1 with a peptide encoding the TM region and part of the intracellular 
domain of TNFR1 has been described, suggesting a potential localisation of TNFR1 in 
caveolae, a subtype of cholesterol-rich membrane compartments (D'Alessio et al., 
2010). Therefore, this localisation may facilitate aggregation of the receptors by 
promoting interactions with lipids or certain proteins in these microdomains. 
 
An important role for receptor localisation in cholesterol- and sphingolipid-rich plasma 
membrane microdomains has already been described for signalling of the TNFR 
superfamily member Fas (Eramo et al., 2004). Fas localisation to cholesterol-rich 
plasma membrane microdomains has been proposed to be required for cluster formation 
of this receptor in response to soluble FasL (Henkler et al., 2005). Formation of larger 
Fas receptor clusters requires the presence of the ligand, which was suggested to 
stabilise the signalling-competent form of Fas (Scott et al., 2009). Furthermore, it has 
been speculated that TRAILR1 and TRAILR2 activation may function accordingly and 
FADD interactions may also stabilise receptor multimerisation of these receptors (Scott 
et al., 2009).  
What controls cluster formation of TNFR2 is also not understood to date. 
TNFR2 contains a membrane-proximal intracellular aa sequence similar to the lysine-
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rich membrane-proximal intracellular sequence of Fas, which is required for 
constitutive localisation of Fas to cholesterol-rich membrane microdomains (Rossin et 
al., 2010). Based on this sequence homology between TNFR2 and Fas a potential 
interaction of TNFR2 with the actin-binding protein ezrin has been proposed, which 
would link TNFR2 localisation and internalisation to the actin cytoskeleton (Fischer et 
al., 2011). However, recent evidence emerged that the membrane-proximal lysine 
residues are not essential for Fas interaction with ezrin but rather palmitoylation of a 
membrane-proximal intracellular cysteine residue of Fas is required (Chakrabandhu et 
al., 2007, Rossin et al., 2010). Fas and TRAILR1 are both palmitoylated. However, this 
receptor modification appears to be not absolutely crucial for localisation in cholesterol-
rich microdomains as TRAILR2 and TNFR1, which are not palmitoylated, still localise 
in these microdomains (Rossin et al., 2009). It is conceivable that the presence of the 
aforementioned cholesterol binding motif may already be sufficient for this localisation 
of TNFR1. 
In contrast, TNFR2 has not been reported to localise in such cholesterol-rich 
microdomains and in fluorescence correlation spectroscopy studies with TNFR-EGFP 
fusion proteins cholesterol depletion with methyl-β-cyclodextrin altered the diffusion of 
TNFR1 but not TNFR2 in the plasma membrane (Gerken et al., 2010). In addition, 
methyl-β-cyclodextrin pre-treatment did not affect the apoptosis kinetics in MF TNFR2-
Fas stimulated with sTNF in combination with the stabilising anti-human TNFR2 
antibody 80M2 (Krippner-Heidenreich et al., 2002).  
By replacing the TM and four adjacent intracellular aa residues of TNFR2 and 
TNFR2-Fas with the ones of TNFR1 a potential cholesterol binding motif was 
introduced into the respective receptors (see above). Whether these receptors show a 
microdomain localisation which differs from the parental TNFR2-Fas chimaera and 
wild type TNFR2, respectively, remains yet to be determined. However, data from the 
stalk region deletion mutants TNFR2-(SΔ42/TM)R2-Fas and TNFR2-(SΔ42/TM)R2-R2 
indicate that TNFR2 cluster formation is rather controlled by the stalk than the TM 
region (Figure 49 M - P and Figure 55 I – L). The exact mechanism of how the stalk 
region interferes with cluster formation remains elusive and whether the TNFR2 stalk 
region plays a role in controlling the localisation of TNFR2 into e.g. cholesterol-rich 
microdomains is yet to be determined. 
 
In addition, TNFR2 contains two more features which could potentially affect its 
tendency to form receptor clusters: N-glycosylation in CRD4 at N149 and N171 
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(Pennica et al., 1993) and a GXXXG (X represents any amino acid) motif in the TM 
region.  
N-glycosylation of cell surface receptors has already been described to play a 
role in dimerisation and microdomain localisation of epidermal growth factor receptor 
(EGFR) and T-cell receptor (TCR; reviewed in Dennis et al., 2009). Galectins, which 
belong to the sugar-binding lectins, have been found to counteract the dimerisation of 
epidermal growth factor receptor 1 (ErbB-1) and the multimerisation and the plasma 
membrane microdomain localisation of TCR. N-glycosylation is less efficient in the 
proximity of disulfide bonds, the TM region and at the termini of proteins (reviewed in 
Dennis et al., 2009). The TNFR2 stalk region could theoretically adopt a bent secondary 
structure which would provide additional space for the N-linked oligosaccharide chains 
in CRD4. When 42 aa in the stalk region of TNFR2-Fas and wild type TNFR2 were 
deleted, we could observe an increase in the number and size of receptor clusters. It is 
conceivable that due to the shorter stalk region and the resulting closer proximity to the 
plasma membrane there would be less space for full-sized N-glycosylation of CRD4 
and, therefore, less potential interaction with inhibitory lectins as described above. 
Moreover, full replacement of the TNFR2 stalk region with artificial linkers can render 
TNFR2-Fas chimaeras responsive towards sTNF, suggesting that a certain rigidity of 
the stalk region as previously discussed (section 6.2.2) may be required. Whether N-
glycosylation could play a role in TNFR2 cluster formation and activation by sTNF 
remains yet to be determined.  
Furthermore, receptor-receptor interactions and receptor oligomerisation of 
TNFR2 may also be influenced to some extent by a GXXXG motif in the TM region. 
Transmembrane helix-helix association by GXXXG motifs has been described to be 
involved in the dimerisation of several cell surface receptors including ErbB-1 and 
ErbB-2 (Bennasroune et al., 2004) and neuropilin-1 (Roth et al., 2008). A GXXXG 
motif would be represented by the aa sequence GLIVG (aa 263 – 267) in the TM region 
of TNFR2. This motif by itself, however, appears to be not sufficient to mediate strong 
homotypic receptor-receptor interactions as only weak bands could be observed for 
TNFR1-TMR2-Fas (data not shown) and TNFR1-(SΔ42/TM)R2-Fas (Figure 46 C) in 
crosslinking experiments. This may be due to the fact that with 30 aa residues the 
predicted TM region of TNFR2 is relatively long and, as determined by in silico 
modelling experiments on artificial lipid bi-layers, is likely to span the plasma 
membrane not in a 90 º angle but rather in a tilted angle (Prof. Peter Scheurich, 
University of Stuttgart, Germany, personal communication). Therefore, the GXXXG 
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motif could alter receptor conformation and/or orientation in the plasma membrane and 
thereby affect receptor pre-assembly and ability to form clusters. 
 
The crystal structures of TNFR1 show that the receptor can exist as either parallel or 
anti-parallel dimers (Naismith et al., 1995, Naismith et al., 1996b, Naismith et al., 
1996a), of which only the parallel ones have been proposed to be able to bind TNF as in 
the anti-parallel dimers the TNF binding site is occluded (Naismith et al., 1996a). 
Recently published crystallographic data of TNFR2 in complex with TNF showed that 
the secondary structure of this receptor is very similar to the one seen for TNFR1 
(Mukai et al., 2010), indicating that TNFR2 may form parallel and anti-parallel dimers 
similar to the ones seen for TNFR1. Therefore, orientation of the TNFR as anti-parallel 
dimers could represent a state in which the receptors would be maintained inactive.  
The crystal structure published by Mukai et al. (2010) showed that in the 
TNF/TNFR2 complex TNF interaction with TNFR2 still occurred although the 
receptors were arranged as anti-parallel dimers. However, it has been suggested that this 
TNFR2 arrangement could represent an artefact from the crystallisation process (Mukai 
et al., 2010). Moreover, if TNFR2 existed in such anti-parallel dimers, four aa residue 
pairs should be available to allow three covalent linkages of the receptor pair by the 
crosslinking reagent BS
3
 (K120 and K120, K120 and R99, R77 and R158, R99 and 
R158; Prof. Richard Lewis, Newcastle University, personal communication). However, 
protein crosslinking data presented in this PhD thesis (Figure 45) together with data by 
Boschert et al. (2010) showed only weak homotypic interactions of TNFR2-Fas 
chimaeras. Therefore, it is very unlikely that TNFR2 exists as such an anti-parallel 
dimer in the plasma membrane.  
In contrast, TNFR2 could exist in a more upright position in the membrane, in 
which receptor dimer formation via the GXXXG motif is potentially supported by the 
loosely associated TNFR2 PLAD. In such a scenario, the rigid, bent TNFR2 stalk 
region together with the tilted TM region would ensure that the cytoplasmic parts of the 
dimeric receptors stay spatially separated and, therefore, in an inactive state. In this 
conformation, TNFR2 dimers would be able to bind sTNF but no signalling initiation 
would occur. This would be in agreement with previously published data, which 
showed that already TNFR2 dimers can bind sTNF with high affinity (Boschert et al., 
2010). Binding of membrane-bound TNF, however, could potentially cause 
conformational rearrangements of the TNFR2 dimer so that the effects of TM and stalk 
region could be overcome, larger receptor/ligand clusters could be formed and the 
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receptors would become activated. Through the deletion of the 42 aa residues in the 
TNFR2 stalk region the inhibitory effect of this region would be abrogated and sTNF 
would already be capable to induce the conformational changes in TNFR2 required for 
signalling initiation. Interestingly, TRAILR2, which has also been reported to be un-
responsive to the soluble form of its ligand (Wajant et al., 2001), also carries such a 
GXXXG motif in its TM region. Hence, further investigations into the mechanisms 
underlying the sTNF responsiveness of TNFR2 may also provide new insights into 
signalling mechanisms of this receptor. 
 
As the TNFR2 stalk region was found to be a major determinant for receptor 
responsiveness to sTNF and both, sTNF and TNFR2 have been identified to be 
critically involved in autoimmune diseases, targeting of this region may represent an 
interesting new therapeutic approach in the treatment of such diseases. It has been 
shown previously that the stalk region of TNFR2 is accessible to polyclonal antibodies, 
which showed a mild agonistic effect (Bigda et al., 1994). However, the effect of 
antibodies against the stalk region in combination with sTNF remains to be determined 
as part of future research.   
 
6.4 Future work 
 
While I could establish a role for the TNFR2 stalk region in receptor responsiveness 
towards sTNF, ligand-independent homotypic receptor-receptor interactions and 
receptor multimerisation/cluster formation, the work in this thesis has also raised a 
number of questions about the underlying mechanism(s). Further work will be required 
to address these questions and, in addition, to confirm some of the conclusions drawn 
here. 
 
 Site directed mutagenesis of further predicted O-glycosylation sites and 
combinations of conserved proline residues in the TNFR2 stalk region, 
respectively, will be performed to elucidate their role in determining 
responsiveness to sTNF.  
 Based on computational analysis of the published crystal structures of the 
parallel and anti-parallel dimers, aa residues which do not affect the overall 
receptor structure but are potentially involved in mediating receptor-
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receptor interactions will be determined for the two TNFR. Site directed 
mutagenesis of these aa residues and subsequent crosslinking experiments 
with crosslinkers of different length will provide insights about 
conformational receptor arrangements and their role in TNFR 
responsiveness towards sTNF.  
 While it could be demonstrated that the TNFR stalk region is an important 
determinant for differential sTNF responsiveness, it remains unknown 
whether the adjacent CRD4 could also play a role here. Especially the N-
glycosylation described in CRD4 may represent a feature which determines 
TNFR2 cluster formation. Therefore, the role of this post-translational 
modification will be further investigated by mutational abrogation of the N-
glycosylation sites in this region and subsequent analysis in the TNFR-Fas 
cell system. 
 The role of receptor membrane localisation in homotypic ligand-
independent receptor-receptor interactions and cluster formation will be 
determined. Protein crosslinking experiments and confocal microscopy 
experiments will be repeated with methyl-β-cyclodextrin-treated cells. This 
will shed light onto the role of the TNFR stalk regions in determining 
receptor localisation to cholesterol-rich plasma membrane microdomains 
and the consequences for ligand-independent receptor pre-assembly and 
cluster formation of TNFR1 and TNFR2. Isolation and biochemical 
characterisation of detergent-resistant membrane microdomains will 
elucidate to which cholesterol-rich membrane compartments the TNFR 
locate in particular. 
 Live cell imaging at 37 ºC will elucidate the role of the stalk region in 
sTNF-mediated cluster formation of TNFR2 under more physiological 
conditions. Furthermore, by using green fluorescent protein-coupled 
versions of TRAF2 and NF-κB it will also be possible to investigate 
whether the observed cluster formation correlates with signalling initiation. 
 The expression of TNFR2 is strongly regulated and mainly restricted to cells 
of the immune system, neuronal tissues, cardiac myocytes, mesenchymal 
stem cells and endothelial cells (reviewed in Faustman and Davis, 2010). As 
TNFR2 has been described to be involved in the proliferation of thymocytes 
(Grell et al., 1998a), modulation of this TNFR2-mediated proliferation will 
be investigated to establish the role of the TNFR stalk region in receptor 
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responsiveness towards sTNF in a more physiological context. For this 
purpose, thymocytes will be isolated from tnfr1
-/- 
and tnfr1
-/-
/tnfr2
-/- 
mice 
and transfected with lentiviral expression vectors for wild type TNFR2 and 
stalk mutants thereof. Analysis of these cells will elucidate whether the data 
obtained from the cellular model systems described in this PhD thesis also 
apply to more physiologically relevant cell types. Furthermore, this 
approach will provide a cellular system in which reagents affecting stalk 
region function can be ultimately tested for their suitability as new TNFR-
selective therapeutics. 
 
6.5 Summary 
 
In this PhD thesis the TNFR2 stalk region could be established as an important 
determinant of TNFR2 responsiveness towards sTNF. Pilot data had already discovered 
a role for CRD1 in differential responsiveness of TNFR (Branschädel et al., 2010) and 
preliminary data also suggested an involvement of the TNFR TM and/or stalk regions 
(Dr Anja Krippner-Heidenreich, personal communication). In this PhD project it could 
be demonstrated for the first time that the stalk region is the main determinant of 
differential sTNF responsiveness of TNFR1 and TNFR2 and that 42 aa residues in the 
TNFR2 stalk region inhibit responsiveness towards sTNF. Furthermore, data from 
various point and exchange mutants highlighted the complexity of the mechanism 
underlying the inhibitory effect of the TNFR2 stalk region on responsiveness towards 
sTNF. In addition, the data presented in this thesis show that the TNFR2 stalk region 
controls homotypic ligand-independent receptor-receptor interactions and receptor 
cluster formation, which both correlate with sTNF responsiveness of the receptor. 
Whether the TNFR stalk regions control these receptor interactions and cluster 
formation by affecting intrinsic structural arrangements, facilitating interactions with 
other proteins or by determining receptor localisation in the plasma membrane requires 
further investigation. 
The findings in this thesis highlight the potential of the TNFR stalk region to serve 
as a potential target for future therapeutic agents for the treatment of sTNF-mediated 
auto-immune diseases and provide, furthermore, insight into signalling mechanisms 
which may also be valid for other members of the TNF/TNFR superfamilies. 
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Appendix 
 
 
Various subcloning plasmids and expression vectors were generated during this PhD 
project. For these vectors plasmids maps were created using the the Clone Manager 9 
software. The appropriate colour code and abbreviations for the plasmid maps are 
depicted in  
 
Table 20. Colour codes and abbreviations for plasmid maps 
 
Colour code/abbreviation Explanation 
 DNA encoding indicated sequence 
 Cytoplasmic portion Fas (aa 191-335) 
 TNFR1 (aa 1-236) 
 TNFR1 TM/stalk region 
 TNFR2 (aa 1-301) 
 TNFR2 TM/stalk region 
 Artificial glycine/serine linker 
 FRT site of recombination 
Amp
R
 Ampicillin resistance gene 
CMV promoter Cytomegalovirus promoter 
ColE1 ori ColE1origin of replication 
f1 ori f1 filamentous phage origin of replication  
Hygro
R
 Hygromycin resistance gene 
PGKpuropolyA Puromycin resistance gene under the control of a 
phosphoglycerate kinase promoter and a poly A 
sequence 
pUC ori pUC origin of replication 
polyA Polyadenylation sequence 
SV40ori EF-1a Simian virus 40 origin of replication and elongation 
factor 1a promoter sequence 
TetO2 Tetracycline operator O2 
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I  Mammalian expression plasmids for wild-type TNFR2 variants 
 
 
 
 
 
 
 
 
pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-R2 (#450) 
8555 bps 
2000 
4000 
6000 
8000 
ScaI 
AhdI 
KpnI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI BamHI 
KpnI 
PshAI 
HpaI 
EcoRV 
PmlI 
Tth111I 
BsiWI 
RsrII 
BstEII 
PfoI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(SΔ42/TM)R2-R2 
polyA 
PGKpuropolyA 
pEF-PGK/puro polyA TNFR2-(S/TM)R1-R2 (#451) 
8537 bps 
2000 
4000 
6000 
8000 
ScaI 
AhdI 
SapI 
KpnI 
AccI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI BamHI 
KpnI 
PshAI 
HpaI 
EcoRV 
PmlI 
Tth111I 
BsiWI 
RsrII 
BstEII 
PfoI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(S/TM)R1-R2 
polyA 
PGKpuro polyA 
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II  Mammalian expression plasmid for TNFR2-(SΔ42/TM)R2-Fas  
 
The mammalian expression plasmid pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-Fas has 
been generated by Dr Andrea Zappe at the University of Stuttgart and has been used for 
stable and transient transfections of this PhD project. 
 
 
 
8243 bps 
2000 
4000 
6000 
8000 
ScaI 
KpnI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BamHI 
KpnI 
BstBI 
Van91I 
EcoRV 
PmlI 
XcmI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(SΔ42/TM)R2-Fas 
poly A 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR2-(SΔ42/TM)R2-Fas (#436) 
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III  Subcloning plasmids for the introduction of SGSL into TNFR-Fas 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2996 bps 
500 
1000 
1500 
2000 
2500 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccI 
StyI 
BseRI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
AflIII 
NspI 
PciI 
BseYI AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker1 for TNFR2-Fas 
Amp
R 
pBS SK(+) subclon. linker 1 for TNFR2-SGSL-TMR2-Fas (#501) 
3007 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
SapI 
AflIII 
NspI 
PciI 
BseYI AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker 1 for TNFR1-Fas 
Amp
R
 
pBS SK(+) subclon. linker 1 for TNFR1-SGSL-TMR1-Fas (#502) 
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3047 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccI 
StyI 
BseRI 
AccIII BglII PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
AflIII 
NspI 
PciI 
BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker 1/2 for TNFR2-Fas 
Amp
R 
pBS SK(+) subclon. linker 1/2 for TNFR2-SGSL-TMR2-Fas (#507) 
pBS SK(+) subclon. linker 1/2 for TNFR1-SGSL-TMR1-Fas (#508) 
3055 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
SapI 
AflIII 
NspI 
PciI 
BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker1/2 for TNFR1-Fas 
Amp
R
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pBS SK(+) subclon. linker 1/2/2 for TNFR2-SGSL-TMR2-Fas (#513) 
3095 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccI 
StyI 
BseRI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
AflIII 
NspI 
PciI 
BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker 1/2/2 for TNFR2-Fas 
Amp
R
 
3103 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
SapI 
AflIII 
NspI 
PciI BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
Linker 1/2/2 for TNFR1-Fas 
Amp
R 
pBS SK(+) subclon. linker 1/2/2 for TNFR1-SGSL-TMR1-Fas (#514) 
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3122 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccI 
StyI 
BseRI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
AflIII 
NspI 
PciI BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker1/2/2/3 for TNFR2-Fas 
Amp
R
 
pBS SK(+) subclon. linker 1/2/2/3 for TNFR2-SGSL-TMR2-Fas (#519) 
3130 bps 
500 
1000 
1500 
2000 
2500 
3000 
PsiI 
BtgZI 
DraIII 
BsaAI 
NaeI 
NgoMIV 
Acc65I 
KpnI 
AccIII 
BglII 
PstI 
XbaI 
NotI 
EagI 
BstXI 
AleI 
BtgI 
SacII 
EcoICRI 
SacI 
SapI 
AflIII 
NspI 
PciI BseYI 
AlwNI 
AhdI 
BsaI 
NmeAIII 
ScaI 
TatI 
BsaHI 
XmnI 
f1 ori 
linker 1/2/2/3 for TNFR1-Fas 
Amp
R
 
pBS SK(+) subclon. linker 1/2/2/3 for TNFR1-SGSL-TMR1-Fas (#520) 
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3700 bps 
500 
1000 
1500 
2000 
2500 
3000 
3500 
SspI 
XmnI 
BsaHI 
ScaI 
PvuI 
FspI 
NmeAIII 
BglI 
BsaI 
BmrI 
BseYI 
DrdI 
AflIII 
PciI SapI 
BssHII 
EcoICRI 
SacI 
BstXI 
SacII 
NotI 
EagI 
XbaI 
BamHI 
NcoI 
PfoI 
Bsu36I 
EcoNI 
BlnI 
BsrGI 
AvaI 
BmeT110I 
SmaI 
XmaI 
BbvCI 
Bpu10I 
MunI 
BstAPI 
AarI 
AccIII 
Acc65I 
KpnI 
HincII 
BstBI 
Tth111I 
Van91I 
HindIII 
EcoRV 
BsaAI 
SnaBI 
NaeI 
NgoMIV 
Amp
R
 
TNFR1-SGSL15-TMR1-Fas 
pBS SK(+) -KpnI TNFR1-SGSL15-TMR1-Fas (#503) 
pBS SK(+) TNFR2-SGSL15-TMR2-Fas (#504) 
4208 bps 
1000 
2000 
3000 
4000 
BsaAI 
BtgZI 
PsiI 
KpnI 
EcoRV 
Van91I 
HindIII 
Tth111I 
BstBI 
HincII 
KpnI 
AccI 
BseRI 
BsmI 
PasI 
EcoO109I 
BmgBI 
SrfI 
BlpI 
SbfI 
AarI 
BspMI 
SexAI 
BbsI 
SfiI 
BbeI 
KasI 
NarI 
SfoI 
NcoI 
XhoI 
BamHI 
NotI 
EagI 
BstXI 
AleI 
SacII 
AflIII 
PciI 
BsaI 
NmeAIII 
ScaI 
XmnI 
TNFR2-SGSL15-TMR2-Fas 
ColEI ori 
Amp
R
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pBS SK(+) -KpnI TNFR1-SGSL56-TMR1-Fas (#521) 
3823 bps 
500 
1000 
1500 
2000 
2500 
3000 
3500 
SspI 
XmnI 
BsaHI 
ScaI 
PvuI 
FspI 
NmeAIII 
BglI 
BsaI 
BmrI 
BseYI 
DrdI 
AflIII 
PciI 
SapI 
BssHII EcoICRI 
SacI 
BstXI 
SacII 
NotI 
EagI 
XbaI 
BamHI 
NcoI 
PfoI 
Bsu36I 
EcoNI 
BlnI 
BsrGI 
AvaI 
BmeT110I 
SmaI 
XmaI 
BbvCI 
Bpu10I 
MunI 
BstAPI 
AarI 
AccIII 
Acc65I 
KpnI 
HincII 
BstBI 
Tth111I 
Van91I 
HindIII 
EcoRV 
BsaAI 
SnaBI 
NaeI 
NgoMIV 
Amp
R 
ColEI ori 
TNFR1-SGSL56-TMR1-Fas 
4334 bps 
1000 
2000 
3000 
4000 
BsaAI 
BtgZI 
PsiI 
EcoRV 
Van91I 
HindIII 
Tth111I 
BstBI 
HincII 
AccI 
BseRI 
AccIII 
BsmI 
PasI ++ 
BmgBI 
SrfI 
BlpI 
SbfI 
AarI 
BspMI 
SexAI 
BbsI 
SfiI 
BbeI 
KasI 
NarI 
SfoI 
NcoI 
XhoI 
BamHI 
NotI 
EagI 
BstXI 
AleI 
SacII 
AflIII 
PciI 
BsaI 
NmeAIII 
ScaI 
XmnI 
TNFR2-SGSL56-TMR2-Fas 
ColEI ori 
Amp
R
 
pBS SK(+) TNFR2-SGSL56-TMR2-Fas (#522) 
  
252 
 
IV Mammalian expression plasmids for TNFR-SGSL-TM-Fas 
chimaeras 
 
 
 
 
 
 
pEF-PGK/puro polyA TNFR1-SGSL15-TMR1-Fas (#505) 
8145 bps 
2000 
4000 
6000 
8000 
ScaI 
SapI 
AccI 
SalI 
ClaI 
SfiI 
FseI 
BamHI 
Bsu36I 
BsrGI 
SmaI 
XmaI 
BstBI 
Van91I 
EcoRV 
XbaI 
PmlI 
XcmI 
BlpI 
BsmI 
BsiWI 
RsrII 
BstEII 
SexAI 
BclI 
BbsI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR1-SGSL15-TMR1-Fas 
polyA 
PGKpuro polyA 
8240 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
XcmI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-SGSL15-TMR2-Fas 
polyA 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR2-SGSL15-TMR2-Fas (#506) 
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8268 bps 
2000 
4000 
6000 
8000 
ScaI 
SapI 
AccI 
SalI 
ClaI 
SfiI 
FseI 
BamHI 
Bsu36I 
BsrGI 
SmaI 
XmaI 
BstBI 
Van91I 
EcoRV 
XbaI 
PmlI 
XcmI 
BlpI 
BsmI 
BsiWI 
RsrII 
BstEII 
SexAI 
BclI 
BbsI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR1-SGSL56-TMR1-Fas 
polyA 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR1-SGSL56-TMR1-Fas (#523) 
8363 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
XcmI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-SGSL56-TMR2-Fas 
polyA 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR2-SGSL56-TMR2-Fas (#524) 
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V  Mammalian expression plasmids for partial stalk exchange 
mutants 
 
 
 
 
 
8363 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
XcmI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(SExaa202-219/TM)R2-Fas 
polyA 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR2-(SExaa202-219/TM)R2-Fas (#532) 
pEF-PGK/puro polyA TNFR2-(SExaa215-232/TM)R2-Fas (#533) 
8363 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(SExaa215-232/TM)R2-Fas 
polyA 
PGKpuro polyA 
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pEF-PGK/puro polyA TNFR2-(SExaa228-249/TM)R2-Fas (#534) 
8363 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
 
SV40ori EF-1a 
TNFR2-(SExaa228-249/TM)R2-Fas 
polyA 
PGKpuro polyA 
pEF-PGK/puro polyA TNFR2-(SExaa241-257/TM)R2-Fas (#535) 
8363 bps 
2000 
4000 
6000 
8000 
ScaI 
SalI 
ClaI 
BlnI 
MunI 
FseI 
BamHI 
SbfI 
SrfI 
BstBI 
Van91I 
EcoRV 
PmlI 
BsiWI 
RsrII 
BstEII 
PfoI 
BclI 
PsiI 
Amp
R
 
SV40ori EF-1a 
TNFR2-(SExaa241-257/TM)R2-Fas 
polyA 
PGKpuro polyA 
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VI Plasmids for the generation of inducible HEK 293 FlpIN T-Rex 
cells 
 
 
 
 
 
 
6860 bps 
1000 
2000 
3000 4000 
5000 
6000 
MunI 
Bpu10I 
NruI 
MluI 
SpeI 
SnaBI 
AflII 
HindIII 
KpnI 
BamHI 
SexAI 
KpnI 
SanDI 
BseRI 
HpaI 
EcoRV 
NotI 
PspXI 
SphI AsiSI 
RsrII 
SacII 
PfoI 
PsiI 
Bst1107I 
PciI 
AhdI 
XmnI 
SspI 
CMV promoter 
TetO2 
TNFR2 
FRT 
Hygro
R
 
polyA 
pUC Ori 
Amp
R
 
pcDNA5/FRT/TO TNFR2 (#539) 
pcDNA5/FRT/TO TNFR2-(S/TM)R1-R2 (#540) 
6722 bps 
1000 
2000 
3000 4000 
5000 
6000 
MunI 
Bpu10I 
NruI 
MluI 
SpeI 
SnaBI 
AflII 
HindIII 
BamHI 
SexAI 
BmgBI 
PasI 
BamHI 
AleI 
SanDI 
XcmI 
HpaI 
EcoRV 
NotI 
PspXI 
SphI 
AsiSI 
RsrII 
SacII 
PfoI 
PsiI 
Bst1107I 
SapI 
PciI 
AhdI 
XmnI 
SspI 
CMV promoter 
TetO2 
TNFR2-(S/TM)R1-R2 
FRT 
Hygro
R
 
polyA 
pUC Ori 
Amp
R
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6740 bps 
1000 
2000 
3000 4000 
5000 
6000 
MunI 
Bpu10I 
NruI 
MluI 
SpeI 
SnaBI 
AflII 
HindIII 
KpnI 
SexAI 
BmgBI 
PasI 
KpnI 
SanDI 
BseRI 
XcmI 
HpaI 
EcoRV 
NotI 
PspXI 
SphI 
AsiSI 
RsrII 
SacII 
PfoI 
PsiI 
Bst1107I 
PciI 
AhdI 
XmnI 
SspI 
CMV promoter 
TetO2 
TNFR2-(SΔ42/TM)R2-R2 
FRT 
Hygro
R
 
polyA 
pUC Ori 
Amp
R
 
pcDNA5/FRT/TO TNFR2-(SΔ42/TM)R2-R2 (#541) 
6399 bps 
1000 
2000 
3000 
4000 
5000 
6000 
MunI 
Bpu10I 
NruI 
MluI 
SnaBI 
AflII 
AleI 
BbeI 
KasI 
NarI 
SfoI 
SfiI 
SexAI 
AarI 
SbfI 
BlpI 
SrfI 
BmgBI 
PasI 
BstBI 
Van91I 
EcoRV 
BstXI 
NotI 
PspXI 
XhoI 
BclI 
SphI 
PshAI 
EcoRI 
AsiSI 
RsrII 
SacII 
PfoI 
PsiI 
Bst1107I 
PciI 
BsaI 
XmnI 
SspI 
CMV promoter 
TetO2 
TNFR2-(SΔ42/TM)R2-Fas 
FRT 
Hygro
R
 
polyA 
pUC Ori 
Amp
R
 
pcDN5/FRT/TO TNFR2-(SΔ42/TM)R2-Fas (#546) 
